id	sid	tid	token	lemma	pos
chd-155	1	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-155	1	2	e1	e1	NOUN
chd-155	1	3	cancer	cancer	NOUN
chd-155	1	4	health	health	NOUN
chd-155	1	5	disparities	disparity	NOUN
chd-155	1	6	research	research	VERB
chd-155	1	7	racial	racial	ADJ
chd-155	1	8	disparities	disparity	NOUN
chd-155	1	9	in	in	ADP
chd-155	1	10	expression	expression	NOUN
chd-155	1	11	of	of	ADP
chd-155	1	12	gdf15	gdf15	NOUN
chd-155	1	13	and	and	CCONJ
chd-155	1	14	nfκb	nfκb	NOUN
chd-155	1	15	in	in	ADP
chd-155	1	16	prostate	prostate	NOUN
chd-155	1	17	cancer	cancer	NOUN
chd-155	1	18	and	and	CCONJ
chd-155	1	19	benign	benign	ADJ
chd-155	1	20	prostatic	prostatic	ADJ
chd-155	1	21	epithelium	epithelium	NOUN
chd-155	1	22	kenneth	kenneth	NOUN
chd-155	1	23	a	a	DET
chd-155	1	24	iczkowski1	iczkowski1	NOUN
chd-155	1	25	,	,	PUNCT
chd-155	1	26	oleksandr	oleksandr	PROPN
chd-155	1	27	kravtsov1	kravtsov1	PROPN
chd-155	1	28	,	,	PUNCT
chd-155	1	29	sudha	sudha	PROPN
chd-155	1	30	sadasivan2	sadasivan2	PROPN
chd-155	1	31	,	,	PUNCT
chd-155	1	32	watchareepohn	watchareepohn	PROPN
chd-155	1	33	palangmonthip1,3	palangmonthip1,3	PROPN
chd-155	1	34	,	,	PUNCT
chd-155	1	35	yalei	yalei	PROPN
chd-155	1	36	chen2	chen2	PROPN
chd-155	1	37	,	,	PUNCT
chd-155	1	38	m	m	PROPN
chd-155	1	39	scott	scott	PROPN
chd-155	1	40	lucia4	lucia4	PROPN
chd-155	1	41	,	,	PUNCT
chd-155	1	42	james	james	PROPN
chd-155	1	43	r	r	PROPN
chd-155	1	44	lambert4	lambert4	NOUN
chd-155	1	45	,	,	PUNCT
chd-155	1	46	kathleen	kathleen	PROPN
chd-155	1	47	c	c	PROPN
chd-155	1	48	torkko4	torkko4	PROPN
chd-155	1	49	,	,	PUNCT
chd-155	1	50	benjamin	benjamin	PROPN
chd-155	1	51	a	a	DET
chd-155	1	52	rybicki2	rybicki2	PROPN
chd-155	1	53	1department	1department	NUM
chd-155	1	54	of	of	ADP
chd-155	1	55	pathology	pathology	PROPN
chd-155	1	56	,	,	PUNCT
chd-155	1	57	medical	medical	ADJ
chd-155	1	58	college	college	PROPN
chd-155	1	59	of	of	ADP
chd-155	1	60	wisconsin	wisconsin	PROPN
chd-155	1	61	,	,	PUNCT
chd-155	1	62	pathology	pathology	PROPN
chd-155	1	63	,	,	PUNCT
chd-155	1	64	milwaukee	milwaukee	PROPN
chd-155	1	65	,	,	PUNCT
chd-155	1	66	wi	wi	PROPN
chd-155	1	67	,	,	PUNCT
chd-155	1	68	united	united	PROPN
chd-155	1	69	states	states	PROPN
chd-155	1	70	,	,	PUNCT
chd-155	1	71	2department	2department	NUM
chd-155	1	72	of	of	ADP
chd-155	1	73	public	public	ADJ
chd-155	1	74	health	health	NOUN
chd-155	1	75	sciences	science	NOUN
chd-155	1	76	,	,	PUNCT
chd-155	1	77	henry	henry	PROPN
chd-155	1	78	ford	ford	PROPN
chd-155	1	79	health	health	PROPN
chd-155	1	80	system	system	PROPN
chd-155	1	81	,	,	PUNCT
chd-155	1	82	detroit	detroit	PROPN
chd-155	1	83	,	,	PUNCT
chd-155	1	84	mi	mi	PROPN
chd-155	1	85	,	,	PUNCT
chd-155	1	86	united	united	PROPN
chd-155	1	87	states	states	PROPN
chd-155	1	88	,	,	PUNCT
chd-155	1	89	3department	3department	NUM
chd-155	1	90	of	of	ADP
chd-155	1	91	pathology	pathology	NOUN
chd-155	1	92	,	,	PUNCT
chd-155	1	93	faculty	faculty	NOUN
chd-155	1	94	of	of	ADP
chd-155	1	95	medicine	medicine	NOUN
chd-155	1	96	,	,	PUNCT
chd-155	1	97	chiang	chiang	PROPN
chd-155	1	98	mai	mai	PROPN
chd-155	1	99	university	university	PROPN
chd-155	1	100	,	,	PUNCT
chd-155	1	101	chiang	chiang	PROPN
chd-155	1	102	mai	mai	PROPN
chd-155	1	103	,	,	PUNCT
chd-155	1	104	thailand	thailand	PROPN
chd-155	1	105	,	,	PUNCT
chd-155	1	106	and	and	CCONJ
chd-155	1	107	4university	4university	NUM
chd-155	1	108	of	of	ADP
chd-155	1	109	colorado	colorado	PROPN
chd-155	1	110	,	,	PUNCT
chd-155	1	111	aurora	aurora	PROPN
chd-155	1	112	,	,	PUNCT
chd-155	1	113	co	co	PROPN
chd-155	1	114	,	,	PUNCT
chd-155	1	115	united	united	PROPN
chd-155	1	116	states	states	PROPN
chd-155	1	117	*	*	PUNCT
chd-155	1	118	corresponding	correspond	VERB
chd-155	1	119	author	author	NOUN
chd-155	1	120	:	:	PUNCT
chd-155	1	121	kenneth	kenneth	PROPN
chd-155	1	122	a.	a.	PROPN
chd-155	1	123	iczkowski	iczkowski	PROPN
chd-155	1	124	,	,	PUNCT
chd-155	1	125	e	e	NOUN
chd-155	1	126	-	-	NOUN
chd-155	1	127	mail	mail	NOUN
chd-155	1	128	:	:	PUNCT
chd-155	1	129	kaiczkowski@mcw.edu	kaiczkowski@mcw.edu	PROPN
chd-155	1	130	abstract	abstract	ADJ
chd-155	1	131	:	:	PUNCT
chd-155	1	132	prostate	prostate	NOUN
chd-155	1	133	cancer	cancer	NOUN
chd-155	1	134	(	(	PUNCT
chd-155	1	135	pc	pc	NOUN
chd-155	1	136	)	)	PUNCT
chd-155	1	137	outcomes	outcome	NOUN
chd-155	1	138	are	be	AUX
chd-155	1	139	more	more	ADV
chd-155	1	140	adverse	adverse	ADJ
chd-155	1	141	for	for	ADP
chd-155	1	142	african	african	ADJ
chd-155	1	143	-	-	PUNCT
chd-155	1	144	american	american	ADJ
chd-155	1	145	(	(	PUNCT
chd-155	1	146	aa	aa	NOUN
chd-155	1	147	)	)	PUNCT
chd-155	1	148	than	than	ADP
chd-155	1	149	white	white	ADJ
chd-155	1	150	/	/	SYM
chd-155	1	151	european	european	ADJ
chd-155	1	152	american	american	PROPN
chd-155	1	153	(	(	PUNCT
chd-155	1	154	ea	ea	NOUN
chd-155	1	155	)	)	PUNCT
chd-155	1	156	men	man	NOUN
chd-155	1	157	.	.	PUNCT
chd-155	2	1	growth	growth	NOUN
chd-155	2	2	differentiation	differentiation	NOUN
chd-155	2	3	factor	factor	NOUN
chd-155	2	4	15	15	NUM
chd-155	2	5	(	(	PUNCT
chd-155	2	6	gdf15	gdf15	NOUN
chd-155	2	7	,	,	PUNCT
chd-155	2	8	pdf	pdf	NOUN
chd-155	2	9	,	,	PUNCT
chd-155	2	10	nag-1	nag-1	NOUN
chd-155	2	11	)	)	PUNCT
chd-155	2	12	is	be	AUX
chd-155	2	13	a	a	DET
chd-155	2	14	stressinduced	stressinduced	ADJ
chd-155	2	15	anti	anti	ADJ
chd-155	2	16	-	-	ADJ
chd-155	2	17	inflammatory	inflammatory	ADJ
chd-155	2	18	cytokine	cytokine	NOUN
chd-155	2	19	with	with	ADP
chd-155	2	20	immunosuppressive	immunosuppressive	ADJ
chd-155	2	21	and	and	CCONJ
chd-155	2	22	tumor	tumor	NOUN
chd-155	2	23	growth	growth	NOUN
chd-155	2	24	-	-	PUNCT
chd-155	2	25	promoting	promote	VERB
chd-155	2	26	functions	function	NOUN
chd-155	2	27	.	.	PUNCT
chd-155	3	1	gdf15	gdf15	PROPN
chd-155	3	2	inversely	inversely	ADV
chd-155	3	3	regulates	regulate	VERB
chd-155	3	4	nfκb	nfκb	NOUN
chd-155	3	5	,	,	PUNCT
chd-155	3	6	a	a	DET
chd-155	3	7	transcription	transcription	NOUN
chd-155	3	8	factor	factor	NOUN
chd-155	3	9	enabling	enable	VERB
chd-155	3	10	pro	pro	ADJ
chd-155	3	11	-	-	ADJ
chd-155	3	12	inflammatory	inflammatory	ADJ
chd-155	3	13	gene	gene	NOUN
chd-155	3	14	expression	expression	NOUN
chd-155	3	15	and	and	CCONJ
chd-155	3	16	becomes	becomes	AUX
chd-155	3	17	constitutively	constitutively	ADV
chd-155	3	18	activated	activate	VERB
chd-155	3	19	in	in	ADP
chd-155	3	20	androgen	androgen	NOUN
chd-155	3	21	-	-	PUNCT
chd-155	3	22	independent	independent	ADJ
chd-155	3	23	pc	pc	NOUN
chd-155	3	24	.	.	PUNCT
chd-155	4	1	tissue	tissue	NOUN
chd-155	4	2	microarrays	microarray	NOUN
chd-155	4	3	(	(	PUNCT
chd-155	4	4	tmas	tma	NOUN
chd-155	4	5	)	)	PUNCT
chd-155	4	6	,	,	PUNCT
chd-155	4	7	prepared	prepare	VERB
chd-155	4	8	from	from	ADP
chd-155	4	9	prostatectomy	prostatectomy	ADP
chd-155	4	10	tissue	tissue	NOUN
chd-155	4	11	at	at	ADP
chd-155	4	12	three	three	NUM
chd-155	4	13	institutions	institution	NOUN
chd-155	4	14	,	,	PUNCT
chd-155	4	15	comprised	comprise	VERB
chd-155	4	16	688	688	NUM
chd-155	4	17	cases	case	NOUN
chd-155	4	18	(	(	PUNCT
chd-155	4	19	364	364	NUM
chd-155	4	20	ea	ea	NOUN
chd-155	4	21	and	and	CCONJ
chd-155	4	22	324	324	NUM
chd-155	4	23	aa	aa	NOUN
chd-155	4	24	)	)	PUNCT
chd-155	4	25	.	.	PUNCT
chd-155	5	1	each	each	DET
chd-155	5	2	case	case	NOUN
chd-155	5	3	included	include	VERB
chd-155	5	4	≥3	≥3	PROPN
chd-155	5	5	tumor	tumor	NOUN
chd-155	5	6	punches	punch	NOUN
chd-155	5	7	plus	plus	CCONJ
chd-155	5	8	≥3	≥3	PROPN
chd-155	5	9	non	non	ADJ
chd-155	5	10	-	-	ADJ
chd-155	5	11	neoplastic	neoplastic	ADJ
chd-155	5	12	punches	punch	NOUN
chd-155	5	13	.	.	PUNCT
chd-155	6	1	tmas	tmas	PROPN
chd-155	6	2	were	be	AUX
chd-155	6	3	stained	stain	VERB
chd-155	6	4	separately	separately	ADV
chd-155	6	5	for	for	ADP
chd-155	6	6	gdf15	gdf15	NOUN
chd-155	6	7	and	and	CCONJ
chd-155	6	8	nfκb	nfκb	NOUN
chd-155	6	9	and	and	CCONJ
chd-155	6	10	evaluated	evaluate	VERB
chd-155	6	11	by	by	ADP
chd-155	6	12	two	two	NUM
chd-155	6	13	pathologists	pathologist	NOUN
chd-155	6	14	,	,	PUNCT
chd-155	6	15	using	use	VERB
chd-155	6	16	the	the	DET
chd-155	6	17	0	0	NUM
chd-155	6	18	-	-	SYM
chd-155	6	19	3	3	NUM
chd-155	6	20	+	+	NUM
chd-155	6	21	scale	scale	NOUN
chd-155	6	22	.	.	PUNCT
chd-155	7	1	pc	pc	NOUN
chd-155	7	2	,	,	PUNCT
chd-155	7	3	compared	compare	VERB
chd-155	7	4	to	to	ADP
chd-155	7	5	benign	benign	ADJ
chd-155	7	6	epithelium	epithelium	NOUN
chd-155	7	7	,	,	PUNCT
chd-155	7	8	had	have	VERB
chd-155	7	9	elevated	elevate	VERB
chd-155	7	10	median	median	ADJ
chd-155	7	11	gdf15	gdf15	NOUN
chd-155	7	12	expression	expression	NOUN
chd-155	7	13	(	(	PUNCT
chd-155	7	14	1.93	1.93	NUM
chd-155	7	15	vs.	vs.	ADP
chd-155	7	16	0.99	0.99	NUM
chd-155	7	17	)	)	PUNCT
chd-155	7	18	and	and	CCONJ
chd-155	7	19	also	also	ADV
chd-155	7	20	,	,	PUNCT
chd-155	7	21	nfκb	nfκb	NOUN
chd-155	7	22	(	(	PUNCT
chd-155	7	23	1.18	1.18	NUM
chd-155	7	24	vs.	vs.	ADP
chd-155	7	25	0.96	0.96	NUM
chd-155	7	26	,	,	PUNCT
chd-155	7	27	both	both	DET
chd-155	7	28	p<0.0001	p<0.0001	NOUN
chd-155	7	29	)	)	PUNCT
chd-155	7	30	.	.	PUNCT
chd-155	8	1	only	only	ADV
chd-155	8	2	in	in	ADP
chd-155	8	3	aa	aa	PROPN
chd-155	8	4	men	man	NOUN
chd-155	8	5	did	do	VERB
chd-155	8	6	pc	pc	NOUN
chd-155	8	7	show	show	NOUN
chd-155	8	8	gradewise	gradewise	NOUN
chd-155	8	9	or	or	CCONJ
chd-155	8	10	stagewise	stagewise	VERB
chd-155	8	11	altered	altered	ADJ
chd-155	8	12	expression	expression	NOUN
chd-155	8	13	of	of	ADP
chd-155	8	14	these	these	DET
chd-155	8	15	markers	marker	NOUN
chd-155	8	16	.	.	PUNCT
chd-155	9	1	in	in	ADP
chd-155	9	2	aa	aa	PROPN
chd-155	9	3	men	man	NOUN
chd-155	9	4	,	,	PUNCT
chd-155	9	5	gdf15	gdf15	NOUN
chd-155	9	6	expression	expression	NOUN
chd-155	9	7	fell	fall	VERB
chd-155	9	8	as	as	SCONJ
chd-155	9	9	stage	stage	NOUN
chd-155	9	10	rose	rise	VERB
chd-155	9	11	in	in	ADP
chd-155	9	12	pc	pc	NOUN
chd-155	9	13	(	(	PUNCT
chd-155	9	14	p=0.007	p=0.007	X
chd-155	9	15	)	)	PUNCT
chd-155	9	16	and	and	CCONJ
chd-155	9	17	also	also	ADV
chd-155	9	18	in	in	ADP
chd-155	9	19	benign	benign	ADJ
chd-155	9	20	epithelium	epithelium	NOUN
chd-155	9	21	(	(	PUNCT
chd-155	9	22	p	p	NOUN
chd-155	9	23	=	=	NOUN
chd-155	9	24	0.003	0.003	NUM
chd-155	9	25	)	)	PUNCT
chd-155	9	26	.	.	PUNCT
chd-155	10	1	in	in	ADP
chd-155	10	2	ea	ea	NOUN
chd-155	10	3	men	man	NOUN
chd-155	10	4	,	,	PUNCT
chd-155	10	5	gdf15	gdf15	ADJ
chd-155	10	6	expression	expression	NOUN
chd-155	10	7	in	in	ADP
chd-155	10	8	benign	benign	ADJ
chd-155	10	9	epithelium	epithelium	NOUN
chd-155	10	10	fell	fall	VERB
chd-155	10	11	as	as	ADP
chd-155	10	12	stage	stage	NOUN
chd-155	10	13	(	(	PUNCT
chd-155	10	14	p=0.01	p=0.01	NUM
chd-155	10	15	)	)	PUNCT
chd-155	10	16	and	and	CCONJ
chd-155	10	17	grade	grade	NOUN
chd-155	10	18	(	(	PUNCT
chd-155	10	19	p=0.01	p=0.01	NOUN
chd-155	10	20	)	)	PUNCT
chd-155	10	21	rose	rise	VERB
chd-155	10	22	.	.	PUNCT
chd-155	11	1	nfκb	nfκb	NOUN
chd-155	11	2	expression	expression	NOUN
chd-155	11	3	was	be	AUX
chd-155	11	4	higher	high	ADJ
chd-155	11	5	in	in	ADP
chd-155	11	6	aa	aa	NOUN
chd-155	11	7	than	than	ADP
chd-155	11	8	ea	ea	NOUN
chd-155	11	9	men	man	NOUN
chd-155	11	10	only	only	ADV
chd-155	11	11	in	in	ADP
chd-155	11	12	high	high	ADJ
chd-155	11	13	-	-	PUNCT
chd-155	11	14	grade	grade	NOUN
chd-155	11	15	pc	pc	NOUN
chd-155	11	16	(	(	PUNCT
chd-155	11	17	p	p	NOUN
chd-155	11	18	=	=	NOUN
chd-155	11	19	0.01	0.01	NUM
chd-155	11	20	)	)	PUNCT
chd-155	11	21	.	.	PUNCT
chd-155	12	1	nfκb	nfκb	PROPN
chd-155	12	2	expression	expression	NOUN
chd-155	12	3	rose	rise	VERB
chd-155	12	4	with	with	ADP
chd-155	12	5	increasing	increase	VERB
chd-155	12	6	tumor	tumor	NOUN
chd-155	12	7	grade	grade	NOUN
chd-155	12	8	only	only	ADV
chd-155	12	9	in	in	ADP
chd-155	12	10	aa	aa	PROPN
chd-155	12	11	men	man	NOUN
chd-155	12	12	(	(	PUNCT
chd-155	12	13	p	p	NOUN
chd-155	12	14	=	=	NOUN
chd-155	12	15	0.027	0.027	NUM
chd-155	12	16	)	)	PUNCT
chd-155	12	17	and	and	CCONJ
chd-155	12	18	in	in	ADP
chd-155	12	19	the	the	DET
chd-155	12	20	benign	benign	ADJ
chd-155	12	21	prostate	prostate	NOUN
chd-155	12	22	component	component	NOUN
chd-155	12	23	only	only	ADV
chd-155	12	24	in	in	ADP
chd-155	12	25	ea	ea	NOUN
chd-155	12	26	men	man	NOUN
chd-155	12	27	(	(	PUNCT
chd-155	12	28	p=0.007	p=0.007	X
chd-155	12	29	)	)	PUNCT
chd-155	12	30	.	.	PUNCT
chd-155	13	1	benign	benign	ADJ
chd-155	13	2	and	and	CCONJ
chd-155	13	3	tumor	tumor	NOUN
chd-155	13	4	nfκb	nfκb	NOUN
chd-155	13	5	expression	expression	NOUN
chd-155	13	6	did	do	AUX
chd-155	13	7	not	not	PART
chd-155	13	8	vary	vary	VERB
chd-155	13	9	with	with	ADP
chd-155	13	10	stage	stage	NOUN
chd-155	13	11	.	.	PUNCT
chd-155	14	1	pc	pc	NOUN
chd-155	14	2	showed	show	VERB
chd-155	14	3	significant	significant	ADJ
chd-155	14	4	alterations	alteration	NOUN
chd-155	14	5	in	in	ADP
chd-155	14	6	gdf15	gdf15	NOUN
chd-155	14	7	and	and	CCONJ
chd-155	14	8	nfκb	nfκb	ADJ
chd-155	14	9	expression	expression	NOUN
chd-155	14	10	in	in	ADP
chd-155	14	11	accord	accord	NOUN
chd-155	14	12	with	with	ADP
chd-155	14	13	cancer	cancer	NOUN
chd-155	14	14	aggressiveness	aggressiveness	NOUN
chd-155	14	15	in	in	ADP
chd-155	14	16	aa	aa	PROPN
chd-155	14	17	men	man	NOUN
chd-155	14	18	only	only	ADV
chd-155	14	19	:	:	PUNCT
chd-155	14	20	stagewise	stagewise	VERB
chd-155	14	21	decrease	decrease	NOUN
chd-155	14	22	in	in	ADP
chd-155	14	23	gdf15	gdf15	NOUN
chd-155	14	24	,	,	PUNCT
chd-155	14	25	and	and	CCONJ
chd-155	14	26	gradewide	gradewide	NOUN
chd-155	14	27	increase	increase	NOUN
chd-155	14	28	in	in	ADP
chd-155	14	29	nfκb	nfκb	NOUN
chd-155	14	30	.	.	PUNCT
chd-155	15	1	findings	finding	NOUN
chd-155	15	2	suggest	suggest	VERB
chd-155	15	3	a	a	DET
chd-155	15	4	racial	racial	ADJ
chd-155	15	5	disparity	disparity	NOUN
chd-155	15	6	in	in	ADP
chd-155	15	7	cell	cell	NOUN
chd-155	15	8	growth	growth	NOUN
chd-155	15	9	,	,	PUNCT
chd-155	15	10	immune	immune	ADJ
chd-155	15	11	response	response	NOUN
chd-155	15	12	,	,	PUNCT
chd-155	15	13	stress	stress	NOUN
chd-155	15	14	response	response	NOUN
chd-155	15	15	,	,	PUNCT
chd-155	15	16	or	or	CCONJ
chd-155	15	17	other	other	ADJ
chd-155	15	18	functions	function	NOUN
chd-155	15	19	relevant	relevant	ADJ
chd-155	15	20	to	to	ADP
chd-155	15	21	prostate	prostate	NOUN
chd-155	15	22	carcinogenesis	carcinogenesis	NOUN
chd-155	15	23	.	.	PUNCT
chd-155	16	1	keywords	keyword	NOUN
chd-155	16	2	:	:	PUNCT
chd-155	16	3	racial	racial	ADJ
chd-155	16	4	disparity	disparity	NOUN
chd-155	16	5	,	,	PUNCT
chd-155	16	6	prostate	prostate	NOUN
chd-155	16	7	cancer	cancer	NOUN
chd-155	16	8	,	,	PUNCT
chd-155	16	9	gdf15	gdf15	NOUN
chd-155	16	10	,	,	PUNCT
chd-155	16	11	nfκb	nfκb	NOUN
chd-155	16	12	.	.	PUNCT
chd-155	17	1	citation	citation	NOUN
chd-155	17	2	:	:	PUNCT
chd-155	17	3	iczkowski1	iczkowski1	X
chd-155	17	4	et	et	PROPN
chd-155	17	5	al	al	PROPN
chd-155	17	6	(	(	PUNCT
chd-155	17	7	2021	2021	NUM
chd-155	17	8	)	)	PUNCT
chd-155	17	9	racial	racial	ADJ
chd-155	17	10	disparities	disparity	NOUN
chd-155	17	11	in	in	ADP
chd-155	17	12	expression	expression	NOUN
chd-155	17	13	of	of	ADP
chd-155	17	14	gdf15	gdf15	NOUN
chd-155	17	15	and	and	CCONJ
chd-155	17	16	nfκb	nfκb	NOUN
chd-155	17	17	in	in	ADP
chd-155	17	18	prostate	prostate	NOUN
chd-155	17	19	cancer	cancer	NOUN
chd-155	17	20	and	and	CCONJ
chd-155	17	21	benign	benign	ADJ
chd-155	17	22	prostatic	prostatic	ADJ
chd-155	17	23	epithelium	epithelium	NOUN
chd-155	17	24	.	.	PUNCT
chd-155	18	1	cancer	cancer	NOUN
chd-155	18	2	health	health	NOUN
chd-155	18	3	disparities	disparity	NOUN
chd-155	18	4	.	.	PUNCT
chd-155	19	1	5	5	NUM
chd-155	19	2	:	:	PUNCT
chd-155	19	3	e1	e1	NOUN
chd-155	19	4	-	-	PUNCT
chd-155	19	5	e22	e22	NOUN
chd-155	19	6	.	.	PUNCT
chd-155	20	1	doi:10.9777	doi:10.9777	PROPN
chd-155	20	2	/	/	SYM
chd-155	20	3	chd.2020.1010	chd.2020.1010	PROPN
chd-155	20	4	mailto:kaiczkowski@mcw.edu	mailto:kaiczkowski@mcw.edu	PROPN
chd-155	20	5	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-155	20	6	e2	e2	PROPN
chd-155	20	7	cancer	cancer	NOUN
chd-155	20	8	health	health	NOUN
chd-155	20	9	disparities	disparity	NOUN
chd-155	20	10	research	research	NOUN
chd-155	20	11	introduction	introduction	NOUN
chd-155	20	12	african	african	ADJ
chd-155	20	13	-	-	PUNCT
chd-155	20	14	american	american	ADJ
chd-155	20	15	(	(	PUNCT
chd-155	20	16	aa	aa	NOUN
chd-155	20	17	)	)	PUNCT
chd-155	20	18	men	man	NOUN
chd-155	20	19	generally	generally	ADV
chd-155	20	20	have	have	VERB
chd-155	20	21	worse	bad	ADJ
chd-155	20	22	prostate	prostate	NOUN
chd-155	20	23	cancer	cancer	NOUN
chd-155	20	24	(	(	PUNCT
chd-155	20	25	pc	pc	NOUN
chd-155	20	26	)	)	PUNCT
chd-155	20	27	outcomes	outcome	NOUN
chd-155	20	28	than	than	ADP
chd-155	20	29	white	white	ADJ
chd-155	20	30	/	/	SYM
chd-155	20	31	european	european	ADJ
chd-155	20	32	american	american	PROPN
chd-155	20	33	(	(	PUNCT
chd-155	20	34	ea	ea	NOUN
chd-155	20	35	)	)	PUNCT
chd-155	20	36	men	man	NOUN
chd-155	20	37	or	or	CCONJ
chd-155	20	38	other	other	ADJ
chd-155	20	39	races	race	NOUN
chd-155	20	40	.	.	PUNCT
chd-155	21	1	the	the	DET
chd-155	21	2	role	role	NOUN
chd-155	21	3	of	of	ADP
chd-155	21	4	chronic	chronic	ADJ
chd-155	21	5	inflammation	inflammation	NOUN
chd-155	21	6	in	in	ADP
chd-155	21	7	development	development	NOUN
chd-155	21	8	of	of	ADP
chd-155	21	9	prostate	prostate	NOUN
chd-155	21	10	cancer	cancer	NOUN
chd-155	21	11	is	be	AUX
chd-155	21	12	well	well	ADV
chd-155	21	13	documented	document	VERB
chd-155	21	14	(	(	PUNCT
chd-155	21	15	puhr	puhr	NOUN
chd-155	21	16	et	et	PROPN
chd-155	21	17	al	al	PROPN
chd-155	21	18	.	.	PROPN
chd-155	21	19	,	,	PUNCT
chd-155	21	20	2016	2016	NUM
chd-155	21	21	)	)	PUNCT
chd-155	21	22	.	.	PUNCT
chd-155	22	1	lymphocytic	lymphocytic	ADJ
chd-155	22	2	infiltration	infiltration	NOUN
chd-155	22	3	is	be	AUX
chd-155	22	4	normal	normal	ADJ
chd-155	22	5	in	in	ADP
chd-155	22	6	the	the	DET
chd-155	22	7	prostate	prostate	NOUN
chd-155	22	8	(	(	PUNCT
chd-155	22	9	bostwick	bostwick	PROPN
chd-155	22	10	et	et	PROPN
chd-155	22	11	al	al	PROPN
chd-155	22	12	.	.	PROPN
chd-155	22	13	,	,	PUNCT
chd-155	22	14	2003	2003	NUM
chd-155	22	15	)	)	PUNCT
chd-155	22	16	,	,	PUNCT
chd-155	22	17	but	but	CCONJ
chd-155	22	18	whether	whether	SCONJ
chd-155	22	19	there	there	PRON
chd-155	22	20	are	be	VERB
chd-155	22	21	racial	racial	ADJ
chd-155	22	22	differences	difference	NOUN
chd-155	22	23	in	in	ADP
chd-155	22	24	the	the	DET
chd-155	22	25	level	level	NOUN
chd-155	22	26	of	of	ADP
chd-155	22	27	prostatic	prostatic	ADJ
chd-155	22	28	inflammation	inflammation	NOUN
chd-155	22	29	is	be	AUX
chd-155	22	30	unclear	unclear	ADJ
chd-155	22	31	.	.	PUNCT
chd-155	23	1	immune	immune	ADJ
chd-155	23	2	response	response	NOUN
chd-155	23	3	-	-	PUNCT
chd-155	23	4	associated	associate	VERB
chd-155	23	5	gene	gene	NOUN
chd-155	23	6	expression	expression	NOUN
chd-155	23	7	differs	differ	VERB
chd-155	23	8	between	between	ADP
chd-155	23	9	aa	aa	PROPN
chd-155	23	10	and	and	CCONJ
chd-155	23	11	ea	ea	NOUN
chd-155	23	12	prostate	prostate	NOUN
chd-155	23	13	cancers	cancer	NOUN
chd-155	23	14	(	(	PUNCT
chd-155	23	15	wallace	wallace	PROPN
chd-155	23	16	et	et	PROPN
chd-155	23	17	al	al	PROPN
chd-155	23	18	.	.	PROPN
chd-155	23	19	,	,	PUNCT
chd-155	23	20	2008	2008	NUM
chd-155	23	21	)	)	PUNCT
chd-155	23	22	;	;	PUNCT
chd-155	23	23	and	and	CCONJ
chd-155	23	24	some	some	DET
chd-155	23	25	studies	study	NOUN
chd-155	23	26	have	have	AUX
chd-155	23	27	found	find	VERB
chd-155	23	28	chronic	chronic	ADJ
chd-155	23	29	inflammation	inflammation	NOUN
chd-155	23	30	to	to	PART
chd-155	23	31	be	be	AUX
chd-155	23	32	more	more	ADV
chd-155	23	33	frequent	frequent	ADJ
chd-155	23	34	in	in	ADP
chd-155	23	35	aa	aa	PROPN
chd-155	23	36	men	man	NOUN
chd-155	23	37	(	(	PUNCT
chd-155	23	38	eastham	eastham	PROPN
chd-155	23	39	et	et	PROPN
chd-155	23	40	al	al	PROPN
chd-155	23	41	.	.	PROPN
chd-155	23	42	,	,	PUNCT
chd-155	23	43	1998	1998	NUM
chd-155	23	44	)	)	PUNCT
chd-155	23	45	while	while	SCONJ
chd-155	23	46	others	other	NOUN
chd-155	23	47	have	have	AUX
chd-155	23	48	noted	note	VERB
chd-155	23	49	no	no	DET
chd-155	23	50	difference	difference	NOUN
chd-155	23	51	(	(	PUNCT
chd-155	23	52	bostwick	bostwick	PROPN
chd-155	23	53	et	et	PROPN
chd-155	23	54	al	al	PROPN
chd-155	23	55	.	.	PROPN
chd-155	23	56	,	,	PUNCT
chd-155	23	57	2003	2003	NUM
chd-155	23	58	;	;	PUNCT
chd-155	23	59	vidal	vidal	PROPN
chd-155	23	60	et	et	PROPN
chd-155	23	61	al	al	PROPN
chd-155	23	62	.	.	PROPN
chd-155	23	63	,	,	PUNCT
chd-155	23	64	2016	2016	NUM
chd-155	23	65	)	)	PUNCT
chd-155	23	66	although	although	SCONJ
chd-155	23	67	the	the	DET
chd-155	23	68	studies	study	NOUN
chd-155	23	69	reporting	report	VERB
chd-155	23	70	no	no	DET
chd-155	23	71	difference	difference	NOUN
chd-155	23	72	did	do	AUX
chd-155	23	73	not	not	PART
chd-155	23	74	distinguish	distinguish	VERB
chd-155	23	75	types	type	NOUN
chd-155	23	76	of	of	ADP
chd-155	23	77	inflammatory	inflammatory	ADJ
chd-155	23	78	cells	cell	NOUN
chd-155	23	79	and	and	CCONJ
chd-155	23	80	digital	digital	ADJ
chd-155	23	81	quantification	quantification	NOUN
chd-155	23	82	was	be	AUX
chd-155	23	83	not	not	PART
chd-155	23	84	used	use	VERB
chd-155	23	85	.	.	PUNCT
chd-155	24	1	observed	observed	ADJ
chd-155	24	2	differences	difference	NOUN
chd-155	24	3	were	be	AUX
chd-155	24	4	not	not	PART
chd-155	24	5	accounted	account	VERB
chd-155	24	6	for	for	ADP
chd-155	24	7	by	by	ADP
chd-155	24	8	race	race	NOUN
chd-155	24	9	-	-	PUNCT
chd-155	24	10	related	relate	VERB
chd-155	24	11	differences	difference	NOUN
chd-155	24	12	in	in	ADP
chd-155	24	13	patients	patient	NOUN
chd-155	24	14	'	'	PART
chd-155	24	15	age	age	NOUN
chd-155	24	16	,	,	PUNCT
chd-155	24	17	serum	serum	NOUN
chd-155	24	18	testosterone	testosterone	NOUN
chd-155	24	19	level	level	NOUN
chd-155	24	20	,	,	PUNCT
chd-155	24	21	or	or	CCONJ
chd-155	24	22	prostate	prostate	NOUN
chd-155	24	23	volume	volume	NOUN
chd-155	24	24	(	(	PUNCT
chd-155	24	25	eastham	eastham	PROPN
chd-155	24	26	et	et	PROPN
chd-155	24	27	al	al	PROPN
chd-155	24	28	.	.	PROPN
chd-155	24	29	,	,	PUNCT
chd-155	24	30	1998	1998	NUM
chd-155	24	31	)	)	PUNCT
chd-155	24	32	.	.	PUNCT
chd-155	25	1	although	although	SCONJ
chd-155	25	2	many	many	ADJ
chd-155	25	3	studies	study	NOUN
chd-155	25	4	have	have	AUX
chd-155	25	5	shown	show	VERB
chd-155	25	6	that	that	SCONJ
chd-155	25	7	interaction	interaction	NOUN
chd-155	25	8	of	of	ADP
chd-155	25	9	inflammatory	inflammatory	ADJ
chd-155	25	10	cytokines	cytokine	NOUN
chd-155	25	11	with	with	ADP
chd-155	25	12	inflammatory	inflammatory	ADJ
chd-155	25	13	pathways	pathway	NOUN
chd-155	25	14	greatly	greatly	ADV
chd-155	25	15	influence	influence	VERB
chd-155	25	16	prostate	prostate	NOUN
chd-155	25	17	cancer	cancer	NOUN
chd-155	25	18	risk	risk	NOUN
chd-155	25	19	,	,	PUNCT
chd-155	25	20	the	the	DET
chd-155	25	21	role	role	NOUN
chd-155	25	22	of	of	ADP
chd-155	25	23	some	some	DET
chd-155	25	24	cytokines	cytokine	NOUN
chd-155	25	25	such	such	ADJ
chd-155	25	26	as	as	ADP
chd-155	25	27	growth	growth	NOUN
chd-155	25	28	differentiation	differentiation	NOUN
chd-155	25	29	factor	factor	NOUN
chd-155	25	30	15	15	NUM
chd-155	25	31	(	(	PUNCT
chd-155	25	32	gdf15	gdf15	NOUN
chd-155	25	33	)	)	PUNCT
chd-155	25	34	in	in	ADP
chd-155	25	35	prostate	prostate	NOUN
chd-155	25	36	cancer	cancer	NOUN
chd-155	25	37	is	be	AUX
chd-155	25	38	ambiguous	ambiguous	ADJ
chd-155	25	39	(	(	PUNCT
chd-155	25	40	vaňhara	vaňhara	NOUN
chd-155	25	41	et	et	NOUN
chd-155	25	42	al	al	PROPN
chd-155	25	43	.	.	PROPN
chd-155	25	44	,	,	PUNCT
chd-155	25	45	2012	2012	NUM
chd-155	25	46	)	)	PUNCT
chd-155	25	47	.	.	PUNCT
chd-155	26	1	gdf15	gdf15	NOUN
chd-155	26	2	,	,	PUNCT
chd-155	26	3	also	also	ADV
chd-155	26	4	called	call	VERB
chd-155	26	5	prostate	prostate	NOUN
chd-155	26	6	-	-	PUNCT
chd-155	26	7	derived	derive	VERB
chd-155	26	8	factor	factor	NOUN
chd-155	26	9	or	or	CCONJ
chd-155	26	10	pdf	pdf	NOUN
chd-155	26	11	,	,	PUNCT
chd-155	26	12	nag-1	nag-1	NOUN
chd-155	26	13	,	,	PUNCT
chd-155	26	14	or	or	CCONJ
chd-155	26	15	mic-1	mic-1	NOUN
chd-155	26	16	,	,	PUNCT
chd-155	26	17	is	be	AUX
chd-155	26	18	a	a	DET
chd-155	26	19	stress	stress	NOUN
chd-155	26	20	-	-	PUNCT
chd-155	26	21	induced	induce	VERB
chd-155	26	22	anti	anti	ADJ
chd-155	26	23	-	-	ADJ
chd-155	26	24	inflammatory	inflammatory	ADJ
chd-155	26	25	cytokine	cytokine	NOUN
chd-155	26	26	possessing	possess	VERB
chd-155	26	27	immunomodulatory	immunomodulatory	ADJ
chd-155	26	28	functions	function	NOUN
chd-155	26	29	.	.	PUNCT
chd-155	27	1	it	it	PRON
chd-155	27	2	is	be	AUX
chd-155	27	3	known	know	VERB
chd-155	27	4	to	to	PART
chd-155	27	5	interact	interact	VERB
chd-155	27	6	with	with	ADP
chd-155	27	7	nuclear	nuclear	ADJ
chd-155	27	8	factor	factor	NOUN
chd-155	27	9	of	of	ADP
chd-155	27	10	kappa	kappa	PROPN
chd-155	27	11	b	b	PROPN
chd-155	27	12	(	(	PUNCT
chd-155	27	13	nfκb	nfκb	PROPN
chd-155	27	14	)	)	PUNCT
chd-155	27	15	which	which	PRON
chd-155	27	16	regulates	regulate	VERB
chd-155	27	17	genes	gene	NOUN
chd-155	27	18	involved	involve	VERB
chd-155	27	19	in	in	ADP
chd-155	27	20	cellular	cellular	ADJ
chd-155	27	21	proliferation	proliferation	NOUN
chd-155	27	22	,	,	PUNCT
chd-155	27	23	apoptosis	apoptosis	NOUN
chd-155	27	24	,	,	PUNCT
chd-155	27	25	migration	migration	NOUN
chd-155	27	26	and	and	CCONJ
chd-155	27	27	angiogenesis	angiogenesis	NOUN
chd-155	27	28	(	(	PUNCT
chd-155	27	29	bennett	bennett	PROPN
chd-155	27	30	et	et	PROPN
chd-155	27	31	al	al	PROPN
chd-155	27	32	.	.	PROPN
chd-155	27	33	,	,	PUNCT
chd-155	27	34	2018	2018	NUM
chd-155	27	35	)	)	PUNCT
chd-155	27	36	.	.	PUNCT
chd-155	28	1	gdf15	gdf15	PROPN
chd-155	28	2	is	be	AUX
chd-155	28	3	known	know	VERB
chd-155	28	4	to	to	PART
chd-155	28	5	have	have	VERB
chd-155	28	6	both	both	CCONJ
chd-155	28	7	pro	pro	ADJ
chd-155	28	8	-	-	ADJ
chd-155	28	9	tumorigenic	tumorigenic	ADJ
chd-155	28	10	and	and	CCONJ
chd-155	28	11	tumorsuppressing	tumorsuppressing	NOUN
chd-155	28	12	functions	function	NOUN
chd-155	28	13	.	.	PUNCT
chd-155	29	1	gdf15	gdf15	NOUN
chd-155	29	2	is	be	AUX
chd-155	29	3	a	a	DET
chd-155	29	4	divergent	divergent	ADJ
chd-155	29	5	member	member	NOUN
chd-155	29	6	of	of	ADP
chd-155	29	7	the	the	DET
chd-155	29	8	tgf	tgf	PROPN
chd-155	29	9	-	-	PUNCT
chd-155	29	10	β	β	PROPN
chd-155	29	11	and	and	CCONJ
chd-155	29	12	bone	bone	NOUN
chd-155	29	13	morphogenic	morphogenic	ADJ
chd-155	29	14	protein	protein	NOUN
chd-155	29	15	family	family	NOUN
chd-155	29	16	.	.	PUNCT
chd-155	30	1	it	it	PRON
chd-155	30	2	directly	directly	ADV
chd-155	30	3	induces	induce	VERB
chd-155	30	4	p53	p53	NOUN
chd-155	30	5	,	,	PUNCT
chd-155	30	6	and	and	CCONJ
chd-155	30	7	its	its	PRON
chd-155	30	8	high	high	ADJ
chd-155	30	9	expression	expression	NOUN
chd-155	30	10	is	be	AUX
chd-155	30	11	associated	associate	VERB
chd-155	30	12	with	with	ADP
chd-155	30	13	progression	progression	NOUN
chd-155	30	14	of	of	ADP
chd-155	30	15	several	several	ADJ
chd-155	30	16	cancers	cancer	NOUN
chd-155	30	17	,	,	PUNCT
chd-155	30	18	including	include	VERB
chd-155	30	19	pc	pc	NOUN
chd-155	30	20	(	(	PUNCT
chd-155	30	21	iczkowski	iczkowski	NOUN
chd-155	30	22	and	and	CCONJ
chd-155	30	23	pantazis	pantazi	NOUN
chd-155	30	24	,	,	PUNCT
chd-155	30	25	2003	2003	NUM
chd-155	30	26	)	)	PUNCT
chd-155	30	27	.	.	PUNCT
chd-155	31	1	gdf15	gdf15	PROPN
chd-155	31	2	was	be	AUX
chd-155	31	3	found	find	VERB
chd-155	31	4	to	to	PART
chd-155	31	5	be	be	AUX
chd-155	31	6	upregulated	upregulate	VERB
chd-155	31	7	in	in	ADP
chd-155	31	8	situ	situ	NOUN
chd-155	31	9	and	and	CCONJ
chd-155	31	10	in	in	ADP
chd-155	31	11	primary	primary	ADJ
chd-155	31	12	cultures	culture	NOUN
chd-155	31	13	of	of	ADP
chd-155	31	14	cancerassociated	cancerassociate	VERB
chd-155	31	15	fibroblasts	fibroblast	NOUN
chd-155	31	16	from	from	ADP
chd-155	31	17	prostate	prostate	NOUN
chd-155	31	18	cancer	cancer	NOUN
chd-155	31	19	.	.	PUNCT
chd-155	32	1	ectopic	ectopic	ADJ
chd-155	32	2	expression	expression	NOUN
chd-155	32	3	of	of	ADP
chd-155	32	4	gdf15	gdf15	NOUN
chd-155	32	5	in	in	ADP
chd-155	32	6	fibroblasts	fibroblast	NOUN
chd-155	32	7	produced	produce	VERB
chd-155	32	8	prominent	prominent	ADJ
chd-155	32	9	paracrine	paracrine	NOUN
chd-155	32	10	effects	effect	NOUN
chd-155	32	11	on	on	ADP
chd-155	32	12	pc	pc	NOUN
chd-155	32	13	cell	cell	NOUN
chd-155	32	14	migration	migration	NOUN
chd-155	32	15	,	,	PUNCT
chd-155	32	16	invasion	invasion	NOUN
chd-155	32	17	,	,	PUNCT
chd-155	32	18	and	and	CCONJ
chd-155	32	19	tumor	tumor	NOUN
chd-155	32	20	growth	growth	NOUN
chd-155	32	21	(	(	PUNCT
chd-155	32	22	bruzzese	bruzzese	NOUN
chd-155	32	23	et	et	PROPN
chd-155	32	24	al	al	PROPN
chd-155	32	25	.	.	PROPN
chd-155	32	26	,	,	PUNCT
chd-155	32	27	2014	2014	NUM
chd-155	32	28	)	)	PUNCT
chd-155	32	29	and	and	CCONJ
chd-155	32	30	the	the	DET
chd-155	32	31	same	same	ADJ
chd-155	32	32	effects	effect	NOUN
chd-155	32	33	were	be	AUX
chd-155	32	34	noted	note	VERB
chd-155	32	35	in	in	ADP
chd-155	32	36	cervical	cervical	ADJ
chd-155	32	37	cancer	cancer	NOUN
chd-155	32	38	(	(	PUNCT
chd-155	32	39	li	li	PROPN
chd-155	32	40	et	et	PROPN
chd-155	32	41	al	al	PROPN
chd-155	32	42	.	.	PROPN
chd-155	32	43	,	,	PUNCT
chd-155	32	44	2018	2018	NUM
chd-155	32	45	)	)	PUNCT
chd-155	32	46	.	.	PUNCT
chd-155	33	1	consistent	consistent	ADJ
chd-155	33	2	with	with	ADP
chd-155	33	3	an	an	DET
chd-155	33	4	anti	anti	ADJ
chd-155	33	5	-	-	ADJ
chd-155	33	6	inflammatory	inflammatory	ADJ
chd-155	33	7	role	role	NOUN
chd-155	33	8	,	,	PUNCT
chd-155	33	9	inflammatory	inflammatory	ADJ
chd-155	33	10	lesions	lesion	NOUN
chd-155	33	11	in	in	ADP
chd-155	33	12	the	the	DET
chd-155	33	13	prostate	prostate	NOUN
chd-155	33	14	correlated	correlate	VERB
chd-155	33	15	with	with	ADP
chd-155	33	16	decreased	decrease	VERB
chd-155	33	17	prostatic	prostatic	ADJ
chd-155	33	18	gdf15	gdf15	NOUN
chd-155	33	19	expression	expression	NOUN
chd-155	33	20	(	(	PUNCT
chd-155	33	21	lambert	lambert	PROPN
chd-155	33	22	et	et	PROPN
chd-155	33	23	al	al	PROPN
chd-155	33	24	.	.	PROPN
chd-155	33	25	,	,	PUNCT
chd-155	33	26	2015	2015	NUM
chd-155	33	27	)	)	PUNCT
chd-155	33	28	.	.	PUNCT
chd-155	34	1	moreover	moreover	ADV
chd-155	34	2	,	,	PUNCT
chd-155	34	3	an	an	DET
chd-155	34	4	inverse	inverse	NOUN
chd-155	34	5	correlation	correlation	NOUN
chd-155	34	6	was	be	AUX
chd-155	34	7	demonstrated	demonstrate	VERB
chd-155	34	8	between	between	ADP
chd-155	34	9	gdf15	gdf15	NOUN
chd-155	34	10	and	and	CCONJ
chd-155	34	11	cd3	cd3	VERB
chd-155	34	12	+	+	PROPN
chd-155	34	13	,	,	PUNCT
chd-155	34	14	cd4	cd4	PROPN
chd-155	34	15	+	+	PROPN
chd-155	34	16	,	,	PUNCT
chd-155	34	17	cd8	cd8	PROPN
chd-155	34	18	+	+	PROPN
chd-155	34	19	,	,	PUNCT
chd-155	34	20	cd68	cd68	PROPN
chd-155	34	21	+	+	PROPN
chd-155	34	22	,	,	PUNCT
chd-155	34	23	and	and	CCONJ
chd-155	34	24	inos	ino	NOUN
chd-155	34	25	(	(	PUNCT
chd-155	34	26	no	no	DET
chd-155	34	27	synthase)+	synthase)+	ADP
chd-155	34	28	leukocytes	leukocyte	NOUN
chd-155	34	29	(	(	PUNCT
chd-155	34	30	bennett	bennett	PROPN
chd-155	34	31	et	et	PROPN
chd-155	34	32	al	al	PROPN
chd-155	34	33	.	.	PROPN
chd-155	34	34	,	,	PUNCT
chd-155	34	35	2018	2018	NUM
chd-155	34	36	)	)	PUNCT
chd-155	34	37	;	;	PUNCT
chd-155	34	38	and	and	CCONJ
chd-155	34	39	gdf15	gdf15	NOUN
chd-155	34	40	exerts	exert	VERB
chd-155	34	41	immunosuppressive	immunosuppressive	ADJ
chd-155	34	42	effects	effect	NOUN
chd-155	34	43	(	(	PUNCT
chd-155	34	44	zhang	zhang	X
chd-155	34	45	et	et	PROPN
chd-155	34	46	al	al	PROPN
chd-155	34	47	.	.	PROPN
chd-155	34	48	,	,	PUNCT
chd-155	34	49	2018	2018	NUM
chd-155	34	50	)	)	PUNCT
chd-155	34	51	.	.	PUNCT
chd-155	35	1	nuclear	nuclear	ADJ
chd-155	35	2	factor	factor	NOUN
chd-155	35	3	kappa	kappa	ADJ
chd-155	35	4	-	-	ADJ
chd-155	35	5	light	light	ADJ
chd-155	35	6	-	-	PUNCT
chd-155	35	7	chain	chain	NOUN
chd-155	35	8	-	-	PUNCT
chd-155	35	9	enhancer	enhancer	NOUN
chd-155	35	10	of	of	ADP
chd-155	35	11	activated	activate	VERB
chd-155	35	12	b	b	NOUN
chd-155	35	13	cells	cell	NOUN
chd-155	35	14	,	,	PUNCT
chd-155	35	15	nfκb	nfκb	NOUN
chd-155	35	16	is	be	AUX
chd-155	35	17	a	a	DET
chd-155	35	18	transcription	transcription	NOUN
chd-155	35	19	factor	factor	NOUN
chd-155	35	20	(	(	PUNCT
chd-155	35	21	also	also	ADV
chd-155	35	22	called	call	VERB
chd-155	35	23	p65(rela	p65(rela	PROPN
chd-155	35	24	)	)	PUNCT
chd-155	35	25	)	)	PUNCT
chd-155	35	26	that	that	PRON
chd-155	35	27	regulates	regulate	VERB
chd-155	35	28	pro	pro	ADJ
chd-155	35	29	-	-	ADJ
chd-155	35	30	inflammatory	inflammatory	ADJ
chd-155	35	31	gene	gene	NOUN
chd-155	35	32	expression	expression	NOUN
chd-155	35	33	and	and	CCONJ
chd-155	35	34	is	be	AUX
chd-155	35	35	constitutively	constitutively	ADV
chd-155	35	36	activated	activate	VERB
chd-155	35	37	in	in	ADP
chd-155	35	38	androgen	androgen	NOUN
chd-155	35	39	-	-	PUNCT
chd-155	35	40	independent	independent	ADJ
chd-155	35	41	prostate	prostate	NOUN
chd-155	35	42	cancer	cancer	NOUN
chd-155	35	43	,	,	PUNCT
chd-155	35	44	increasing	increase	VERB
chd-155	35	45	anti	anti	ADJ
chd-155	35	46	-	-	ADJ
chd-155	35	47	apoptotic	apoptotic	ADJ
chd-155	35	48	bcl-2	bcl-2	NOUN
chd-155	35	49	and	and	CCONJ
chd-155	35	50	angiogenesis	angiogenesis	NOUN
chd-155	35	51	(	(	PUNCT
chd-155	35	52	jin	jin	NOUN
chd-155	35	53	et	et	PROPN
chd-155	35	54	al	al	PROPN
chd-155	35	55	.	.	PROPN
chd-155	35	56	,	,	PUNCT
chd-155	35	57	2008	2008	NUM
chd-155	35	58	)	)	PUNCT
chd-155	35	59	.	.	PUNCT
chd-155	36	1	gdf15	gdf15	ADJ
chd-155	36	2	expression	expression	NOUN
chd-155	36	3	was	be	AUX
chd-155	36	4	shown	show	VERB
chd-155	36	5	to	to	PART
chd-155	36	6	correlate	correlate	VERB
chd-155	36	7	inversely	inversely	ADV
chd-155	36	8	with	with	ADP
chd-155	36	9	inflammatory	inflammatory	ADJ
chd-155	36	10	lesions	lesion	NOUN
chd-155	36	11	in	in	ADP
chd-155	36	12	the	the	DET
chd-155	36	13	prostate	prostate	NOUN
chd-155	36	14	and	and	CCONJ
chd-155	36	15	acts	act	VERB
chd-155	36	16	through	through	ADP
chd-155	36	17	the	the	DET
chd-155	36	18	pi3k	pi3k	PROPN
chd-155	36	19	pathway	pathway	NOUN
chd-155	36	20	to	to	PART
chd-155	36	21	suppress	suppress	VERB
chd-155	36	22	nfκb	nfκb	ADJ
chd-155	36	23	activity	activity	NOUN
chd-155	36	24	(	(	PUNCT
chd-155	36	25	lambert	lambert	PROPN
chd-155	36	26	et	et	PROPN
chd-155	36	27	al	al	PROPN
chd-155	36	28	.	.	PROPN
chd-155	36	29	,	,	PUNCT
chd-155	36	30	2015	2015	NUM
chd-155	36	31	)	)	PUNCT
chd-155	36	32	;	;	PUNCT
chd-155	36	33	cervical	cervical	ADJ
chd-155	36	34	cancer	cancer	NOUN
chd-155	36	35	demonstrated	demonstrate	VERB
chd-155	36	36	this	this	DET
chd-155	36	37	same	same	ADJ
chd-155	36	38	inverse	inverse	NOUN
chd-155	36	39	relationship	relationship	NOUN
chd-155	36	40	(	(	PUNCT
chd-155	36	41	li	li	PROPN
chd-155	36	42	et	et	PROPN
chd-155	36	43	al	al	PROPN
chd-155	36	44	.	.	PROPN
chd-155	36	45	,	,	PUNCT
chd-155	36	46	2018	2018	NUM
chd-155	36	47	)	)	PUNCT
chd-155	36	48	.	.	PUNCT
chd-155	37	1	expression	expression	NOUN
chd-155	37	2	of	of	ADP
chd-155	37	3	the	the	DET
chd-155	37	4	nfκb	nfκb	NOUN
chd-155	37	5	target	target	NOUN
chd-155	37	6	,	,	PUNCT
chd-155	37	7	interleukin	interleukin	NOUN
chd-155	37	8	8	8	NUM
chd-155	37	9	(	(	PUNCT
chd-155	37	10	il-8	il-8	NUM
chd-155	37	11	)	)	PUNCT
chd-155	37	12	,	,	PUNCT
chd-155	37	13	was	be	AUX
chd-155	37	14	downregulated	downregulate	VERB
chd-155	37	15	by	by	ADP
chd-155	37	16	gdf15	gdf15	NOUN
chd-155	37	17	in	in	ADP
chd-155	37	18	pc3	pc3	PROPN
chd-155	37	19	cells	cell	NOUN
chd-155	37	20	(	(	PUNCT
chd-155	37	21	lambert	lambert	PROPN
chd-155	37	22	et	et	PROPN
chd-155	37	23	al	al	PROPN
chd-155	37	24	.	.	PROPN
chd-155	37	25	,	,	PUNCT
chd-155	37	26	2015	2015	NUM
chd-155	37	27	)	)	PUNCT
chd-155	37	28	.	.	PUNCT
chd-155	38	1	whether	whether	SCONJ
chd-155	38	2	these	these	DET
chd-155	38	3	pro	pro	ADJ
chd-155	38	4	-	-	ADJ
chd-155	38	5	tumorigenic	tumorigenic	ADJ
chd-155	38	6	factors	factor	NOUN
chd-155	38	7	show	show	VERB
chd-155	38	8	a	a	DET
chd-155	38	9	racial	racial	ADJ
chd-155	38	10	disparity	disparity	NOUN
chd-155	38	11	in	in	ADP
chd-155	38	12	pc	pc	NOUN
chd-155	38	13	is	be	AUX
chd-155	38	14	uncertain	uncertain	ADJ
chd-155	38	15	.	.	PUNCT
chd-155	39	1	in	in	ADP
chd-155	39	2	this	this	DET
chd-155	39	3	study	study	NOUN
chd-155	39	4	we	we	PRON
chd-155	39	5	examined	examine	VERB
chd-155	39	6	immunoexpression	immunoexpression	NOUN
chd-155	39	7	of	of	ADP
chd-155	39	8	gdf15	gdf15	NOUN
chd-155	39	9	and	and	CCONJ
chd-155	39	10	nfκb	nfκb	NOUN
chd-155	39	11	in	in	ADP
chd-155	39	12	tissue	tissue	NOUN
chd-155	39	13	from	from	ADP
chd-155	39	14	african	african	ADJ
chd-155	39	15	-	-	PUNCT
chd-155	39	16	american	american	ADJ
chd-155	39	17	and	and	CCONJ
chd-155	39	18	white	white	ADJ
chd-155	39	19	cancerous	cancerous	ADJ
chd-155	39	20	and	and	CCONJ
chd-155	39	21	benign	benign	ADJ
chd-155	39	22	prostate	prostate	NOUN
chd-155	39	23	.	.	PUNCT
chd-155	40	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-155	40	2	e3	e3	NOUN
chd-155	40	3	cancer	cancer	NOUN
chd-155	40	4	health	health	NOUN
chd-155	40	5	disparities	disparity	NOUN
chd-155	40	6	research	research	NOUN
chd-155	40	7	materials	material	NOUN
chd-155	40	8	and	and	CCONJ
chd-155	40	9	methods	method	NOUN
chd-155	40	10	retrospective	retrospective	ADJ
chd-155	40	11	study	study	NOUN
chd-155	40	12	in	in	ADP
chd-155	40	13	prostatectomy	prostatectomy	ADP
chd-155	40	14	tissue	tissue	NOUN
chd-155	40	15	tissue	tissue	NOUN
chd-155	40	16	microarrays	microarray	NOUN
chd-155	40	17	(	(	PUNCT
chd-155	40	18	tmas	tma	NOUN
chd-155	40	19	)	)	PUNCT
chd-155	40	20	,	,	PUNCT
chd-155	40	21	prepared	prepare	VERB
chd-155	40	22	at	at	ADP
chd-155	40	23	three	three	NUM
chd-155	40	24	different	different	ADJ
chd-155	40	25	institutions	institution	NOUN
chd-155	40	26	,	,	PUNCT
chd-155	40	27	comprised	comprise	VERB
chd-155	40	28	prostatectomy	prostatectomy	ADP
chd-155	40	29	tissue	tissue	NOUN
chd-155	40	30	from	from	ADP
chd-155	40	31	697	697	NUM
chd-155	40	32	cases	case	NOUN
chd-155	40	33	.	.	PUNCT
chd-155	41	1	each	each	DET
chd-155	41	2	tma	tma	PROPN
chd-155	41	3	contained	contain	VERB
chd-155	41	4	at	at	ADP
chd-155	41	5	least	least	ADV
chd-155	41	6	3	3	NUM
chd-155	41	7	individual	individual	ADJ
chd-155	41	8	0.6	0.6	NUM
chd-155	41	9	mm	mm	NOUN
chd-155	41	10	punches	punch	NOUN
chd-155	41	11	of	of	ADP
chd-155	41	12	the	the	DET
chd-155	41	13	dominant	dominant	ADJ
chd-155	41	14	tumor	tumor	NOUN
chd-155	41	15	nodule	nodule	NOUN
chd-155	41	16	plus	plus	CCONJ
chd-155	41	17	at	at	ADP
chd-155	41	18	least	least	ADJ
chd-155	41	19	3	3	NUM
chd-155	41	20	punches	punch	NOUN
chd-155	41	21	of	of	ADP
chd-155	41	22	non	non	ADJ
chd-155	41	23	-	-	ADJ
chd-155	41	24	neoplastic	neoplastic	ADJ
chd-155	41	25	epithelium	epithelium	NOUN
chd-155	41	26	.	.	PUNCT
chd-155	42	1	sources	source	NOUN
chd-155	42	2	were	be	AUX
chd-155	42	3	medical	medical	ADJ
chd-155	42	4	college	college	PROPN
chd-155	42	5	of	of	ADP
chd-155	42	6	wisconsin	wisconsin	PROPN
chd-155	42	7	(	(	PUNCT
chd-155	42	8	57	57	NUM
chd-155	42	9	cases	case	NOUN
chd-155	42	10	)	)	PUNCT
chd-155	42	11	,	,	PUNCT
chd-155	42	12	prostate	prostate	NOUN
chd-155	42	13	cancer	cancer	NOUN
chd-155	42	14	biorepository	biorepository	NOUN
chd-155	42	15	network	network	NOUN
chd-155	42	16	(	(	PUNCT
chd-155	42	17	pcbn	pcbn	NOUN
chd-155	42	18	,	,	PUNCT
chd-155	42	19	via	via	ADP
chd-155	42	20	johns	johns	PROPN
chd-155	42	21	hopkins	hopkins	PROPN
chd-155	42	22	)	)	PUNCT
chd-155	42	23	(	(	PUNCT
chd-155	42	24	153	153	NUM
chd-155	42	25	cases	case	NOUN
chd-155	42	26	)	)	PUNCT
chd-155	42	27	,	,	PUNCT
chd-155	42	28	pcbn	pcbn	VERB
chd-155	42	29	high	high	ADJ
chd-155	42	30	-	-	PUNCT
chd-155	42	31	grade	grade	NOUN
chd-155	42	32	racial	racial	ADJ
chd-155	42	33	disparity	disparity	NOUN
chd-155	42	34	(	(	PUNCT
chd-155	42	35	120	120	NUM
chd-155	42	36	cases	case	NOUN
chd-155	42	37	)	)	PUNCT
chd-155	42	38	,	,	PUNCT
chd-155	42	39	and	and	CCONJ
chd-155	42	40	henry	henry	PROPN
chd-155	42	41	ford	ford	PROPN
chd-155	42	42	hospital	hospital	PROPN
chd-155	42	43	(	(	PUNCT
chd-155	42	44	up	up	ADP
chd-155	42	45	to	to	PART
chd-155	42	46	12	12	NUM
chd-155	42	47	evaluable	evaluable	ADJ
chd-155	42	48	cores	core	NOUN
chd-155	42	49	each	each	PRON
chd-155	42	50	of	of	ADP
chd-155	42	51	tumor	tumor	NOUN
chd-155	42	52	and	and	CCONJ
chd-155	42	53	benign	benign	ADJ
chd-155	42	54	,	,	PUNCT
chd-155	42	55	367	367	NUM
chd-155	42	56	cases	case	NOUN
chd-155	42	57	)	)	PUNCT
chd-155	42	58	.	.	PUNCT
chd-155	43	1	each	each	DET
chd-155	43	2	study	study	NOUN
chd-155	43	3	set	set	NOUN
chd-155	43	4	contained	contain	VERB
chd-155	43	5	an	an	DET
chd-155	43	6	approximate	approximate	ADJ
chd-155	43	7	1:1	1:1	NUM
chd-155	43	8	match	match	NOUN
chd-155	43	9	of	of	ADP
chd-155	43	10	aa	aa	NOUN
chd-155	43	11	to	to	ADP
chd-155	43	12	white	white	ADJ
chd-155	43	13	cases	case	NOUN
chd-155	43	14	,	,	PUNCT
chd-155	43	15	based	base	VERB
chd-155	43	16	on	on	ADP
chd-155	43	17	grade	grade	NOUN
chd-155	43	18	and	and	CCONJ
chd-155	43	19	stage	stage	NOUN
chd-155	43	20	,	,	PUNCT
chd-155	43	21	for	for	ADP
chd-155	43	22	a	a	DET
chd-155	43	23	total	total	NOUN
chd-155	43	24	of	of	ADP
chd-155	43	25	364	364	NUM
chd-155	43	26	ea	ea	NOUN
chd-155	43	27	and	and	CCONJ
chd-155	43	28	324	324	NUM
chd-155	43	29	aa	aa	NOUN
chd-155	43	30	men	man	NOUN
chd-155	43	31	.	.	PUNCT
chd-155	44	1	gleason	gleason	PROPN
chd-155	44	2	score	score	PROPN
chd-155	44	3	according	accord	VERB
chd-155	44	4	to	to	ADP
chd-155	44	5	current	current	ADJ
chd-155	44	6	consensus	consensus	NOUN
chd-155	44	7	(	(	PUNCT
chd-155	44	8	epstein	epstein	PROPN
chd-155	44	9	et	et	PROPN
chd-155	44	10	al	al	PROPN
chd-155	44	11	.	.	PROPN
chd-155	44	12	,	,	PUNCT
chd-155	44	13	2016	2016	NUM
chd-155	44	14	)	)	PUNCT
chd-155	44	15	and	and	CCONJ
chd-155	44	16	tumor	tumor	NOUN
chd-155	44	17	pathologic	pathologic	ADJ
chd-155	44	18	stage	stage	NOUN
chd-155	44	19	(	(	PUNCT
chd-155	44	20	pt	pt	X
chd-155	44	21	)	)	PUNCT
chd-155	44	22	were	be	AUX
chd-155	44	23	available	available	ADJ
chd-155	44	24	for	for	ADP
chd-155	44	25	all	all	DET
chd-155	44	26	groups	group	NOUN
chd-155	44	27	;	;	PUNCT
chd-155	44	28	for	for	ADP
chd-155	44	29	analysis	analysis	NOUN
chd-155	44	30	,	,	PUNCT
chd-155	44	31	grade	grade	NOUN
chd-155	44	32	was	be	AUX
chd-155	44	33	expressed	express	VERB
chd-155	44	34	according	accord	VERB
chd-155	44	35	to	to	ADP
chd-155	44	36	the	the	DET
chd-155	44	37	5tier	5tier	NUM
chd-155	44	38	international	international	ADJ
chd-155	44	39	society	society	NOUN
chd-155	44	40	of	of	ADP
chd-155	44	41	urological	urological	ADJ
chd-155	44	42	pathology	pathology	NOUN
chd-155	44	43	(	(	PUNCT
chd-155	44	44	isup	isup	NOUN
chd-155	44	45	)	)	PUNCT
chd-155	44	46	grade	grade	NOUN
chd-155	44	47	group	group	NOUN
chd-155	44	48	system	system	NOUN
chd-155	44	49	(	(	PUNCT
chd-155	44	50	epstein	epstein	PROPN
chd-155	44	51	et	et	PROPN
chd-155	44	52	al	al	PROPN
chd-155	44	53	.	.	PROPN
chd-155	44	54	,	,	PUNCT
chd-155	44	55	2016	2016	NUM
chd-155	44	56	)	)	PUNCT
chd-155	44	57	.	.	PUNCT
chd-155	45	1	patient	patient	ADJ
chd-155	45	2	ages	age	NOUN
chd-155	45	3	were	be	AUX
chd-155	45	4	available	available	ADJ
chd-155	45	5	only	only	ADV
chd-155	45	6	for	for	ADP
chd-155	45	7	the	the	DET
chd-155	45	8	henry	henry	PROPN
chd-155	45	9	ford	ford	PROPN
chd-155	45	10	and	and	CCONJ
chd-155	45	11	medical	medical	ADJ
chd-155	45	12	college	college	PROPN
chd-155	45	13	of	of	ADP
chd-155	45	14	wisconsin	wisconsin	PROPN
chd-155	45	15	cases	case	NOUN
chd-155	45	16	.	.	PUNCT
chd-155	46	1	the	the	DET
chd-155	46	2	results	result	NOUN
chd-155	46	3	from	from	ADP
chd-155	46	4	two	two	NUM
chd-155	46	5	hopkins	hopkin	NOUN
chd-155	46	6	study	study	NOUN
chd-155	46	7	sets	set	NOUN
chd-155	46	8	were	be	AUX
chd-155	46	9	combined	combine	VERB
chd-155	46	10	in	in	ADP
chd-155	46	11	all	all	DET
chd-155	46	12	analyses	analysis	NOUN
chd-155	46	13	going	go	VERB
chd-155	46	14	forward	forward	ADV
chd-155	46	15	.	.	PUNCT
chd-155	47	1	separate	separate	ADJ
chd-155	47	2	slides	slide	NOUN
chd-155	47	3	were	be	AUX
chd-155	47	4	stained	stain	VERB
chd-155	47	5	with	with	ADP
chd-155	47	6	polyclonal	polyclonal	ADJ
chd-155	47	7	antibody	antibody	NOUN
chd-155	47	8	to	to	ADP
chd-155	47	9	gdf15	gdf15	NOUN
chd-155	47	10	or	or	CCONJ
chd-155	47	11	monoclonal	monoclonal	NOUN
chd-155	47	12	antibody	antibody	NOUN
chd-155	47	13	to	to	ADP
chd-155	47	14	nfκb	nfκb	NOUN
chd-155	47	15	.	.	PUNCT
chd-155	48	1	slides	slide	NOUN
chd-155	48	2	were	be	AUX
chd-155	48	3	dried	dry	VERB
chd-155	48	4	30	30	NUM
chd-155	48	5	min	min	NOUN
chd-155	48	6	at	at	ADP
chd-155	48	7	60	60	NUM
chd-155	48	8	°	°	NOUN
chd-155	48	9	c	c	NOUN
chd-155	48	10	,	,	PUNCT
chd-155	48	11	then	then	ADV
chd-155	48	12	deparaffinized	deparaffinize	VERB
chd-155	48	13	down	down	ADP
chd-155	48	14	to	to	ADP
chd-155	48	15	deionized	deionize	VERB
chd-155	48	16	water	water	NOUN
chd-155	48	17	.	.	PUNCT
chd-155	49	1	antigen	antigen	PROPN
chd-155	49	2	retrieval	retrieval	NOUN
chd-155	49	3	was	be	AUX
chd-155	49	4	performed	perform	VERB
chd-155	49	5	on	on	ADP
chd-155	49	6	a	a	DET
chd-155	49	7	pt	pt	NOUN
chd-155	49	8	link	link	NOUN
chd-155	49	9	(	(	PUNCT
chd-155	49	10	dako	dako	PROPN
chd-155	49	11	)	)	PUNCT
chd-155	49	12	by	by	ADP
chd-155	49	13	preheating	preheat	VERB
chd-155	49	14	target	target	NOUN
chd-155	49	15	retrieval	retrieval	NOUN
chd-155	49	16	solution	solution	NOUN
chd-155	49	17	to	to	ADP
chd-155	49	18	65	65	NUM
chd-155	49	19	°	°	NOUN
chd-155	49	20	c	c	NOUN
chd-155	49	21	and	and	CCONJ
chd-155	49	22	heating	heat	VERB
chd-155	49	23	for	for	ADP
chd-155	49	24	20	20	NUM
chd-155	49	25	min	min	NOUN
chd-155	49	26	at	at	ADP
chd-155	49	27	97	97	NUM
chd-155	49	28	°	°	NOUN
chd-155	49	29	c	c	NOUN
chd-155	49	30	in	in	ADP
chd-155	49	31	ph=6	ph=6	PROPN
chd-155	49	32	(	(	PUNCT
chd-155	49	33	dako	dako	PROPN
chd-155	49	34	)	)	PUNCT
chd-155	49	35	.	.	PUNCT
chd-155	50	1	slides	slide	NOUN
chd-155	50	2	were	be	AUX
chd-155	50	3	washed	wash	VERB
chd-155	50	4	with	with	ADP
chd-155	50	5	buffer	buffer	NOUN
chd-155	50	6	for	for	ADP
chd-155	50	7	5	5	NUM
chd-155	50	8	minutes	minute	NOUN
chd-155	50	9	.	.	PUNCT
chd-155	51	1	all	all	DET
chd-155	51	2	ihc	ihc	PROPN
chd-155	51	3	staining	stain	VERB
chd-155	51	4	was	be	AUX
chd-155	51	5	performed	perform	VERB
chd-155	51	6	on	on	ADP
chd-155	51	7	the	the	DET
chd-155	51	8	dako	dako	PROPN
chd-155	51	9	autostainer	autostainer	NOUN
chd-155	51	10	plus	plus	CCONJ
chd-155	51	11	(	(	PUNCT
chd-155	51	12	agilent	agilent	PROPN
chd-155	51	13	)	)	PUNCT
chd-155	51	14	using	use	VERB
chd-155	51	15	the	the	DET
chd-155	51	16	dako	dako	PROPN
chd-155	51	17	envision	envision	NOUN
chd-155	51	18	™	™	VERB
chd-155	51	19	flex	flex	ADJ
chd-155	51	20	high	high	ADJ
chd-155	51	21	ph	ph	NOUN
chd-155	51	22	detection	detection	NOUN
chd-155	51	23	kit	kit	NOUN
chd-155	51	24	(	(	PUNCT
chd-155	51	25	catalog	catalog	NOUN
chd-155	51	26	k8010	k8010	NOUN
chd-155	51	27	)	)	PUNCT
chd-155	51	28	with	with	ADP
chd-155	51	29	3	3	NUM
chd-155	51	30	drop	drop	NOUN
chd-155	51	31	zones	zone	NOUN
chd-155	51	32	at	at	ADP
chd-155	51	33	100	100	NUM
chd-155	51	34	µl	µl	ADP
chd-155	51	35	each	each	DET
chd-155	51	36	and	and	CCONJ
chd-155	51	37	dako	dako	PROPN
chd-155	51	38	protein	protein	NOUN
chd-155	51	39	block	block	NOUN
chd-155	51	40	(	(	PUNCT
chd-155	51	41	agilent	agilent	PROPN
chd-155	51	42	)	)	PUNCT
chd-155	51	43	.	.	PUNCT
chd-155	52	1	antibodies	antibody	NOUN
chd-155	52	2	used	use	VERB
chd-155	52	3	were	be	AUX
chd-155	52	4	goat	goat	PROPN
chd-155	52	5	polyclonal	polyclonal	ADJ
chd-155	52	6	antibody	antibody	NOUN
chd-155	52	7	to	to	ADP
chd-155	52	8	gdf15	gdf15	PROPN
chd-155	52	9	(	(	PUNCT
chd-155	52	10	1:150	1:150	NUM
chd-155	52	11	,	,	PUNCT
chd-155	52	12	20	20	NUM
chd-155	52	13	min	min	NOUN
chd-155	52	14	incubation	incubation	NOUN
chd-155	52	15	,	,	PUNCT
chd-155	52	16	catalog	catalog	NOUN
chd-155	52	17	af957	af957	PROPN
chd-155	52	18	,	,	PUNCT
chd-155	52	19	r&d	r&d	NOUN
chd-155	52	20	systems	system	NOUN
chd-155	52	21	,	,	PUNCT
chd-155	52	22	minneapolis	minneapolis	PROPN
chd-155	52	23	)	)	PUNCT
chd-155	52	24	or	or	CCONJ
chd-155	52	25	rabbit	rabbit	NOUN
chd-155	52	26	monoclonal	monoclonal	NOUN
chd-155	52	27	antibody	antibody	NOUN
chd-155	52	28	to	to	ADP
chd-155	52	29	nfκb	nfκb	NOUN
chd-155	52	30	(	(	PUNCT
chd-155	52	31	1:2000	1:2000	NUM
chd-155	52	32	,	,	PUNCT
chd-155	52	33	10	10	NUM
chd-155	52	34	min	min	NOUN
chd-155	52	35	incubation	incubation	NOUN
chd-155	52	36	,	,	PUNCT
chd-155	52	37	clone	clone	NOUN
chd-155	52	38	d14e12	d14e12	NOUN
chd-155	52	39	,	,	PUNCT
chd-155	52	40	cell	cell	NOUN
chd-155	52	41	signaling	signal	VERB
chd-155	52	42	technologies	technology	NOUN
chd-155	52	43	,	,	PUNCT
chd-155	52	44	beverly	beverly	PROPN
chd-155	52	45	,	,	PUNCT
chd-155	52	46	ma	ma	PROPN
chd-155	52	47	)	)	PUNCT
chd-155	52	48	.	.	PUNCT
chd-155	53	1	background	background	NOUN
chd-155	53	2	was	be	AUX
chd-155	53	3	stained	stain	VERB
chd-155	53	4	with	with	ADP
chd-155	53	5	hematoxylin	hematoxylin	PROPN
chd-155	53	6	dako	dako	PROPN
chd-155	53	7	flex	flex	PROPN
chd-155	53	8	.	.	PUNCT
chd-155	54	1	slides	slide	NOUN
chd-155	54	2	were	be	AUX
chd-155	54	3	rinsed	rinse	VERB
chd-155	54	4	with	with	ADP
chd-155	54	5	deionized	deionize	VERB
chd-155	54	6	water	water	NOUN
chd-155	54	7	and	and	CCONJ
chd-155	54	8	oven	oven	VERB
chd-155	54	9	dried	dry	VERB
chd-155	54	10	15	15	NUM
chd-155	54	11	min	min	NOUN
chd-155	54	12	.	.	PROPN
chd-155	54	13	evaluation	evaluation	NOUN
chd-155	54	14	of	of	ADP
chd-155	54	15	immunostaining	immunostaine	VERB
chd-155	54	16	tma	tma	PROPN
chd-155	54	17	cores	core	NOUN
chd-155	54	18	of	of	ADP
chd-155	54	19	tumor	tumor	NOUN
chd-155	54	20	and	and	CCONJ
chd-155	54	21	benign	benign	ADJ
chd-155	54	22	prostatic	prostatic	ADJ
chd-155	54	23	tissue	tissue	NOUN
chd-155	54	24	for	for	ADP
chd-155	54	25	each	each	DET
chd-155	54	26	case	case	NOUN
chd-155	54	27	were	be	AUX
chd-155	54	28	evaluated	evaluate	VERB
chd-155	54	29	by	by	ADP
chd-155	54	30	two	two	NUM
chd-155	54	31	pathologists	pathologist	NOUN
chd-155	54	32	.	.	PUNCT
chd-155	55	1	(	(	PUNCT
chd-155	55	2	digital	digital	ADJ
chd-155	55	3	evaluation	evaluation	NOUN
chd-155	55	4	of	of	ADP
chd-155	55	5	the	the	DET
chd-155	55	6	tmas	tma	NOUN
chd-155	55	7	was	be	AUX
chd-155	55	8	not	not	PART
chd-155	55	9	feasible	feasible	ADJ
chd-155	55	10	because	because	SCONJ
chd-155	55	11	the	the	DET
chd-155	55	12	frequent	frequent	ADJ
chd-155	55	13	admixture	admixture	NOUN
chd-155	55	14	of	of	ADP
chd-155	55	15	tumor	tumor	NOUN
chd-155	55	16	glands	gland	NOUN
chd-155	55	17	and	and	CCONJ
chd-155	55	18	benign	benign	ADJ
chd-155	55	19	glands	gland	NOUN
chd-155	55	20	in	in	ADP
chd-155	55	21	many	many	ADJ
chd-155	55	22	spots	spot	NOUN
chd-155	55	23	required	require	VERB
chd-155	55	24	assessment	assessment	NOUN
chd-155	55	25	by	by	ADP
chd-155	55	26	pathologists	pathologist	NOUN
chd-155	55	27	.	.	PUNCT
chd-155	56	1	moreover	moreover	ADV
chd-155	56	2	,	,	PUNCT
chd-155	56	3	occasional	occasional	ADJ
chd-155	56	4	spots	spot	NOUN
chd-155	56	5	that	that	PRON
chd-155	56	6	were	be	AUX
chd-155	56	7	sampled	sample	VERB
chd-155	56	8	as	as	ADP
chd-155	56	9	benign	benign	ADJ
chd-155	56	10	were	be	AUX
chd-155	56	11	actually	actually	ADV
chd-155	56	12	cancer	cancer	NOUN
chd-155	56	13	and	and	CCONJ
chd-155	56	14	vice	vice	NOUN
chd-155	56	15	versa	versa	ADV
chd-155	56	16	,	,	PUNCT
chd-155	56	17	and	and	CCONJ
chd-155	56	18	again	again	ADV
chd-155	56	19	pathologists	pathologist	NOUN
chd-155	56	20	’	'	PUNCT
chd-155	56	21	interpretations	interpretation	NOUN
chd-155	56	22	were	be	AUX
chd-155	56	23	needed	need	VERB
chd-155	56	24	to	to	PART
chd-155	56	25	visually	visually	ADV
chd-155	56	26	dissect	dissect	VERB
chd-155	56	27	out	out	ADP
chd-155	56	28	the	the	DET
chd-155	56	29	admixture	admixture	NOUN
chd-155	56	30	and	and	CCONJ
chd-155	56	31	evaluate	evaluate	VERB
chd-155	56	32	the	the	DET
chd-155	56	33	tumor	tumor	NOUN
chd-155	56	34	or	or	CCONJ
chd-155	56	35	benign	benign	ADJ
chd-155	56	36	epithelium	epithelium	NOUN
chd-155	56	37	separately	separately	ADV
chd-155	56	38	.	.	PUNCT
chd-155	56	39	)	)	PUNCT
chd-155	57	1	immunoreactivity	immunoreactivity	NOUN
chd-155	57	2	(	(	PUNCT
chd-155	57	3	figures	figure	NOUN
chd-155	57	4	1	1	NUM
chd-155	57	5	-	-	SYM
chd-155	57	6	2	2	NUM
chd-155	57	7	)	)	PUNCT
chd-155	57	8	was	be	AUX
chd-155	57	9	scored	score	VERB
chd-155	57	10	on	on	ADP
chd-155	57	11	a	a	DET
chd-155	57	12	scale	scale	NOUN
chd-155	57	13	of	of	ADP
chd-155	57	14	0	0	NUM
chd-155	57	15	(	(	PUNCT
chd-155	57	16	negative	negative	ADJ
chd-155	57	17	)	)	PUNCT
chd-155	57	18	to	to	ADP
chd-155	57	19	3	3	NUM
chd-155	57	20	+	+	CCONJ
chd-155	57	21	(	(	PUNCT
chd-155	57	22	strong	strong	ADJ
chd-155	57	23	and	and	CCONJ
chd-155	57	24	diffuse	diffuse	NOUN
chd-155	57	25	)	)	PUNCT
chd-155	57	26	,	,	PUNCT
chd-155	57	27	including	include	VERB
chd-155	57	28	half	half	ADJ
chd-155	57	29	-	-	PUNCT
chd-155	57	30	steps	step	NOUN
chd-155	57	31	(	(	PUNCT
chd-155	57	32	0.5	0.5	NUM
chd-155	57	33	)	)	PUNCT
chd-155	57	34	.	.	PUNCT
chd-155	58	1	disagreements	disagreement	NOUN
chd-155	58	2	≥1	≥1	NUM
chd-155	58	3	were	be	AUX
chd-155	58	4	resolved	resolve	VERB
chd-155	58	5	by	by	ADP
chd-155	58	6	consensus	consensus	NOUN
chd-155	58	7	.	.	PUNCT
chd-155	59	1	figure	figure	NOUN
chd-155	59	2	1	1	NUM
chd-155	59	3	.	.	NOUN
chd-155	59	4	example	example	NOUN
chd-155	59	5	of	of	ADP
chd-155	59	6	strong	strong	ADJ
chd-155	59	7	gdf	gdf	NOUN
chd-155	59	8	reactivity	reactivity	NOUN
chd-155	59	9	in	in	ADP
chd-155	59	10	cancer	cancer	NOUN
chd-155	59	11	.	.	PUNCT
chd-155	60	1	non	non	ADJ
chd-155	60	2	-	-	ADJ
chd-155	60	3	neoplastic	neoplastic	ADJ
chd-155	60	4	glands	gland	NOUN
chd-155	60	5	at	at	ADP
chd-155	60	6	lower	low	ADJ
chd-155	60	7	left	left	NOUN
chd-155	60	8	are	be	AUX
chd-155	60	9	negative	negative	ADJ
chd-155	60	10	.	.	PUNCT
chd-155	61	1	10x	10x	NOUN
chd-155	61	2	objective	objective	NOUN
chd-155	61	3	.	.	PUNCT
chd-155	62	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-155	62	2	e4	e4	PROPN
chd-155	62	3	cancer	cancer	NOUN
chd-155	62	4	health	health	NOUN
chd-155	62	5	disparities	disparity	NOUN
chd-155	62	6	research	research	NOUN
chd-155	62	7	figure	figure	NOUN
chd-155	62	8	2	2	NUM
chd-155	62	9	.	.	NOUN
chd-155	62	10	example	example	NOUN
chd-155	62	11	of	of	ADP
chd-155	62	12	strong	strong	ADJ
chd-155	62	13	nfκb	nfκb	ADJ
chd-155	62	14	reactivity	reactivity	NOUN
chd-155	62	15	in	in	ADP
chd-155	62	16	cancer	cancer	NOUN
chd-155	62	17	.	.	PUNCT
chd-155	63	1	non	non	ADJ
chd-155	63	2	-	-	ADJ
chd-155	63	3	neoplastic	neoplastic	ADJ
chd-155	63	4	glands	gland	NOUN
chd-155	63	5	at	at	ADP
chd-155	63	6	lower	low	ADJ
chd-155	63	7	left	left	NOUN
chd-155	63	8	are	be	AUX
chd-155	63	9	negative	negative	ADJ
chd-155	63	10	.	.	PUNCT
chd-155	64	1	10x	10x	NOUN
chd-155	64	2	objective	objective	NOUN
chd-155	64	3	.	.	PUNCT
chd-155	65	1	statistical	statistical	ADJ
chd-155	65	2	analysis	analysis	NOUN
chd-155	65	3	to	to	PART
chd-155	65	4	adjust	adjust	VERB
chd-155	65	5	for	for	ADP
chd-155	65	6	potential	potential	ADJ
chd-155	65	7	batch	batch	NOUN
chd-155	65	8	effects	effect	NOUN
chd-155	65	9	from	from	ADP
chd-155	65	10	tmas	tma	NOUN
chd-155	65	11	from	from	ADP
chd-155	65	12	3	3	NUM
chd-155	65	13	sites	site	NOUN
chd-155	65	14	,	,	PUNCT
chd-155	65	15	we	we	PRON
chd-155	65	16	first	first	ADV
chd-155	65	17	digitally	digitally	ADV
chd-155	65	18	measured	measure	VERB
chd-155	65	19	the	the	DET
chd-155	65	20	expression	expression	NOUN
chd-155	65	21	of	of	ADP
chd-155	65	22	both	both	DET
chd-155	65	23	markers	marker	NOUN
chd-155	65	24	in	in	ADP
chd-155	65	25	the	the	DET
chd-155	65	26	benign	benign	ADJ
chd-155	65	27	tissue	tissue	NOUN
chd-155	65	28	spots	spot	NOUN
chd-155	65	29	corresponding	correspond	VERB
chd-155	65	30	to	to	ADP
chd-155	65	31	gleason	gleason	PROPN
chd-155	65	32	grade	grade	PROPN
chd-155	65	33	group	group	NOUN
chd-155	65	34	2	2	NUM
chd-155	65	35	tumors	tumor	NOUN
chd-155	65	36	from	from	ADP
chd-155	65	37	all	all	DET
chd-155	65	38	sites	site	NOUN
chd-155	65	39	using	use	VERB
chd-155	65	40	the	the	DET
chd-155	65	41	qupath	qupath	NOUN
chd-155	65	42	software	software	NOUN
chd-155	65	43	(	(	PUNCT
chd-155	65	44	bankhead	bankhead	PROPN
chd-155	65	45	et	et	PROPN
chd-155	65	46	al	al	PROPN
chd-155	65	47	.	.	PROPN
chd-155	65	48	,	,	PUNCT
chd-155	65	49	2017	2017	NUM
chd-155	65	50	)	)	PUNCT
chd-155	65	51	.	.	PUNCT
chd-155	66	1	in	in	ADP
chd-155	66	2	qupath	qupath	NOUN
chd-155	66	3	,	,	PUNCT
chd-155	66	4	the	the	DET
chd-155	66	5	stained	stain	VERB
chd-155	66	6	color	color	NOUN
chd-155	66	7	for	for	ADP
chd-155	66	8	a	a	DET
chd-155	66	9	marker	marker	NOUN
chd-155	66	10	(	(	PUNCT
chd-155	66	11	brown	brown	NOUN
chd-155	66	12	)	)	PUNCT
chd-155	66	13	is	be	AUX
chd-155	66	14	separated	separate	VERB
chd-155	66	15	from	from	ADP
chd-155	66	16	counter	counter	ADJ
chd-155	66	17	stain	stain	NOUN
chd-155	66	18	(	(	PUNCT
chd-155	66	19	blue	blue	ADJ
chd-155	66	20	)	)	PUNCT
chd-155	66	21	using	use	VERB
chd-155	66	22	stain	stain	NOUN
chd-155	66	23	vectors	vector	NOUN
chd-155	66	24	autoestimated	autoestimate	VERB
chd-155	66	25	by	by	ADP
chd-155	66	26	the	the	DET
chd-155	66	27	software	software	NOUN
chd-155	66	28	.	.	PUNCT
chd-155	67	1	percentage	percentage	NOUN
chd-155	67	2	of	of	ADP
chd-155	67	3	positive	positive	ADJ
chd-155	67	4	expression	expression	NOUN
chd-155	67	5	area	area	NOUN
chd-155	67	6	(	(	PUNCT
chd-155	67	7	ppea	ppea	PROPN
chd-155	67	8	)	)	PUNCT
chd-155	67	9	is	be	AUX
chd-155	67	10	determined	determine	VERB
chd-155	67	11	as	as	ADP
chd-155	67	12	the	the	DET
chd-155	67	13	ratio	ratio	NOUN
chd-155	67	14	of	of	ADP
chd-155	67	15	the	the	DET
chd-155	67	16	number	number	NOUN
chd-155	67	17	of	of	ADP
chd-155	67	18	positive	positive	ADJ
chd-155	67	19	brown	brown	ADJ
chd-155	67	20	stained	stain	VERB
chd-155	67	21	pixels	pixel	NOUN
chd-155	67	22	(	(	PUNCT
chd-155	67	23	brown	brown	ADJ
chd-155	67	24	optical	optical	ADJ
chd-155	67	25	density	density	NOUN
chd-155	67	26	(	(	PUNCT
chd-155	67	27	od	od	NOUN
chd-155	67	28	)	)	PUNCT
chd-155	67	29	>	>	X
chd-155	68	1	0.2	0.2	NUM
chd-155	68	2	)	)	PUNCT
chd-155	68	3	over	over	ADP
chd-155	68	4	total	total	ADJ
chd-155	68	5	number	number	NOUN
chd-155	68	6	of	of	ADP
chd-155	68	7	tissue	tissue	NOUN
chd-155	68	8	pixels	pixel	NOUN
chd-155	68	9	(	(	PUNCT
chd-155	68	10	overall	overall	ADV
chd-155	68	11	od	od	X
chd-155	68	12	>	>	X
chd-155	68	13	0.05	0.05	NUM
chd-155	68	14	)	)	PUNCT
chd-155	68	15	.	.	PUNCT
chd-155	69	1	the	the	DET
chd-155	69	2	average	average	ADJ
chd-155	69	3	expression	expression	NOUN
chd-155	69	4	intensity	intensity	NOUN
chd-155	69	5	(	(	PUNCT
chd-155	69	6	aei	aei	X
chd-155	69	7	)	)	PUNCT
chd-155	69	8	is	be	AUX
chd-155	69	9	calculated	calculate	VERB
chd-155	69	10	as	as	ADP
chd-155	69	11	the	the	DET
chd-155	69	12	mean	mean	ADJ
chd-155	69	13	brown	brown	NOUN
chd-155	69	14	od	od	ADV
chd-155	69	15	of	of	ADP
chd-155	69	16	positively	positively	ADV
chd-155	69	17	stained	stain	VERB
chd-155	69	18	pixels	pixel	NOUN
chd-155	69	19	.	.	PUNCT
chd-155	70	1	the	the	DET
chd-155	70	2	log	log	NOUN
chd-155	70	3	transformed	transform	VERB
chd-155	70	4	product	product	NOUN
chd-155	70	5	of	of	ADP
chd-155	70	6	ppea	ppea	NOUN
chd-155	70	7	and	and	CCONJ
chd-155	70	8	aei	aei	PROPN
chd-155	70	9	,	,	PUNCT
chd-155	70	10	log(ppea*aei	log(ppea*aei	PROPN
chd-155	70	11	)	)	PUNCT
chd-155	70	12	,	,	PUNCT
chd-155	70	13	is	be	AUX
chd-155	70	14	used	use	VERB
chd-155	70	15	as	as	ADP
chd-155	70	16	the	the	DET
chd-155	70	17	marker	marker	NOUN
chd-155	70	18	expression	expression	NOUN
chd-155	70	19	level	level	NOUN
chd-155	70	20	of	of	ADP
chd-155	70	21	a	a	DET
chd-155	70	22	subject	subject	NOUN
chd-155	70	23	.	.	PUNCT
chd-155	71	1	under	under	ADP
chd-155	71	2	the	the	DET
chd-155	71	3	assumption	assumption	NOUN
chd-155	71	4	that	that	SCONJ
chd-155	71	5	the	the	DET
chd-155	71	6	marker	marker	NOUN
chd-155	71	7	expression	expression	NOUN
chd-155	71	8	in	in	ADP
chd-155	71	9	benign	benign	ADJ
chd-155	71	10	regions	region	NOUN
chd-155	71	11	of	of	ADP
chd-155	71	12	gleason	gleason	PROPN
chd-155	71	13	grade	grade	PROPN
chd-155	71	14	group	group	NOUN
chd-155	71	15	2	2	NUM
chd-155	71	16	tumors	tumor	NOUN
chd-155	71	17	should	should	AUX
chd-155	71	18	be	be	AUX
chd-155	71	19	the	the	DET
chd-155	71	20	same	same	ADJ
chd-155	71	21	across	across	ADP
chd-155	71	22	the	the	DET
chd-155	71	23	3	3	NUM
chd-155	71	24	study	study	NOUN
chd-155	71	25	sites	site	NOUN
chd-155	71	26	,	,	PUNCT
chd-155	71	27	the	the	DET
chd-155	71	28	batch	batch	NOUN
chd-155	71	29	correction	correction	NOUN
chd-155	71	30	factor	factor	NOUN
chd-155	71	31	for	for	ADP
chd-155	71	32	a	a	DET
chd-155	71	33	study	study	NOUN
chd-155	71	34	site	site	NOUN
chd-155	71	35	with	with	ADP
chd-155	71	36	respect	respect	NOUN
chd-155	71	37	to	to	ADP
chd-155	71	38	the	the	DET
chd-155	71	39	reference	reference	NOUN
chd-155	71	40	henry	henry	PROPN
chd-155	71	41	ford	ford	PROPN
chd-155	71	42	study	study	PROPN
chd-155	71	43	site	site	NOUN
chd-155	71	44	was	be	AUX
chd-155	71	45	defined	define	VERB
chd-155	71	46	as	as	ADP
chd-155	71	47	the	the	DET
chd-155	71	48	ratio	ratio	NOUN
chd-155	71	49	of	of	ADP
chd-155	71	50	median	median	ADJ
chd-155	71	51	marker	marker	NOUN
chd-155	71	52	expression	expression	NOUN
chd-155	71	53	level	level	NOUN
chd-155	71	54	for	for	ADP
chd-155	71	55	the	the	DET
chd-155	71	56	benign	benign	ADJ
chd-155	71	57	prostate	prostate	NOUN
chd-155	71	58	spots	spot	NOUN
chd-155	71	59	evaluated	evaluate	VERB
chd-155	71	60	for	for	ADP
chd-155	71	61	the	the	DET
chd-155	71	62	study	study	NOUN
chd-155	71	63	site	site	NOUN
chd-155	71	64	over	over	ADP
chd-155	71	65	median	median	ADJ
chd-155	71	66	marker	marker	NOUN
chd-155	71	67	expression	expression	NOUN
chd-155	71	68	level	level	NOUN
chd-155	71	69	of	of	ADP
chd-155	71	70	benign	benign	ADJ
chd-155	71	71	prostate	prostate	NOUN
chd-155	71	72	spots	spot	NOUN
chd-155	71	73	of	of	ADP
chd-155	71	74	the	the	DET
chd-155	71	75	henry	henry	PROPN
chd-155	71	76	ford	ford	PROPN
chd-155	71	77	study	study	PROPN
chd-155	71	78	site	site	NOUN
chd-155	71	79	.	.	PUNCT
chd-155	72	1	subsequently	subsequently	ADV
chd-155	72	2	,	,	PUNCT
chd-155	72	3	all	all	DET
chd-155	72	4	pathologist	pathologist	NOUN
chd-155	72	5	-	-	PUNCT
chd-155	72	6	assessed	assess	VERB
chd-155	72	7	data	datum	NOUN
chd-155	72	8	for	for	ADP
chd-155	72	9	each	each	DET
chd-155	72	10	study	study	NOUN
chd-155	72	11	site	site	NOUN
chd-155	72	12	were	be	AUX
chd-155	72	13	adjusted	adjust	VERB
chd-155	72	14	by	by	ADP
chd-155	72	15	dividing	divide	VERB
chd-155	72	16	original	original	ADJ
chd-155	72	17	measures	measure	NOUN
chd-155	72	18	over	over	ADP
chd-155	72	19	the	the	DET
chd-155	72	20	batch	batch	NOUN
chd-155	72	21	correction	correction	NOUN
chd-155	72	22	factor	factor	NOUN
chd-155	72	23	(	(	PUNCT
chd-155	72	24	the	the	DET
chd-155	72	25	reference	reference	NOUN
chd-155	72	26	henry	henry	PROPN
chd-155	72	27	ford	ford	PROPN
chd-155	72	28	site	site	NOUN
chd-155	72	29	had	have	VERB
chd-155	72	30	a	a	DET
chd-155	72	31	batch	batch	NOUN
chd-155	72	32	correction	correction	NOUN
chd-155	72	33	factor	factor	NOUN
chd-155	72	34	of	of	ADP
chd-155	72	35	1	1	NUM
chd-155	72	36	)	)	PUNCT
chd-155	72	37	.	.	PUNCT
chd-155	73	1	mean	mean	VERB
chd-155	73	2	age	age	NOUN
chd-155	73	3	difference	difference	NOUN
chd-155	73	4	between	between	ADP
chd-155	73	5	races	race	NOUN
chd-155	73	6	was	be	AUX
chd-155	73	7	tested	test	VERB
chd-155	73	8	by	by	ADP
chd-155	73	9	wilcoxon	wilcoxon	PROPN
chd-155	73	10	signed	sign	VERB
chd-155	73	11	rank	rank	NOUN
chd-155	73	12	test	test	NOUN
chd-155	73	13	.	.	PUNCT
chd-155	74	1	comparisons	comparison	NOUN
chd-155	74	2	of	of	ADP
chd-155	74	3	expression	expression	NOUN
chd-155	74	4	in	in	ADP
chd-155	74	5	pc	pc	NOUN
chd-155	74	6	vs.	vs.	ADP
chd-155	74	7	benign	benign	ADJ
chd-155	74	8	prostate	prostate	NOUN
chd-155	74	9	were	be	AUX
chd-155	74	10	done	do	VERB
chd-155	74	11	by	by	ADP
chd-155	74	12	wilcoxon	wilcoxon	PROPN
chd-155	74	13	signed	sign	VERB
chd-155	74	14	rank	rank	NOUN
chd-155	74	15	test	test	NOUN
chd-155	74	16	.	.	PUNCT
chd-155	75	1	the	the	DET
chd-155	75	2	non	non	ADJ
chd-155	75	3	-	-	ADJ
chd-155	75	4	parametric	parametric	ADJ
chd-155	75	5	mann	mann	PROPN
chd-155	75	6	-	-	PUNCT
chd-155	75	7	whitney	whitney	PROPN
chd-155	75	8	test	test	NOUN
chd-155	75	9	was	be	AUX
chd-155	75	10	used	use	VERB
chd-155	75	11	for	for	ADP
chd-155	75	12	testing	test	VERB
chd-155	75	13	expression	expression	NOUN
chd-155	75	14	differences	difference	NOUN
chd-155	75	15	between	between	ADP
chd-155	75	16	two	two	NUM
chd-155	75	17	races	race	NOUN
chd-155	75	18	.	.	PUNCT
chd-155	76	1	kruskal	kruskal	PROPN
chd-155	76	2	-	-	PUNCT
chd-155	76	3	wallis	wallis	PROPN
chd-155	76	4	test	test	NOUN
chd-155	76	5	was	be	AUX
chd-155	76	6	applied	apply	VERB
chd-155	76	7	for	for	ADP
chd-155	76	8	testing	testing	NOUN
chd-155	76	9	expression	expression	NOUN
chd-155	76	10	differences	difference	NOUN
chd-155	76	11	across	across	ADP
chd-155	76	12	tumor	tumor	NOUN
chd-155	76	13	stages	stage	NOUN
chd-155	76	14	(	(	PUNCT
chd-155	76	15	pt2	pt2	NOUN
chd-155	76	16	,	,	PUNCT
chd-155	76	17	pt3a	pt3a	PROPN
chd-155	76	18	,	,	PUNCT
chd-155	76	19	or	or	CCONJ
chd-155	76	20	pt3b	pt3b	NOUN
chd-155	76	21	)	)	PUNCT
chd-155	76	22	and	and	CCONJ
chd-155	76	23	gleason	gleason	PROPN
chd-155	76	24	grade	grade	NOUN
chd-155	76	25	groups	group	NOUN
chd-155	76	26	(	(	PUNCT
chd-155	76	27	isup	isup	ADJ
chd-155	76	28	groups	group	NOUN
chd-155	76	29	1	1	NUM
chd-155	76	30	-	-	SYM
chd-155	76	31	5	5	NUM
chd-155	76	32	)	)	PUNCT
chd-155	76	33	.	.	PUNCT
chd-155	77	1	correlation	correlation	NOUN
chd-155	77	2	of	of	ADP
chd-155	77	3	the	the	DET
chd-155	77	4	two	two	NUM
chd-155	77	5	markers	marker	NOUN
chd-155	77	6	with	with	ADP
chd-155	77	7	each	each	DET
chd-155	77	8	other	other	ADJ
chd-155	77	9	(	(	PUNCT
chd-155	77	10	in	in	ADP
chd-155	77	11	benign	benign	NOUN
chd-155	77	12	or	or	CCONJ
chd-155	77	13	tumor	tumor	NOUN
chd-155	77	14	)	)	PUNCT
chd-155	77	15	was	be	AUX
chd-155	77	16	examined	examine	VERB
chd-155	77	17	by	by	ADP
chd-155	77	18	pearson	pearson	PROPN
chd-155	77	19	and	and	CCONJ
chd-155	77	20	spearman	spearman	NOUN
chd-155	77	21	correlation	correlation	NOUN
chd-155	77	22	tests	test	NOUN
chd-155	77	23	.	.	PUNCT
chd-155	78	1	statistical	statistical	ADJ
chd-155	78	2	significance	significance	NOUN
chd-155	78	3	was	be	AUX
chd-155	78	4	set	set	VERB
chd-155	78	5	at	at	ADP
chd-155	78	6	p	p	X
chd-155	78	7	<	<	X
chd-155	78	8	0.05	0.05	NUM
chd-155	78	9	.	.	PUNCT
chd-155	79	1	results	result	VERB
chd-155	79	2	the	the	DET
chd-155	79	3	racial	racial	ADJ
chd-155	79	4	distribution	distribution	NOUN
chd-155	79	5	of	of	ADP
chd-155	79	6	cases	case	NOUN
chd-155	79	7	did	do	AUX
chd-155	79	8	not	not	PART
chd-155	79	9	differ	differ	VERB
chd-155	79	10	by	by	ADP
chd-155	79	11	grade	grade	NOUN
chd-155	79	12	(	(	PUNCT
chd-155	79	13	p=0.9	p=0.9	NOUN
chd-155	79	14	)	)	PUNCT
chd-155	79	15	or	or	CCONJ
chd-155	79	16	pt	pt	NOUN
chd-155	79	17	stage	stage	NOUN
chd-155	79	18	(	(	PUNCT
chd-155	79	19	2	2	NUM
chd-155	79	20	,	,	PUNCT
chd-155	79	21	3a	3a	NUM
chd-155	79	22	,	,	PUNCT
chd-155	79	23	or	or	CCONJ
chd-155	79	24	3b	3b	NUM
chd-155	79	25	)	)	PUNCT
chd-155	79	26	(	(	PUNCT
chd-155	79	27	p=0.9	p=0.9	NOUN
chd-155	79	28	)	)	PUNCT
chd-155	79	29	.	.	PUNCT
chd-155	80	1	the	the	DET
chd-155	80	2	mean	mean	ADJ
chd-155	80	3	age	age	NOUN
chd-155	80	4	of	of	ADP
chd-155	80	5	aa	aa	PROPN
chd-155	80	6	men	man	NOUN
chd-155	80	7	was	be	AUX
chd-155	80	8	60.7	60.7	NUM
chd-155	80	9	;	;	PUNCT
chd-155	80	10	this	this	PRON
chd-155	80	11	was	be	AUX
chd-155	80	12	less	less	ADJ
chd-155	80	13	than	than	ADP
chd-155	80	14	for	for	ADP
chd-155	80	15	ea	ea	NOUN
chd-155	80	16	men	man	NOUN
chd-155	80	17	at	at	ADP
chd-155	80	18	62.2	62.2	NUM
chd-155	80	19	(	(	PUNCT
chd-155	80	20	p=0.03	p=0.03	ADJ
chd-155	80	21	)	)	PUNCT
chd-155	80	22	.	.	PUNCT
chd-155	81	1	gdf15	gdf15	ADJ
chd-155	81	2	reactivity	reactivity	NOUN
chd-155	81	3	was	be	AUX
chd-155	81	4	cytoplasmic	cytoplasmic	ADJ
chd-155	81	5	,	,	PUNCT
chd-155	81	6	while	while	SCONJ
chd-155	81	7	nfκb	nfκb	ADJ
chd-155	81	8	reactivity	reactivity	NOUN
chd-155	81	9	was	be	AUX
chd-155	81	10	both	both	CCONJ
chd-155	81	11	cytoplasmic	cytoplasmic	ADJ
chd-155	81	12	and	and	CCONJ
chd-155	81	13	nuclear	nuclear	ADJ
chd-155	81	14	,	,	PUNCT
chd-155	81	15	as	as	SCONJ
chd-155	81	16	expected	expect	VERB
chd-155	81	17	(	(	PUNCT
chd-155	81	18	domingodomenech	domingodomenech	PROPN
chd-155	81	19	et	et	PROPN
chd-155	81	20	al	al	PROPN
chd-155	81	21	.	.	PROPN
chd-155	81	22	,	,	PUNCT
chd-155	81	23	2005	2005	NUM
chd-155	81	24	)	)	PUNCT
chd-155	81	25	.	.	PUNCT
chd-155	82	1	between	between	ADP
chd-155	82	2	mean	mean	ADJ
chd-155	82	3	reactivities	reactivity	NOUN
chd-155	82	4	of	of	ADP
chd-155	82	5	the	the	DET
chd-155	82	6	tmas	tma	NOUN
chd-155	82	7	from	from	ADP
chd-155	82	8	3	3	NUM
chd-155	82	9	study	study	NOUN
chd-155	82	10	sites	site	NOUN
chd-155	82	11	—	—	PUNCT
chd-155	82	12	in	in	ADP
chd-155	82	13	both	both	CCONJ
chd-155	82	14	cancer	cancer	NOUN
chd-155	82	15	and	and	CCONJ
chd-155	82	16	benign	benign	ADJ
chd-155	82	17	spots	spot	NOUN
chd-155	82	18	,	,	PUNCT
chd-155	82	19	some	some	DET
chd-155	82	20	batch	batch	NOUN
chd-155	82	21	effect	effect	NOUN
chd-155	82	22	was	be	AUX
chd-155	82	23	noted	note	VERB
chd-155	82	24	in	in	ADP
chd-155	82	25	both	both	CCONJ
chd-155	82	26	normal	normal	ADJ
chd-155	82	27	and	and	CCONJ
chd-155	82	28	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-155	82	29	e5	e5	PROPN
chd-155	82	30	cancer	cancer	NOUN
chd-155	82	31	health	health	NOUN
chd-155	82	32	disparities	disparity	NOUN
chd-155	82	33	research	research	VERB
chd-155	82	34	tumor	tumor	NOUN
chd-155	82	35	regions	region	NOUN
chd-155	82	36	.	.	PUNCT
chd-155	83	1	this	this	PRON
chd-155	83	2	was	be	AUX
chd-155	83	3	attributed	attribute	VERB
chd-155	83	4	to	to	ADP
chd-155	83	5	differences	difference	NOUN
chd-155	83	6	in	in	ADP
chd-155	83	7	tissue	tissue	NOUN
chd-155	83	8	processing	processing	NOUN
chd-155	83	9	across	across	ADP
chd-155	83	10	institutions	institution	NOUN
chd-155	83	11	,	,	PUNCT
chd-155	83	12	different	different	ADJ
chd-155	83	13	lots	lot	NOUN
chd-155	83	14	of	of	ADP
chd-155	83	15	antibodies	antibody	NOUN
chd-155	83	16	used	use	VERB
chd-155	83	17	,	,	PUNCT
chd-155	83	18	and	and	CCONJ
chd-155	83	19	other	other	ADJ
chd-155	83	20	technical	technical	ADJ
chd-155	83	21	procedures	procedure	NOUN
chd-155	83	22	.	.	PUNCT
chd-155	84	1	therefore	therefore	ADV
chd-155	84	2	,	,	PUNCT
chd-155	84	3	the	the	DET
chd-155	84	4	above	above	ADV
chd-155	84	5	-	-	PUNCT
chd-155	84	6	described	describe	VERB
chd-155	84	7	normalization	normalization	NOUN
chd-155	84	8	was	be	AUX
chd-155	84	9	applied	apply	VERB
chd-155	84	10	to	to	ADP
chd-155	84	11	all	all	DET
chd-155	84	12	benign	benign	ADJ
chd-155	84	13	and	and	CCONJ
chd-155	84	14	tumor	tumor	NOUN
chd-155	84	15	results	result	NOUN
chd-155	84	16	.	.	PUNCT
chd-155	85	1	the	the	DET
chd-155	85	2	degrees	degree	NOUN
chd-155	85	3	of	of	ADP
chd-155	85	4	deviation	deviation	NOUN
chd-155	85	5	in	in	ADP
chd-155	85	6	expression	expression	NOUN
chd-155	85	7	before	before	ADV
chd-155	85	8	and	and	CCONJ
chd-155	85	9	after	after	ADP
chd-155	85	10	batch	batch	NOUN
chd-155	85	11	correction	correction	NOUN
chd-155	85	12	are	be	AUX
chd-155	85	13	shown	show	VERB
chd-155	85	14	in	in	ADP
chd-155	85	15	normal	normal	ADJ
chd-155	85	16	and	and	CCONJ
chd-155	85	17	tumor	tumor	NOUN
chd-155	85	18	spots	spot	NOUN
chd-155	85	19	of	of	ADP
chd-155	85	20	prostate	prostate	NOUN
chd-155	85	21	tissue	tissue	NOUN
chd-155	85	22	from	from	ADP
chd-155	85	23	men	man	NOUN
chd-155	85	24	from	from	ADP
chd-155	85	25	all	all	DET
chd-155	85	26	sites	site	NOUN
chd-155	85	27	for	for	ADP
chd-155	85	28	gdf15	gdf15	ADJ
chd-155	85	29	expression	expression	NOUN
chd-155	85	30	and	and	CCONJ
chd-155	85	31	nfκb	nfκb	NOUN
chd-155	85	32	expression	expression	NOUN
chd-155	85	33	(	(	PUNCT
chd-155	85	34	supplementary	supplementary	ADJ
chd-155	85	35	figure	figure	NOUN
chd-155	85	36	1	1	NUM
chd-155	85	37	)	)	PUNCT
chd-155	85	38	.	.	PUNCT
chd-155	86	1	representative	representative	ADJ
chd-155	86	2	marker	marker	NOUN
chd-155	86	3	reactivity	reactivity	NOUN
chd-155	86	4	is	be	AUX
chd-155	86	5	shown	show	VERB
chd-155	86	6	(	(	PUNCT
chd-155	86	7	figure	figure	NOUN
chd-155	86	8	3	3	NUM
chd-155	86	9	)	)	PUNCT
chd-155	86	10	.	.	PUNCT
chd-155	87	1	median	median	ADJ
chd-155	87	2	gdf15	gdf15	PROPN
chd-155	87	3	(	(	PUNCT
chd-155	87	4	1.93	1.93	NUM
chd-155	87	5	vs.	vs.	ADP
chd-155	87	6	0.19	0.19	NUM
chd-155	87	7	,	,	PUNCT
chd-155	87	8	p<0.0001	p<0.0001	NOUN
chd-155	87	9	)	)	PUNCT
chd-155	87	10	and	and	CCONJ
chd-155	87	11	nfκb	nfκb	NOUN
chd-155	87	12	(	(	PUNCT
chd-155	87	13	1.18	1.18	NUM
chd-155	87	14	vs.	vs.	ADP
chd-155	87	15	0.96	0.96	NUM
chd-155	87	16	,	,	PUNCT
chd-155	87	17	p<0.0001	p<0.0001	NOUN
chd-155	87	18	)	)	PUNCT
chd-155	87	19	expression	expression	NOUN
chd-155	87	20	was	be	AUX
chd-155	87	21	elevated	elevate	VERB
chd-155	87	22	in	in	ADP
chd-155	87	23	pc	pc	NOUN
chd-155	87	24	compared	compare	VERB
chd-155	87	25	to	to	ADP
chd-155	87	26	benign	benign	ADJ
chd-155	87	27	prostate	prostate	NOUN
chd-155	87	28	(	(	PUNCT
chd-155	87	29	table	table	NOUN
chd-155	87	30	1	1	NUM
chd-155	87	31	)	)	PUNCT
chd-155	87	32	.	.	PUNCT
chd-155	88	1	median	median	ADJ
chd-155	88	2	gdf15	gdf15	NOUN
chd-155	88	3	expression	expression	NOUN
chd-155	88	4	for	for	ADP
chd-155	88	5	ea	ea	NOUN
chd-155	88	6	men	man	NOUN
chd-155	88	7	was	be	AUX
chd-155	88	8	2.06	2.06	NUM
chd-155	88	9	in	in	ADP
chd-155	88	10	tumor	tumor	NOUN
chd-155	88	11	versus	versus	ADP
chd-155	88	12	0.87	0.87	NUM
chd-155	88	13	in	in	ADP
chd-155	88	14	benign	benign	ADJ
chd-155	88	15	(	(	PUNCT
chd-155	88	16	p<0.0001	p<0.0001	NOUN
chd-155	88	17	)	)	PUNCT
chd-155	88	18	;	;	PUNCT
chd-155	88	19	comparable	comparable	ADJ
chd-155	88	20	values	value	NOUN
chd-155	88	21	for	for	ADP
chd-155	88	22	aa	aa	PROPN
chd-155	88	23	men	man	NOUN
chd-155	88	24	were	be	AUX
chd-155	88	25	2.06	2.06	NUM
chd-155	88	26	vs.	vs.	ADP
chd-155	88	27	0.83	0.83	NUM
chd-155	88	28	(	(	PUNCT
chd-155	88	29	p<0.0001	p<0.0001	NOUN
chd-155	88	30	)	)	PUNCT
chd-155	88	31	.	.	PUNCT
chd-155	89	1	median	median	ADJ
chd-155	89	2	nfκb	nfκb	NOUN
chd-155	89	3	expression	expression	NOUN
chd-155	89	4	for	for	ADP
chd-155	89	5	ea	ea	NOUN
chd-155	89	6	men	man	NOUN
chd-155	89	7	was	be	AUX
chd-155	89	8	1.04	1.04	NUM
chd-155	89	9	in	in	ADP
chd-155	89	10	tumor	tumor	NOUN
chd-155	89	11	versus	versus	ADP
chd-155	89	12	0.88	0.88	NUM
chd-155	89	13	in	in	ADP
chd-155	89	14	benign	benign	ADJ
chd-155	89	15	(	(	PUNCT
chd-155	89	16	p<0.0001	p<0.0001	NOUN
chd-155	89	17	)	)	PUNCT
chd-155	89	18	;	;	PUNCT
chd-155	89	19	comparable	comparable	ADJ
chd-155	89	20	values	value	NOUN
chd-155	89	21	for	for	ADP
chd-155	89	22	aa	aa	PROPN
chd-155	89	23	men	man	NOUN
chd-155	89	24	were	be	AUX
chd-155	89	25	1.04	1.04	NUM
chd-155	89	26	vs.	vs.	ADP
chd-155	89	27	0.96	0.96	NUM
chd-155	89	28	(	(	PUNCT
chd-155	89	29	p<0.0001	p<0.0001	NOUN
chd-155	89	30	)	)	PUNCT
chd-155	89	31	.	.	PUNCT
chd-155	90	1	tumor	tumor	NOUN
chd-155	90	2	-	-	PUNCT
chd-155	90	3	tumor	tumor	NOUN
chd-155	90	4	and	and	CCONJ
chd-155	90	5	benign	benign	ADJ
chd-155	90	6	-	-	PUNCT
chd-155	90	7	benign	benign	ADJ
chd-155	90	8	comparisons	comparison	NOUN
chd-155	90	9	of	of	ADP
chd-155	90	10	expression	expression	NOUN
chd-155	90	11	levels	level	NOUN
chd-155	90	12	for	for	ADP
chd-155	90	13	both	both	DET
chd-155	90	14	proteins	protein	NOUN
chd-155	90	15	by	by	ADP
chd-155	90	16	race	race	NOUN
chd-155	90	17	were	be	AUX
chd-155	90	18	not	not	PART
chd-155	90	19	significant	significant	ADJ
chd-155	90	20	except	except	SCONJ
chd-155	90	21	that	that	PRON
chd-155	90	22	nfκb	nfκb	NOUN
chd-155	90	23	was	be	AUX
chd-155	90	24	borderline	borderline	NOUN
chd-155	90	25	-	-	PUNCT
chd-155	90	26	higher	high	ADJ
chd-155	90	27	in	in	ADP
chd-155	90	28	the	the	DET
chd-155	90	29	prostate	prostate	NOUN
chd-155	90	30	benign	benign	ADJ
chd-155	90	31	epithelium	epithelium	NOUN
chd-155	90	32	of	of	ADP
chd-155	90	33	aa	aa	PROPN
chd-155	90	34	men	man	NOUN
chd-155	90	35	(	(	PUNCT
chd-155	90	36	p=0.06	p=0.06	NOUN
chd-155	90	37	)	)	PUNCT
chd-155	90	38	.	.	PUNCT
chd-155	91	1	(	(	PUNCT
chd-155	91	2	nfκb	nfκb	NOUN
chd-155	91	3	expression	expression	NOUN
chd-155	91	4	in	in	ADP
chd-155	91	5	prostate	prostate	NOUN
chd-155	91	6	benign	benign	ADJ
chd-155	91	7	epithelium	epithelium	NOUN
chd-155	91	8	was	be	AUX
chd-155	91	9	also	also	ADV
chd-155	91	10	significantly	significantly	ADV
chd-155	91	11	higher	high	ADJ
chd-155	91	12	in	in	ADP
chd-155	91	13	aa	aa	NOUN
chd-155	91	14	than	than	ADP
chd-155	91	15	ea	ea	NUM
chd-155	91	16	men	man	NOUN
chd-155	91	17	when	when	SCONJ
chd-155	91	18	we	we	PRON
chd-155	91	19	separately	separately	ADV
chd-155	91	20	analyzed	analyze	VERB
chd-155	91	21	the	the	DET
chd-155	91	22	pcbn	pcbn	NOUN
chd-155	91	23	highgrade	highgrade	NOUN
chd-155	91	24	tma	tma	PROPN
chd-155	91	25	set	set	PROPN
chd-155	91	26	(	(	PUNCT
chd-155	91	27	p=0.01	p=0.01	PROPN
chd-155	91	28	)	)	PUNCT
chd-155	91	29	but	but	CCONJ
chd-155	91	30	not	not	PART
chd-155	91	31	in	in	ADP
chd-155	91	32	the	the	DET
chd-155	91	33	other	other	ADJ
chd-155	91	34	cases	case	NOUN
chd-155	91	35	;	;	PUNCT
chd-155	91	36	namely	namely	ADV
chd-155	91	37	41.4	41.4	NUM
chd-155	91	38	%	%	NOUN
chd-155	91	39	of	of	ADP
chd-155	91	40	aa	aa	PROPN
chd-155	91	41	men	man	NOUN
chd-155	91	42	had	have	VERB
chd-155	91	43	reactivity	reactivity	NOUN
chd-155	91	44	>	>	ADV
chd-155	91	45	1	1	NUM
chd-155	91	46	in	in	ADP
chd-155	91	47	benign	benign	ADJ
chd-155	91	48	glands	gland	NOUN
chd-155	91	49	but	but	CCONJ
chd-155	91	50	30.2	30.2	NUM
chd-155	91	51	%	%	NOUN
chd-155	91	52	of	of	ADP
chd-155	91	53	ea	ea	NOUN
chd-155	91	54	did	do	VERB
chd-155	91	55	(	(	PUNCT
chd-155	91	56	p=0.03	p=0.03	ADJ
chd-155	91	57	)	)	PUNCT
chd-155	91	58	;	;	PUNCT
chd-155	91	59	for	for	ADP
chd-155	91	60	further	further	ADJ
chd-155	91	61	analysis	analysis	NOUN
chd-155	91	62	,	,	PUNCT
chd-155	91	63	however	however	ADV
chd-155	91	64	,	,	PUNCT
chd-155	91	65	both	both	PRON
chd-155	91	66	pcbn	pcbn	NOUN
chd-155	91	67	cohorts	cohort	NOUN
chd-155	91	68	were	be	AUX
chd-155	91	69	combined	combine	VERB
chd-155	91	70	.	.	PUNCT
chd-155	91	71	)	)	PUNCT
chd-155	91	72	figure	figure	NOUN
chd-155	91	73	3	3	NUM
chd-155	91	74	.	.	X
chd-155	91	75	representative	representative	ADJ
chd-155	91	76	tma	tma	PROPN
chd-155	91	77	spots	spot	NOUN
chd-155	91	78	illustrating	illustrate	VERB
chd-155	91	79	trends	trend	NOUN
chd-155	91	80	in	in	ADP
chd-155	91	81	aa	aa	NOUN
chd-155	91	82	patients	patient	NOUN
chd-155	91	83	.	.	PUNCT
chd-155	92	1	(	(	PUNCT
chd-155	92	2	a	a	X
chd-155	92	3	)	)	PUNCT
chd-155	92	4	gdf15	gdf15	NOUN
chd-155	92	5	in	in	ADP
chd-155	92	6	stage	stage	NOUN
chd-155	92	7	2	2	NUM
chd-155	92	8	tumor	tumor	NOUN
chd-155	92	9	,	,	PUNCT
chd-155	92	10	(	(	PUNCT
chd-155	92	11	b	b	X
chd-155	92	12	)	)	PUNCT
chd-155	92	13	gdf15	gdf15	NOUN
chd-155	92	14	in	in	ADP
chd-155	92	15	stage	stage	NOUN
chd-155	92	16	3b	3b	NUM
chd-155	92	17	tumor	tumor	NOUN
chd-155	92	18	,	,	PUNCT
chd-155	92	19	(	(	PUNCT
chd-155	92	20	c	c	NOUN
chd-155	92	21	)	)	PUNCT
chd-155	92	22	nfκb	nfκb	NOUN
chd-155	92	23	in	in	ADP
chd-155	92	24	low	low	ADJ
chd-155	92	25	grade	grade	NOUN
chd-155	92	26	(	(	PUNCT
chd-155	92	27	group	group	NOUN
chd-155	92	28	1	1	NUM
chd-155	92	29	)	)	PUNCT
chd-155	92	30	tumor	tumor	NOUN
chd-155	92	31	with	with	ADP
chd-155	92	32	a	a	DET
chd-155	92	33	few	few	ADJ
chd-155	92	34	stronger	strong	ADJ
chd-155	92	35	-	-	PUNCT
chd-155	92	36	staining	stain	VERB
chd-155	92	37	benign	benign	ADJ
chd-155	92	38	glands	gland	NOUN
chd-155	92	39	at	at	ADP
chd-155	92	40	bottom	bottom	NOUN
chd-155	92	41	,	,	PUNCT
chd-155	92	42	(	(	PUNCT
chd-155	92	43	d	d	X
chd-155	92	44	)	)	PUNCT
chd-155	92	45	nfκb	nfκb	NOUN
chd-155	92	46	in	in	ADP
chd-155	92	47	high	high	ADJ
chd-155	92	48	grade	grade	NOUN
chd-155	92	49	(	(	PUNCT
chd-155	92	50	group	group	NOUN
chd-155	92	51	5	5	NUM
chd-155	92	52	)	)	PUNCT
chd-155	92	53	tumor	tumor	NOUN
chd-155	92	54	.	.	PUNCT
chd-155	93	1	gradewise	gradewise	PROPN
chd-155	93	2	gdf15	gdf15	PROPN
chd-155	93	3	in	in	ADP
chd-155	93	4	tumor	tumor	NOUN
chd-155	93	5	showed	show	VERB
chd-155	93	6	changes	change	NOUN
chd-155	93	7	of	of	ADP
chd-155	93	8	indeterminate	indeterminate	ADJ
chd-155	93	9	direction	direction	NOUN
chd-155	93	10	(	(	PUNCT
chd-155	93	11	p=0.010	p=0.010	PROPN
chd-155	93	12	)	)	PUNCT
chd-155	93	13	,	,	PUNCT
chd-155	93	14	while	while	SCONJ
chd-155	93	15	nfκb	nfκb	ADJ
chd-155	93	16	expression	expression	NOUN
chd-155	93	17	was	be	AUX
chd-155	93	18	increased	increase	VERB
chd-155	93	19	in	in	ADP
chd-155	93	20	gleason	gleason	PROPN
chd-155	93	21	grade	grade	NOUN
chd-155	93	22	groups	group	NOUN
chd-155	93	23	3	3	NUM
chd-155	93	24	,	,	PUNCT
chd-155	93	25	4	4	NUM
chd-155	93	26	,	,	PUNCT
chd-155	93	27	and	and	CCONJ
chd-155	93	28	5	5	NUM
chd-155	93	29	in	in	ADP
chd-155	93	30	tumor	tumor	NOUN
chd-155	93	31	(	(	PUNCT
chd-155	93	32	p=0.009	p=0.009	X
chd-155	93	33	)	)	PUNCT
chd-155	93	34	and	and	CCONJ
chd-155	93	35	benign	benign	ADJ
chd-155	93	36	(	(	PUNCT
chd-155	93	37	p=0.003	p=0.003	NOUN
chd-155	93	38	)	)	PUNCT
chd-155	93	39	(	(	PUNCT
chd-155	93	40	table	table	NOUN
chd-155	93	41	2	2	NUM
chd-155	93	42	)	)	PUNCT
chd-155	93	43	.	.	PUNCT
chd-155	94	1	by	by	ADP
chd-155	94	2	pathologic	pathologic	ADJ
chd-155	94	3	stage	stage	NOUN
chd-155	94	4	(	(	PUNCT
chd-155	94	5	table	table	NOUN
chd-155	94	6	3	3	NUM
chd-155	94	7	)	)	PUNCT
chd-155	94	8	,	,	PUNCT
chd-155	94	9	gdf15	gdf15	ADJ
chd-155	94	10	expression	expression	NOUN
chd-155	94	11	markedly	markedly	ADV
chd-155	94	12	decreased	decrease	VERB
chd-155	94	13	in	in	ADP
chd-155	94	14	tumor	tumor	NOUN
chd-155	94	15	(	(	PUNCT
chd-155	94	16	p=0.001	p=0.001	NUM
chd-155	94	17	)	)	PUNCT
chd-155	94	18	and	and	CCONJ
chd-155	94	19	benign	benign	ADJ
chd-155	94	20	epithelium	epithelium	NOUN
chd-155	94	21	(	(	PUNCT
chd-155	94	22	p<0.001	p<0.001	PROPN
chd-155	94	23	)	)	PUNCT
chd-155	94	24	with	with	ADP
chd-155	94	25	increasing	increase	VERB
chd-155	94	26	stage	stage	NOUN
chd-155	94	27	.	.	PUNCT
chd-155	95	1	nfκb	nfκb	NOUN
chd-155	95	2	expression	expression	NOUN
chd-155	95	3	rose	rise	VERB
chd-155	95	4	in	in	ADP
chd-155	95	5	tumor	tumor	NOUN
chd-155	95	6	(	(	PUNCT
chd-155	95	7	p=0.02	p=0.02	NOUN
chd-155	95	8	)	)	PUNCT
chd-155	95	9	with	with	ADP
chd-155	95	10	increasing	increase	VERB
chd-155	95	11	stage	stage	NOUN
chd-155	95	12	.	.	PUNCT
chd-155	96	1	results	result	NOUN
chd-155	96	2	for	for	ADP
chd-155	96	3	each	each	DET
chd-155	96	4	site	site	NOUN
chd-155	96	5	-	-	PUNCT
chd-155	96	6	specific	specific	ADJ
chd-155	96	7	sampling	sampling	NOUN
chd-155	96	8	generally	generally	ADV
chd-155	96	9	followed	follow	VERB
chd-155	96	10	similar	similar	ADJ
chd-155	96	11	trends	trend	NOUN
chd-155	96	12	as	as	ADP
chd-155	96	13	the	the	DET
chd-155	96	14	combined	combined	ADJ
chd-155	96	15	sample	sample	NOUN
chd-155	96	16	(	(	PUNCT
chd-155	96	17	supplementary	supplementary	ADJ
chd-155	96	18	tables	table	NOUN
chd-155	96	19	1	1	NUM
chd-155	96	20	-	-	SYM
chd-155	96	21	5	5	NUM
chd-155	96	22	)	)	PUNCT
chd-155	96	23	.	.	PUNCT
chd-155	97	1	racial	racial	ADJ
chd-155	97	2	disparities	disparity	NOUN
chd-155	97	3	of	of	ADP
chd-155	97	4	gdf15	gdf15	NOUN
chd-155	97	5	and	and	CCONJ
chd-155	97	6	nfκb	nfκb	ADJ
chd-155	97	7	expression	expression	NOUN
chd-155	97	8	emerged	emerge	VERB
chd-155	97	9	,	,	PUNCT
chd-155	97	10	according	accord	VERB
chd-155	97	11	to	to	ADP
chd-155	97	12	tumor	tumor	NOUN
chd-155	97	13	grade	grade	NOUN
chd-155	97	14	and	and	CCONJ
chd-155	97	15	stage	stage	NOUN
chd-155	97	16	,	,	PUNCT
chd-155	97	17	in	in	ADP
chd-155	97	18	both	both	CCONJ
chd-155	97	19	tumor	tumor	NOUN
chd-155	97	20	and	and	CCONJ
chd-155	97	21	non	non	ADJ
chd-155	97	22	-	-	ADJ
chd-155	97	23	neoplastic	neoplastic	ADJ
chd-155	97	24	prostate	prostate	NOUN
chd-155	97	25	.	.	PUNCT
chd-155	98	1	the	the	DET
chd-155	98	2	only	only	ADJ
chd-155	98	3	expression	expression	NOUN
chd-155	98	4	trend	trend	NOUN
chd-155	98	5	by	by	ADP
chd-155	98	6	grade	grade	NOUN
chd-155	98	7	in	in	ADP
chd-155	98	8	tumor	tumor	NOUN
chd-155	98	9	was	be	AUX
chd-155	98	10	for	for	ADP
chd-155	98	11	increasing	increase	VERB
chd-155	98	12	nfκb	nfκb	ADJ
chd-155	98	13	expression	expression	NOUN
chd-155	98	14	with	with	ADP
chd-155	98	15	grade	grade	NOUN
chd-155	98	16	in	in	ADP
chd-155	98	17	aa	aa	PROPN
chd-155	98	18	(	(	PUNCT
chd-155	98	19	p=0.03	p=0.03	ADJ
chd-155	98	20	)	)	PUNCT
chd-155	98	21	(	(	PUNCT
chd-155	98	22	table	table	NOUN
chd-155	98	23	4	4	NUM
chd-155	98	24	)	)	PUNCT
chd-155	98	25	.	.	PUNCT
chd-155	99	1	gdf15	gdf15	PROPN
chd-155	99	2	significantly	significantly	ADV
chd-155	99	3	increased	increase	VERB
chd-155	99	4	with	with	ADP
chd-155	99	5	grade	grade	NOUN
chd-155	99	6	only	only	ADV
chd-155	99	7	in	in	ADP
chd-155	99	8	ea	ea	NOUN
chd-155	99	9	men	man	NOUN
chd-155	99	10	(	(	PUNCT
chd-155	99	11	p=0.01	p=0.01	NUM
chd-155	99	12	)	)	PUNCT
chd-155	99	13	.	.	PUNCT
chd-155	100	1	by	by	ADP
chd-155	100	2	stage	stage	NOUN
chd-155	100	3	(	(	PUNCT
chd-155	100	4	table	table	NOUN
chd-155	100	5	5	5	NUM
chd-155	100	6	)	)	PUNCT
chd-155	100	7	,	,	PUNCT
chd-155	100	8	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-155	100	9	e6	e6	VERB
chd-155	100	10	cancer	cancer	NOUN
chd-155	100	11	health	health	NOUN
chd-155	100	12	disparities	disparity	NOUN
chd-155	100	13	research	research	NOUN
chd-155	100	14	gdf15	gdf15	PROPN
chd-155	100	15	significantly	significantly	ADV
chd-155	100	16	decreased	decrease	VERB
chd-155	100	17	in	in	ADP
chd-155	100	18	aa	aa	PROPN
chd-155	100	19	men	man	NOUN
chd-155	100	20	in	in	ADP
chd-155	100	21	prostate	prostate	NOUN
chd-155	100	22	tumor	tumor	NOUN
chd-155	100	23	(	(	PUNCT
chd-155	100	24	p=0.007	p=0.007	ADP
chd-155	100	25	)	)	PUNCT
chd-155	100	26	,	,	PUNCT
chd-155	100	27	compared	compare	VERB
chd-155	100	28	to	to	ADP
chd-155	100	29	a	a	DET
chd-155	100	30	non	non	ADJ
chd-155	100	31	-	-	ADJ
chd-155	100	32	significant	significant	ADJ
chd-155	100	33	trend	trend	NOUN
chd-155	100	34	in	in	ADP
chd-155	100	35	the	the	DET
chd-155	100	36	same	same	ADJ
chd-155	100	37	direction	direction	NOUN
chd-155	100	38	observed	observe	VERB
chd-155	100	39	in	in	ADP
chd-155	100	40	ea	ea	NOUN
chd-155	100	41	men	man	NOUN
chd-155	100	42	(	(	PUNCT
chd-155	100	43	p=0.07	p=0.07	PROPN
chd-155	100	44	)	)	PUNCT
chd-155	100	45	;	;	PUNCT
chd-155	100	46	thus	thus	ADV
chd-155	100	47	the	the	DET
chd-155	100	48	significant	significant	ADJ
chd-155	100	49	decrease	decrease	NOUN
chd-155	100	50	in	in	ADP
chd-155	100	51	the	the	DET
chd-155	100	52	overall	overall	ADJ
chd-155	100	53	study	study	NOUN
chd-155	100	54	group	group	NOUN
chd-155	100	55	was	be	AUX
chd-155	100	56	driven	drive	VERB
chd-155	100	57	by	by	ADP
chd-155	100	58	aa	aa	NOUN
chd-155	100	59	men	man	NOUN
chd-155	100	60	.	.	PUNCT
chd-155	101	1	gdf15	gdf15	ADJ
chd-155	101	2	expression	expression	NOUN
chd-155	101	3	in	in	ADP
chd-155	101	4	benign	benign	ADJ
chd-155	101	5	epithelium	epithelium	NOUN
chd-155	101	6	decreased	decrease	VERB
chd-155	101	7	in	in	ADP
chd-155	101	8	ea	ea	NOUN
chd-155	101	9	men	man	NOUN
chd-155	101	10	with	with	ADP
chd-155	101	11	increasing	increase	VERB
chd-155	101	12	stage	stage	NOUN
chd-155	101	13	(	(	PUNCT
chd-155	101	14	p=0.01	p=0.01	NUM
chd-155	101	15	)	)	PUNCT
chd-155	101	16	,	,	PUNCT
chd-155	101	17	as	as	ADV
chd-155	101	18	well	well	ADV
chd-155	101	19	as	as	ADP
chd-155	101	20	in	in	ADP
chd-155	101	21	aa	aa	PROPN
chd-155	101	22	men	man	NOUN
chd-155	101	23	(	(	PUNCT
chd-155	101	24	p=0.003	p=0.003	NOUN
chd-155	101	25	)	)	PUNCT
chd-155	101	26	.	.	PUNCT
chd-155	102	1	nfκb	nfκb	PROPN
chd-155	102	2	showed	show	VERB
chd-155	102	3	no	no	DET
chd-155	102	4	race	race	NOUN
chd-155	102	5	-	-	PUNCT
chd-155	102	6	specific	specific	ADJ
chd-155	102	7	trends	trend	NOUN
chd-155	102	8	according	accord	VERB
chd-155	102	9	to	to	ADP
chd-155	102	10	stage	stage	NOUN
chd-155	102	11	in	in	ADP
chd-155	102	12	either	either	CCONJ
chd-155	102	13	tumor	tumor	NOUN
chd-155	102	14	or	or	CCONJ
chd-155	102	15	benign	benign	ADJ
chd-155	102	16	epithelium	epithelium	NOUN
chd-155	102	17	.	.	PUNCT
chd-155	103	1	finally	finally	ADV
chd-155	103	2	,	,	PUNCT
chd-155	103	3	the	the	DET
chd-155	103	4	two	two	NUM
chd-155	103	5	markers	marker	NOUN
chd-155	103	6	did	do	AUX
chd-155	103	7	not	not	PART
chd-155	103	8	correlate	correlate	VERB
chd-155	103	9	with	with	ADP
chd-155	103	10	each	each	DET
chd-155	103	11	other	other	ADJ
chd-155	103	12	in	in	ADP
chd-155	103	13	normal	normal	ADJ
chd-155	103	14	(	(	PUNCT
chd-155	103	15	supplementary	supplementary	ADJ
chd-155	103	16	figure	figure	NOUN
chd-155	103	17	1a1c	1a1c	NOUN
chd-155	103	18	)	)	PUNCT
chd-155	103	19	or	or	CCONJ
chd-155	103	20	tumor	tumor	NOUN
chd-155	103	21	samples	sample	NOUN
chd-155	103	22	(	(	PUNCT
chd-155	103	23	supplementary	supplementary	ADJ
chd-155	103	24	figure	figure	NOUN
chd-155	103	25	1d-1f	1d-1f	NOUN
chd-155	103	26	)	)	PUNCT
chd-155	103	27	,	,	PUNCT
chd-155	103	28	either	either	CCONJ
chd-155	103	29	overall	overall	ADJ
chd-155	103	30	or	or	CCONJ
chd-155	103	31	in	in	ADP
chd-155	103	32	ea	ea	NOUN
chd-155	103	33	or	or	CCONJ
chd-155	103	34	aa	aa	NOUN
chd-155	103	35	cohorts	cohort	NOUN
chd-155	103	36	,	,	PUNCT
chd-155	103	37	shown	show	VERB
chd-155	103	38	as	as	ADP
chd-155	103	39	scatter	scatter	NOUN
chd-155	103	40	plots	plot	NOUN
chd-155	103	41	.	.	PUNCT
chd-155	104	1	trends	trend	NOUN
chd-155	104	2	are	be	AUX
chd-155	104	3	summarized	summarize	VERB
chd-155	104	4	(	(	PUNCT
chd-155	104	5	table	table	NOUN
chd-155	104	6	6	6	NUM
chd-155	104	7	)	)	PUNCT
chd-155	104	8	.	.	PUNCT
chd-155	105	1	discussion	discussion	NOUN
chd-155	105	2	the	the	DET
chd-155	105	3	current	current	ADJ
chd-155	105	4	study	study	NOUN
chd-155	105	5	shows	show	VERB
chd-155	105	6	a	a	DET
chd-155	105	7	newly	newly	ADV
chd-155	105	8	-	-	PUNCT
chd-155	105	9	described	describe	VERB
chd-155	105	10	,	,	PUNCT
chd-155	105	11	significant	significant	ADJ
chd-155	105	12	stagewise	stagewise	NOUN
chd-155	105	13	decline	decline	NOUN
chd-155	105	14	in	in	ADP
chd-155	105	15	gdf15	gdf15	ADJ
chd-155	105	16	expression	expression	NOUN
chd-155	105	17	in	in	ADP
chd-155	105	18	prostate	prostate	NOUN
chd-155	105	19	tumors	tumor	NOUN
chd-155	105	20	of	of	ADP
chd-155	105	21	african	african	ADJ
chd-155	105	22	-	-	PUNCT
chd-155	105	23	american	american	ADJ
chd-155	105	24	(	(	PUNCT
chd-155	105	25	aa	aa	NOUN
chd-155	105	26	)	)	PUNCT
chd-155	105	27	men	man	NOUN
chd-155	105	28	not	not	PART
chd-155	105	29	observed	observe	VERB
chd-155	105	30	in	in	ADP
chd-155	105	31	european	european	PROPN
chd-155	105	32	american	american	PROPN
chd-155	105	33	(	(	PUNCT
chd-155	105	34	ea	ea	NOUN
chd-155	105	35	)	)	PUNCT
chd-155	105	36	men	man	NOUN
chd-155	105	37	,	,	PUNCT
chd-155	105	38	and	and	CCONJ
chd-155	105	39	a	a	DET
chd-155	105	40	grade	grade	NOUN
chd-155	105	41	-	-	PUNCT
chd-155	105	42	proportional	proportional	ADJ
chd-155	105	43	rise	rise	NOUN
chd-155	105	44	of	of	ADP
chd-155	105	45	nfκb	nfκb	ADJ
chd-155	105	46	expression	expression	NOUN
chd-155	105	47	in	in	ADP
chd-155	105	48	aa	aa	ADJ
chd-155	105	49	tumors	tumor	NOUN
chd-155	105	50	.	.	PUNCT
chd-155	106	1	also	also	ADV
chd-155	106	2	,	,	PUNCT
chd-155	106	3	nfκb	nfκb	ADJ
chd-155	106	4	expression	expression	NOUN
chd-155	106	5	was	be	AUX
chd-155	106	6	higher	high	ADJ
chd-155	106	7	in	in	ADP
chd-155	106	8	benign	benign	ADJ
chd-155	106	9	epithelium	epithelium	NOUN
chd-155	106	10	of	of	ADP
chd-155	106	11	aa	aa	NOUN
chd-155	106	12	men	man	NOUN
chd-155	106	13	than	than	ADP
chd-155	106	14	ea	ea	ADP
chd-155	106	15	men	man	NOUN
chd-155	106	16	in	in	ADP
chd-155	106	17	the	the	DET
chd-155	106	18	pcbn	pcbn	NOUN
chd-155	106	19	high	high	ADJ
chd-155	106	20	-	-	PUNCT
chd-155	106	21	grade	grade	NOUN
chd-155	106	22	disparity	disparity	NOUN
chd-155	106	23	cohort	cohort	NOUN
chd-155	106	24	.	.	PUNCT
chd-155	107	1	although	although	SCONJ
chd-155	107	2	aa	aa	NOUN
chd-155	107	3	men	man	NOUN
chd-155	107	4	have	have	AUX
chd-155	107	5	shown	show	VERB
chd-155	107	6	higher	high	ADJ
chd-155	107	7	gleason	gleason	PROPN
chd-155	107	8	scores	score	NOUN
chd-155	107	9	in	in	ADP
chd-155	107	10	other	other	ADJ
chd-155	107	11	series	series	NOUN
chd-155	107	12	(	(	PUNCT
chd-155	107	13	p	p	NOUN
chd-155	107	14	=	=	NOUN
chd-155	107	15	0.037	0.037	NUM
chd-155	107	16	)	)	PUNCT
chd-155	107	17	(	(	PUNCT
chd-155	107	18	powell	powell	PROPN
chd-155	107	19	et	et	PROPN
chd-155	107	20	al	al	PROPN
chd-155	107	21	.	.	PROPN
chd-155	107	22	,	,	PUNCT
chd-155	107	23	2013	2013	NUM
chd-155	107	24	)	)	PUNCT
chd-155	107	25	the	the	DET
chd-155	107	26	lack	lack	NOUN
chd-155	107	27	of	of	ADP
chd-155	107	28	significant	significant	ADJ
chd-155	107	29	differences	difference	NOUN
chd-155	107	30	between	between	ADP
chd-155	107	31	our	our	PRON
chd-155	107	32	aa	aa	NOUN
chd-155	107	33	and	and	CCONJ
chd-155	107	34	ea	ea	NOUN
chd-155	107	35	men	man	NOUN
chd-155	107	36	groups	group	NOUN
chd-155	107	37	rules	rule	VERB
chd-155	107	38	out	out	ADP
chd-155	107	39	differing	differ	VERB
chd-155	107	40	average	average	ADJ
chd-155	107	41	grades	grade	NOUN
chd-155	107	42	as	as	ADP
chd-155	107	43	a	a	DET
chd-155	107	44	cause	cause	NOUN
chd-155	107	45	of	of	ADP
chd-155	107	46	the	the	DET
chd-155	107	47	differences	difference	NOUN
chd-155	107	48	observed	observe	VERB
chd-155	107	49	.	.	PUNCT
chd-155	108	1	since	since	SCONJ
chd-155	108	2	gdf15	gdf15	NOUN
chd-155	108	3	is	be	AUX
chd-155	108	4	considered	consider	VERB
chd-155	108	5	to	to	PART
chd-155	108	6	repress	repress	VERB
chd-155	108	7	nfκb	nfκb	NOUN
chd-155	108	8	,	,	PUNCT
chd-155	108	9	this	this	PRON
chd-155	108	10	may	may	AUX
chd-155	108	11	explain	explain	VERB
chd-155	108	12	the	the	DET
chd-155	108	13	increase	increase	NOUN
chd-155	108	14	in	in	ADP
chd-155	108	15	nfκb	nfκb	ADJ
chd-155	108	16	expression	expression	NOUN
chd-155	108	17	in	in	ADP
chd-155	108	18	tumor	tumor	NOUN
chd-155	108	19	(	(	PUNCT
chd-155	108	20	although	although	SCONJ
chd-155	108	21	the	the	DET
chd-155	108	22	latter	latter	ADJ
chd-155	108	23	was	be	AUX
chd-155	108	24	gradewise	gradewise	NOUN
chd-155	108	25	,	,	PUNCT
chd-155	108	26	not	not	PART
chd-155	108	27	stagewise	stagewise	VERB
chd-155	108	28	)	)	PUNCT
chd-155	108	29	that	that	PRON
chd-155	108	30	was	be	AUX
chd-155	108	31	noted	note	VERB
chd-155	108	32	in	in	ADP
chd-155	108	33	aa	aa	PROPN
chd-155	108	34	men	man	NOUN
chd-155	108	35	but	but	CCONJ
chd-155	108	36	not	not	PART
chd-155	108	37	ea	ea	NOUN
chd-155	108	38	,	,	PUNCT
chd-155	108	39	a	a	DET
chd-155	108	40	finding	finding	NOUN
chd-155	108	41	possibly	possibly	ADV
chd-155	108	42	related	relate	VERB
chd-155	108	43	to	to	ADP
chd-155	108	44	androgen	androgen	NOUN
chd-155	108	45	independence	independence	NOUN
chd-155	108	46	(	(	PUNCT
chd-155	108	47	jin	jin	NOUN
chd-155	108	48	et	et	PROPN
chd-155	108	49	al	al	PROPN
chd-155	108	50	.	.	PROPN
chd-155	108	51	,	,	PUNCT
chd-155	108	52	2008	2008	NUM
chd-155	108	53	)	)	PUNCT
chd-155	108	54	.	.	PUNCT
chd-155	109	1	these	these	DET
chd-155	109	2	findings	finding	NOUN
chd-155	109	3	suggest	suggest	VERB
chd-155	109	4	racially	racially	ADV
chd-155	109	5	differing	differ	VERB
chd-155	109	6	effects	effect	NOUN
chd-155	109	7	of	of	ADP
chd-155	109	8	these	these	DET
chd-155	109	9	molecules	molecule	NOUN
chd-155	109	10	on	on	ADP
chd-155	109	11	biologic	biologic	NOUN
chd-155	109	12	functions	function	NOUN
chd-155	109	13	including	include	VERB
chd-155	109	14	immune	immune	ADJ
chd-155	109	15	response	response	NOUN
chd-155	109	16	.	.	PUNCT
chd-155	110	1	gdf15	gdf15	NOUN
chd-155	110	2	is	be	AUX
chd-155	110	3	widely	widely	ADV
chd-155	110	4	associated	associate	VERB
chd-155	110	5	with	with	ADP
chd-155	110	6	inflammation	inflammation	NOUN
chd-155	110	7	,	,	PUNCT
chd-155	110	8	regulating	regulate	VERB
chd-155	110	9	apoptosis	apoptosis	NOUN
chd-155	110	10	,	,	PUNCT
chd-155	110	11	cell	cell	NOUN
chd-155	110	12	repair	repair	NOUN
chd-155	110	13	,	,	PUNCT
chd-155	110	14	growth	growth	NOUN
chd-155	110	15	,	,	PUNCT
chd-155	110	16	and	and	CCONJ
chd-155	110	17	tumorigenesis	tumorigenesis	NOUN
chd-155	110	18	.	.	PUNCT
chd-155	111	1	gdf15	gdf15	ADJ
chd-155	111	2	expression	expression	NOUN
chd-155	111	3	is	be	AUX
chd-155	111	4	normally	normally	ADV
chd-155	111	5	relatively	relatively	ADV
chd-155	111	6	high	high	ADJ
chd-155	111	7	in	in	ADP
chd-155	111	8	the	the	DET
chd-155	111	9	prostate	prostate	NOUN
chd-155	111	10	,	,	PUNCT
chd-155	111	11	and	and	CCONJ
chd-155	111	12	gdf15	gdf15	VERB
chd-155	111	13	immunoreactivity	immunoreactivity	NOUN
chd-155	111	14	in	in	ADP
chd-155	111	15	human	human	ADJ
chd-155	111	16	prostatectomy	prostatectomy	NOUN
chd-155	111	17	specimens	specimen	NOUN
chd-155	111	18	had	have	AUX
chd-155	111	19	shown	show	VERB
chd-155	111	20	an	an	DET
chd-155	111	21	inverse	inverse	NOUN
chd-155	111	22	relationship	relationship	NOUN
chd-155	111	23	to	to	ADP
chd-155	111	24	inflammatory	inflammatory	ADJ
chd-155	111	25	cells	cell	NOUN
chd-155	111	26	(	(	PUNCT
chd-155	111	27	bruzzese	bruzzese	PROPN
chd-155	111	28	et	et	PROPN
chd-155	111	29	al	al	PROPN
chd-155	111	30	.	.	PROPN
chd-155	111	31	,	,	PUNCT
chd-155	111	32	2014	2014	NUM
chd-155	111	33	)	)	PUNCT
chd-155	111	34	.	.	PUNCT
chd-155	112	1	the	the	DET
chd-155	112	2	lowering	lowering	NOUN
chd-155	112	3	of	of	ADP
chd-155	112	4	gdf15	gdf15	ADJ
chd-155	112	5	expression	expression	NOUN
chd-155	112	6	in	in	ADP
chd-155	112	7	aa	aa	PROPN
chd-155	112	8	tumor	tumor	NOUN
chd-155	112	9	progression	progression	NOUN
chd-155	112	10	may	may	AUX
chd-155	112	11	be	be	AUX
chd-155	112	12	consistent	consistent	ADJ
chd-155	112	13	with	with	ADP
chd-155	112	14	the	the	DET
chd-155	112	15	known	know	VERB
chd-155	112	16	effect	effect	NOUN
chd-155	112	17	of	of	ADP
chd-155	112	18	vitamin	vitamin	NOUN
chd-155	112	19	d	d	NOUN
chd-155	112	20	to	to	PART
chd-155	112	21	upregulate	upregulate	VERB
chd-155	112	22	gdf15	gdf15	NOUN
chd-155	112	23	(	(	PUNCT
chd-155	112	24	lambert	lambert	PROPN
chd-155	112	25	et	et	PROPN
chd-155	112	26	al	al	PROPN
chd-155	112	27	.	.	PROPN
chd-155	112	28	,	,	PUNCT
chd-155	112	29	2015	2015	NUM
chd-155	112	30	)	)	PUNCT
chd-155	112	31	.	.	PUNCT
chd-155	113	1	that	that	PRON
chd-155	113	2	is	be	AUX
chd-155	113	3	,	,	PUNCT
chd-155	113	4	higher	high	ADJ
chd-155	113	5	prevalence	prevalence	NOUN
chd-155	113	6	of	of	ADP
chd-155	113	7	vitamin	vitamin	NOUN
chd-155	113	8	d	d	NOUN
chd-155	113	9	deficiency	deficiency	NOUN
chd-155	113	10	in	in	ADP
chd-155	113	11	aa	aa	PROPN
chd-155	113	12	men	man	NOUN
chd-155	113	13	(	(	PUNCT
chd-155	113	14	hollis	hollis	PROPN
chd-155	113	15	et	et	PROPN
chd-155	113	16	al	al	PROPN
chd-155	113	17	.	.	PROPN
chd-155	113	18	,	,	PUNCT
chd-155	113	19	2013	2013	NUM
chd-155	113	20	)	)	PUNCT
chd-155	113	21	could	could	AUX
chd-155	113	22	explain	explain	VERB
chd-155	113	23	our	our	PRON
chd-155	113	24	finding	finding	NOUN
chd-155	113	25	that	that	SCONJ
chd-155	113	26	aa	aa	PROPN
chd-155	113	27	men	man	NOUN
chd-155	113	28	have	have	VERB
chd-155	113	29	lower	low	ADJ
chd-155	113	30	tumor	tumor	NOUN
chd-155	113	31	gdf15	gdf15	NOUN
chd-155	113	32	expression	expression	NOUN
chd-155	113	33	as	as	SCONJ
chd-155	113	34	the	the	DET
chd-155	113	35	stage	stage	NOUN
chd-155	113	36	progresses	progress	VERB
chd-155	113	37	.	.	PUNCT
chd-155	114	1	stated	state	VERB
chd-155	114	2	differently	differently	ADV
chd-155	114	3	,	,	PUNCT
chd-155	114	4	whereas	whereas	SCONJ
chd-155	114	5	white	white	ADJ
chd-155	114	6	men	man	NOUN
chd-155	114	7	do	do	AUX
chd-155	114	8	not	not	PART
chd-155	114	9	show	show	VERB
chd-155	114	10	a	a	DET
chd-155	114	11	lowering	lowering	NOUN
chd-155	114	12	of	of	ADP
chd-155	114	13	gdf15	gdf15	ADJ
chd-155	114	14	expression	expression	NOUN
chd-155	114	15	as	as	SCONJ
chd-155	114	16	tumor	tumor	NOUN
chd-155	114	17	spreads	spread	VERB
chd-155	114	18	outside	outside	ADP
chd-155	114	19	the	the	DET
chd-155	114	20	prostate	prostate	NOUN
chd-155	114	21	,	,	PUNCT
chd-155	114	22	such	such	DET
chd-155	114	23	a	a	DET
chd-155	114	24	reduction	reduction	NOUN
chd-155	114	25	occurs	occur	VERB
chd-155	114	26	in	in	ADP
chd-155	114	27	aa	aa	NOUN
chd-155	114	28	men	man	NOUN
chd-155	114	29	.	.	PUNCT
chd-155	115	1	whether	whether	SCONJ
chd-155	115	2	this	this	DET
chd-155	115	3	highly	highly	ADV
chd-155	115	4	significant	significant	ADJ
chd-155	115	5	(	(	PUNCT
chd-155	115	6	p=0.003	p=0.003	NOUN
chd-155	115	7	)	)	PUNCT
chd-155	115	8	lowering	lower	VERB
chd-155	115	9	of	of	ADP
chd-155	115	10	gdf15	gdf15	ADJ
chd-155	115	11	expression	expression	NOUN
chd-155	115	12	in	in	ADP
chd-155	115	13	benign	benign	ADJ
chd-155	115	14	epithelium	epithelium	NOUN
chd-155	115	15	in	in	ADP
chd-155	115	16	aa	aa	PROPN
chd-155	115	17	men	man	NOUN
chd-155	115	18	predicts	predict	VERB
chd-155	115	19	future	future	ADJ
chd-155	115	20	cancer	cancer	NOUN
chd-155	115	21	detection	detection	NOUN
chd-155	115	22	will	will	AUX
chd-155	115	23	require	require	VERB
chd-155	115	24	a	a	DET
chd-155	115	25	prospective	prospective	ADJ
chd-155	115	26	trial	trial	NOUN
chd-155	115	27	,	,	PUNCT
chd-155	115	28	based	base	VERB
chd-155	115	29	on	on	ADP
chd-155	115	30	repeated	repeat	VERB
chd-155	115	31	biopsies	biopsy	NOUN
chd-155	115	32	.	.	PUNCT
chd-155	116	1	notably	notably	ADV
chd-155	116	2	,	,	PUNCT
chd-155	116	3	increased	increased	ADJ
chd-155	116	4	circulating	circulate	VERB
chd-155	116	5	gdf15	gdf15	NOUN
chd-155	116	6	was	be	AUX
chd-155	116	7	significantly	significantly	ADV
chd-155	116	8	correlated	correlate	VERB
chd-155	116	9	with	with	ADP
chd-155	116	10	aa	aa	PROPN
chd-155	116	11	race	race	NOUN
chd-155	116	12	,	,	PUNCT
chd-155	116	13	smoking	smoking	NOUN
chd-155	116	14	,	,	PUNCT
chd-155	116	15	and	and	CCONJ
chd-155	116	16	hypertension	hypertension	NOUN
chd-155	116	17	(	(	PUNCT
chd-155	116	18	powell	powell	PROPN
chd-155	116	19	et	et	PROPN
chd-155	116	20	al	al	PROPN
chd-155	116	21	.	.	PROPN
chd-155	116	22	,	,	PUNCT
chd-155	116	23	2013	2013	NUM
chd-155	116	24	)	)	PUNCT
chd-155	116	25	,	,	PUNCT
chd-155	116	26	suggesting	suggest	VERB
chd-155	116	27	that	that	SCONJ
chd-155	116	28	some	some	DET
chd-155	116	29	gdf15	gdf15	NOUN
chd-155	116	30	originates	originate	NOUN
chd-155	116	31	from	from	ADP
chd-155	116	32	extraprostatic	extraprostatic	ADJ
chd-155	116	33	sources	source	NOUN
chd-155	116	34	.	.	PUNCT
chd-155	117	1	this	this	DET
chd-155	117	2	finding	finding	NOUN
chd-155	117	3	supports	support	VERB
chd-155	117	4	a	a	DET
chd-155	117	5	role	role	NOUN
chd-155	117	6	for	for	ADP
chd-155	117	7	gdf15	gdf15	NOUN
chd-155	117	8	in	in	ADP
chd-155	117	9	tumor	tumor	NOUN
chd-155	117	10	development	development	NOUN
chd-155	117	11	;	;	PUNCT
chd-155	117	12	for	for	ADP
chd-155	117	13	example	example	NOUN
chd-155	117	14	,	,	PUNCT
chd-155	117	15	increased	increase	VERB
chd-155	117	16	gdf15	gdf15	NOUN
chd-155	117	17	targets	target	NOUN
chd-155	117	18	p53	p53	NOUN
chd-155	117	19	and	and	CCONJ
chd-155	117	20	acts	act	VERB
chd-155	117	21	through	through	ADP
chd-155	117	22	the	the	DET
chd-155	117	23	pi3k	pi3k	PROPN
chd-155	117	24	/	/	SYM
chd-155	117	25	akt	akt	PROPN
chd-155	117	26	and	and	CCONJ
chd-155	117	27	mapk	mapk	PROPN
chd-155	117	28	/	/	SYM
chd-155	117	29	erk	erk	PROPN
chd-155	117	30	signaling	signal	VERB
chd-155	117	31	pathways	pathway	NOUN
chd-155	117	32	,	,	PUNCT
chd-155	117	33	with	with	ADP
chd-155	117	34	upregulation	upregulation	NOUN
chd-155	117	35	of	of	ADP
chd-155	117	36	cyclins	cyclin	NOUN
chd-155	117	37	d1	d1	PROPN
chd-155	117	38	and	and	CCONJ
chd-155	117	39	e1	e1	NOUN
chd-155	117	40	,	,	PUNCT
chd-155	117	41	to	to	PART
chd-155	117	42	promote	promote	VERB
chd-155	117	43	proliferation	proliferation	NOUN
chd-155	117	44	in	in	ADP
chd-155	117	45	cervical	cervical	ADJ
chd-155	117	46	carcinogenesis	carcinogenesis	NOUN
chd-155	117	47	(	(	PUNCT
chd-155	117	48	li	li	PROPN
chd-155	117	49	et	et	PROPN
chd-155	117	50	al	al	PROPN
chd-155	117	51	.	.	PROPN
chd-155	117	52	,	,	PUNCT
chd-155	117	53	2018	2018	NUM
chd-155	117	54	)	)	PUNCT
chd-155	117	55	.	.	PUNCT
chd-155	118	1	recent	recent	ADJ
chd-155	118	2	evidence	evidence	NOUN
chd-155	118	3	supports	support	VERB
chd-155	118	4	the	the	DET
chd-155	118	5	concept	concept	NOUN
chd-155	118	6	that	that	SCONJ
chd-155	118	7	the	the	DET
chd-155	118	8	greater	great	ADJ
chd-155	118	9	modulation	modulation	NOUN
chd-155	118	10	of	of	ADP
chd-155	118	11	gdf15	gdf15	NOUN
chd-155	118	12	in	in	ADP
chd-155	118	13	aa	aa	PROPN
chd-155	118	14	men	man	NOUN
chd-155	118	15	is	be	AUX
chd-155	118	16	related	relate	VERB
chd-155	118	17	to	to	ADP
chd-155	118	18	higher	high	ADJ
chd-155	118	19	risk	risk	NOUN
chd-155	118	20	of	of	ADP
chd-155	118	21	pc	pc	NOUN
chd-155	118	22	progression	progression	NOUN
chd-155	118	23	.	.	PUNCT
chd-155	119	1	a	a	DET
chd-155	119	2	racial	racial	ADJ
chd-155	119	3	disparity	disparity	NOUN
chd-155	119	4	was	be	AUX
chd-155	119	5	found	find	VERB
chd-155	119	6	in	in	ADP
chd-155	119	7	the	the	DET
chd-155	119	8	link	link	NOUN
chd-155	119	9	between	between	ADP
chd-155	119	10	psa	psa	NOUN
chd-155	119	11	velocity	velocity	NOUN
chd-155	119	12	and	and	CCONJ
chd-155	119	13	eventual	eventual	ADJ
chd-155	119	14	pc	pc	NOUN
chd-155	119	15	diagnosis	diagnosis	NOUN
chd-155	119	16	such	such	ADJ
chd-155	119	17	that	that	SCONJ
chd-155	119	18	nsaid	nsaid	PROPN
chd-155	119	19	use	use	NOUN
chd-155	119	20	was	be	AUX
chd-155	119	21	associated	associate	VERB
chd-155	119	22	with	with	ADP
chd-155	119	23	increased	increase	VERB
chd-155	119	24	pc	pc	NOUN
chd-155	119	25	risk	risk	NOUN
chd-155	119	26	only	only	ADV
chd-155	119	27	in	in	ADP
chd-155	119	28	aa	aa	PROPN
chd-155	119	29	men	man	NOUN
chd-155	119	30	but	but	CCONJ
chd-155	119	31	not	not	PART
chd-155	119	32	ea	ea	NUM
chd-155	119	33	men	man	NOUN
chd-155	119	34	(	(	PUNCT
chd-155	119	35	wallace	wallace	PROPN
chd-155	119	36	et	et	PROPN
chd-155	119	37	al	al	PROPN
chd-155	119	38	.	.	PROPN
chd-155	119	39	,	,	PUNCT
chd-155	119	40	2008	2008	NUM
chd-155	119	41	;	;	PUNCT
chd-155	119	42	kryvenko	kryvenko	PROPN
chd-155	119	43	et	et	PROPN
chd-155	119	44	al	al	PROPN
chd-155	119	45	.	.	PROPN
chd-155	119	46	,	,	PUNCT
chd-155	119	47	2019	2019	NUM
chd-155	119	48	)	)	PUNCT
chd-155	119	49	.	.	PUNCT
chd-155	120	1	since	since	SCONJ
chd-155	120	2	nsaid	nsaid	PROPN
chd-155	120	3	use	use	NOUN
chd-155	120	4	induces	induce	VERB
chd-155	120	5	gdf15	gdf15	ADJ
chd-155	120	6	expression	expression	NOUN
chd-155	120	7	(	(	PUNCT
chd-155	120	8	wang	wang	PROPN
chd-155	120	9	et	et	PROPN
chd-155	120	10	al	al	PROPN
chd-155	120	11	.	.	PROPN
chd-155	120	12	,	,	PUNCT
chd-155	120	13	2013	2013	NUM
chd-155	120	14	)	)	PUNCT
chd-155	120	15	,	,	PUNCT
chd-155	120	16	this	this	PRON
chd-155	120	17	aligns	align	VERB
chd-155	120	18	with	with	ADP
chd-155	120	19	astronger	astronger	ADJ
chd-155	120	20	role	role	NOUN
chd-155	120	21	of	of	ADP
chd-155	120	22	immunerelated	immunerelate	VERB
chd-155	120	23	genes	gene	NOUN
chd-155	120	24	in	in	ADP
chd-155	120	25	tumor	tumor	NOUN
chd-155	120	26	development	development	NOUN
chd-155	120	27	in	in	ADP
chd-155	120	28	aa	aa	NOUN
chd-155	120	29	men	man	NOUN
chd-155	120	30	than	than	SCONJ
chd-155	120	31	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-155	120	32	e7	e7	PROPN
chd-155	120	33	cancer	cancer	NOUN
chd-155	120	34	health	health	NOUN
chd-155	120	35	disparities	disparity	NOUN
chd-155	120	36	research	research	VERB
chd-155	120	37	in	in	ADP
chd-155	120	38	ea	ea	NOUN
chd-155	120	39	men	man	NOUN
chd-155	120	40	(	(	PUNCT
chd-155	120	41	wallace	wallace	PROPN
chd-155	120	42	et	et	PROPN
chd-155	120	43	al	al	PROPN
chd-155	120	44	.	.	PROPN
chd-155	120	45	,	,	PUNCT
chd-155	120	46	2008	2008	NUM
chd-155	120	47	)	)	PUNCT
chd-155	120	48	,	,	PUNCT
chd-155	120	49	and	and	CCONJ
chd-155	120	50	may	may	AUX
chd-155	120	51	relate	relate	VERB
chd-155	120	52	to	to	ADP
chd-155	120	53	the	the	DET
chd-155	120	54	current	current	ADJ
chd-155	120	55	study	study	NOUN
chd-155	120	56	where	where	SCONJ
chd-155	120	57	a	a	DET
chd-155	120	58	greater	great	ADJ
chd-155	120	59	stagewise	stagewise	NOUN
chd-155	120	60	modulation	modulation	NOUN
chd-155	120	61	of	of	ADP
chd-155	120	62	gdf15	gdf15	NOUN
chd-155	120	63	was	be	AUX
chd-155	120	64	found	find	VERB
chd-155	120	65	in	in	ADP
chd-155	120	66	aa	aa	NOUN
chd-155	120	67	men	man	NOUN
chd-155	120	68	than	than	ADP
chd-155	120	69	in	in	ADP
chd-155	120	70	ea	ea	NOUN
chd-155	120	71	men	man	NOUN
chd-155	120	72	(	(	PUNCT
chd-155	120	73	table	table	NOUN
chd-155	120	74	5	5	NUM
chd-155	120	75	)	)	PUNCT
chd-155	120	76	.	.	PUNCT
chd-155	121	1	nfκb	nfκb	PROPN
chd-155	121	2	is	be	AUX
chd-155	121	3	the	the	DET
chd-155	121	4	most	most	ADV
chd-155	121	5	important	important	ADJ
chd-155	121	6	transcription	transcription	NOUN
chd-155	121	7	factor	factor	NOUN
chd-155	121	8	for	for	ADP
chd-155	121	9	oxidative	oxidative	ADJ
chd-155	121	10	susceptibility	susceptibility	NOUN
chd-155	121	11	in	in	ADP
chd-155	121	12	the	the	DET
chd-155	121	13	body	body	NOUN
chd-155	121	14	.	.	PUNCT
chd-155	122	1	after	after	ADP
chd-155	122	2	activation	activation	NOUN
chd-155	122	3	,	,	PUNCT
chd-155	122	4	nfκb	nfκb	NOUN
chd-155	122	5	can	can	AUX
chd-155	122	6	activate	activate	VERB
chd-155	122	7	and	and	CCONJ
chd-155	122	8	regulate	regulate	VERB
chd-155	122	9	the	the	DET
chd-155	122	10	expression	expression	NOUN
chd-155	122	11	of	of	ADP
chd-155	122	12	many	many	ADJ
chd-155	122	13	inflammatory	inflammatory	ADJ
chd-155	122	14	factors	factor	NOUN
chd-155	122	15	,	,	PUNCT
chd-155	122	16	which	which	PRON
chd-155	122	17	makes	make	VERB
chd-155	122	18	it	it	PRON
chd-155	122	19	the	the	DET
chd-155	122	20	key	key	ADJ
chd-155	122	21	promoter	promoter	NOUN
chd-155	122	22	of	of	ADP
chd-155	122	23	the	the	DET
chd-155	122	24	inflammatory	inflammatory	ADJ
chd-155	122	25	response	response	NOUN
chd-155	122	26	.	.	PUNCT
chd-155	123	1	infection	infection	NOUN
chd-155	123	2	or	or	CCONJ
chd-155	123	3	hypoxia	hypoxia	NOUN
chd-155	123	4	activates	activate	VERB
chd-155	123	5	nfκb	nfκb	NOUN
chd-155	123	6	,	,	PUNCT
chd-155	123	7	which	which	PRON
chd-155	123	8	is	be	AUX
chd-155	123	9	inactive	inactive	ADJ
chd-155	123	10	in	in	ADP
chd-155	123	11	cells	cell	NOUN
chd-155	123	12	,	,	PUNCT
chd-155	123	13	and	and	CCONJ
chd-155	123	14	activates	activate	VERB
chd-155	123	15	inflammatory	inflammatory	ADJ
chd-155	123	16	genes	gene	NOUN
chd-155	123	17	,	,	PUNCT
chd-155	123	18	induces	induce	VERB
chd-155	123	19	the	the	DET
chd-155	123	20	upregulation	upregulation	NOUN
chd-155	123	21	of	of	ADP
chd-155	123	22	cytokines	cytokine	NOUN
chd-155	123	23	,	,	PUNCT
chd-155	123	24	adhesion	adhesion	NOUN
chd-155	123	25	molecules	molecule	NOUN
chd-155	123	26	,	,	PUNCT
chd-155	123	27	and	and	CCONJ
chd-155	123	28	vasoactive	vasoactive	ADJ
chd-155	123	29	regulators	regulator	NOUN
chd-155	123	30	and	and	CCONJ
chd-155	123	31	increases	increase	VERB
chd-155	123	32	the	the	DET
chd-155	123	33	concentration	concentration	NOUN
chd-155	123	34	of	of	ADP
chd-155	123	35	further	further	ADJ
chd-155	123	36	downstream	downstream	ADJ
chd-155	123	37	cytokines	cytokine	NOUN
chd-155	123	38	such	such	ADJ
chd-155	123	39	as	as	ADP
chd-155	123	40	tumor	tumor	NOUN
chd-155	123	41	necrosis	necrosis	NOUN
chd-155	123	42	factor	factor	NOUN
chd-155	123	43	-	-	PUNCT
chd-155	123	44	α	α	X
chd-155	123	45	(	(	PUNCT
chd-155	123	46	tnf	tnf	PROPN
chd-155	123	47	-	-	PUNCT
chd-155	123	48	α	α	NOUN
chd-155	123	49	)	)	PUNCT
chd-155	123	50	,	,	PUNCT
chd-155	123	51	interleukin-6	interleukin-6	PROPN
chd-155	123	52	(	(	PUNCT
chd-155	123	53	il6	il6	NOUN
chd-155	123	54	)	)	PUNCT
chd-155	123	55	,	,	PUNCT
chd-155	123	56	interleukin-8	interleukin-8	NUM
chd-155	123	57	(	(	PUNCT
chd-155	123	58	il-8	il-8	NOUN
chd-155	123	59	)	)	PUNCT
chd-155	123	60	and	and	CCONJ
chd-155	123	61	others	other	NOUN
chd-155	123	62	(	(	PUNCT
chd-155	123	63	moresco	moresco	PROPN
chd-155	123	64	et	et	PROPN
chd-155	123	65	al	al	PROPN
chd-155	123	66	.	.	PROPN
chd-155	123	67	,	,	PUNCT
chd-155	123	68	2011	2011	NUM
chd-155	123	69	)	)	PUNCT
chd-155	123	70	.	.	PUNCT
chd-155	124	1	our	our	PRON
chd-155	124	2	finding	finding	NOUN
chd-155	124	3	of	of	ADP
chd-155	124	4	more	more	ADJ
chd-155	124	5	pronounced	pronounced	ADJ
chd-155	124	6	rises	rise	NOUN
chd-155	124	7	in	in	ADP
chd-155	124	8	nfκb	nfκb	NOUN
chd-155	124	9	in	in	ADP
chd-155	124	10	cancer	cancer	NOUN
chd-155	124	11	glands	gland	NOUN
chd-155	124	12	in	in	ADP
chd-155	124	13	aa	aa	PROPN
chd-155	124	14	tumor	tumor	NOUN
chd-155	124	15	development	development	NOUN
chd-155	124	16	may	may	AUX
chd-155	124	17	correlate	correlate	VERB
chd-155	124	18	with	with	ADP
chd-155	124	19	the	the	DET
chd-155	124	20	more	more	ADV
chd-155	124	21	frequent	frequent	ADJ
chd-155	124	22	prostatic	prostatic	ADJ
chd-155	124	23	inflammation	inflammation	NOUN
chd-155	124	24	reported	report	VERB
chd-155	124	25	by	by	ADP
chd-155	124	26	some	some	PRON
chd-155	124	27	(	(	PUNCT
chd-155	124	28	eastham	eastham	PROPN
chd-155	124	29	et	et	PROPN
chd-155	124	30	al	al	PROPN
chd-155	124	31	.	.	PROPN
chd-155	124	32	,	,	PUNCT
chd-155	124	33	1998	1998	NUM
chd-155	124	34	)	)	PUNCT
chd-155	124	35	(	(	PUNCT
chd-155	124	36	but	but	CCONJ
chd-155	124	37	not	not	PART
chd-155	124	38	all	all	PRON
chd-155	124	39	)	)	PUNCT
chd-155	124	40	studies	study	NOUN
chd-155	124	41	in	in	ADP
chd-155	124	42	aa	aa	PROPN
chd-155	124	43	men	man	NOUN
chd-155	124	44	(	(	PUNCT
chd-155	124	45	bostwick	bostwick	PROPN
chd-155	124	46	et	et	PROPN
chd-155	124	47	al	al	PROPN
chd-155	124	48	.	.	PROPN
chd-155	124	49	,	,	PUNCT
chd-155	124	50	2003	2003	NUM
chd-155	124	51	)	)	PUNCT
chd-155	124	52	.	.	PUNCT
chd-155	125	1	previous	previous	ADJ
chd-155	125	2	studies	study	NOUN
chd-155	125	3	suggested	suggest	VERB
chd-155	125	4	nfκb	nfκb	NOUN
chd-155	125	5	to	to	PART
chd-155	125	6	have	have	VERB
chd-155	125	7	a	a	DET
chd-155	125	8	reciprocal	reciprocal	ADJ
chd-155	125	9	interaction	interaction	NOUN
chd-155	125	10	with	with	ADP
chd-155	125	11	gdf15	gdf15	PROPN
chd-155	125	12	(	(	PUNCT
chd-155	125	13	lambert	lambert	PROPN
chd-155	125	14	et	et	PROPN
chd-155	125	15	al	al	PROPN
chd-155	125	16	.	.	PROPN
chd-155	125	17	,	,	PUNCT
chd-155	125	18	2015	2015	NUM
chd-155	125	19	;	;	PUNCT
chd-155	125	20	zhang	zhang	PROPN
chd-155	125	21	et	et	PROPN
chd-155	125	22	al	al	PROPN
chd-155	125	23	.	.	PROPN
chd-155	125	24	,	,	PUNCT
chd-155	125	25	2018	2018	NUM
chd-155	125	26	)	)	PUNCT
chd-155	125	27	.	.	PUNCT
chd-155	126	1	thus	thus	ADV
chd-155	126	2	,	,	PUNCT
chd-155	126	3	a	a	DET
chd-155	126	4	firefly	firefly	NOUN
chd-155	126	5	luciferase	luciferase	NOUN
chd-155	126	6	construct	construct	NOUN
chd-155	126	7	was	be	AUX
chd-155	126	8	used	use	VERB
chd-155	126	9	to	to	PART
chd-155	126	10	show	show	VERB
chd-155	126	11	that	that	SCONJ
chd-155	126	12	expression	expression	NOUN
chd-155	126	13	of	of	ADP
chd-155	126	14	the	the	DET
chd-155	126	15	nfκb	nfκb	NOUN
chd-155	126	16	target	target	NOUN
chd-155	126	17	,	,	PUNCT
chd-155	126	18	interleukin	interleukin	NOUN
chd-155	126	19	8	8	NUM
chd-155	126	20	(	(	PUNCT
chd-155	126	21	il-8	il-8	NUM
chd-155	126	22	)	)	PUNCT
chd-155	126	23	,	,	PUNCT
chd-155	126	24	was	be	AUX
chd-155	126	25	downregulated	downregulate	VERB
chd-155	126	26	by	by	ADP
chd-155	126	27	gdf15	gdf15	NOUN
chd-155	126	28	in	in	ADP
chd-155	126	29	pc3	pc3	PROPN
chd-155	126	30	cells	cell	NOUN
chd-155	126	31	(	(	PUNCT
chd-155	126	32	lambert	lambert	PROPN
chd-155	126	33	et	et	PROPN
chd-155	126	34	al	al	PROPN
chd-155	126	35	.	.	PROPN
chd-155	126	36	,	,	PUNCT
chd-155	126	37	2015	2015	NUM
chd-155	126	38	)	)	PUNCT
chd-155	126	39	.	.	PUNCT
chd-155	127	1	gdf15	gdf15	PROPN
chd-155	127	2	also	also	ADV
chd-155	127	3	inactivates	inactivate	VERB
chd-155	127	4	nfκb	nfκb	NOUN
chd-155	127	5	signaling	signal	VERB
chd-155	127	6	in	in	ADP
chd-155	127	7	dendritic	dendritic	ADJ
chd-155	127	8	cells	cell	NOUN
chd-155	127	9	,	,	PUNCT
chd-155	127	10	enabling	enable	VERB
chd-155	127	11	induction	induction	NOUN
chd-155	127	12	of	of	ADP
chd-155	127	13	immune	immune	ADJ
chd-155	127	14	tolerance	tolerance	NOUN
chd-155	127	15	after	after	ADP
chd-155	127	16	heart	heart	NOUN
chd-155	127	17	transplantation	transplantation	NOUN
chd-155	127	18	(	(	PUNCT
chd-155	127	19	zhang	zhang	X
chd-155	127	20	et	et	PROPN
chd-155	127	21	al	al	PROPN
chd-155	127	22	.	.	PROPN
chd-155	127	23	,	,	PUNCT
chd-155	127	24	2018	2018	NUM
chd-155	127	25	)	)	PUNCT
chd-155	127	26	.	.	PUNCT
chd-155	128	1	on	on	ADP
chd-155	128	2	this	this	DET
chd-155	128	3	basis	basis	NOUN
chd-155	128	4	,	,	PUNCT
chd-155	128	5	upregulation	upregulation	NOUN
chd-155	128	6	of	of	ADP
chd-155	128	7	nfκb	nfκb	NOUN
chd-155	128	8	with	with	ADP
chd-155	128	9	tumor	tumor	NOUN
chd-155	128	10	stage	stage	NOUN
chd-155	128	11	might	might	AUX
chd-155	128	12	be	be	AUX
chd-155	128	13	expected	expect	VERB
chd-155	128	14	,	,	PUNCT
chd-155	128	15	but	but	CCONJ
chd-155	128	16	this	this	PRON
chd-155	128	17	was	be	AUX
chd-155	128	18	noted	note	VERB
chd-155	128	19	in	in	ADP
chd-155	128	20	the	the	DET
chd-155	128	21	tumor	tumor	NOUN
chd-155	128	22	only	only	ADV
chd-155	128	23	in	in	ADP
chd-155	128	24	aa	aa	PROPN
chd-155	128	25	men	man	NOUN
chd-155	128	26	(	(	PUNCT
chd-155	128	27	with	with	ADP
chd-155	128	28	stagewise	stagewise	NOUN
chd-155	128	29	upregulation	upregulation	NOUN
chd-155	128	30	in	in	ADP
chd-155	128	31	benign	benign	ADJ
chd-155	128	32	glands	gland	NOUN
chd-155	128	33	in	in	ADP
chd-155	128	34	ea	ea	NOUN
chd-155	128	35	men	man	NOUN
chd-155	128	36	)	)	PUNCT
chd-155	128	37	.	.	PUNCT
chd-155	129	1	this	this	PRON
chd-155	129	2	could	could	AUX
chd-155	129	3	be	be	AUX
chd-155	129	4	explained	explain	VERB
chd-155	129	5	by	by	ADP
chd-155	129	6	lower	low	ADJ
chd-155	129	7	gdf15	gdf15	NOUN
chd-155	129	8	in	in	ADP
chd-155	129	9	progression	progression	NOUN
chd-155	129	10	of	of	ADP
chd-155	129	11	aa	aa	PROPN
chd-155	129	12	men	man	NOUN
chd-155	129	13	’s	’s	PART
chd-155	129	14	tumors	tumor	NOUN
chd-155	129	15	,	,	PUNCT
chd-155	129	16	allowing	allow	VERB
chd-155	129	17	a	a	DET
chd-155	129	18	greater	great	ADJ
chd-155	129	19	rise	rise	NOUN
chd-155	129	20	in	in	ADP
chd-155	129	21	nfκb	nfκb	ADJ
chd-155	129	22	expression	expression	NOUN
chd-155	129	23	in	in	ADP
chd-155	129	24	response	response	NOUN
chd-155	129	25	to	to	ADP
chd-155	129	26	tumor	tumor	NOUN
chd-155	129	27	.	.	PUNCT
chd-155	130	1	the	the	DET
chd-155	130	2	altered	alter	VERB
chd-155	130	3	nfκb	nfκb	NOUN
chd-155	130	4	in	in	ADP
chd-155	130	5	aa	aa	PROPN
chd-155	130	6	men	man	NOUN
chd-155	130	7	could	could	AUX
chd-155	130	8	correlate	correlate	VERB
chd-155	130	9	with	with	ADP
chd-155	130	10	inflammatory	inflammatory	ADJ
chd-155	130	11	response	response	NOUN
chd-155	130	12	to	to	ADP
chd-155	130	13	the	the	DET
chd-155	130	14	cancer	cancer	NOUN
chd-155	130	15	tissue	tissue	NOUN
chd-155	130	16	,	,	PUNCT
chd-155	130	17	but	but	CCONJ
chd-155	130	18	the	the	DET
chd-155	130	19	non	non	ADJ
chd-155	130	20	-	-	ADJ
chd-155	130	21	neoplastic	neoplastic	ADJ
chd-155	130	22	cells	cell	NOUN
chd-155	130	23	also	also	ADV
chd-155	130	24	have	have	VERB
chd-155	130	25	a	a	DET
chd-155	130	26	greater	great	ADJ
chd-155	130	27	rise	rise	NOUN
chd-155	130	28	in	in	ADP
chd-155	130	29	ea	ea	NOUN
chd-155	130	30	men	man	NOUN
chd-155	130	31	which	which	PRON
chd-155	130	32	may	may	AUX
chd-155	130	33	cause	cause	VERB
chd-155	130	34	localization	localization	NOUN
chd-155	130	35	of	of	ADP
chd-155	130	36	inflammatory	inflammatory	ADJ
chd-155	130	37	cells	cell	NOUN
chd-155	130	38	to	to	ADP
chd-155	130	39	the	the	DET
chd-155	130	40	tumor	tumor	NOUN
chd-155	130	41	.	.	PUNCT
chd-155	131	1	in	in	ADP
chd-155	131	2	cancer	cancer	NOUN
chd-155	131	3	,	,	PUNCT
chd-155	131	4	nfκb	nfκb	NOUN
chd-155	131	5	becomes	becomes	AUX
chd-155	131	6	constitutively	constitutively	ADV
chd-155	131	7	activated	activate	VERB
chd-155	131	8	in	in	ADP
chd-155	131	9	a	a	DET
chd-155	131	10	high	high	ADJ
chd-155	131	11	proportion	proportion	NOUN
chd-155	131	12	of	of	ADP
chd-155	131	13	androgen	androgen	NOUN
chd-155	131	14	-	-	PUNCT
chd-155	131	15	independent	independent	ADJ
chd-155	131	16	prostate	prostate	NOUN
chd-155	131	17	cancers	cancer	NOUN
chd-155	131	18	(	(	PUNCT
chd-155	131	19	jin	jin	NOUN
chd-155	131	20	et	et	PROPN
chd-155	131	21	al	al	PROPN
chd-155	131	22	.	.	PROPN
chd-155	131	23	,	,	PUNCT
chd-155	131	24	2008	2008	NUM
chd-155	131	25	;	;	PUNCT
chd-155	131	26	nadiminty	nadiminty	NUM
chd-155	131	27	et	et	PROPN
chd-155	131	28	al	al	PROPN
chd-155	131	29	.	.	PROPN
chd-155	131	30	,	,	PUNCT
chd-155	131	31	2008	2008	NUM
chd-155	131	32	)	)	PUNCT
chd-155	131	33	.	.	PUNCT
chd-155	132	1	apparently	apparently	ADV
chd-155	132	2	,	,	PUNCT
chd-155	132	3	the	the	DET
chd-155	132	4	ability	ability	NOUN
chd-155	132	5	of	of	ADP
chd-155	132	6	nfκb	nfκb	NOUN
chd-155	132	7	to	to	PART
chd-155	132	8	promote	promote	VERB
chd-155	132	9	transcription	transcription	NOUN
chd-155	132	10	of	of	ADP
chd-155	132	11	the	the	DET
chd-155	132	12	prominent	prominent	ADJ
chd-155	132	13	anti	anti	ADJ
chd-155	132	14	-	-	ADJ
chd-155	132	15	apoptotic	apoptotic	ADJ
chd-155	132	16	protein	protein	NOUN
chd-155	132	17	bcl-2	bcl-2	PUNCT
chd-155	132	18	and	and	CCONJ
chd-155	132	19	cyclin	cyclin	NOUN
chd-155	132	20	d1	d1	PROPN
chd-155	132	21	,	,	PUNCT
chd-155	132	22	cyclooxygenase-2	cyclooxygenase-2	X
chd-155	132	23	,	,	PUNCT
chd-155	132	24	matrix	matrix	NOUN
chd-155	132	25	metalloproteinase	metalloproteinase	NOUN
chd-155	132	26	9	9	NUM
chd-155	132	27	,	,	PUNCT
chd-155	132	28	nitric	nitric	ADJ
chd-155	132	29	oxide	oxide	NOUN
chd-155	132	30	synthase-2	synthase-2	CCONJ
chd-155	132	31	(	(	PUNCT
chd-155	132	32	nos-2	nos-2	NOUN
chd-155	132	33	)	)	PUNCT
chd-155	132	34	,	,	PUNCT
chd-155	132	35	and	and	CCONJ
chd-155	132	36	vascular	vascular	ADJ
chd-155	132	37	endothelial	endothelial	ADJ
chd-155	132	38	growth	growth	NOUN
chd-155	132	39	factor	factor	NOUN
chd-155	132	40	aids	aid	VERB
chd-155	132	41	the	the	DET
chd-155	132	42	survival	survival	NOUN
chd-155	132	43	of	of	ADP
chd-155	132	44	cells	cell	NOUN
chd-155	132	45	that	that	PRON
chd-155	132	46	would	would	AUX
chd-155	132	47	otherwise	otherwise	ADV
chd-155	132	48	die	die	VERB
chd-155	132	49	owing	owe	VERB
chd-155	132	50	to	to	ADP
chd-155	132	51	loss	loss	NOUN
chd-155	132	52	of	of	ADP
chd-155	132	53	androgen	androgen	NOUN
chd-155	132	54	activity	activity	NOUN
chd-155	132	55	(	(	PUNCT
chd-155	132	56	shukla	shukla	NOUN
chd-155	132	57	et	et	NOUN
chd-155	132	58	al	al	PROPN
chd-155	132	59	.	.	PROPN
chd-155	132	60	,	,	PUNCT
chd-155	132	61	2004	2004	NUM
chd-155	132	62	)	)	PUNCT
chd-155	132	63	.	.	PUNCT
chd-155	133	1	we	we	PRON
chd-155	133	2	observed	observe	VERB
chd-155	133	3	a	a	DET
chd-155	133	4	gradewise	gradewise	NOUN
chd-155	133	5	increase	increase	NOUN
chd-155	133	6	of	of	ADP
chd-155	133	7	tumor	tumor	NOUN
chd-155	133	8	expression	expression	NOUN
chd-155	133	9	of	of	ADP
chd-155	133	10	nfκb	nfκb	NOUN
chd-155	133	11	in	in	ADP
chd-155	133	12	aa	aa	PROPN
chd-155	133	13	men	man	NOUN
chd-155	133	14	but	but	CCONJ
chd-155	133	15	not	not	PART
chd-155	133	16	ea	ea	NUM
chd-155	133	17	men	man	NOUN
chd-155	133	18	,	,	PUNCT
chd-155	133	19	a	a	DET
chd-155	133	20	finding	finding	NOUN
chd-155	133	21	possibly	possibly	ADV
chd-155	133	22	related	relate	VERB
chd-155	133	23	to	to	ADP
chd-155	133	24	greater	great	ADJ
chd-155	133	25	attainment	attainment	NOUN
chd-155	133	26	of	of	ADP
chd-155	133	27	androgen	androgen	NOUN
chd-155	133	28	independence	independence	NOUN
chd-155	133	29	in	in	ADP
chd-155	133	30	aa	aa	PROPN
chd-155	133	31	men	man	NOUN
chd-155	133	32	.	.	PUNCT
chd-155	134	1	signaling	signal	VERB
chd-155	134	2	linked	link	VERB
chd-155	134	3	to	to	ADP
chd-155	134	4	nfκb	nfκb	NOUN
chd-155	134	5	and	and	CCONJ
chd-155	134	6	inflammatory	inflammatory	ADJ
chd-155	134	7	cytokine	cytokine	NOUN
chd-155	134	8	factors	factor	NOUN
chd-155	134	9	was	be	AUX
chd-155	134	10	preferentially	preferentially	ADV
chd-155	134	11	upregulated	upregulate	VERB
chd-155	134	12	in	in	ADP
chd-155	134	13	pc	pc	NOUN
chd-155	134	14	from	from	ADP
chd-155	134	15	aa	aa	PROPN
chd-155	134	16	race	race	NOUN
chd-155	134	17	(	(	PUNCT
chd-155	134	18	powell	powell	PROPN
chd-155	134	19	et	et	PROPN
chd-155	134	20	al	al	PROPN
chd-155	134	21	.	.	PROPN
chd-155	134	22	,	,	PUNCT
chd-155	134	23	2013	2013	NUM
chd-155	134	24	)	)	PUNCT
chd-155	134	25	.	.	PUNCT
chd-155	135	1	in	in	ADP
chd-155	135	2	the	the	DET
chd-155	135	3	face	face	NOUN
chd-155	135	4	of	of	ADP
chd-155	135	5	lower	low	ADJ
chd-155	135	6	nfκb	nfκb	NOUN
chd-155	135	7	expression	expression	NOUN
chd-155	135	8	by	by	ADP
chd-155	135	9	the	the	DET
chd-155	135	10	tumor	tumor	NOUN
chd-155	135	11	,	,	PUNCT
chd-155	135	12	this	this	PRON
chd-155	135	13	suggests	suggest	VERB
chd-155	135	14	a	a	DET
chd-155	135	15	greater	great	ADJ
chd-155	135	16	sensitivity	sensitivity	NOUN
chd-155	135	17	of	of	ADP
chd-155	135	18	the	the	DET
chd-155	135	19	post	post	ADJ
chd-155	135	20	-	-	ADJ
chd-155	135	21	nfκb	nfκb	ADJ
chd-155	135	22	cascade	cascade	NOUN
chd-155	135	23	in	in	ADP
chd-155	135	24	aa	aa	NOUN
chd-155	135	25	men	man	NOUN
chd-155	135	26	.	.	PUNCT
chd-155	136	1	aside	aside	ADV
chd-155	136	2	from	from	ADP
chd-155	136	3	these	these	DET
chd-155	136	4	two	two	NUM
chd-155	136	5	molecules	molecule	NOUN
chd-155	136	6	,	,	PUNCT
chd-155	136	7	other	other	ADJ
chd-155	136	8	signaling	signal	VERB
chd-155	136	9	pathways	pathway	NOUN
chd-155	136	10	involved	involve	VERB
chd-155	136	11	in	in	ADP
chd-155	136	12	the	the	DET
chd-155	136	13	immune	immune	ADJ
chd-155	136	14	response	response	NOUN
chd-155	136	15	have	have	AUX
chd-155	136	16	also	also	ADV
chd-155	136	17	been	be	AUX
chd-155	136	18	noted	note	VERB
chd-155	136	19	to	to	PART
chd-155	136	20	show	show	VERB
chd-155	136	21	a	a	DET
chd-155	136	22	racial	racial	ADJ
chd-155	136	23	disparity	disparity	NOUN
chd-155	136	24	in	in	ADP
chd-155	136	25	prostate	prostate	NOUN
chd-155	136	26	cancer	cancer	NOUN
chd-155	136	27	.	.	PUNCT
chd-155	137	1	a	a	DET
chd-155	137	2	germline	germline	NOUN
chd-155	137	3	variant	variant	NOUN
chd-155	137	4	called	call	VERB
chd-155	137	5	interferon	interferon	ADJ
chd-155	137	6	lambda	lambda	NOUN
chd-155	137	7	4	4	NUM
chd-155	137	8	was	be	AUX
chd-155	137	9	twice	twice	ADV
chd-155	137	10	as	as	ADV
chd-155	137	11	common	common	ADJ
chd-155	137	12	in	in	ADP
chd-155	137	13	prostate	prostate	NOUN
chd-155	137	14	tumors	tumor	NOUN
chd-155	137	15	of	of	ADP
chd-155	137	16	aa	aa	PROPN
chd-155	137	17	men	man	NOUN
chd-155	137	18	than	than	ADP
chd-155	137	19	white	white	ADJ
chd-155	137	20	men	man	NOUN
chd-155	137	21	(	(	PUNCT
chd-155	137	22	42	42	NUM
chd-155	137	23	-	-	SYM
chd-155	137	24	67	67	NUM
chd-155	137	25	%	%	NOUN
chd-155	137	26	versus	versus	ADP
chd-155	137	27	18	18	NUM
chd-155	137	28	-	-	SYM
chd-155	137	29	33	33	NUM
chd-155	137	30	%	%	NOUN
chd-155	137	31	)	)	PUNCT
chd-155	137	32	;	;	PUNCT
chd-155	137	33	this	this	PRON
chd-155	137	34	relied	rely	VERB
chd-155	137	35	on	on	ADP
chd-155	137	36	pro	pro	ADJ
chd-155	137	37	-	-	ADJ
chd-155	137	38	tumorigenic	tumorigenic	ADJ
chd-155	137	39	jak	jak	PROPN
chd-155	137	40	-	-	PUNCT
chd-155	137	41	stat	stat	NOUN
chd-155	137	42	signaling	signal	VERB
chd-155	137	43	,	,	PUNCT
chd-155	137	44	and	and	CCONJ
chd-155	137	45	was	be	AUX
chd-155	137	46	associated	associate	VERB
chd-155	137	47	with	with	ADP
chd-155	137	48	decreased	decrease	VERB
chd-155	137	49	survival	survival	NOUN
chd-155	137	50	(	(	PUNCT
chd-155	137	51	tang	tang	X
chd-155	137	52	et	et	PROPN
chd-155	137	53	al	al	PROPN
chd-155	137	54	.	.	PROPN
chd-155	137	55	,	,	PUNCT
chd-155	137	56	2018	2018	NUM
chd-155	137	57	)	)	PUNCT
chd-155	137	58	.	.	PUNCT
chd-155	138	1	it	it	PRON
chd-155	138	2	is	be	AUX
chd-155	138	3	uncertain	uncertain	ADJ
chd-155	138	4	whether	whether	SCONJ
chd-155	138	5	our	our	PRON
chd-155	138	6	results	result	NOUN
chd-155	138	7	are	be	AUX
chd-155	138	8	consistent	consistent	ADJ
chd-155	138	9	with	with	ADP
chd-155	138	10	the	the	DET
chd-155	138	11	current	current	ADJ
chd-155	138	12	understanding	understanding	NOUN
chd-155	138	13	of	of	ADP
chd-155	138	14	the	the	DET
chd-155	138	15	prostatic	prostatic	ADJ
chd-155	138	16	inflammatory	inflammatory	ADJ
chd-155	138	17	environment	environment	NOUN
chd-155	138	18	.	.	PUNCT
chd-155	139	1	the	the	DET
chd-155	139	2	normal	normal	ADJ
chd-155	139	3	prostate	prostate	NOUN
chd-155	139	4	contains	contain	VERB
chd-155	139	5	lymphocytes	lymphocyte	NOUN
chd-155	139	6	,	,	PUNCT
chd-155	139	7	of	of	ADP
chd-155	139	8	which	which	PRON
chd-155	139	9	>	>	SYM
chd-155	139	10	90	90	NUM
chd-155	139	11	%	%	NOUN
chd-155	139	12	are	be	AUX
chd-155	139	13	t	t	NOUN
chd-155	139	14	cells	cell	NOUN
chd-155	139	15	;	;	PUNCT
chd-155	139	16	and	and	CCONJ
chd-155	139	17	those	those	PRON
chd-155	139	18	in	in	ADP
chd-155	139	19	the	the	DET
chd-155	139	20	epithelium	epithelium	NOUN
chd-155	139	21	are	be	AUX
chd-155	139	22	predominantly	predominantly	ADV
chd-155	139	23	cytotoxic	cytotoxic	ADJ
chd-155	139	24	/	/	SYM
chd-155	139	25	suppressor	suppressor	NOUN
chd-155	139	26	(	(	PUNCT
chd-155	139	27	cd8	cd8	PROPN
chd-155	139	28	+	+	PROPN
chd-155	139	29	)	)	PUNCT
chd-155	139	30	(	(	PUNCT
chd-155	139	31	bostwick	bostwick	PROPN
chd-155	139	32	et	et	PROPN
chd-155	139	33	al	al	PROPN
chd-155	139	34	.	.	PROPN
chd-155	139	35	,	,	PUNCT
chd-155	139	36	2003	2003	NUM
chd-155	139	37	;	;	PUNCT
chd-155	139	38	eastham	eastham	PROPN
chd-155	139	39	et	et	PROPN
chd-155	139	40	al	al	PROPN
chd-155	139	41	.	.	PROPN
chd-155	139	42	,	,	PUNCT
chd-155	139	43	1998	1998	NUM
chd-155	139	44	)	)	PUNCT
chd-155	139	45	.	.	PUNCT
chd-155	140	1	studying	study	VERB
chd-155	140	2	just	just	ADV
chd-155	140	3	tumor	tumor	NOUN
chd-155	140	4	-	-	PUNCT
chd-155	140	5	infiltrating	infiltrate	VERB
chd-155	140	6	t	t	NOUN
chd-155	140	7	-	-	PUNCT
chd-155	140	8	cell	cell	NOUN
chd-155	140	9	density	density	NOUN
chd-155	140	10	with	with	ADP
chd-155	140	11	three	three	NUM
chd-155	140	12	immunohistochemical	immunohistochemical	ADJ
chd-155	140	13	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-155	140	14	e8	e8	PROPN
chd-155	140	15	cancer	cancer	NOUN
chd-155	140	16	health	health	NOUN
chd-155	140	17	disparities	disparity	NOUN
chd-155	140	18	research	research	NOUN
chd-155	140	19	markers	marker	NOUN
chd-155	140	20	and	and	CCONJ
chd-155	140	21	image	image	NOUN
chd-155	140	22	analysis	analysis	NOUN
chd-155	140	23	,	,	PUNCT
chd-155	140	24	kaur	kaur	PROPN
chd-155	140	25	et	et	PROPN
chd-155	140	26	al	al	PROPN
chd-155	140	27	.	.	PROPN
chd-155	140	28	found	find	VERB
chd-155	140	29	no	no	DET
chd-155	140	30	association	association	NOUN
chd-155	140	31	with	with	ADP
chd-155	140	32	ea	ea	NOUN
chd-155	140	33	or	or	CCONJ
chd-155	140	34	aa	aa	INTJ
chd-155	140	35	racial	racial	ADJ
chd-155	140	36	ancestry	ancestry	NOUN
chd-155	140	37	(	(	PUNCT
chd-155	140	38	kaur	kaur	PROPN
chd-155	140	39	et	et	PROPN
chd-155	140	40	al	al	PROPN
chd-155	140	41	.	.	PROPN
chd-155	140	42	,	,	PUNCT
chd-155	140	43	2018	2018	NUM
chd-155	140	44	)	)	PUNCT
chd-155	140	45	although	although	SCONJ
chd-155	140	46	increased	increase	VERB
chd-155	140	47	t	t	PROPN
chd-155	140	48	-	-	PUNCT
chd-155	140	49	cell	cell	NOUN
chd-155	140	50	density	density	NOUN
chd-155	140	51	was	be	AUX
chd-155	140	52	associated	associate	VERB
chd-155	140	53	with	with	ADP
chd-155	140	54	erg	erg	PROPN
chd-155	140	55	positivity	positivity	NOUN
chd-155	140	56	and	and	CCONJ
chd-155	140	57	pten	pten	VERB
chd-155	140	58	loss	loss	NOUN
chd-155	140	59	in	in	ADP
chd-155	140	60	both	both	DET
chd-155	140	61	races	race	NOUN
chd-155	140	62	.	.	PUNCT
chd-155	141	1	the	the	DET
chd-155	141	2	reduce	reduce	NOUN
chd-155	141	3	study	study	NOUN
chd-155	141	4	,	,	PUNCT
chd-155	141	5	a	a	DET
chd-155	141	6	4	4	NUM
chd-155	141	7	-	-	PUNCT
chd-155	141	8	year	year	NOUN
chd-155	141	9	,	,	PUNCT
chd-155	141	10	multicenter	multicenter	NOUN
chd-155	141	11	,	,	PUNCT
chd-155	141	12	placebo	placebo	NOUN
chd-155	141	13	-	-	PUNCT
chd-155	141	14	controlled	control	VERB
chd-155	141	15	study	study	NOUN
chd-155	141	16	in	in	ADP
chd-155	141	17	which	which	PRON
chd-155	141	18	a	a	DET
chd-155	141	19	negative	negative	ADJ
chd-155	141	20	prostate	prostate	NOUN
chd-155	141	21	biopsy	biopsy	NOUN
chd-155	141	22	was	be	AUX
chd-155	141	23	criterion	criterion	NOUN
chd-155	141	24	for	for	ADP
chd-155	141	25	enrollment	enrollment	NOUN
chd-155	141	26	,	,	PUNCT
chd-155	141	27	involved	involve	VERB
chd-155	141	28	7,982	7,982	NUM
chd-155	141	29	men	man	NOUN
chd-155	141	30	:	:	PUNCT
chd-155	141	31	7,271	7,271	NUM
chd-155	141	32	white	white	ADJ
chd-155	141	33	and	and	CCONJ
chd-155	141	34	180	180	NUM
chd-155	141	35	aa	aa	NOUN
chd-155	141	36	men	man	NOUN
chd-155	141	37	.	.	PUNCT
chd-155	142	1	no	no	DET
chd-155	142	2	differences	difference	NOUN
chd-155	142	3	were	be	AUX
chd-155	142	4	noted	note	VERB
chd-155	142	5	in	in	ADP
chd-155	142	6	chronic	chronic	ADJ
chd-155	142	7	inflammation	inflammation	NOUN
chd-155	142	8	,	,	PUNCT
chd-155	142	9	but	but	CCONJ
chd-155	142	10	aa	aa	ADJ
chd-155	142	11	men	man	NOUN
chd-155	142	12	were	be	AUX
chd-155	142	13	less	less	ADV
chd-155	142	14	likely	likely	ADJ
chd-155	142	15	(	(	PUNCT
chd-155	142	16	or	or	CCONJ
chd-155	142	17	=	=	SYM
chd-155	142	18	0.65	0.65	NUM
chd-155	142	19	,	,	PUNCT
chd-155	142	20	95%ci	95%ci	NUM
chd-155	142	21	:	:	PUNCT
chd-155	142	22	0.41	0.41	NUM
chd-155	142	23	-	-	SYM
chd-155	142	24	1.03	1.03	NUM
chd-155	142	25	,	,	PUNCT
chd-155	142	26	p=	p=	NOUN
chd-155	142	27	0.07	0.07	NUM
chd-155	142	28	)	)	PUNCT
chd-155	142	29	and	and	CCONJ
chd-155	142	30	asian	asian	ADJ
chd-155	142	31	men	man	NOUN
chd-155	142	32	(	(	PUNCT
chd-155	142	33	or	or	CCONJ
chd-155	142	34	=	=	SYM
chd-155	142	35	1.74	1.74	NUM
chd-155	142	36	,	,	PUNCT
chd-155	142	37	95%ci	95%ci	NUM
chd-155	142	38	:	:	PUNCT
chd-155	142	39	1.142.65	1.142.65	NUM
chd-155	142	40	,	,	PUNCT
chd-155	142	41	p=	p=	NOUN
chd-155	142	42	0.001	0.001	NUM
chd-155	142	43	)	)	PUNCT
chd-155	142	44	more	more	ADV
chd-155	142	45	likely	likely	ADJ
chd-155	142	46	,	,	PUNCT
chd-155	142	47	to	to	PART
chd-155	142	48	have	have	VERB
chd-155	142	49	acute	acute	ADJ
chd-155	142	50	inflammation	inflammation	NOUN
chd-155	142	51	(	(	PUNCT
chd-155	142	52	vidal	vidal	PROPN
chd-155	142	53	et	et	PROPN
chd-155	142	54	al	al	PROPN
chd-155	142	55	.	.	PROPN
chd-155	142	56	,	,	PUNCT
chd-155	142	57	2016	2016	NUM
chd-155	142	58	)	)	PUNCT
chd-155	142	59	.	.	PUNCT
chd-155	143	1	inflammation	inflammation	NOUN
chd-155	143	2	in	in	ADP
chd-155	143	3	biopsies	biopsy	NOUN
chd-155	143	4	was	be	AUX
chd-155	143	5	associated	associate	VERB
chd-155	143	6	with	with	ADP
chd-155	143	7	decreased	decrease	VERB
chd-155	143	8	cancer	cancer	NOUN
chd-155	143	9	risk	risk	NOUN
chd-155	143	10	in	in	ADP
chd-155	143	11	other	other	ADJ
chd-155	143	12	case	case	NOUN
chd-155	143	13	-	-	PUNCT
chd-155	143	14	control	control	NOUN
chd-155	143	15	studies	study	NOUN
chd-155	143	16	(	(	PUNCT
chd-155	143	17	kryvenko	kryvenko	PROPN
chd-155	143	18	et	et	PROPN
chd-155	143	19	al	al	PROPN
chd-155	143	20	.	.	PROPN
chd-155	143	21	,	,	PUNCT
chd-155	143	22	2012	2012	NUM
chd-155	143	23	;	;	PUNCT
chd-155	143	24	ylihemminki	ylihemminki	PROPN
chd-155	143	25	et	et	PROPN
chd-155	143	26	al	al	PROPN
chd-155	143	27	.	.	PROPN
chd-155	143	28	,	,	PUNCT
chd-155	143	29	2013	2013	NUM
chd-155	143	30	)	)	PUNCT
chd-155	143	31	.	.	PUNCT
chd-155	144	1	our	our	PRON
chd-155	144	2	topographic	topographic	PROPN
chd-155	144	3	/	/	SYM
chd-155	144	4	spatial	spatial	ADJ
chd-155	144	5	study	study	NOUN
chd-155	144	6	of	of	ADP
chd-155	144	7	atrophy	atrophy	NOUN
chd-155	144	8	had	have	AUX
chd-155	144	9	found	find	VERB
chd-155	144	10	only	only	ADV
chd-155	144	11	a	a	DET
chd-155	144	12	weak	weak	ADJ
chd-155	144	13	association	association	NOUN
chd-155	144	14	of	of	ADP
chd-155	144	15	inflammation	inflammation	NOUN
chd-155	144	16	with	with	ADP
chd-155	144	17	cancer	cancer	NOUN
chd-155	144	18	provided	provide	VERB
chd-155	144	19	the	the	DET
chd-155	144	20	inflammation	inflammation	NOUN
chd-155	144	21	was	be	AUX
chd-155	144	22	accompanied	accompany	VERB
chd-155	144	23	by	by	ADP
chd-155	144	24	atrophy	atrophy	NOUN
chd-155	144	25	(	(	PUNCT
chd-155	144	26	iczkowski	iczkowski	PROPN
chd-155	144	27	et	et	PROPN
chd-155	144	28	al	al	PROPN
chd-155	144	29	.	.	PROPN
chd-155	144	30	,	,	PUNCT
chd-155	144	31	2014	2014	NUM
chd-155	144	32	)	)	PUNCT
chd-155	144	33	.	.	PUNCT
chd-155	145	1	acute	acute	ADJ
chd-155	145	2	inflammation	inflammation	NOUN
chd-155	145	3	has	have	AUX
chd-155	145	4	also	also	ADV
chd-155	145	5	been	be	AUX
chd-155	145	6	linked	link	VERB
chd-155	145	7	with	with	ADP
chd-155	145	8	lower	low	ADJ
chd-155	145	9	future	future	ADJ
chd-155	145	10	pc	pc	NOUN
chd-155	145	11	risk	risk	NOUN
chd-155	145	12	(	(	PUNCT
chd-155	145	13	allott	allott	NOUN
chd-155	145	14	et	et	PROPN
chd-155	145	15	al	al	PROPN
chd-155	145	16	.	.	PROPN
chd-155	145	17	,	,	PUNCT
chd-155	145	18	2018	2018	NUM
chd-155	145	19	;	;	PUNCT
chd-155	145	20	moreira	moreira	PROPN
chd-155	145	21	et	et	PROPN
chd-155	145	22	al	al	PROPN
chd-155	145	23	,	,	PUNCT
chd-155	145	24	2014	2014	NUM
chd-155	145	25	)	)	PUNCT
chd-155	145	26	.	.	PUNCT
chd-155	146	1	inflammation	inflammation	NOUN
chd-155	146	2	was	be	AUX
chd-155	146	3	not	not	PART
chd-155	146	4	significantly	significantly	ADV
chd-155	146	5	predictive	predictive	ADJ
chd-155	146	6	of	of	ADP
chd-155	146	7	pc	pc	NOUN
chd-155	146	8	in	in	ADP
chd-155	146	9	another	another	DET
chd-155	146	10	study	study	NOUN
chd-155	146	11	(	(	PUNCT
chd-155	146	12	khani	khani	PROPN
chd-155	146	13	et	et	PROPN
chd-155	146	14	al	al	PROPN
chd-155	146	15	.	.	PROPN
chd-155	146	16	,	,	PUNCT
chd-155	146	17	2014	2014	NUM
chd-155	146	18	)	)	PUNCT
chd-155	146	19	.	.	PUNCT
chd-155	147	1	high	high	ADJ
chd-155	147	2	bmi	bmi	PROPN
chd-155	147	3	was	be	AUX
chd-155	147	4	a	a	DET
chd-155	147	5	greater	great	ADJ
chd-155	147	6	risk	risk	NOUN
chd-155	147	7	factor	factor	NOUN
chd-155	147	8	for	for	ADP
chd-155	147	9	pc	pc	NOUN
chd-155	147	10	in	in	ADP
chd-155	147	11	aa	aa	NOUN
chd-155	147	12	men	man	NOUN
chd-155	147	13	than	than	ADP
chd-155	147	14	in	in	ADP
chd-155	147	15	white	white	ADJ
chd-155	147	16	men	man	NOUN
chd-155	147	17	(	(	PUNCT
chd-155	147	18	barrington	barrington	PROPN
chd-155	147	19	et	et	PROPN
chd-155	147	20	al	al	PROPN
chd-155	147	21	.	.	PROPN
chd-155	147	22	,	,	PUNCT
chd-155	147	23	2015	2015	NUM
chd-155	147	24	)	)	PUNCT
chd-155	147	25	,	,	PUNCT
chd-155	147	26	and	and	CCONJ
chd-155	147	27	adiposity	adiposity	NOUN
chd-155	147	28	causes	cause	VERB
chd-155	147	29	generalized	generalized	ADJ
chd-155	147	30	inflammation	inflammation	NOUN
chd-155	147	31	.	.	PUNCT
chd-155	148	1	one	one	NUM
chd-155	148	2	limitation	limitation	NOUN
chd-155	148	3	of	of	ADP
chd-155	148	4	the	the	DET
chd-155	148	5	study	study	NOUN
chd-155	148	6	was	be	AUX
chd-155	148	7	its	its	PRON
chd-155	148	8	exclusion	exclusion	NOUN
chd-155	148	9	of	of	ADP
chd-155	148	10	stromal	stromal	ADJ
chd-155	148	11	changes	change	NOUN
chd-155	148	12	.	.	PUNCT
chd-155	149	1	there	there	PRON
chd-155	149	2	is	be	VERB
chd-155	149	3	increased	increase	VERB
chd-155	149	4	reactive	reactive	ADJ
chd-155	149	5	stroma	stroma	NOUN
chd-155	149	6	associated	associate	VERB
chd-155	149	7	with	with	ADP
chd-155	149	8	chronic	chronic	ADJ
chd-155	149	9	inflammation	inflammation	NOUN
chd-155	149	10	in	in	ADP
chd-155	149	11	prostate	prostate	NOUN
chd-155	149	12	cancer	cancer	NOUN
chd-155	149	13	of	of	ADP
chd-155	149	14	aa	aa	PROPN
chd-155	149	15	men	man	NOUN
chd-155	149	16	,	,	PUNCT
chd-155	149	17	and	and	CCONJ
chd-155	149	18	fibroblasts	fibroblast	NOUN
chd-155	149	19	isolated	isolate	VERB
chd-155	149	20	from	from	ADP
chd-155	149	21	aa	aa	NOUN
chd-155	149	22	prostate	prostate	NOUN
chd-155	149	23	cancer	cancer	NOUN
chd-155	149	24	tissues	tissue	NOUN
chd-155	149	25	showed	show	VERB
chd-155	149	26	increased	increase	VERB
chd-155	149	27	growth	growth	NOUN
chd-155	149	28	response	response	NOUN
chd-155	149	29	to	to	ADP
chd-155	149	30	androgens	androgen	NOUN
chd-155	149	31	,	,	PUNCT
chd-155	149	32	fibroblast	fibroblast	ADJ
chd-155	149	33	growth	growth	NOUN
chd-155	149	34	factor	factor	NOUN
chd-155	149	35	2	2	NUM
chd-155	149	36	,	,	PUNCT
chd-155	149	37	and	and	CCONJ
chd-155	149	38	platelet	platelet	ADJ
chd-155	149	39	-	-	PUNCT
chd-155	149	40	derived	derive	VERB
chd-155	149	41	growth	growth	NOUN
chd-155	149	42	factor	factor	NOUN
chd-155	149	43	.	.	PUNCT
chd-155	150	1	conditioned	condition	VERB
chd-155	150	2	media	medium	NOUN
chd-155	150	3	from	from	ADP
chd-155	150	4	aaderived	aaderived	ADJ
chd-155	150	5	fibroblasts	fibroblast	NOUN
chd-155	150	6	enhanced	enhance	VERB
chd-155	150	7	the	the	DET
chd-155	150	8	proliferation	proliferation	NOUN
chd-155	150	9	,	,	PUNCT
chd-155	150	10	motility	motility	NOUN
chd-155	150	11	,	,	PUNCT
chd-155	150	12	and	and	CCONJ
chd-155	150	13	in	in	ADP
chd-155	150	14	vivo	vivo	ADJ
chd-155	150	15	tumorigenicity	tumorigenicity	NOUN
chd-155	150	16	of	of	ADP
chd-155	150	17	prostate	prostate	NOUN
chd-155	150	18	cancer	cancer	NOUN
chd-155	150	19	cells	cell	NOUN
chd-155	150	20	more	more	ADJ
chd-155	150	21	than	than	SCONJ
chd-155	150	22	european	european	ADJ
chd-155	150	23	-	-	PUNCT
chd-155	150	24	americanderived	americanderive	VERB
chd-155	150	25	fibroblasts	fibroblast	NOUN
chd-155	150	26	did	do	VERB
chd-155	150	27	,	,	PUNCT
chd-155	150	28	and	and	CCONJ
chd-155	150	29	they	they	PRON
chd-155	150	30	had	have	VERB
chd-155	150	31	elevated	elevated	ADJ
chd-155	150	32	markers	marker	NOUN
chd-155	150	33	of	of	ADP
chd-155	150	34	myofibroblast	myofibroblast	ADJ
chd-155	150	35	activation	activation	NOUN
chd-155	150	36	such	such	ADJ
chd-155	150	37	as	as	ADP
chd-155	150	38	expression	expression	NOUN
chd-155	150	39	of	of	ADP
chd-155	150	40	sma	sma	PROPN
chd-155	150	41	,	,	PUNCT
chd-155	150	42	vimentin	vimentin	NOUN
chd-155	150	43	,	,	PUNCT
chd-155	150	44	and	and	CCONJ
chd-155	150	45	tenascin	tenascin	PROPN
chd-155	150	46	-	-	PUNCT
chd-155	150	47	c.	c.	PROPN
chd-155	150	48	also	also	ADV
chd-155	150	49	,	,	PUNCT
chd-155	150	50	proinflammatory	proinflammatory	ADJ
chd-155	150	51	paracrine	paracrine	NOUN
chd-155	150	52	mediators	mediator	NOUN
chd-155	150	53	bdnf	bdnf	ADJ
chd-155	150	54	,	,	PUNCT
chd-155	150	55	c	c	PROPN
chd-155	150	56	hi3l1	hi3l1	PROPN
chd-155	150	57	,	,	PUNCT
chd-155	150	58	dppiv	dppiv	NOUN
chd-155	150	59	,	,	PUNCT
chd-155	150	60	fgf7	fgf7	PROPN
chd-155	150	61	,	,	PUNCT
chd-155	150	62	ili8bp	ili8bp	PROPN
chd-155	150	63	,	,	PUNCT
chd-155	150	64	il6	il6	NOUN
chd-155	150	65	,	,	PUNCT
chd-155	150	66	and	and	CCONJ
chd-155	150	67	vegf	vegf	PROPN
chd-155	150	68	were	be	AUX
chd-155	150	69	comparatively	comparatively	ADV
chd-155	150	70	enriched	enriched	ADJ
chd-155	150	71	in	in	ADP
chd-155	150	72	aa	aa	NOUN
chd-155	150	73	-	-	PUNCT
chd-155	150	74	derived	derive	VERB
chd-155	150	75	fibroblasts	fibroblast	NOUN
chd-155	150	76	(	(	PUNCT
chd-155	150	77	gillard	gillard	PROPN
chd-155	150	78	et	et	PROPN
chd-155	150	79	al	al	PROPN
chd-155	150	80	.	.	PROPN
chd-155	150	81	,	,	PUNCT
chd-155	150	82	2018	2018	NUM
chd-155	150	83	)	)	PUNCT
chd-155	150	84	.	.	PUNCT
chd-155	151	1	it	it	PRON
chd-155	151	2	is	be	AUX
chd-155	151	3	possible	possible	ADJ
chd-155	151	4	that	that	SCONJ
chd-155	151	5	the	the	DET
chd-155	151	6	high	high	ADJ
chd-155	151	7	,	,	PUNCT
chd-155	151	8	and	and	CCONJ
chd-155	151	9	rather	rather	ADV
chd-155	151	10	constant	constant	ADJ
chd-155	151	11	level	level	NOUN
chd-155	151	12	of	of	ADP
chd-155	151	13	gdf15	gdf15	NOUN
chd-155	151	14	we	we	PRON
chd-155	151	15	observed	observe	VERB
chd-155	151	16	in	in	ADP
chd-155	151	17	the	the	DET
chd-155	151	18	benign	benign	NOUN
chd-155	151	19	and	and	CCONJ
chd-155	151	20	cancer	cancer	NOUN
chd-155	151	21	epithelia	epithelia	PROPN
chd-155	151	22	is	be	AUX
chd-155	151	23	counteracting	counteract	VERB
chd-155	151	24	these	these	DET
chd-155	151	25	stromal	stromal	ADJ
chd-155	151	26	proinflammatory	proinflammatory	ADJ
chd-155	151	27	mediators	mediator	NOUN
chd-155	151	28	.	.	PUNCT
chd-155	152	1	a	a	DET
chd-155	152	2	second	second	ADJ
chd-155	152	3	limitation	limitation	NOUN
chd-155	152	4	is	be	AUX
chd-155	152	5	not	not	PART
chd-155	152	6	knowing	know	VERB
chd-155	152	7	the	the	DET
chd-155	152	8	anatomic	anatomic	ADJ
chd-155	152	9	sites	site	NOUN
chd-155	152	10	within	within	ADP
chd-155	152	11	the	the	DET
chd-155	152	12	prostate	prostate	NOUN
chd-155	152	13	from	from	ADP
chd-155	152	14	which	which	PRON
chd-155	152	15	tma	tma	PROPN
chd-155	152	16	cancer	cancer	NOUN
chd-155	152	17	cores	core	NOUN
chd-155	152	18	were	be	AUX
chd-155	152	19	derived	derive	VERB
chd-155	152	20	.	.	PUNCT
chd-155	153	1	dominant	dominant	ADJ
chd-155	153	2	tumor	tumor	NOUN
chd-155	153	3	nodules	nodule	NOUN
chd-155	153	4	in	in	ADP
chd-155	153	5	aa	aa	PROPN
chd-155	153	6	men	man	NOUN
chd-155	153	7	are	be	AUX
chd-155	153	8	larger	large	ADJ
chd-155	153	9	and	and	CCONJ
chd-155	153	10	more	more	ADV
chd-155	153	11	often	often	ADV
chd-155	153	12	in	in	ADP
chd-155	153	13	the	the	DET
chd-155	153	14	anterior	anterior	ADJ
chd-155	153	15	peripheral	peripheral	ADJ
chd-155	153	16	zone	zone	NOUN
chd-155	153	17	,	,	PUNCT
chd-155	153	18	making	make	VERB
chd-155	153	19	them	they	PRON
chd-155	153	20	less	less	ADV
chd-155	153	21	amenable	amenable	ADJ
chd-155	153	22	to	to	ADP
chd-155	153	23	rectal	rectal	ADJ
chd-155	153	24	palpation	palpation	NOUN
chd-155	153	25	than	than	ADP
chd-155	153	26	posterior	posterior	ADJ
chd-155	153	27	tumors	tumor	NOUN
chd-155	153	28	,	,	PUNCT
chd-155	153	29	and	and	CCONJ
chd-155	153	30	this	this	DET
chd-155	153	31	location	location	NOUN
chd-155	153	32	correlates	correlate	VERB
chd-155	153	33	with	with	ADP
chd-155	153	34	an	an	DET
chd-155	153	35	adverse	adverse	ADJ
chd-155	153	36	outcome	outcome	NOUN
chd-155	153	37	(	(	PUNCT
chd-155	153	38	sundi	sundi	PROPN
chd-155	153	39	et	et	PROPN
chd-155	153	40	al	al	PROPN
chd-155	153	41	.	.	PROPN
chd-155	153	42	,	,	PUNCT
chd-155	153	43	2014	2014	NUM
chd-155	153	44	)	)	PUNCT
chd-155	153	45	.	.	PUNCT
chd-155	154	1	a	a	DET
chd-155	154	2	third	third	ADJ
chd-155	154	3	limitation	limitation	NOUN
chd-155	154	4	was	be	AUX
chd-155	154	5	that	that	PRON
chd-155	154	6	serum	serum	NOUN
chd-155	154	7	psa	psa	NOUN
chd-155	154	8	measurements	measurement	NOUN
chd-155	154	9	were	be	AUX
chd-155	154	10	not	not	PART
chd-155	154	11	available	available	ADJ
chd-155	154	12	for	for	ADP
chd-155	154	13	comparison	comparison	NOUN
chd-155	154	14	to	to	ADP
chd-155	154	15	marker	marker	NOUN
chd-155	154	16	expression	expression	NOUN
chd-155	154	17	;	;	PUNCT
chd-155	154	18	this	this	PRON
chd-155	154	19	would	would	AUX
chd-155	154	20	have	have	AUX
chd-155	154	21	given	give	VERB
chd-155	154	22	further	further	ADJ
chd-155	154	23	insight	insight	NOUN
chd-155	154	24	into	into	ADP
chd-155	154	25	their	their	PRON
chd-155	154	26	roles	role	NOUN
chd-155	154	27	in	in	ADP
chd-155	154	28	tumor	tumor	NOUN
chd-155	154	29	development	development	NOUN
chd-155	154	30	,	,	PUNCT
chd-155	154	31	although	although	SCONJ
chd-155	154	32	inflammation	inflammation	NOUN
chd-155	154	33	had	have	AUX
chd-155	154	34	been	be	AUX
chd-155	154	35	shown	show	VERB
chd-155	154	36	to	to	PART
chd-155	154	37	be	be	AUX
chd-155	154	38	unrelated	unrelated	ADJ
chd-155	154	39	to	to	ADP
chd-155	154	40	the	the	DET
chd-155	154	41	racial	racial	ADJ
chd-155	154	42	disparity	disparity	NOUN
chd-155	154	43	in	in	ADP
chd-155	154	44	serum	serum	NOUN
chd-155	154	45	psa	psa	PROPN
chd-155	154	46	(	(	PUNCT
chd-155	154	47	zhang	zhang	X
chd-155	154	48	et	et	PROPN
chd-155	154	49	al	al	PROPN
chd-155	154	50	.	.	PROPN
chd-155	154	51	,	,	PUNCT
chd-155	154	52	2000	2000	NUM
chd-155	154	53	)	)	PUNCT
chd-155	154	54	.	.	PUNCT
chd-155	155	1	in	in	ADP
chd-155	155	2	summary	summary	NOUN
chd-155	155	3	,	,	PUNCT
chd-155	155	4	we	we	PRON
chd-155	155	5	report	report	VERB
chd-155	155	6	that	that	SCONJ
chd-155	155	7	tumor	tumor	NOUN
chd-155	155	8	immunoreactivity	immunoreactivity	NOUN
chd-155	155	9	showed	show	VERB
chd-155	155	10	significant	significant	ADJ
chd-155	155	11	alterations	alteration	NOUN
chd-155	155	12	with	with	ADP
chd-155	155	13	progression	progression	NOUN
chd-155	155	14	in	in	ADP
chd-155	155	15	aa	aa	PROPN
chd-155	155	16	men	man	NOUN
chd-155	155	17	only	only	ADV
chd-155	155	18	:	:	PUNCT
chd-155	155	19	a	a	DET
chd-155	155	20	stagewise	stagewise	NOUN
chd-155	155	21	decrease	decrease	NOUN
chd-155	155	22	in	in	ADP
chd-155	155	23	gdf15	gdf15	ADJ
chd-155	155	24	expression	expression	NOUN
chd-155	155	25	,	,	PUNCT
chd-155	155	26	and	and	CCONJ
chd-155	155	27	a	a	DET
chd-155	155	28	gradewide	gradewide	NOUN
chd-155	155	29	increase	increase	NOUN
chd-155	155	30	in	in	ADP
chd-155	155	31	nfκb	nfκb	ADJ
chd-155	155	32	expression	expression	NOUN
chd-155	155	33	.	.	PUNCT
chd-155	156	1	these	these	DET
chd-155	156	2	findings	finding	NOUN
chd-155	156	3	have	have	VERB
chd-155	156	4	ramifications	ramification	NOUN
chd-155	156	5	for	for	ADP
chd-155	156	6	tumor	tumor	NOUN
chd-155	156	7	development	development	NOUN
chd-155	156	8	and	and	CCONJ
chd-155	156	9	androgen	androgen	NOUN
chd-155	156	10	independence	independence	NOUN
chd-155	156	11	,	,	PUNCT
chd-155	156	12	and	and	CCONJ
chd-155	156	13	further	further	ADJ
chd-155	156	14	work	work	NOUN
chd-155	156	15	is	be	AUX
chd-155	156	16	needed	need	VERB
chd-155	156	17	to	to	PART
chd-155	156	18	determine	determine	VERB
chd-155	156	19	whether	whether	SCONJ
chd-155	156	20	the	the	DET
chd-155	156	21	racial	racial	ADJ
chd-155	156	22	disparities	disparity	NOUN
chd-155	156	23	observed	observe	VERB
chd-155	156	24	in	in	ADP
chd-155	156	25	non	non	ADJ
chd-155	156	26	-	-	ADJ
chd-155	156	27	neoplastic	neoplastic	ADJ
chd-155	156	28	prostate	prostate	NOUN
chd-155	156	29	are	be	AUX
chd-155	156	30	influenced	influence	VERB
chd-155	156	31	by	by	ADP
chd-155	156	32	the	the	DET
chd-155	156	33	presence	presence	NOUN
chd-155	156	34	of	of	ADP
chd-155	156	35	tumor	tumor	NOUN
chd-155	156	36	or	or	CCONJ
chd-155	156	37	independent	independent	ADJ
chd-155	156	38	of	of	ADP
chd-155	156	39	it	it	PRON
chd-155	156	40	.	.	PUNCT
chd-155	157	1	acknowledgements	acknowledgement	NOUN
chd-155	157	2	this	this	DET
chd-155	157	3	work	work	NOUN
chd-155	157	4	is	be	AUX
chd-155	157	5	supported	support	VERB
chd-155	157	6	by	by	ADP
chd-155	157	7	nih	nih	PROPN
chd-155	157	8	grant	grant	PROPN
chd-155	157	9	5r01es01112614	5r01es01112614	NUM
chd-155	157	10	[	[	X
chd-155	157	11	bar	bar	NOUN
chd-155	157	12	]	]	PUNCT
chd-155	157	13	and	and	CCONJ
chd-155	157	14	department	department	NOUN
chd-155	157	15	of	of	ADP
chd-155	157	16	defense	defense	PROPN
chd-155	157	17	pcbn	pcbn	NOUN
chd-155	157	18	,	,	PUNCT
chd-155	157	19	award	award	NOUN
chd-155	157	20	no	no	INTJ
chd-155	157	21	.	.	PUNCT
chd-155	158	1	w81xwh-10	w81xwh-10	PROPN
chd-155	158	2	-	-	PUNCT
chd-155	158	3	2	2	NUM
chd-155	158	4	-	-	PUNCT
chd-155	158	5	0056	0056	NUM
chd-155	158	6	and	and	CCONJ
chd-155	158	7	w81xwh-10	w81xwh-10	PROPN
chd-155	158	8	-	-	PUNCT
chd-155	158	9	2	2	NUM
chd-155	158	10	-	-	PUNCT
chd-155	158	11	0046	0046	NUM
chd-155	158	12	(	(	PUNCT
chd-155	158	13	tissue	tissue	NOUN
chd-155	158	14	microarrays	microarray	NOUN
chd-155	158	15	)	)	PUNCT
chd-155	158	16	.	.	PUNCT
chd-155	159	1	conflict	conflict	NOUN
chd-155	159	2	of	of	ADP
chd-155	159	3	interest	interest	NOUN
chd-155	159	4	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-155	159	5	e9	e9	PROPN
chd-155	159	6	cancer	cancer	NOUN
chd-155	159	7	health	health	NOUN
chd-155	159	8	disparities	disparity	NOUN
chd-155	159	9	research	research	PROPN
chd-155	159	10	dr	dr	PROPN
chd-155	159	11	.	.	PROPN
chd-155	159	12	iczkowski	iczkowski	PROPN
chd-155	159	13	has	have	VERB
chd-155	159	14	no	no	DET
chd-155	159	15	consultancies	consultancy	NOUN
chd-155	159	16	,	,	PUNCT
chd-155	159	17	stock	stock	NOUN
chd-155	159	18	ownership	ownership	NOUN
chd-155	159	19	,	,	PUNCT
chd-155	159	20	equity	equity	NOUN
chd-155	159	21	interest	interest	NOUN
chd-155	159	22	,	,	PUNCT
chd-155	159	23	patent	patent	NOUN
chd-155	159	24	-	-	PUNCT
chd-155	159	25	licensing	license	VERB
chd-155	159	26	agreements	agreement	NOUN
chd-155	159	27	,	,	PUNCT
chd-155	159	28	research	research	NOUN
chd-155	159	29	support	support	NOUN
chd-155	159	30	,	,	PUNCT
chd-155	159	31	or	or	CCONJ
chd-155	159	32	honoraria	honorarium	NOUN
chd-155	159	33	from	from	ADP
chd-155	159	34	companies	company	NOUN
chd-155	159	35	whose	whose	DET
chd-155	159	36	product	product	NOUN
chd-155	159	37	figures	figure	VERB
chd-155	159	38	prominently	prominently	ADV
chd-155	159	39	in	in	ADP
chd-155	159	40	this	this	DET
chd-155	159	41	manuscript	manuscript	NOUN
chd-155	159	42	.	.	PUNCT
chd-155	160	1	authors	author	NOUN
chd-155	160	2	’	’	PART
chd-155	160	3	contributions	contribution	NOUN
chd-155	160	4	study	study	NOUN
chd-155	160	5	design	design	NOUN
chd-155	160	6	:	:	PUNCT
chd-155	160	7	kai	kai	PROPN
chd-155	160	8	,	,	PUNCT
chd-155	160	9	msl	msl	PROPN
chd-155	160	10	,	,	PUNCT
chd-155	160	11	bar	bar	NOUN
chd-155	160	12	.	.	PUNCT
chd-155	161	1	immunostain	immunostain	NOUN
chd-155	161	2	protocol	protocol	NOUN
chd-155	161	3	and	and	CCONJ
chd-155	161	4	science	science	NOUN
chd-155	161	5	background	background	NOUN
chd-155	161	6	:	:	PUNCT
chd-155	161	7	jrl	jrl	NOUN
chd-155	161	8	.	.	PUNCT
chd-155	162	1	data	data	PROPN
chd-155	162	2	acquisition	acquisition	PROPN
chd-155	162	3	:	:	PUNCT
chd-155	162	4	kai	kai	PROPN
chd-155	162	5	,	,	PUNCT
chd-155	162	6	ok	ok	INTJ
chd-155	162	7	,	,	PUNCT
chd-155	162	8	ss	ss	PROPN
chd-155	162	9	,	,	PUNCT
chd-155	162	10	wp	wp	PROPN
chd-155	162	11	,	,	PUNCT
chd-155	162	12	bar	bar	NOUN
chd-155	162	13	.	.	PUNCT
chd-155	163	1	statistical	statistical	ADJ
chd-155	163	2	analysis	analysis	NOUN
chd-155	163	3	:	:	PUNCT
chd-155	163	4	yc	yc	PROPN
chd-155	163	5	,	,	PUNCT
chd-155	163	6	kct	kct	PROPN
chd-155	163	7	.	.	PROPN
chd-155	164	1	references	reference	NOUN
chd-155	164	2	1	1	NUM
chd-155	164	3	.	.	PUNCT
chd-155	164	4	allott	allott	VERB
chd-155	164	5	eh	eh	INTJ
chd-155	164	6	,	,	PUNCT
chd-155	164	7	markt	markt	PROPN
chd-155	164	8	sc	sc	PROPN
chd-155	164	9	,	,	PUNCT
chd-155	164	10	howard	howard	PROPN
chd-155	164	11	le	le	PROPN
chd-155	164	12	,	,	PUNCT
chd-155	164	13	vidal	vidal	PROPN
chd-155	164	14	ac	ac	PROPN
chd-155	164	15	,	,	PUNCT
chd-155	164	16	moreira	moreira	PROPN
chd-155	164	17	dm	dm	PROPN
chd-155	164	18	,	,	PUNCT
chd-155	164	19	castro	castro	PROPN
chd-155	164	20	-	-	PUNCT
chd-155	164	21	santamaria	santamaria	PROPN
chd-155	164	22	r	r	PROPN
chd-155	164	23	,	,	PUNCT
chd-155	164	24	andriole	andriole	PROPN
chd-155	164	25	gl	gl	PROPN
chd-155	164	26	,	,	PUNCT
chd-155	164	27	mucci	mucci	PROPN
chd-155	164	28	la	la	PROPN
chd-155	164	29	,	,	PUNCT
chd-155	164	30	and	and	CCONJ
chd-155	164	31	freedland	freedland	VERB
chd-155	164	32	sj	sj	INTJ
chd-155	164	33	(	(	PUNCT
chd-155	164	34	2018	2018	NUM
chd-155	164	35	)	)	PUNCT
chd-155	164	36	.	.	PUNCT
chd-155	165	1	geographic	geographic	ADJ
chd-155	165	2	differences	difference	NOUN
chd-155	165	3	in	in	ADP
chd-155	165	4	baseline	baseline	ADJ
chd-155	165	5	prostate	prostate	NOUN
chd-155	165	6	inflammation	inflammation	NOUN
chd-155	165	7	and	and	CCONJ
chd-155	165	8	relationship	relationship	NOUN
chd-155	165	9	with	with	ADP
chd-155	165	10	subsequent	subsequent	ADJ
chd-155	165	11	prostate	prostate	NOUN
chd-155	165	12	cancer	cancer	NOUN
chd-155	165	13	risk	risk	NOUN
chd-155	165	14	:	:	PUNCT
chd-155	165	15	results	result	NOUN
chd-155	165	16	from	from	ADP
chd-155	165	17	the	the	DET
chd-155	165	18	multinational	multinational	ADJ
chd-155	165	19	reduce	reduce	VERB
chd-155	165	20	trial	trial	NOUN
chd-155	165	21	.	.	PUNCT
chd-155	166	1	cancer	cancer	NOUN
chd-155	166	2	epidemiol	epidemiol	PROPN
chd-155	166	3	biomarkers	biomarkers	PROPN
chd-155	166	4	prev	prev	VERB
chd-155	166	5	27	27	NUM
chd-155	166	6	,	,	PUNCT
chd-155	166	7	783789	783789	NUM
chd-155	166	8	.	.	PUNCT
chd-155	167	1	2	2	X
chd-155	167	2	.	.	X
chd-155	167	3	bankhead	bankhead	PROPN
chd-155	167	4	p	p	PROPN
chd-155	167	5	,	,	PUNCT
chd-155	167	6	loughrey	loughrey	PROPN
chd-155	167	7	mb	mb	PROPN
chd-155	167	8	,	,	PUNCT
chd-155	167	9	fernández	fernández	PROPN
chd-155	167	10	ja	ja	PROPN
chd-155	167	11	,	,	PUNCT
chd-155	167	12	dombrowski	dombrowski	PROPN
chd-155	167	13	y	y	PROPN
chd-155	167	14	,	,	PUNCT
chd-155	167	15	mcart	mcart	PROPN
chd-155	167	16	dg	dg	PROPN
chd-155	167	17	,	,	PUNCT
chd-155	167	18	dunne	dunne	PROPN
chd-155	167	19	pd	pd	PROPN
chd-155	167	20	,	,	PUNCT
chd-155	167	21	mcquiad	mcquiad	PROPN
chd-155	167	22	s	s	PROPN
chd-155	167	23	,	,	PUNCT
chd-155	167	24	gray	gray	PROPN
chd-155	167	25	rt	rt	PROPN
chd-155	167	26	,	,	PUNCT
chd-155	167	27	murray	murray	PROPN
chd-155	167	28	lj	lj	PROPN
chd-155	167	29	,	,	PUNCT
chd-155	167	30	coleman	coleman	PROPN
chd-155	167	31	hg	hg	PROPN
chd-155	167	32	,	,	PUNCT
chd-155	167	33	james	james	PROPN
chd-155	167	34	ja	ja	PROPN
chd-155	167	35	,	,	PUNCT
chd-155	167	36	salto	salto	PROPN
chd-155	167	37	-	-	PUNCT
chd-155	167	38	tellez	tellez	PROPN
chd-155	167	39	m	m	PROPN
chd-155	167	40	,	,	PUNCT
chd-155	167	41	and	and	CCONJ
chd-155	167	42	hamilton	hamilton	PROPN
chd-155	167	43	pw	pw	PROPN
chd-155	167	44	(	(	PUNCT
chd-155	167	45	2017	2017	NUM
chd-155	167	46	)	)	PUNCT
chd-155	167	47	.	.	PUNCT
chd-155	167	48	qupath	qupath	NOUN
chd-155	167	49	:	:	PUNCT
chd-155	167	50	open	open	ADJ
chd-155	167	51	source	source	NOUN
chd-155	167	52	software	software	NOUN
chd-155	167	53	for	for	ADP
chd-155	167	54	digital	digital	ADJ
chd-155	167	55	pathology	pathology	NOUN
chd-155	167	56	image	image	NOUN
chd-155	167	57	analysis	analysis	NOUN
chd-155	167	58	.	.	PUNCT
chd-155	168	1	sci	sci	PROPN
chd-155	168	2	rep	rep	PROPN
chd-155	168	3	7	7	NUM
chd-155	168	4	,	,	PUNCT
chd-155	168	5	16878	16878	NUM
chd-155	168	6	.	.	PUNCT
chd-155	169	1	3	3	X
chd-155	169	2	.	.	X
chd-155	169	3	barrington	barrington	PROPN
chd-155	169	4	we	we	PRON
chd-155	169	5	,	,	PUNCT
chd-155	169	6	schenk	schenk	PROPN
chd-155	169	7	jm	jm	PROPN
chd-155	169	8	,	,	PUNCT
chd-155	169	9	etzioni	etzioni	PROPN
chd-155	169	10	r	r	PROPN
chd-155	169	11	,	,	PUNCT
chd-155	169	12	arnold	arnold	PROPN
chd-155	169	13	kb	kb	PROPN
chd-155	169	14	,	,	PUNCT
chd-155	169	15	neuhouser	neuhouser	PROPN
chd-155	169	16	ml	ml	PROPN
chd-155	169	17	,	,	PUNCT
chd-155	169	18	thompson	thompson	PROPN
chd-155	169	19	i	i	NOUN
chd-155	169	20	m	m	PROPN
chd-155	169	21	jr	jr	PROPN
chd-155	169	22	,	,	PUNCT
chd-155	169	23	lucia	lucia	PROPN
chd-155	169	24	ms	ms	PROPN
chd-155	169	25	,	,	PUNCT
chd-155	169	26	and	and	CCONJ
chd-155	169	27	kristal	kristal	PROPN
chd-155	169	28	ar	ar	PROPN
chd-155	169	29	(	(	PUNCT
chd-155	169	30	2015	2015	NUM
chd-155	169	31	)	)	PUNCT
chd-155	169	32	.	.	PUNCT
chd-155	170	1	difference	difference	NOUN
chd-155	170	2	in	in	ADP
chd-155	170	3	association	association	NOUN
chd-155	170	4	of	of	ADP
chd-155	170	5	obesity	obesity	NOUN
chd-155	170	6	with	with	ADP
chd-155	170	7	prostate	prostate	NOUN
chd-155	170	8	cancer	cancer	NOUN
chd-155	170	9	risk	risk	NOUN
chd-155	170	10	between	between	ADP
chd-155	170	11	us	we	PRON
chd-155	170	12	african	african	ADJ
chd-155	170	13	american	american	PROPN
chd-155	170	14	and	and	CCONJ
chd-155	170	15	non	non	ADJ
chd-155	170	16	-	-	ADJ
chd-155	170	17	hispanic	hispanic	ADJ
chd-155	170	18	white	white	ADJ
chd-155	170	19	men	man	NOUN
chd-155	170	20	in	in	ADP
chd-155	170	21	the	the	DET
chd-155	170	22	selenium	selenium	NOUN
chd-155	170	23	and	and	CCONJ
chd-155	170	24	vitamin	vitamin	NOUN
chd-155	170	25	e	e	NOUN
chd-155	170	26	cancer	cancer	NOUN
chd-155	170	27	prevention	prevention	NOUN
chd-155	170	28	trial	trial	NOUN
chd-155	170	29	(	(	PUNCT
chd-155	170	30	select	select	ADJ
chd-155	170	31	)	)	PUNCT
chd-155	170	32	.	.	PUNCT
chd-155	171	1	jama	jama	PROPN
chd-155	171	2	oncol	oncol	ADJ
chd-155	171	3	1	1	NUM
chd-155	171	4	,	,	PUNCT
chd-155	171	5	342	342	NUM
chd-155	171	6	-	-	SYM
chd-155	171	7	349	349	NUM
chd-155	171	8	.	.	PUNCT
chd-155	172	1	4	4	NUM
chd-155	172	2	.	.	X
chd-155	172	3	bennett	bennett	PROPN
chd-155	172	4	j	j	PROPN
chd-155	172	5	,	,	PUNCT
chd-155	172	6	capece	capece	PROPN
chd-155	172	7	d	d	PROPN
chd-155	172	8	,	,	PUNCT
chd-155	172	9	begalli	begalli	PROPN
chd-155	172	10	f	f	PROPN
chd-155	172	11	,	,	PUNCT
chd-155	172	12	verzella	verzella	PROPN
chd-155	172	13	d	d	PROPN
chd-155	172	14	,	,	PUNCT
chd-155	172	15	d’andrea	d’andrea	PROPN
chd-155	172	16	d	d	NOUN
chd-155	172	17	,	,	PUNCT
chd-155	172	18	tornatore	tornatore	NOUN
chd-155	172	19	l	l	NOUN
chd-155	172	20	,	,	PUNCT
chd-155	172	21	and	and	CCONJ
chd-155	172	22	franzoso	franzoso	NOUN
chd-155	172	23	g	g	PROPN
chd-155	172	24	(	(	PUNCT
chd-155	172	25	2018	2018	NUM
chd-155	172	26	)	)	PUNCT
chd-155	172	27	.	.	PUNCT
chd-155	173	1	nf	nf	X
chd-155	173	2	-	-	PUNCT
chd-155	173	3	κb	κb	NOUN
chd-155	173	4	in	in	ADP
chd-155	173	5	the	the	DET
chd-155	173	6	crosshairs	crosshair	NOUN
chd-155	173	7	:	:	PUNCT
chd-155	173	8	rethinking	rethink	VERB
chd-155	173	9	an	an	DET
chd-155	173	10	old	old	ADJ
chd-155	173	11	riddle	riddle	NOUN
chd-155	173	12	.	.	PUNCT
chd-155	174	1	int	int	PROPN
chd-155	174	2	j	j	PROPN
chd-155	174	3	biochem	biochem	PROPN
chd-155	174	4	cell	cell	NOUN
chd-155	174	5	biol	biol	PROPN
chd-155	174	6	95	95	NUM
chd-155	174	7	,	,	PUNCT
chd-155	174	8	108	108	NUM
chd-155	174	9	-	-	SYM
chd-155	174	10	112	112	NUM
chd-155	174	11	.	.	PUNCT
chd-155	175	1	5	5	NUM
chd-155	175	2	.	.	X
chd-155	175	3	bostwick	bostwick	PROPN
chd-155	175	4	dg	dg	PROPN
chd-155	175	5	,	,	PUNCT
chd-155	175	6	de	de	PROPN
chd-155	175	7	la	la	PROPN
chd-155	175	8	roza	roza	PROPN
chd-155	175	9	g	g	PROPN
chd-155	175	10	,	,	PUNCT
chd-155	175	11	dundore	dundore	NOUN
chd-155	175	12	p	p	NOUN
chd-155	175	13	,	,	PUNCT
chd-155	175	14	corica	corica	NOUN
chd-155	175	15	fa	fa	PROPN
chd-155	175	16	,	,	PUNCT
chd-155	175	17	and	and	CCONJ
chd-155	175	18	iczkowski	iczkowski	PROPN
chd-155	175	19	ka	ka	PROPN
chd-155	175	20	(	(	PUNCT
chd-155	175	21	2003	2003	NUM
chd-155	175	22	)	)	PUNCT
chd-155	175	23	.	.	PUNCT
chd-155	176	1	intraepithelial	intraepithelial	ADJ
chd-155	176	2	and	and	CCONJ
chd-155	176	3	stromal	stromal	ADJ
chd-155	176	4	lymphocytes	lymphocyte	NOUN
chd-155	176	5	in	in	ADP
chd-155	176	6	the	the	DET
chd-155	176	7	normal	normal	ADJ
chd-155	176	8	human	human	ADJ
chd-155	176	9	prostate	prostate	NOUN
chd-155	176	10	.	.	PUNCT
chd-155	177	1	prostate	prostate	NOUN
chd-155	177	2	55	55	NUM
chd-155	177	3	,	,	PUNCT
chd-155	177	4	187	187	NUM
chd-155	177	5	-	-	SYM
chd-155	177	6	193	193	NUM
chd-155	177	7	.	.	PUNCT
chd-155	177	8	6	6	NUM
chd-155	177	9	.	.	X
chd-155	178	1	bruzzese	bruzzese	PROPN
chd-155	178	2	f	f	PROPN
chd-155	178	3	,	,	PUNCT
chd-155	178	4	hägglöf	hägglöf	NOUN
chd-155	178	5	c	c	NOUN
chd-155	178	6	,	,	PUNCT
chd-155	178	7	leone	leone	NOUN
chd-155	178	8	a	a	PRON
chd-155	178	9	,	,	PUNCT
chd-155	178	10	sjöberg	sjöberg	PROPN
chd-155	178	11	e	e	PROPN
chd-155	178	12	,	,	PUNCT
chd-155	178	13	roca	roca	PROPN
chd-155	178	14	ms	ms	PROPN
chd-155	178	15	,	,	PUNCT
chd-155	178	16	kiflemariam	kiflemariam	PROPN
chd-155	178	17	s	s	PROPN
chd-155	178	18	,	,	PUNCT
chd-155	178	19	sjöblom	sjöblom	PROPN
chd-155	178	20	t	t	PROPN
chd-155	178	21	,	,	PUNCT
chd-155	178	22	hammarsten	hammarsten	NOUN
chd-155	178	23	p	p	NOUN
chd-155	178	24	,	,	PUNCT
chd-155	178	25	egevad	egevad	NOUN
chd-155	178	26	l	l	PROPN
chd-155	178	27	,	,	PUNCT
chd-155	178	28	bergh	bergh	PROPN
chd-155	178	29	a	a	PROPN
chd-155	178	30	,	,	PUNCT
chd-155	179	1	ostman	ostman	PROPN
chd-155	179	2	a	a	NOUN
chd-155	179	3	,	,	PUNCT
chd-155	179	4	budilon	budilon	NOUN
chd-155	179	5	a	a	NOUN
chd-155	179	6	,	,	PUNCT
chd-155	179	7	and	and	CCONJ
chd-155	179	8	augsten	augsten	VERB
chd-155	179	9	m	m	PROPN
chd-155	179	10	(	(	PUNCT
chd-155	179	11	2014	2014	NUM
chd-155	179	12	)	)	PUNCT
chd-155	179	13	.	.	PUNCT
chd-155	180	1	local	local	ADJ
chd-155	180	2	and	and	CCONJ
chd-155	180	3	systemic	systemic	ADJ
chd-155	180	4	protumorigenic	protumorigenic	ADJ
chd-155	180	5	effects	effect	NOUN
chd-155	180	6	of	of	ADP
chd-155	180	7	cancerassociated	cancerassociate	VERB
chd-155	180	8	fibroblast	fibroblast	ADJ
chd-155	180	9	-	-	PUNCT
chd-155	180	10	derived	derive	VERB
chd-155	180	11	gdf15	gdf15	NOUN
chd-155	180	12	.	.	PUNCT
chd-155	181	1	cancer	cancer	NOUN
chd-155	181	2	res	re	NOUN
chd-155	181	3	74	74	NUM
chd-155	181	4	,	,	PUNCT
chd-155	181	5	3408	3408	NUM
chd-155	181	6	-	-	SYM
chd-155	181	7	3417	3417	NUM
chd-155	181	8	.	.	PUNCT
chd-155	182	1	7	7	NUM
chd-155	182	2	.	.	X
chd-155	182	3	domingo	domingo	PROPN
chd-155	182	4	-	-	PUNCT
chd-155	182	5	domenech	domenech	PROPN
chd-155	182	6	j	j	PROPN
chd-155	182	7	,	,	PUNCT
chd-155	182	8	mellado	mellado	PROPN
chd-155	182	9	b	b	PROPN
chd-155	182	10	,	,	PUNCT
chd-155	182	11	ferrer	ferrer	PROPN
chd-155	182	12	b	b	PROPN
chd-155	182	13	,	,	PUNCT
chd-155	182	14	truan	truan	PROPN
chd-155	182	15	d	d	NOUN
chd-155	182	16	,	,	PUNCT
chd-155	182	17	codony	codony	ADJ
chd-155	182	18	-	-	PUNCT
chd-155	182	19	servat	servat	PROPN
chd-155	182	20	j	j	PROPN
chd-155	182	21	,	,	PUNCT
chd-155	182	22	sauleda	sauleda	PROPN
chd-155	182	23	s	s	PROPN
chd-155	182	24	,	,	PUNCT
chd-155	182	25	alcover	alcover	ADP
chd-155	182	26	j	j	PROPN
chd-155	182	27	,	,	PUNCT
chd-155	182	28	campo	campo	PROPN
chd-155	182	29	e	e	PROPN
chd-155	182	30	,	,	PUNCT
chd-155	182	31	gascon	gascon	PROPN
chd-155	182	32	p	p	PROPN
chd-155	182	33	,	,	PUNCT
chd-155	182	34	rovira	rovira	PROPN
chd-155	182	35	a	a	PROPN
chd-155	182	36	,	,	PUNCT
chd-155	182	37	ross	ross	PROPN
chd-155	182	38	js	js	PROPN
chd-155	182	39	,	,	PUNCT
chd-155	182	40	fernández	fernández	PROPN
chd-155	182	41	pl	pl	PROPN
chd-155	182	42	,	,	PUNCT
chd-155	182	43	albanell	albanell	PROPN
chd-155	182	44	j.	j.	PROPN
chd-155	182	45	(	(	PUNCT
chd-155	182	46	2005	2005	NUM
chd-155	182	47	)	)	PUNCT
chd-155	182	48	.	.	PUNCT
chd-155	183	1	activation	activation	NOUN
chd-155	183	2	of	of	ADP
chd-155	183	3	nuclear	nuclear	ADJ
chd-155	183	4	factor	factor	NOUN
chd-155	183	5	-	-	PUNCT
chd-155	183	6	κb	κb	NOUN
chd-155	183	7	in	in	ADP
chd-155	183	8	human	human	ADJ
chd-155	183	9	prostate	prostate	NOUN
chd-155	183	10	carcinogenesis	carcinogenesis	NOUN
chd-155	183	11	and	and	CCONJ
chd-155	183	12	association	association	NOUN
chd-155	183	13	to	to	ADP
chd-155	183	14	biochemical	biochemical	ADJ
chd-155	183	15	relapse	relapse	NOUN
chd-155	183	16	.	.	PUNCT
chd-155	184	1	british	british	ADJ
chd-155	184	2	journal	journal	PROPN
chd-155	184	3	of	of	ADP
chd-155	184	4	cancer	cancer	NOUN
chd-155	184	5	93	93	NUM
chd-155	184	6	,	,	PUNCT
chd-155	184	7	1285–1294	1285–1294	NUM
chd-155	184	8	.	.	PUNCT
chd-155	185	1	8	8	NUM
chd-155	185	2	.	.	PUNCT
chd-155	185	3	eastham	eastham	PROPN
chd-155	185	4	ja	ja	PROPN
chd-155	185	5	,	,	PUNCT
chd-155	185	6	may	may	PROPN
chd-155	185	7	ra	ra	PROPN
chd-155	185	8	,	,	PUNCT
chd-155	185	9	whatley	whatley	PROPN
chd-155	185	10	t	t	PROPN
chd-155	185	11	,	,	PUNCT
chd-155	185	12	crow	crow	VERB
chd-155	185	13	a	a	DET
chd-155	185	14	,	,	PUNCT
chd-155	185	15	venable	venable	PROPN
chd-155	185	16	dd	dd	PROPN
chd-155	185	17	,	,	PUNCT
chd-155	185	18	and	and	CCONJ
chd-155	185	19	sartor	sartor	NOUN
chd-155	185	20	o	o	PROPN
chd-155	185	21	(	(	PUNCT
chd-155	185	22	1998	1998	NUM
chd-155	185	23	)	)	PUNCT
chd-155	185	24	.	.	PUNCT
chd-155	186	1	clinical	clinical	ADJ
chd-155	186	2	characteristics	characteristic	NOUN
chd-155	186	3	and	and	CCONJ
chd-155	186	4	biopsy	biopsy	NOUN
chd-155	186	5	specimen	speciman	NOUN
chd-155	186	6	features	feature	VERB
chd-155	186	7	in	in	ADP
chd-155	186	8	african	african	ADJ
chd-155	186	9	-	-	PUNCT
chd-155	186	10	american	american	ADJ
chd-155	186	11	and	and	CCONJ
chd-155	186	12	white	white	ADJ
chd-155	186	13	men	man	NOUN
chd-155	186	14	without	without	ADP
chd-155	186	15	prostate	prostate	NOUN
chd-155	186	16	cancer	cancer	NOUN
chd-155	186	17	.	.	PUNCT
chd-155	187	1	j	j	PROPN
chd-155	187	2	natl	natl	PROPN
chd-155	187	3	cancer	cancer	PROPN
chd-155	187	4	inst	inst	PROPN
chd-155	187	5	90	90	NUM
chd-155	187	6	,	,	PUNCT
chd-155	187	7	756	756	NUM
chd-155	187	8	-	-	SYM
chd-155	187	9	760	760	NUM
chd-155	187	10	.	.	NOUN
chd-155	187	11	9	9	NUM
chd-155	187	12	..	..	PUNCT
chd-155	187	13	epstein	epstein	PROPN
chd-155	187	14	ji	ji	PROPN
chd-155	187	15	,	,	PUNCT
chd-155	187	16	egevad	egevad	PROPN
chd-155	187	17	l	l	PROPN
chd-155	187	18	,	,	PUNCT
chd-155	187	19	amin	amin	NOUN
chd-155	187	20	mb	mb	PROPN
chd-155	187	21	,	,	PUNCT
chd-155	187	22	delahunt	delahunt	PROPN
chd-155	187	23	b	b	PROPN
chd-155	187	24	,	,	PUNCT
chd-155	187	25	srigley	srigley	PROPN
chd-155	187	26	jr	jr	PROPN
chd-155	187	27	,	,	PUNCT
chd-155	187	28	humphrey	humphrey	PROPN
chd-155	187	29	pa	pa	PROPN
chd-155	187	30	;	;	PUNCT
chd-155	187	31	grading	grade	VERB
chd-155	187	32	committee	committee	NOUN
chd-155	187	33	(	(	PUNCT
chd-155	187	34	2016	2016	NUM
chd-155	187	35	)	)	PUNCT
chd-155	187	36	.	.	PUNCT
chd-155	188	1	the	the	DET
chd-155	188	2	2014	2014	NUM
chd-155	188	3	international	international	ADJ
chd-155	188	4	society	society	NOUN
chd-155	188	5	of	of	ADP
chd-155	188	6	urological	urological	ADJ
chd-155	188	7	pathology	pathology	NOUN
chd-155	188	8	(	(	PUNCT
chd-155	188	9	isup	isup	NOUN
chd-155	188	10	)	)	PUNCT
chd-155	188	11	consensus	consensus	NOUN
chd-155	188	12	conference	conference	NOUN
chd-155	188	13	on	on	ADP
chd-155	188	14	gleason	gleason	PROPN
chd-155	188	15	grading	grade	VERB
chd-155	188	16	of	of	ADP
chd-155	188	17	prostatic	prostatic	ADJ
chd-155	188	18	carcinoma	carcinoma	NOUN
chd-155	188	19	:	:	PUNCT
chd-155	188	20	definition	definition	NOUN
chd-155	188	21	of	of	ADP
chd-155	188	22	grading	grade	VERB
chd-155	188	23	patterns	pattern	NOUN
chd-155	188	24	and	and	CCONJ
chd-155	188	25	proposal	proposal	NOUN
chd-155	188	26	for	for	ADP
chd-155	188	27	a	a	DET
chd-155	188	28	new	new	ADJ
chd-155	188	29	grading	grade	VERB
chd-155	188	30	system	system	NOUN
chd-155	188	31	.	.	PUNCT
chd-155	188	32	am	be	AUX
chd-155	188	33	j	j	PROPN
chd-155	188	34	surg	surg	NOUN
chd-155	188	35	pathol	pathol	VERB
chd-155	188	36	40	40	NUM
chd-155	188	37	,	,	PUNCT
chd-155	188	38	244	244	NUM
chd-155	188	39	-	-	SYM
chd-155	188	40	252	252	NUM
chd-155	188	41	.	.	PUNCT
chd-155	188	42	10	10	NUM
chd-155	188	43	.	.	PUNCT
chd-155	189	1	gillard	gillard	PROPN
chd-155	189	2	m	m	PROPN
chd-155	189	3	,	,	PUNCT
chd-155	189	4	javier	javier	PROPN
chd-155	189	5	r	r	PROPN
chd-155	189	6	,	,	PUNCT
chd-155	189	7	ji	ji	PROPN
chd-155	189	8	y	y	PROPN
chd-155	189	9	,	,	PUNCT
chd-155	189	10	zheng	zheng	PROPN
chd-155	189	11	sl	sl	PROPN
chd-155	189	12	,	,	PUNCT
chd-155	189	13	xu	xu	PROPN
chd-155	189	14	j	j	PROPN
chd-155	189	15	,	,	PUNCT
chd-155	189	16	brendler	brendler	PROPN
chd-155	189	17	cb	cb	PROPN
chd-155	189	18	,	,	PUNCT
chd-155	189	19	crawford	crawford	PROPN
chd-155	189	20	se	se	PROPN
chd-155	189	21	,	,	PUNCT
chd-155	189	22	pierce	pierce	PROPN
chd-155	189	23	bl	bl	PROPN
chd-155	189	24	,	,	PUNCT
chd-155	189	25	griend	griend	PROPN
chd-155	189	26	djv	djv	PROPN
chd-155	189	27	,	,	PUNCT
chd-155	189	28	and	and	CCONJ
chd-155	189	29	franco	franco	PROPN
chd-155	189	30	oe	oe	PROPN
chd-155	189	31	(	(	PUNCT
chd-155	189	32	2018	2018	NUM
chd-155	189	33	)	)	PUNCT
chd-155	189	34	.	.	PUNCT
chd-155	190	1	elevation	elevation	NOUN
chd-155	190	2	of	of	ADP
chd-155	190	3	stromal	stromal	ADJ
chd-155	190	4	-	-	PUNCT
chd-155	190	5	derived	derive	VERB
chd-155	190	6	mediators	mediator	NOUN
chd-155	190	7	of	of	ADP
chd-155	190	8	inflammation	inflammation	NOUN
chd-155	190	9	promote	promote	VERB
chd-155	190	10	prostate	prostate	NOUN
chd-155	190	11	cancer	cancer	NOUN
chd-155	190	12	progression	progression	NOUN
chd-155	190	13	in	in	ADP
chd-155	190	14	african	african	ADJ
chd-155	190	15	-	-	PUNCT
chd-155	190	16	american	american	ADJ
chd-155	190	17	men	man	NOUN
chd-155	190	18	.	.	PUNCT
chd-155	191	1	cancer	cancer	NOUN
chd-155	191	2	res	re	NOUN
chd-155	191	3	78	78	NUM
chd-155	191	4	,	,	PUNCT
chd-155	191	5	6134	6134	NUM
chd-155	191	6	-	-	SYM
chd-155	191	7	6145	6145	NUM
chd-155	191	8	.	.	PUNCT
chd-155	192	1	11	11	NUM
chd-155	192	2	.	.	PUNCT
chd-155	193	1	hollis	hollis	PROPN
chd-155	193	2	bw	bw	PROPN
chd-155	193	3	,	,	PUNCT
chd-155	193	4	marshall	marshall	PROPN
chd-155	193	5	dt	dt	PROPN
chd-155	193	6	,	,	PUNCT
chd-155	193	7	savage	savage	NOUN
chd-155	193	8	sj	sj	NOUN
chd-155	193	9	,	,	PUNCT
chd-155	193	10	garrett	garrett	PROPN
chd-155	193	11	-	-	PUNCT
chd-155	193	12	mayer	mayer	PROPN
chd-155	193	13	e	e	PROPN
chd-155	193	14	,	,	PUNCT
chd-155	193	15	kindy	kindy	PROPN
chd-155	193	16	ms	ms	PROPN
chd-155	193	17	,	,	PUNCT
chd-155	193	18	and	and	CCONJ
chd-155	193	19	gattoni	gattoni	NOUN
chd-155	193	20	-	-	PUNCT
chd-155	193	21	celli	celli	NOUN
chd-155	193	22	s	s	PART
chd-155	193	23	(	(	PUNCT
chd-155	193	24	2013	2013	NUM
chd-155	193	25	)	)	PUNCT
chd-155	193	26	.	.	PUNCT
chd-155	194	1	vitamin	vitamin	NOUN
chd-155	194	2	d3	d3	PROPN
chd-155	194	3	supplementation	supplementation	NOUN
chd-155	194	4	,	,	PUNCT
chd-155	194	5	low	low	ADJ
chd-155	194	6	-	-	PUNCT
chd-155	194	7	risk	risk	NOUN
chd-155	194	8	prostate	prostate	NOUN
chd-155	194	9	cancer	cancer	NOUN
chd-155	194	10	,	,	PUNCT
chd-155	194	11	and	and	CCONJ
chd-155	194	12	health	health	NOUN
chd-155	194	13	disparities	disparity	NOUN
chd-155	194	14	.	.	PUNCT
chd-155	195	1	j	j	PROPN
chd-155	195	2	steroid	steroid	PROPN
chd-155	195	3	biochem	biochem	PROPN
chd-155	195	4	mol	mol	ADP
chd-155	195	5	biol	biol	PROPN
chd-155	195	6	136	136	NUM
chd-155	195	7	,	,	PUNCT
chd-155	195	8	233	233	NUM
chd-155	195	9	-	-	SYM
chd-155	195	10	237	237	NUM
chd-155	195	11	.	.	PUNCT
chd-155	196	1	12	12	NUM
chd-155	196	2	.	.	PUNCT
chd-155	197	1	iczkowski	iczkowski	PROPN
chd-155	197	2	ka	ka	PROPN
chd-155	197	3	,	,	PUNCT
chd-155	197	4	and	and	CCONJ
chd-155	197	5	pantazis	pantazi	VERB
chd-155	197	6	cg	cg	NOUN
chd-155	197	7	(	(	PUNCT
chd-155	197	8	2003	2003	NUM
chd-155	197	9	)	)	PUNCT
chd-155	197	10	.	.	PUNCT
chd-155	198	1	overexpression	overexpression	NOUN
chd-155	198	2	of	of	ADP
chd-155	198	3	nsaid	nsaid	ADJ
chd-155	198	4	-	-	PUNCT
chd-155	198	5	activated	activate	VERB
chd-155	198	6	gene	gene	NOUN
chd-155	198	7	product	product	NOUN
chd-155	198	8	in	in	ADP
chd-155	198	9	prostate	prostate	NOUN
chd-155	198	10	cancer	cancer	NOUN
chd-155	198	11	.	.	PUNCT
chd-155	199	1	int	int	PROPN
chd-155	199	2	j	j	PROPN
chd-155	199	3	surg	surg	NOUN
chd-155	199	4	pathol	pathol	VERB
chd-155	199	5	11	11	NUM
chd-155	199	6	,	,	PUNCT
chd-155	199	7	159	159	NUM
chd-155	199	8	-	-	SYM
chd-155	199	9	166	166	NUM
chd-155	199	10	.	.	PUNCT
chd-155	199	11	13	13	NUM
chd-155	199	12	.	.	PUNCT
chd-155	200	1	iczkowski	iczkowski	PROPN
chd-155	200	2	ka	ka	PROPN
chd-155	200	3	,	,	PUNCT
chd-155	200	4	torkko	torkko	PROPN
chd-155	200	5	kc	kc	PROPN
chd-155	200	6	,	,	PUNCT
chd-155	200	7	wilson	wilson	PROPN
chd-155	200	8	rs	rs	PROPN
chd-155	200	9	,	,	PUNCT
chd-155	200	10	lucia	lucia	PROPN
chd-155	200	11	ms	ms	PROPN
chd-155	200	12	,	,	PUNCT
chd-155	200	13	and	and	CCONJ
chd-155	200	14	bostwick	bostwick	PROPN
chd-155	200	15	dg	dg	PROPN
chd-155	200	16	(	(	PUNCT
chd-155	200	17	2014	2014	NUM
chd-155	200	18	)	)	PUNCT
chd-155	200	19	.	.	PUNCT
chd-155	201	1	prostatic	prostatic	ADJ
chd-155	201	2	atrophy	atrophy	NOUN
chd-155	201	3	:	:	PUNCT
chd-155	201	4	its	its	PRON
chd-155	201	5	spatial	spatial	ADJ
chd-155	201	6	proximity	proximity	NOUN
chd-155	201	7	to	to	ADP
chd-155	201	8	carcinoma	carcinoma	NOUN
chd-155	201	9	and	and	CCONJ
chd-155	201	10	intraepithelial	intraepithelial	ADJ
chd-155	201	11	neoplasia	neoplasia	NOUN
chd-155	201	12	based	base	VERB
chd-155	201	13	on	on	ADP
chd-155	201	14	annotation	annotation	NOUN
chd-155	201	15	of	of	ADP
chd-155	201	16	digital	digital	ADJ
chd-155	201	17	slides	slide	NOUN
chd-155	201	18	.	.	PUNCT
chd-155	202	1	hum	hum	PROPN
chd-155	202	2	pathol	pathol	PROPN
chd-155	202	3	45	45	NUM
chd-155	202	4	,	,	PUNCT
chd-155	202	5	54	54	NUM
chd-155	202	6	-	-	SYM
chd-155	202	7	58	58	NUM
chd-155	202	8	.	.	PUNCT
chd-155	203	1	14	14	NUM
chd-155	203	2	.	.	PUNCT
chd-155	204	1	jin	jin	PROPN
chd-155	204	2	rj	rj	PROPN
chd-155	204	3	,	,	PUNCT
chd-155	204	4	lho	lho	PROPN
chd-155	204	5	y	y	PROPN
chd-155	204	6	,	,	PUNCT
chd-155	204	7	connelly	connelly	PROPN
chd-155	204	8	l	l	PROPN
chd-155	204	9	,	,	PUNCT
chd-155	204	10	wang	wang	PROPN
chd-155	204	11	y	y	PROPN
chd-155	204	12	,	,	PUNCT
chd-155	204	13	yu	yu	PROPN
chd-155	204	14	x	x	PROPN
chd-155	204	15	,	,	PUNCT
chd-155	204	16	saint	saint	PROPN
chd-155	204	17	jean	jean	PROPN
chd-155	204	18	l	l	PROPN
chd-155	204	19	,	,	PUNCT
chd-155	204	20	case	case	NOUN
chd-155	204	21	tc	tc	NUM
chd-155	204	22	,	,	PUNCT
chd-155	204	23	ellwood	ellwood	NOUN
chd-155	204	24	-	-	PUNCT
chd-155	204	25	yen	yen	PROPN
chd-155	204	26	k	k	PROPN
chd-155	204	27	,	,	PUNCT
chd-155	204	28	sawyers	sawyer	NOUN
chd-155	204	29	cl	cl	NOUN
chd-155	204	30	,	,	PUNCT
chd-155	204	31	bhowmick	bhowmick	PROPN
chd-155	204	32	na	na	PROPN
chd-155	204	33	,	,	PUNCT
chd-155	204	34	blackwell	blackwell	PROPN
chd-155	204	35	ts	ts	PROPN
chd-155	204	36	,	,	PUNCT
chd-155	204	37	yull	yull	PROPN
chd-155	204	38	fe	fe	PROPN
chd-155	204	39	,	,	PUNCT
chd-155	204	40	and	and	CCONJ
chd-155	204	41	matusik	matusik	PROPN
chd-155	204	42	rj	rj	PROPN
chd-155	204	43	(	(	PUNCT
chd-155	204	44	2008	2008	NUM
chd-155	204	45	)	)	PUNCT
chd-155	204	46	.	.	PUNCT
chd-155	205	1	the	the	DET
chd-155	205	2	nuclear	nuclear	ADJ
chd-155	205	3	factorkappab	factorkappab	NOUN
chd-155	205	4	pathway	pathway	NOUN
chd-155	205	5	controls	control	VERB
chd-155	205	6	the	the	DET
chd-155	205	7	progression	progression	NOUN
chd-155	205	8	of	of	ADP
chd-155	205	9	prostate	prostate	NOUN
chd-155	205	10	cancer	cancer	NOUN
chd-155	205	11	to	to	ADP
chd-155	205	12	androgen	androgen	NOUN
chd-155	205	13	-	-	PUNCT
chd-155	205	14	independent	independent	ADJ
chd-155	205	15	growth	growth	NOUN
chd-155	205	16	.	.	PUNCT
chd-155	206	1	cancer	cancer	NOUN
chd-155	206	2	res	re	NOUN
chd-155	206	3	68	68	NUM
chd-155	206	4	,	,	PUNCT
chd-155	206	5	6762	6762	NUM
chd-155	206	6	-	-	SYM
chd-155	206	7	6769	6769	NUM
chd-155	206	8	.	.	PUNCT
chd-155	207	1	15	15	NUM
chd-155	207	2	.	.	PUNCT
chd-155	208	1	kaur	kaur	PROPN
chd-155	208	2	hb	hb	PROPN
chd-155	208	3	,	,	PUNCT
chd-155	208	4	guedes	guede	VERB
chd-155	208	5	lb	lb	NUM
chd-155	208	6	,	,	PUNCT
chd-155	208	7	lu	lu	PROPN
chd-155	208	8	j	j	PROPN
chd-155	208	9	,	,	PUNCT
chd-155	208	10	maldonado	maldonado	PROPN
chd-155	208	11	l	l	PROPN
chd-155	208	12	,	,	PUNCT
chd-155	208	13	reitz	reitz	PROPN
chd-155	208	14	l	l	PROPN
chd-155	208	15	,	,	PUNCT
chd-155	208	16	barber	barber	PROPN
chd-155	208	17	jr	jr	PROPN
chd-155	208	18	,	,	PUNCT
chd-155	208	19	de	de	PROPN
chd-155	208	20	marzo	marzo	X
chd-155	208	21	am	be	AUX
chd-155	208	22	,	,	PUNCT
chd-155	208	23	tosoian	tosoian	PROPN
chd-155	208	24	jj	jj	PROPN
chd-155	208	25	,	,	PUNCT
chd-155	208	26	tomlins	tomlins	PROPN
chd-155	208	27	sa	sa	PROPN
chd-155	208	28	,	,	PUNCT
chd-155	208	29	schaeffer	schaeffer	VERB
chd-155	208	30	em	em	PRON
chd-155	208	31	,	,	PUNCT
chd-155	208	32	joshu	joshu	PROPN
chd-155	208	33	ce	ce	PROPN
chd-155	208	34	,	,	PUNCT
chd-155	208	35	sfanos	sfanos	PROPN
chd-155	208	36	ks	ks	PROPN
chd-155	208	37	,	,	PUNCT
chd-155	208	38	and	and	CCONJ
chd-155	208	39	lotan	lotan	PROPN
chd-155	208	40	tl	tl	PROPN
chd-155	208	41	(	(	PUNCT
chd-155	208	42	2018	2018	NUM
chd-155	208	43	)	)	PUNCT
chd-155	208	44	.	.	PUNCT
chd-155	209	1	association	association	NOUN
chd-155	209	2	of	of	ADP
chd-155	209	3	tumor	tumor	NOUN
chd-155	209	4	-	-	PUNCT
chd-155	209	5	infiltrating	infiltrate	VERB
chd-155	209	6	t	t	NOUN
chd-155	209	7	-	-	PUNCT
chd-155	209	8	cell	cell	NOUN
chd-155	209	9	density	density	NOUN
chd-155	209	10	with	with	ADP
chd-155	209	11	molecular	molecular	ADJ
chd-155	209	12	subtype	subtype	NOUN
chd-155	209	13	,	,	PUNCT
chd-155	209	14	racial	racial	ADJ
chd-155	209	15	ancestry	ancestry	NOUN
chd-155	209	16	and	and	CCONJ
chd-155	209	17	clinical	clinical	ADJ
chd-155	209	18	outcomes	outcome	NOUN
chd-155	209	19	in	in	ADP
chd-155	209	20	prostate	prostate	NOUN
chd-155	209	21	cancer	cancer	NOUN
chd-155	209	22	.	.	PUNCT
chd-155	210	1	mod	mod	PROPN
chd-155	210	2	pathol	pathol	PROPN
chd-155	210	3	31	31	NUM
chd-155	210	4	,	,	PUNCT
chd-155	210	5	1539	1539	NUM
chd-155	210	6	-	-	SYM
chd-155	210	7	1552	1552	NUM
chd-155	210	8	.	.	PUNCT
chd-155	211	1	16	16	NUM
chd-155	211	2	.	.	PUNCT
chd-155	212	1	khani	khani	PROPN
chd-155	212	2	f	f	PROPN
chd-155	212	3	,	,	PUNCT
chd-155	212	4	mosquera	mosquera	PROPN
chd-155	212	5	jm	jm	PROPN
chd-155	212	6	,	,	PUNCT
chd-155	212	7	park	park	PROPN
chd-155	212	8	k	k	PROPN
chd-155	212	9	,	,	PUNCT
chd-155	212	10	blattner	blattner	NOUN
chd-155	212	11	m	m	PROPN
chd-155	212	12	,	,	PUNCT
chd-155	212	13	o’reilly	o’reilly	ADV
chd-155	212	14	c	c	X
chd-155	212	15	,	,	PUNCT
chd-155	212	16	macdonald	macdonald	PROPN
chd-155	212	17	ty	ty	PROPN
chd-155	212	18	,	,	PUNCT
chd-155	212	19	chen	chen	PROPN
chd-155	212	20	z	z	PROPN
chd-155	212	21	,	,	PUNCT
chd-155	212	22	srivastava	srivastava	PROPN
chd-155	212	23	a	a	PROPN
chd-155	212	24	,	,	PUNCT
chd-155	212	25	tewari	tewari	PROPN
chd-155	212	26	ak	ak	PROPN
chd-155	212	27	,	,	PUNCT
chd-155	212	28	barbieri	barbieri	PROPN
chd-155	212	29	ce	ce	PROPN
chd-155	212	30	,	,	PUNCT
chd-155	212	31	rubin	rubin	PROPN
chd-155	212	32	ma	ma	PROPN
chd-155	212	33	,	,	PUNCT
chd-155	212	34	and	and	CCONJ
chd-155	212	35	robinson	robinson	PROPN
chd-155	212	36	bd	bd	PROPN
chd-155	212	37	(	(	PUNCT
chd-155	212	38	2014	2014	NUM
chd-155	212	39	)	)	PUNCT
chd-155	212	40	.	.	PUNCT
chd-155	213	1	evidence	evidence	NOUN
chd-155	213	2	for	for	ADP
chd-155	213	3	molecular	molecular	ADJ
chd-155	213	4	differences	difference	NOUN
chd-155	213	5	in	in	ADP
chd-155	213	6	prostate	prostate	NOUN
chd-155	213	7	cancer	cancer	NOUN
chd-155	213	8	between	between	ADP
chd-155	213	9	african	african	ADJ
chd-155	213	10	american	american	ADJ
chd-155	213	11	and	and	CCONJ
chd-155	213	12	caucasian	caucasian	ADJ
chd-155	213	13	men	man	NOUN
chd-155	213	14	.	.	PUNCT
chd-155	214	1	clin	clin	PROPN
chd-155	214	2	cancer	cancer	NOUN
chd-155	214	3	res	re	VERB
chd-155	214	4	20	20	NUM
chd-155	214	5	,	,	PUNCT
chd-155	214	6	49254934	49254934	NUM
chd-155	214	7	.	.	PUNCT
chd-155	215	1	17	17	NUM
chd-155	215	2	.	.	X
chd-155	215	3	kryvenko	kryvenko	PROPN
chd-155	215	4	on	on	ADP
chd-155	215	5	,	,	PUNCT
chd-155	215	6	jankowski	jankowski	PROPN
chd-155	215	7	m	m	PROPN
chd-155	215	8	,	,	PUNCT
chd-155	215	9	chitale	chitale	PROPN
chd-155	215	10	da	da	PROPN
chd-155	215	11	,	,	PUNCT
chd-155	215	12	tang	tang	X
chd-155	216	1	d	d	NOUN
chd-155	216	2	,	,	PUNCT
chd-155	216	3	rundle	rundle	PROPN
chd-155	216	4	a	a	PRON
chd-155	216	5	,	,	PUNCT
chd-155	216	6	trudeau	trudeau	PROPN
chd-155	216	7	s	s	PART
chd-155	216	8	,	,	PUNCT
chd-155	216	9	and	and	CCONJ
chd-155	216	10	rybicki	rybicki	VERB
chd-155	216	11	ba	ba	PROPN
chd-155	216	12	(	(	PUNCT
chd-155	216	13	2012	2012	NUM
chd-155	216	14	)	)	PUNCT
chd-155	216	15	.	.	PUNCT
chd-155	217	1	inflammation	inflammation	NOUN
chd-155	217	2	and	and	CCONJ
chd-155	217	3	preneoplastic	preneoplastic	ADJ
chd-155	217	4	lesions	lesion	NOUN
chd-155	217	5	in	in	ADP
chd-155	217	6	benign	benign	ADJ
chd-155	217	7	prostate	prostate	NOUN
chd-155	217	8	as	as	ADP
chd-155	217	9	risk	risk	NOUN
chd-155	217	10	factors	factor	NOUN
chd-155	217	11	for	for	ADP
chd-155	217	12	prostate	prostate	NOUN
chd-155	217	13	cancer	cancer	NOUN
chd-155	217	14	.	.	PUNCT
chd-155	218	1	mod	mod	PROPN
chd-155	218	2	pathol	pathol	PROPN
chd-155	218	3	25	25	NUM
chd-155	218	4	,	,	PUNCT
chd-155	218	5	1023	1023	NUM
chd-155	218	6	-	-	SYM
chd-155	218	7	1032	1032	NUM
chd-155	218	8	.	.	PUNCT
chd-155	219	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-155	219	2	e10	e10	NUM
chd-155	219	3	cancer	cancer	NOUN
chd-155	219	4	health	health	NOUN
chd-155	219	5	disparities	disparity	NOUN
chd-155	219	6	research	research	VERB
chd-155	219	7	18	18	NUM
chd-155	219	8	.	.	PUNCT
chd-155	219	9	kryvenko	kryvenko	PROPN
chd-155	219	10	on	on	ADP
chd-155	219	11	,	,	PUNCT
chd-155	219	12	wang	wang	PROPN
chd-155	219	13	y	y	PROPN
chd-155	219	14	,	,	PUNCT
chd-155	219	15	sadasivan	sadasivan	VERB
chd-155	219	16	s	s	PRON
chd-155	219	17	,	,	PUNCT
chd-155	219	18	gupta	gupta	PROPN
chd-155	219	19	ns	ns	NUM
chd-155	219	20	,	,	PUNCT
chd-155	219	21	rogers	rogers	PROPN
chd-155	219	22	c	c	PROPN
chd-155	219	23	,	,	PUNCT
chd-155	219	24	bobbitt	bobbitt	PROPN
chd-155	219	25	k	k	PROPN
chd-155	219	26	,	,	PUNCT
chd-155	219	27	chitale	chitale	NOUN
chd-155	219	28	da	da	PROPN
chd-155	219	29	,	,	PUNCT
chd-155	219	30	rundle	rundle	NOUN
chd-155	219	31	a	a	PRON
chd-155	219	32	,	,	PUNCT
chd-155	219	33	tang	tang	PROPN
chd-155	220	1	d	d	NOUN
chd-155	220	2	,	,	PUNCT
chd-155	220	3	and	and	CCONJ
chd-155	220	4	rybicki	rybicki	VERB
chd-155	220	5	ba	ba	PROPN
chd-155	220	6	(	(	PUNCT
chd-155	220	7	2019	2019	NUM
chd-155	220	8	)	)	PUNCT
chd-155	220	9	.	.	PUNCT
chd-155	221	1	potential	potential	ADJ
chd-155	221	2	effect	effect	NOUN
chd-155	221	3	of	of	ADP
chd-155	221	4	anti	anti	ADJ
chd-155	221	5	-	-	ADJ
chd-155	221	6	inflammatory	inflammatory	ADJ
chd-155	221	7	drug	drug	NOUN
chd-155	221	8	use	use	NOUN
chd-155	221	9	on	on	ADP
chd-155	221	10	psa	psa	NOUN
chd-155	221	11	kinetics	kinetic	NOUN
chd-155	221	12	and	and	CCONJ
chd-155	221	13	subsequent	subsequent	ADJ
chd-155	221	14	prostate	prostate	NOUN
chd-155	221	15	cancer	cancer	NOUN
chd-155	221	16	diagnosis	diagnosis	NOUN
chd-155	221	17	:	:	PUNCT
chd-155	221	18	risk	risk	NOUN
chd-155	221	19	stratification	stratification	NOUN
chd-155	221	20	in	in	ADP
chd-155	221	21	black	black	ADJ
chd-155	221	22	and	and	CCONJ
chd-155	221	23	white	white	ADJ
chd-155	221	24	men	man	NOUN
chd-155	221	25	with	with	ADP
chd-155	221	26	benign	benign	ADJ
chd-155	221	27	prostate	prostate	NOUN
chd-155	221	28	biopsy	biopsy	NOUN
chd-155	221	29	.	.	PUNCT
chd-155	222	1	prostate	prostate	NOUN
chd-155	222	2	79	79	NUM
chd-155	222	3	,	,	PUNCT
chd-155	222	4	1090	1090	NUM
chd-155	222	5	-	-	SYM
chd-155	222	6	1098	1098	NUM
chd-155	222	7	.	.	PUNCT
chd-155	223	1	19	19	NUM
chd-155	223	2	.	.	PUNCT
chd-155	223	3	lambert	lambert	PROPN
chd-155	223	4	jr	jr	PROPN
chd-155	223	5	,	,	PUNCT
chd-155	223	6	whitson	whitson	PROPN
chd-155	223	7	rj	rj	PROPN
chd-155	223	8	,	,	PUNCT
chd-155	223	9	iczkowski	iczkowski	PROPN
chd-155	223	10	ka	ka	PROPN
chd-155	223	11	,	,	PUNCT
chd-155	223	12	la	la	PROPN
chd-155	223	13	rosa	rosa	PROPN
chd-155	223	14	fg	fg	PROPN
chd-155	223	15	,	,	PUNCT
chd-155	223	16	smith	smith	PROPN
chd-155	223	17	ml	ml	PROPN
chd-155	223	18	,	,	PUNCT
chd-155	223	19	wilson	wilson	PROPN
chd-155	223	20	rs	rs	PROPN
chd-155	223	21	,	,	PUNCT
chd-155	223	22	smith	smith	PROPN
chd-155	223	23	ee	ee	PROPN
chd-155	223	24	,	,	PUNCT
chd-155	223	25	torkko	torkko	PROPN
chd-155	223	26	kc	kc	PROPN
chd-155	223	27	,	,	PUNCT
chd-155	223	28	gari	gari	PROPN
chd-155	223	29	hh	hh	PROPN
chd-155	223	30	,	,	PUNCT
chd-155	223	31	and	and	CCONJ
chd-155	223	32	lucia	lucia	PROPN
chd-155	223	33	ms	ms	PROPN
chd-155	223	34	(	(	PUNCT
chd-155	223	35	2015	2015	NUM
chd-155	223	36	)	)	PUNCT
chd-155	223	37	.	.	PUNCT
chd-155	224	1	reduced	reduce	VERB
chd-155	224	2	expression	expression	NOUN
chd-155	224	3	of	of	ADP
chd-155	224	4	gdf-15	gdf-15	X
chd-155	224	5	is	be	AUX
chd-155	224	6	associated	associate	VERB
chd-155	224	7	with	with	ADP
chd-155	224	8	atrophic	atrophic	ADJ
chd-155	224	9	inflammatory	inflammatory	ADJ
chd-155	224	10	lesions	lesion	NOUN
chd-155	224	11	of	of	ADP
chd-155	224	12	the	the	DET
chd-155	224	13	prostate	prostate	NOUN
chd-155	224	14	.	.	PUNCT
chd-155	225	1	prostate	prostate	NOUN
chd-155	225	2	75	75	NUM
chd-155	225	3	,	,	PUNCT
chd-155	225	4	255–265	255–265	NUM
chd-155	225	5	.	.	PUNCT
chd-155	226	1	20	20	NUM
chd-155	226	2	.	.	PUNCT
chd-155	227	1	li	li	PROPN
chd-155	227	2	s	s	PROPN
chd-155	227	3	,	,	PUNCT
chd-155	227	4	ma	ma	PROPN
chd-155	227	5	ym	ym	PROPN
chd-155	227	6	,	,	PUNCT
chd-155	227	7	zheng	zheng	PROPN
chd-155	227	8	ps	ps	PROPN
chd-155	227	9	,	,	PUNCT
chd-155	227	10	and	and	CCONJ
chd-155	227	11	zhang	zhang	PROPN
chd-155	227	12	p	p	X
chd-155	227	13	(	(	PUNCT
chd-155	227	14	2018	2018	NUM
chd-155	227	15	)	)	PUNCT
chd-155	227	16	.	.	PUNCT
chd-155	228	1	gdf15	gdf15	PROPN
chd-155	228	2	promotes	promote	VERB
chd-155	228	3	the	the	DET
chd-155	228	4	proliferation	proliferation	NOUN
chd-155	228	5	of	of	ADP
chd-155	228	6	cervical	cervical	ADJ
chd-155	228	7	cancer	cancer	NOUN
chd-155	228	8	cells	cell	NOUN
chd-155	228	9	by	by	ADP
chd-155	228	10	phosphorylating	phosphorylate	VERB
chd-155	228	11	akt1	akt1	NOUN
chd-155	228	12	and	and	CCONJ
chd-155	228	13	erk1/2	erk1/2	PROPN
chd-155	228	14	through	through	ADP
chd-155	228	15	the	the	DET
chd-155	228	16	receptor	receptor	NOUN
chd-155	228	17	erbb2	erbb2	PROPN
chd-155	228	18	.	.	PUNCT
chd-155	229	1	j	j	PROPN
chd-155	229	2	exp	exp	PROPN
chd-155	229	3	clin	clin	PROPN
chd-155	229	4	cancer	cancer	NOUN
chd-155	229	5	res	re	VERB
chd-155	229	6	37	37	NUM
chd-155	229	7	,	,	PUNCT
chd-155	229	8	80	80	NUM
chd-155	229	9	.	.	NOUN
chd-155	230	1	21	21	NUM
chd-155	230	2	.	.	PUNCT
chd-155	230	3	moreira	moreira	PROPN
chd-155	230	4	dm	dm	PROPN
chd-155	230	5	,	,	PUNCT
chd-155	230	6	nickel	nickel	NOUN
chd-155	230	7	jc	jc	PROPN
chd-155	230	8	,	,	PUNCT
chd-155	230	9	gerber	gerber	PROPN
chd-155	230	10	l	l	PROPN
chd-155	230	11	,	,	PUNCT
chd-155	230	12	muller	muller	PROPN
chd-155	230	13	rl	rl	PROPN
chd-155	230	14	,	,	PUNCT
chd-155	230	15	andriole	andriole	PROPN
chd-155	230	16	gl	gl	PROPN
chd-155	230	17	,	,	PUNCT
chd-155	230	18	castro	castro	PROPN
chd-155	230	19	-	-	PUNCT
chd-155	230	20	santamaria	santamaria	PROPN
chd-155	230	21	r	r	PROPN
chd-155	230	22	,	,	PUNCT
chd-155	230	23	and	and	CCONJ
chd-155	230	24	freedland	freedland	VERB
chd-155	230	25	sj	sj	INTJ
chd-155	230	26	(	(	PUNCT
chd-155	230	27	2014	2014	NUM
chd-155	230	28	)	)	PUNCT
chd-155	230	29	.	.	PUNCT
chd-155	231	1	baseline	baseline	PROPN
chd-155	231	2	prostate	prostate	NOUN
chd-155	231	3	inflammation	inflammation	NOUN
chd-155	231	4	is	be	AUX
chd-155	231	5	associated	associate	VERB
chd-155	231	6	with	with	ADP
chd-155	231	7	a	a	DET
chd-155	231	8	reduced	reduced	ADJ
chd-155	231	9	risk	risk	NOUN
chd-155	231	10	of	of	ADP
chd-155	231	11	prostate	prostate	NOUN
chd-155	231	12	cancer	cancer	NOUN
chd-155	231	13	in	in	ADP
chd-155	231	14	men	man	NOUN
chd-155	231	15	undergoing	undergo	VERB
chd-155	231	16	repeat	repeat	NOUN
chd-155	231	17	prostate	prostate	NOUN
chd-155	231	18	biopsy	biopsy	NOUN
chd-155	231	19	:	:	PUNCT
chd-155	231	20	results	result	NOUN
chd-155	231	21	from	from	ADP
chd-155	231	22	the	the	DET
chd-155	231	23	reduce	reduce	NOUN
chd-155	231	24	study	study	NOUN
chd-155	231	25	.	.	PUNCT
chd-155	232	1	cancer	cancer	NOUN
chd-155	232	2	20	20	NUM
chd-155	232	3	,	,	PUNCT
chd-155	232	4	190196	190196	NUM
chd-155	232	5	.	.	PUNCT
chd-155	233	1	22	22	NUM
chd-155	233	2	.	.	PUNCT
chd-155	234	1	moresco	moresco	PROPN
chd-155	234	2	em	em	PRON
chd-155	234	3	,	,	PUNCT
chd-155	234	4	lavine	lavine	PROPN
chd-155	234	5	d	d	PROPN
chd-155	234	6	,	,	PUNCT
chd-155	234	7	and	and	CCONJ
chd-155	234	8	beutler	beutler	NOUN
chd-155	234	9	b	b	PROPN
chd-155	234	10	(	(	PUNCT
chd-155	234	11	2011	2011	NUM
chd-155	234	12	)	)	PUNCT
chd-155	234	13	.	.	PUNCT
chd-155	235	1	toll	toll	NOUN
chd-155	235	2	-	-	PUNCT
chd-155	235	3	like	like	ADJ
chd-155	235	4	receptors	receptor	NOUN
chd-155	235	5	.	.	PUNCT
chd-155	236	1	curr	curr	PROPN
chd-155	236	2	biol	biol	PROPN
chd-155	236	3	21	21	NUM
chd-155	236	4	,	,	PUNCT
chd-155	236	5	r488	r488	PROPN
chd-155	236	6	-	-	PUNCT
chd-155	236	7	493	493	NUM
chd-155	236	8	.	.	PUNCT
chd-155	237	1	23	23	NUM
chd-155	237	2	.	.	PUNCT
chd-155	237	3	nadiminty	nadiminty	PROPN
chd-155	237	4	n	n	CCONJ
chd-155	237	5	,	,	PUNCT
chd-155	237	6	chun	chun	PROPN
chd-155	237	7	jy	jy	PROPN
chd-155	237	8	,	,	PUNCT
chd-155	237	9	lou	lou	PROPN
chd-155	237	10	w	w	PROPN
chd-155	237	11	,	,	PUNCT
chd-155	237	12	lin	lin	PROPN
chd-155	237	13	x	x	X
chd-155	237	14	,	,	PUNCT
chd-155	237	15	and	and	CCONJ
chd-155	237	16	gao	gao	PROPN
chd-155	237	17	ac	ac	PROPN
chd-155	237	18	(	(	PUNCT
chd-155	237	19	2008	2008	NUM
chd-155	237	20	)	)	PUNCT
chd-155	237	21	.	.	PUNCT
chd-155	238	1	nf	nf	X
chd-155	238	2	-	-	PUNCT
chd-155	238	3	kappab2	kappab2	NOUN
chd-155	238	4	/	/	SYM
chd-155	238	5	p52	p52	NOUN
chd-155	238	6	enhances	enhance	VERB
chd-155	238	7	androgen	androgen	NOUN
chd-155	238	8	-	-	PUNCT
chd-155	238	9	independent	independent	ADJ
chd-155	238	10	growth	growth	NOUN
chd-155	238	11	of	of	ADP
chd-155	238	12	human	human	ADJ
chd-155	238	13	lncap	lncap	NOUN
chd-155	238	14	cells	cell	NOUN
chd-155	238	15	via	via	ADP
chd-155	238	16	protection	protection	NOUN
chd-155	238	17	from	from	ADP
chd-155	238	18	apoptotic	apoptotic	ADJ
chd-155	238	19	cell	cell	NOUN
chd-155	238	20	death	death	NOUN
chd-155	238	21	and	and	CCONJ
chd-155	238	22	cell	cell	NOUN
chd-155	238	23	cycle	cycle	NOUN
chd-155	238	24	arrest	arrest	NOUN
chd-155	238	25	induced	induce	VERB
chd-155	238	26	by	by	ADP
chd-155	238	27	androgen	androgen	NOUN
chd-155	238	28	-	-	PUNCT
chd-155	238	29	deprivation	deprivation	NOUN
chd-155	238	30	.	.	PUNCT
chd-155	239	1	prostate	prostate	NOUN
chd-155	239	2	68	68	NUM
chd-155	239	3	,	,	PUNCT
chd-155	239	4	1725	1725	NUM
chd-155	239	5	-	-	SYM
chd-155	239	6	1733	1733	NUM
chd-155	239	7	.	.	PUNCT
chd-155	240	1	24	24	NUM
chd-155	240	2	.	.	PUNCT
chd-155	241	1	powell	powell	PROPN
chd-155	241	2	ij	ij	PROPN
chd-155	241	3	,	,	PUNCT
chd-155	241	4	dyson	dyson	PROPN
chd-155	241	5	g	g	PROPN
chd-155	241	6	,	,	PUNCT
chd-155	241	7	land	land	NOUN
chd-155	241	8	s	s	PART
chd-155	241	9	,	,	PUNCT
chd-155	241	10	ruterbusch	ruterbusch	VERB
chd-155	241	11	j	j	PROPN
chd-155	241	12	,	,	PUNCT
chd-155	241	13	bock	bock	NOUN
chd-155	241	14	ch	ch	PROPN
chd-155	241	15	,	,	PUNCT
chd-155	241	16	lenk	lenk	PROPN
chd-155	241	17	s	s	PROPN
chd-155	241	18	,	,	PUNCT
chd-155	241	19	herawi	herawi	PROPN
chd-155	241	20	m	m	PROPN
chd-155	241	21	,	,	PUNCT
chd-155	241	22	everson	everson	PROPN
chd-155	241	23	r	r	PROPN
chd-155	241	24	,	,	PUNCT
chd-155	241	25	giroux	giroux	NOUN
chd-155	241	26	cn	cn	PROPN
chd-155	241	27	,	,	PUNCT
chd-155	241	28	schwartz	schwartz	PROPN
chd-155	241	29	ag	ag	PROPN
chd-155	241	30	,	,	PUNCT
chd-155	241	31	and	and	CCONJ
chd-155	241	32	bollig	bollig	NOUN
chd-155	241	33	-	-	PUNCT
chd-155	241	34	fischer	fischer	PROPN
chd-155	241	35	a	a	PRON
chd-155	241	36	(	(	PUNCT
chd-155	241	37	2013	2013	NUM
chd-155	241	38	)	)	PUNCT
chd-155	241	39	.	.	PUNCT
chd-155	242	1	genes	gene	NOUN
chd-155	242	2	associated	associate	VERB
chd-155	242	3	with	with	ADP
chd-155	242	4	prostate	prostate	NOUN
chd-155	242	5	cancer	cancer	NOUN
chd-155	242	6	are	be	AUX
chd-155	242	7	differentially	differentially	ADV
chd-155	242	8	expressed	express	VERB
chd-155	242	9	in	in	ADP
chd-155	242	10	african	african	ADJ
chd-155	242	11	american	american	ADJ
chd-155	242	12	and	and	CCONJ
chd-155	242	13	european	european	ADJ
chd-155	242	14	american	american	ADJ
chd-155	242	15	men	man	NOUN
chd-155	242	16	.	.	PUNCT
chd-155	243	1	cancer	cancer	NOUN
chd-155	243	2	epidemiol	epidemiol	PROPN
chd-155	243	3	biomarkers	biomarkers	PROPN
chd-155	243	4	prev	prev	VERB
chd-155	243	5	22	22	NUM
chd-155	243	6	,	,	PUNCT
chd-155	243	7	891	891	NUM
chd-155	243	8	-	-	SYM
chd-155	243	9	897	897	NUM
chd-155	243	10	.	.	PUNCT
chd-155	244	1	25	25	NUM
chd-155	244	2	.	.	PUNCT
chd-155	245	1	puhr	puhr	PROPN
chd-155	245	2	m	m	PROPN
chd-155	245	3	,	,	PUNCT
chd-155	245	4	de	de	ADP
chd-155	245	5	marzo	marzo	X
chd-155	245	6	a	a	X
chd-155	245	7	,	,	PUNCT
chd-155	245	8	isaacs	isaacs	PROPN
chd-155	245	9	w	w	PROPN
chd-155	245	10	,	,	PUNCT
chd-155	245	11	lucia	lucia	PROPN
chd-155	245	12	ms	ms	PROPN
chd-155	245	13	,	,	PUNCT
chd-155	245	14	sfanos	sfanos	PROPN
chd-155	245	15	k	k	PROPN
chd-155	245	16	,	,	PUNCT
chd-155	245	17	yegnasubramanian	yegnasubramanian	PROPN
chd-155	245	18	s	s	PROPN
chd-155	245	19	,	,	PUNCT
chd-155	245	20	and	and	CCONJ
chd-155	245	21	culig	culig	PROPN
chd-155	245	22	z	z	PROPN
chd-155	245	23	(	(	PUNCT
chd-155	245	24	2016	2016	NUM
chd-155	245	25	)	)	PUNCT
chd-155	245	26	.	.	PUNCT
chd-155	246	1	inflammation	inflammation	NOUN
chd-155	246	2	,	,	PUNCT
chd-155	246	3	microbiota	microbiota	NOUN
chd-155	246	4	,	,	PUNCT
chd-155	246	5	and	and	CCONJ
chd-155	246	6	prostate	prostate	NOUN
chd-155	246	7	cancer	cancer	NOUN
chd-155	246	8	.	.	PUNCT
chd-155	247	1	eur	eur	PROPN
chd-155	247	2	urol	urol	PROPN
chd-155	247	3	focus	focus	NOUN
chd-155	247	4	2	2	NUM
chd-155	247	5	,	,	PUNCT
chd-155	247	6	374382	374382	NUM
chd-155	247	7	.	.	PUNCT
chd-155	248	1	26	26	NUM
chd-155	248	2	.	.	X
chd-155	249	1	shukla	shukla	PROPN
chd-155	249	2	s	s	PROPN
chd-155	249	3	,	,	PUNCT
chd-155	249	4	and	and	CCONJ
chd-155	249	5	gupta	gupta	PROPN
chd-155	249	6	s	s	X
chd-155	249	7	(	(	PUNCT
chd-155	249	8	2004	2004	NUM
chd-155	249	9	)	)	PUNCT
chd-155	249	10	.	.	PUNCT
chd-155	250	1	suppression	suppression	NOUN
chd-155	250	2	of	of	ADP
chd-155	250	3	constitutive	constitutive	ADJ
chd-155	250	4	and	and	CCONJ
chd-155	250	5	tumor	tumor	NOUN
chd-155	250	6	necrosis	necrosis	NOUN
chd-155	250	7	factor	factor	NOUN
chd-155	250	8	alpha	alpha	NOUN
chd-155	250	9	-	-	PUNCT
chd-155	250	10	induced	induce	VERB
chd-155	250	11	nuclear	nuclear	ADJ
chd-155	250	12	factor	factor	NOUN
chd-155	250	13	(	(	PUNCT
chd-155	250	14	nf)-kappab	nf)-kappab	NOUN
chd-155	250	15	activation	activation	NOUN
chd-155	250	16	and	and	CCONJ
chd-155	250	17	induction	induction	NOUN
chd-155	250	18	of	of	ADP
chd-155	250	19	apoptosis	apoptosis	NOUN
chd-155	250	20	by	by	ADP
chd-155	250	21	apigenin	apigenin	PROPN
chd-155	250	22	in	in	ADP
chd-155	250	23	human	human	ADJ
chd-155	250	24	prostate	prostate	NOUN
chd-155	250	25	carcinoma	carcinoma	NOUN
chd-155	250	26	pc-3	pc-3	PUNCT
chd-155	250	27	cells	cell	NOUN
chd-155	250	28	:	:	PUNCT
chd-155	250	29	correlation	correlation	NOUN
chd-155	250	30	with	with	ADP
chd-155	250	31	down	down	NOUN
chd-155	250	32	-	-	PUNCT
chd-155	250	33	regulation	regulation	NOUN
chd-155	250	34	of	of	ADP
chd-155	250	35	nf	nf	ADJ
chd-155	250	36	-	-	PUNCT
chd-155	250	37	kappabresponsive	kappabresponsive	ADJ
chd-155	250	38	genes	gene	NOUN
chd-155	250	39	.	.	PUNCT
chd-155	251	1	clin	clin	PROPN
chd-155	251	2	cancer	cancer	NOUN
chd-155	251	3	res	re	NOUN
chd-155	251	4	10	10	NUM
chd-155	251	5	,	,	PUNCT
chd-155	251	6	3169	3169	NUM
chd-155	251	7	-	-	SYM
chd-155	251	8	3178	3178	NUM
chd-155	251	9	.	.	PUNCT
chd-155	252	1	27	27	NUM
chd-155	252	2	.	.	PUNCT
chd-155	253	1	sundi	sundi	PROPN
chd-155	253	2	d	d	PROPN
chd-155	253	3	,	,	PUNCT
chd-155	253	4	kryvenko	kryvenko	PROPN
chd-155	253	5	on	on	ADP
chd-155	253	6	,	,	PUNCT
chd-155	253	7	carter	carter	PROPN
chd-155	253	8	hb	hb	PROPN
chd-155	253	9	,	,	PUNCT
chd-155	253	10	ross	ross	PROPN
chd-155	253	11	ae	ae	PROPN
chd-155	253	12	,	,	PUNCT
chd-155	253	13	epstein	epstein	PROPN
chd-155	253	14	ji	ji	PROPN
chd-155	253	15	,	,	PUNCT
chd-155	253	16	and	and	CCONJ
chd-155	253	17	schaeffer	schaeffer	VERB
chd-155	253	18	em	em	PRON
chd-155	253	19	(	(	PUNCT
chd-155	253	20	2014	2014	NUM
chd-155	253	21	)	)	PUNCT
chd-155	253	22	.	.	PUNCT
chd-155	254	1	pathological	pathological	ADJ
chd-155	254	2	examination	examination	NOUN
chd-155	254	3	of	of	ADP
chd-155	254	4	radical	radical	ADJ
chd-155	254	5	prostatectomy	prostatectomy	NOUN
chd-155	254	6	specimens	specimen	NOUN
chd-155	254	7	in	in	ADP
chd-155	254	8	men	man	NOUN
chd-155	254	9	with	with	ADP
chd-155	254	10	very	very	ADV
chd-155	254	11	low	low	ADJ
chd-155	254	12	risk	risk	NOUN
chd-155	254	13	disease	disease	NOUN
chd-155	254	14	at	at	ADP
chd-155	254	15	biopsy	biopsy	NOUN
chd-155	254	16	reveals	reveal	VERB
chd-155	254	17	distinct	distinct	ADJ
chd-155	254	18	zonal	zonal	ADJ
chd-155	254	19	distribution	distribution	NOUN
chd-155	254	20	of	of	ADP
chd-155	254	21	cancer	cancer	NOUN
chd-155	254	22	in	in	ADP
chd-155	254	23	black	black	ADJ
chd-155	254	24	american	american	ADJ
chd-155	254	25	men	man	NOUN
chd-155	254	26	.	.	PUNCT
chd-155	255	1	j	j	PROPN
chd-155	255	2	urol	urol	PROPN
chd-155	255	3	191	191	NUM
chd-155	255	4	,	,	PUNCT
chd-155	255	5	60	60	NUM
chd-155	255	6	-	-	SYM
chd-155	255	7	67	67	NUM
chd-155	255	8	.	.	PUNCT
chd-155	255	9	28	28	NUM
chd-155	255	10	.	.	X
chd-155	256	1	tang	tang	PROPN
chd-155	256	2	w	w	PROPN
chd-155	256	3	,	,	PUNCT
chd-155	256	4	wallace	wallace	PROPN
chd-155	256	5	ta	ta	PROPN
chd-155	256	6	,	,	PUNCT
chd-155	256	7	yi	yi	PROPN
chd-155	256	8	m	m	PROPN
chd-155	256	9	,	,	PUNCT
chd-155	256	10	magi	magi	NOUN
chd-155	256	11	-	-	PUNCT
chd-155	256	12	galluzzi	galluzzi	NOUN
chd-155	256	13	c	c	NOUN
chd-155	256	14	,	,	PUNCT
chd-155	256	15	dorsey	dorsey	PROPN
chd-155	256	16	th	th	PROPN
chd-155	256	17	,	,	PUNCT
chd-155	256	18	onabajo	onabajo	NOUN
chd-155	256	19	oo	oo	ADV
chd-155	256	20	,	,	PUNCT
chd-155	256	21	obajemu	obajemu	AUX
chd-155	256	22	a	a	PRON
chd-155	256	23	,	,	PUNCT
chd-155	256	24	jordan	jordan	PROPN
chd-155	256	25	sv	sv	PROPN
chd-155	256	26	,	,	PUNCT
chd-155	256	27	loffredo	loffredo	PROPN
chd-155	256	28	ca	ca	PROPN
chd-155	256	29	,	,	PUNCT
chd-155	256	30	stephens	stephens	PROPN
chd-155	256	31	rm	rm	PROPN
chd-155	256	32	,	,	PUNCT
chd-155	256	33	silverman	silverman	PROPN
chd-155	256	34	rh	rh	PROPN
chd-155	256	35	,	,	PUNCT
chd-155	256	36	stark	stark	PROPN
chd-155	256	37	gr	gr	PROPN
chd-155	256	38	,	,	PUNCT
chd-155	256	39	klein	klein	PROPN
chd-155	256	40	ea	ea	PROPN
chd-155	256	41	,	,	PUNCT
chd-155	256	42	prokunina	prokunina	PROPN
chd-155	256	43	-	-	PUNCT
chd-155	256	44	olsson	olsson	NOUN
chd-155	256	45	l	l	NOUN
chd-155	256	46	,	,	PUNCT
chd-155	256	47	and	and	CCONJ
chd-155	256	48	ambs	ambs	PROPN
chd-155	256	49	s	s	X
chd-155	256	50	(	(	PUNCT
chd-155	256	51	2018	2018	NUM
chd-155	256	52	)	)	PUNCT
chd-155	256	53	.	.	PUNCT
chd-155	257	1	ifnl4	ifnl4	ADJ
chd-155	257	2	-	-	PUNCT
chd-155	257	3	δg	δg	ADJ
chd-155	257	4	allele	allele	NOUN
chd-155	257	5	is	be	AUX
chd-155	257	6	associated	associate	VERB
chd-155	257	7	with	with	ADP
chd-155	257	8	an	an	DET
chd-155	257	9	interferon	interferon	ADJ
chd-155	257	10	signature	signature	NOUN
chd-155	257	11	in	in	ADP
chd-155	257	12	tumors	tumor	NOUN
chd-155	257	13	and	and	CCONJ
chd-155	257	14	survival	survival	NOUN
chd-155	257	15	of	of	ADP
chd-155	257	16	african	african	ADJ
chd-155	257	17	-	-	PUNCT
chd-155	257	18	american	american	ADJ
chd-155	257	19	men	man	NOUN
chd-155	257	20	with	with	ADP
chd-155	257	21	prostate	prostate	NOUN
chd-155	257	22	cancer	cancer	NOUN
chd-155	257	23	.	.	PUNCT
chd-155	258	1	clin	clin	PROPN
chd-155	258	2	cancer	cancer	NOUN
chd-155	258	3	res	re	NOUN
chd-155	258	4	24	24	NUM
chd-155	258	5	,	,	PUNCT
chd-155	258	6	5471	5471	NUM
chd-155	258	7	-	-	SYM
chd-155	258	8	5481	5481	NUM
chd-155	258	9	.	.	PUNCT
chd-155	259	1	29	29	NUM
chd-155	259	2	.	.	PUNCT
chd-155	260	1	vaňhara	vaňhara	NOUN
chd-155	260	2	p	p	NOUN
chd-155	260	3	,	,	PUNCT
chd-155	260	4	hampl	hampl	PROPN
chd-155	260	5	a	a	NOUN
chd-155	260	6	,	,	PUNCT
chd-155	260	7	kozubík	kozubík	NOUN
chd-155	260	8	a	a	NOUN
chd-155	260	9	,	,	PUNCT
chd-155	260	10	and	and	CCONJ
chd-155	260	11	souček	souček	PROPN
chd-155	260	12	k	k	PROPN
chd-155	260	13	(	(	PUNCT
chd-155	260	14	2012	2012	NUM
chd-155	260	15	)	)	PUNCT
chd-155	260	16	.	.	PUNCT
chd-155	261	1	growth	growth	NOUN
chd-155	261	2	/	/	SYM
chd-155	261	3	differentiation	differentiation	NOUN
chd-155	261	4	factor-15	factor-15	NUM
chd-155	261	5	:	:	PUNCT
chd-155	261	6	prostate	prostate	NOUN
chd-155	261	7	cancer	cancer	NOUN
chd-155	261	8	suppressor	suppressor	NOUN
chd-155	261	9	or	or	CCONJ
chd-155	261	10	promoter	promoter	NOUN
chd-155	261	11	?	?	PUNCT
chd-155	262	1	prostate	prostate	NOUN
chd-155	262	2	cancer	cancer	NOUN
chd-155	262	3	prostatic	prostatic	NOUN
chd-155	262	4	dis	dis	PROPN
chd-155	262	5	15	15	NUM
chd-155	262	6	,	,	PUNCT
chd-155	262	7	320	320	NUM
chd-155	262	8	-	-	SYM
chd-155	262	9	328	328	NUM
chd-155	262	10	.	.	PUNCT
chd-155	262	11	30	30	NUM
chd-155	262	12	.	.	PUNCT
chd-155	263	1	vidal	vidal	PROPN
chd-155	263	2	ac	ac	PROPN
chd-155	263	3	,	,	PUNCT
chd-155	263	4	chen	chen	PROPN
chd-155	263	5	z	z	PROPN
chd-155	263	6	,	,	PUNCT
chd-155	263	7	howard	howard	PROPN
chd-155	263	8	le	le	PROPN
chd-155	263	9	,	,	PUNCT
chd-155	263	10	moreira	moreira	PROPN
chd-155	263	11	dm	dm	PROPN
chd-155	263	12	,	,	PUNCT
chd-155	263	13	castrosantamaria	castrosantamaria	NOUN
chd-155	263	14	r	r	PROPN
chd-155	263	15	,	,	PUNCT
chd-155	263	16	andriole	andriole	PROPN
chd-155	263	17	gl	gl	PROPN
chd-155	263	18	,	,	PUNCT
chd-155	263	19	taioli	taioli	NOUN
chd-155	263	20	e	e	NOUN
chd-155	263	21	,	,	PUNCT
chd-155	263	22	fowke	fowke	VERB
chd-155	263	23	jh	jh	PROPN
chd-155	263	24	,	,	PUNCT
chd-155	263	25	knudsen	knudsen	PROPN
chd-155	263	26	b	b	PROPN
chd-155	263	27	,	,	PUNCT
chd-155	263	28	drake	drake	PROPN
chd-155	263	29	cg	cg	PROPN
chd-155	263	30	,	,	PUNCT
chd-155	263	31	nickel	nickel	NOUN
chd-155	263	32	jc	jc	PROPN
chd-155	263	33	,	,	PUNCT
chd-155	263	34	and	and	CCONJ
chd-155	263	35	freedland	freedland	VERB
chd-155	263	36	sj	sj	INTJ
chd-155	263	37	(	(	PUNCT
chd-155	263	38	2016	2016	NUM
chd-155	263	39	)	)	PUNCT
chd-155	263	40	.	.	PUNCT
chd-155	264	1	racial	racial	ADJ
chd-155	264	2	differences	difference	NOUN
chd-155	264	3	in	in	ADP
chd-155	264	4	prostate	prostate	NOUN
chd-155	264	5	inflammation	inflammation	NOUN
chd-155	264	6	:	:	PUNCT
chd-155	264	7	results	result	NOUN
chd-155	264	8	from	from	ADP
chd-155	264	9	the	the	DET
chd-155	264	10	reduce	reduce	NOUN
chd-155	264	11	study	study	NOUN
chd-155	264	12	.	.	PUNCT
chd-155	265	1	oncotarget	oncotarget	NOUN
chd-155	265	2	8	8	NUM
chd-155	265	3	,	,	PUNCT
chd-155	265	4	71393	71393	NUM
chd-155	265	5	-	-	SYM
chd-155	265	6	71399	71399	NUM
chd-155	265	7	.	.	PUNCT
chd-155	266	1	31	31	NUM
chd-155	266	2	.	.	PUNCT
chd-155	267	1	wallace	wallace	PROPN
chd-155	267	2	ta	ta	PROPN
chd-155	267	3	,	,	PUNCT
chd-155	267	4	prueitt	prueitt	X
chd-155	267	5	rl	rl	PROPN
chd-155	267	6	,	,	PUNCT
chd-155	267	7	yi	yi	PROPN
chd-155	267	8	m	m	PROPN
chd-155	267	9	,	,	PUNCT
chd-155	267	10	howe	howe	PROPN
chd-155	267	11	tm	tm	PROPN
chd-155	267	12	,	,	PUNCT
chd-155	267	13	gillespie	gillespie	PROPN
chd-155	267	14	jw	jw	PROPN
chd-155	267	15	,	,	PUNCT
chd-155	267	16	yfantis	yfantis	ADJ
chd-155	267	17	hg	hg	NOUN
chd-155	267	18	,	,	PUNCT
chd-155	267	19	stephens	stephens	PROPN
chd-155	267	20	rm	rm	PROPN
chd-155	267	21	,	,	PUNCT
chd-155	267	22	caporaso	caporaso	PROPN
chd-155	267	23	ne	ne	PROPN
chd-155	267	24	,	,	PUNCT
chd-155	267	25	loffredo	loffredo	PROPN
chd-155	267	26	ca	ca	PROPN
chd-155	267	27	,	,	PUNCT
chd-155	267	28	and	and	CCONJ
chd-155	267	29	ambs	ambs	PROPN
chd-155	267	30	s	s	X
chd-155	267	31	(	(	PUNCT
chd-155	267	32	2008	2008	NUM
chd-155	267	33	)	)	PUNCT
chd-155	267	34	.	.	PUNCT
chd-155	268	1	tumor	tumor	NOUN
chd-155	268	2	immunobiological	immunobiological	ADJ
chd-155	268	3	differences	difference	NOUN
chd-155	268	4	in	in	ADP
chd-155	268	5	prostate	prostate	NOUN
chd-155	268	6	cancer	cancer	NOUN
chd-155	268	7	between	between	ADP
chd-155	268	8	african	african	ADJ
chd-155	268	9	-	-	PUNCT
chd-155	268	10	american	american	ADJ
chd-155	268	11	and	and	CCONJ
chd-155	268	12	european	european	ADJ
chd-155	268	13	-	-	PUNCT
chd-155	268	14	american	american	ADJ
chd-155	268	15	men	man	NOUN
chd-155	268	16	.	.	PUNCT
chd-155	269	1	cancer	cancer	NOUN
chd-155	269	2	res	re	NOUN
chd-155	269	3	68	68	NUM
chd-155	269	4	,	,	PUNCT
chd-155	269	5	927	927	NUM
chd-155	269	6	-	-	SYM
chd-155	269	7	936	936	NUM
chd-155	269	8	.	.	PUNCT
chd-155	270	1	32	32	NUM
chd-155	270	2	.	.	PUNCT
chd-155	271	1	wang	wang	PROPN
chd-155	271	2	x	x	PROPN
chd-155	271	3	,	,	PUNCT
chd-155	271	4	baek	baek	NOUN
chd-155	271	5	sj	sj	PROPN
chd-155	271	6	,	,	PUNCT
chd-155	271	7	and	and	CCONJ
chd-155	271	8	eling	eling	PROPN
chd-155	271	9	te	te	PROPN
chd-155	271	10	(	(	PUNCT
chd-155	271	11	2013	2013	NUM
chd-155	271	12	)	)	PUNCT
chd-155	271	13	.	.	PUNCT
chd-155	272	1	the	the	DET
chd-155	272	2	diverse	diverse	ADJ
chd-155	272	3	roles	role	NOUN
chd-155	272	4	of	of	ADP
chd-155	272	5	nonsteroidal	nonsteroidal	ADJ
chd-155	272	6	anti	anti	ADJ
chd-155	272	7	-	-	ADJ
chd-155	272	8	inflammatory	inflammatory	ADJ
chd-155	272	9	drug	drug	NOUN
chd-155	272	10	activated	activate	VERB
chd-155	272	11	gene	gene	NOUN
chd-155	272	12	(	(	PUNCT
chd-155	272	13	nag-1	nag-1	NOUN
chd-155	272	14	/	/	SYM
chd-155	272	15	gdf15	gdf15	NOUN
chd-155	272	16	)	)	PUNCT
chd-155	272	17	in	in	ADP
chd-155	272	18	cancer	cancer	NOUN
chd-155	272	19	.	.	PUNCT
chd-155	273	1	biochem	biochem	PROPN
chd-155	273	2	pharmacol	pharmacol	PROPN
chd-155	273	3	.	.	PROPN
chd-155	273	4	85	85	NUM
chd-155	273	5	,	,	PUNCT
chd-155	273	6	597	597	NUM
chd-155	273	7	–	–	PUNCT
chd-155	273	8	606	606	NUM
chd-155	273	9	.	.	PUNCT
chd-155	274	1	33	33	NUM
chd-155	274	2	.	.	PUNCT
chd-155	275	1	yli	yli	NOUN
chd-155	275	2	-	-	NOUN
chd-155	275	3	hemminki	hemminki	PROPN
chd-155	275	4	th	th	NOUN
chd-155	275	5	,	,	PUNCT
chd-155	275	6	laurila	laurila	PROPN
chd-155	275	7	m	m	PROPN
chd-155	275	8	,	,	PUNCT
chd-155	275	9	auvinen	auvinen	PROPN
chd-155	275	10	a	a	NOUN
chd-155	275	11	,	,	PUNCT
chd-155	275	12	määttänen	määttänen	PROPN
chd-155	275	13	l	l	PROPN
chd-155	275	14	,	,	PUNCT
chd-155	275	15	huhtala	huhtala	PROPN
chd-155	275	16	h	h	PROPN
chd-155	275	17	,	,	PUNCT
chd-155	275	18	tammela	tammela	PROPN
chd-155	275	19	tl	tl	PROPN
chd-155	275	20	,	,	PUNCT
chd-155	275	21	and	and	CCONJ
chd-155	275	22	kujala	kujala	NOUN
chd-155	275	23	pm	pm	PROPN
chd-155	275	24	(	(	PUNCT
chd-155	275	25	2013	2013	NUM
chd-155	275	26	)	)	PUNCT
chd-155	275	27	.	.	PUNCT
chd-155	276	1	histological	histological	ADJ
chd-155	276	2	inflammation	inflammation	NOUN
chd-155	276	3	and	and	CCONJ
chd-155	276	4	risk	risk	NOUN
chd-155	276	5	of	of	ADP
chd-155	276	6	subsequent	subsequent	ADJ
chd-155	276	7	prostate	prostate	NOUN
chd-155	276	8	cancer	cancer	NOUN
chd-155	276	9	among	among	ADP
chd-155	276	10	men	man	NOUN
chd-155	276	11	with	with	ADP
chd-155	276	12	initially	initially	ADV
chd-155	276	13	elevated	elevate	VERB
chd-155	276	14	serum	serum	NOUN
chd-155	276	15	prostatespecific	prostatespecific	NOUN
chd-155	276	16	antigen	antigen	NOUN
chd-155	276	17	(	(	PUNCT
chd-155	276	18	psa	psa	NOUN
chd-155	276	19	)	)	PUNCT
chd-155	276	20	concentration	concentration	NOUN
chd-155	276	21	in	in	ADP
chd-155	276	22	the	the	DET
chd-155	276	23	finnish	finnish	ADJ
chd-155	276	24	prostate	prostate	NOUN
chd-155	276	25	cancer	cancer	NOUN
chd-155	276	26	screening	screen	VERB
chd-155	276	27	trial	trial	NOUN
chd-155	276	28	.	.	PUNCT
chd-155	277	1	bju	bju	NOUN
chd-155	277	2	int	int	PROPN
chd-155	277	3	112	112	NUM
chd-155	277	4	,	,	PUNCT
chd-155	277	5	735	735	NUM
chd-155	277	6	-	-	SYM
chd-155	277	7	741	741	NUM
chd-155	277	8	.	.	PUNCT
chd-155	278	1	34	34	NUM
chd-155	278	2	.	.	PUNCT
chd-155	279	1	zhang	zhang	PROPN
chd-155	279	2	w	w	PROPN
chd-155	279	3	,	,	PUNCT
chd-155	279	4	sesterhenn	sesterhenn	PROPN
chd-155	279	5	ia	ia	PROPN
chd-155	279	6	,	,	PUNCT
chd-155	279	7	connelly	connelly	PROPN
chd-155	279	8	rr	rr	PROPN
chd-155	279	9	,	,	PUNCT
chd-155	279	10	mostafi	mostafi	PROPN
chd-155	279	11	fk	fk	PROPN
chd-155	279	12	,	,	PUNCT
chd-155	279	13	and	and	CCONJ
chd-155	279	14	moul	moul	PROPN
chd-155	279	15	jw	jw	PROPN
chd-155	279	16	(	(	PUNCT
chd-155	279	17	2000	2000	NUM
chd-155	279	18	)	)	PUNCT
chd-155	279	19	.	.	PUNCT
chd-155	280	1	inflammatory	inflammatory	ADJ
chd-155	280	2	infiltrate	infiltrate	ADJ
chd-155	280	3	(	(	PUNCT
chd-155	280	4	prostatitis	prostatitis	NOUN
chd-155	280	5	)	)	PUNCT
chd-155	280	6	in	in	ADP
chd-155	280	7	whole	whole	ADJ
chd-155	280	8	mounted	mount	VERB
chd-155	280	9	radical	radical	ADJ
chd-155	280	10	prostatectomy	prostatectomy	NOUN
chd-155	280	11	specimens	specimen	NOUN
chd-155	280	12	from	from	ADP
chd-155	280	13	black	black	ADJ
chd-155	280	14	and	and	CCONJ
chd-155	280	15	white	white	ADJ
chd-155	280	16	patients	patient	NOUN
chd-155	280	17	is	be	AUX
chd-155	280	18	not	not	PART
chd-155	280	19	an	an	DET
chd-155	280	20	etiology	etiology	NOUN
chd-155	280	21	for	for	ADP
chd-155	280	22	racial	racial	ADJ
chd-155	280	23	difference	difference	NOUN
chd-155	280	24	in	in	ADP
chd-155	280	25	prostate	prostate	NOUN
chd-155	280	26	specific	specific	ADJ
chd-155	280	27	antigen	antigen	NOUN
chd-155	280	28	.	.	PUNCT
chd-155	281	1	j	j	PROPN
chd-155	281	2	urol	urol	PROPN
chd-155	281	3	163	163	NUM
chd-155	281	4	,	,	PUNCT
chd-155	281	5	131	131	NUM
chd-155	281	6	-	-	SYM
chd-155	281	7	136	136	NUM
chd-155	281	8	.	.	PUNCT
chd-155	281	9	35	35	NUM
chd-155	281	10	.	.	PUNCT
chd-155	282	1	zhang	zhang	PROPN
chd-155	282	2	y	y	PROPN
chd-155	282	3	,	,	PUNCT
chd-155	282	4	zhang	zhang	PROPN
chd-155	282	5	g	g	PROPN
chd-155	282	6	,	,	PUNCT
chd-155	282	7	liu	liu	PROPN
chd-155	282	8	y	y	PROPN
chd-155	282	9	,	,	PUNCT
chd-155	282	10	chen	chen	PROPN
chd-155	282	11	r	r	PROPN
chd-155	282	12	,	,	PUNCT
chd-155	282	13	zhao	zhao	PROPN
chd-155	282	14	d	d	PROPN
chd-155	282	15	,	,	PUNCT
chd-155	282	16	mcalister	mcalister	PROPN
chd-155	282	17	v	v	PROPN
chd-155	282	18	,	,	PUNCT
chd-155	282	19	mele	mele	PROPN
chd-155	282	20	t	t	PROPN
chd-155	282	21	,	,	PUNCT
chd-155	282	22	liu	liu	PROPN
chd-155	282	23	k	k	PROPN
chd-155	282	24	,	,	PUNCT
chd-155	282	25	and	and	CCONJ
chd-155	282	26	zheng	zheng	PROPN
chd-155	282	27	x	x	X
chd-155	282	28	(	(	PUNCT
chd-155	282	29	2018	2018	NUM
chd-155	282	30	)	)	PUNCT
chd-155	282	31	.	.	PUNCT
chd-155	283	1	gdf15	gdf15	PROPN
chd-155	283	2	regulates	regulate	VERB
chd-155	283	3	malat-1	malat-1	NUM
chd-155	283	4	circular	circular	ADJ
chd-155	283	5	rna	rna	NOUN
chd-155	283	6	and	and	CCONJ
chd-155	283	7	inactivates	inactivate	VERB
chd-155	283	8	nf	nf	ADJ
chd-155	283	9	-	-	PUNCT
chd-155	283	10	κb	κb	NOUN
chd-155	283	11	signaling	signal	VERB
chd-155	283	12	leading	lead	VERB
chd-155	283	13	to	to	ADP
chd-155	283	14	immune	immune	ADJ
chd-155	283	15	tolerogenic	tolerogenic	PROPN
chd-155	283	16	dcs	dcs	PROPN
chd-155	283	17	for	for	ADP
chd-155	283	18	preventing	prevent	VERB
chd-155	283	19	alloimmune	alloimmune	ADJ
chd-155	283	20	rejection	rejection	NOUN
chd-155	283	21	in	in	ADP
chd-155	283	22	heart	heart	NOUN
chd-155	283	23	transplantation	transplantation	NOUN
chd-155	283	24	.	.	PUNCT
chd-155	284	1	front	front	ADJ
chd-155	284	2	immunol	immunol	NOUN
chd-155	284	3	9	9	NUM
chd-155	284	4	,	,	PUNCT
chd-155	284	5	2407	2407	NUM
chd-155	284	6	.	.	PUNCT
chd-155	285	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-155	285	2	e11	e11	ADJ
chd-155	285	3	cancer	cancer	NOUN
chd-155	285	4	health	health	NOUN
chd-155	285	5	disparities	disparity	NOUN
chd-155	285	6	research	research	NOUN
chd-155	285	7	table	table	NOUN
chd-155	285	8	1	1	NUM
chd-155	285	9	.	.	PUNCT
chd-155	286	1	expression	expression	NOUN
chd-155	286	2	of	of	ADP
chd-155	286	3	gdf15	gdf15	NOUN
chd-155	286	4	(	(	PUNCT
chd-155	286	5	top	top	ADJ
chd-155	286	6	)	)	PUNCT
chd-155	286	7	and	and	CCONJ
chd-155	286	8	nfκb	nfκb	NOUN
chd-155	286	9	(	(	PUNCT
chd-155	286	10	bottom	bottom	NOUN
chd-155	286	11	)	)	PUNCT
chd-155	286	12	according	accord	VERB
chd-155	286	13	to	to	ADP
chd-155	286	14	race	race	NOUN
chd-155	286	15	in	in	ADP
chd-155	286	16	benign	benign	ADJ
chd-155	286	17	and	and	CCONJ
chd-155	286	18	tumor	tumor	NOUN
chd-155	286	19	,	,	PUNCT
chd-155	286	20	tissue	tissue	NOUN
chd-155	286	21	microarray	microarray	NOUN
chd-155	286	22	.	.	PUNCT
chd-155	287	1	african	african	ADJ
chd-155	287	2	-	-	PUNCT
chd-155	287	3	american	american	ADJ
chd-155	287	4	,	,	PUNCT
chd-155	287	5	median	median	ADJ
chd-155	287	6	(	(	PUNCT
chd-155	287	7	range	range	NOUN
chd-155	287	8	)	)	PUNCT
chd-155	287	9	european	european	PROPN
chd-155	287	10	american	american	PROPN
chd-155	287	11	,	,	PUNCT
chd-155	287	12	median	median	PROPN
chd-155	287	13	(	(	PUNCT
chd-155	287	14	range	range	NOUN
chd-155	287	15	)	)	PUNCT
chd-155	287	16	overall	overall	ADJ
chd-155	287	17	population	population	NOUN
chd-155	287	18	,	,	PUNCT
chd-155	287	19	median	median	ADJ
chd-155	287	20	tumor	tumor	NOUN
chd-155	287	21	benign	benign	ADJ
chd-155	287	22	p	p	X
chd-155	287	23	tumor	tumor	NOUN
chd-155	287	24	benign	benign	NOUN
chd-155	287	25	p	p	X
chd-155	287	26	tumor	tumor	NOUN
chd-155	287	27	benign	benign	ADJ
chd-155	287	28	p	p	PROPN
chd-155	287	29	gdf15	gdf15	NOUN
chd-155	287	30	2.06	2.06	NUM
chd-155	287	31	(	(	PUNCT
chd-155	287	32	0	0	NUM
chd-155	287	33	,	,	PUNCT
chd-155	287	34	3	3	X
chd-155	287	35	)	)	PUNCT
chd-155	287	36	0.83	0.83	NUM
chd-155	287	37	(	(	PUNCT
chd-155	287	38	0	0	NUM
chd-155	287	39	,	,	PUNCT
chd-155	287	40	3	3	NUM
chd-155	287	41	)	)	PUNCT
chd-155	287	42	<	<	X
chd-155	287	43	0.0001	0.0001	NUM
chd-155	287	44	2.06	2.06	NUM
chd-155	287	45	(	(	PUNCT
chd-155	287	46	0	0	NUM
chd-155	287	47	,	,	PUNCT
chd-155	287	48	3	3	NUM
chd-155	287	49	)	)	PUNCT
chd-155	287	50	0.87	0.87	NUM
chd-155	287	51	(	(	PUNCT
chd-155	287	52	0	0	NUM
chd-155	287	53	,	,	PUNCT
chd-155	287	54	3	3	NUM
chd-155	287	55	)	)	PUNCT
chd-155	287	56	<	<	X
chd-155	288	1	0.0001	0.0001	NUM
chd-155	288	2	1.93	1.93	NUM
chd-155	288	3	0.99	0.99	NUM
chd-155	288	4	<	<	NOUN
chd-155	288	5	0.0001	0.0001	NUM
chd-155	288	6	p	p	NOUN
chd-155	288	7	(	(	PUNCT
chd-155	288	8	aa	aa	NOUN
chd-155	288	9	-	-	PUNCT
chd-155	288	10	ea	ea	NOUN
chd-155	288	11	)	)	PUNCT
chd-155	288	12	0.96	0.96	NUM
chd-155	288	13	0.08	0.08	NUM
chd-155	288	14	nfκb	nfκb	NOUN
chd-155	288	15	1.04	1.04	NUM
chd-155	288	16	(	(	PUNCT
chd-155	288	17	0	0	NUM
chd-155	288	18	,	,	PUNCT
chd-155	288	19	3	3	NUM
chd-155	288	20	)	)	PUNCT
chd-155	288	21	0.96	0.96	NUM
chd-155	288	22	(	(	PUNCT
chd-155	288	23	0	0	NUM
chd-155	288	24	,	,	PUNCT
chd-155	288	25	3	3	NUM
chd-155	288	26	)	)	PUNCT
chd-155	288	27	<	<	X
chd-155	288	28	0.0001	0.0001	NUM
chd-155	288	29	1.04	1.04	NUM
chd-155	288	30	(	(	PUNCT
chd-155	288	31	0	0	NUM
chd-155	288	32	,	,	PUNCT
chd-155	288	33	3	3	NUM
chd-155	288	34	)	)	PUNCT
chd-155	288	35	0.88	0.88	NUM
chd-155	288	36	(	(	PUNCT
chd-155	288	37	0	0	NUM
chd-155	288	38	,	,	PUNCT
chd-155	288	39	2.83	2.83	NUM
chd-155	288	40	)	)	PUNCT
chd-155	288	41	<	<	X
chd-155	288	42	0.0001	0.0001	NUM
chd-155	288	43	1.18	1.18	NUM
chd-155	288	44	0.96	0.96	NUM
chd-155	288	45	<	<	NOUN
chd-155	288	46	0.0001	0.0001	NUM
chd-155	288	47	p	p	NOUN
chd-155	288	48	(	(	PUNCT
chd-155	288	49	aa	aa	NOUN
chd-155	288	50	-	-	PUNCT
chd-155	288	51	ea	ea	NOUN
chd-155	288	52	)	)	PUNCT
chd-155	288	53	0.82	0.82	NUM
chd-155	288	54	0.06	0.06	NUM
chd-155	288	55	aa=	aa=	PROPN
chd-155	288	56	african	african	PROPN
chd-155	288	57	-	-	PUNCT
chd-155	288	58	american	american	ADJ
chd-155	288	59	;	;	PUNCT
chd-155	288	60	ea	ea	X
chd-155	288	61	=	=	SYM
chd-155	288	62	european	european	ADJ
chd-155	288	63	-	-	PUNCT
chd-155	288	64	american	american	ADJ
chd-155	288	65	white	white	PROPN
chd-155	288	66	table	table	NOUN
chd-155	288	67	2	2	NUM
chd-155	288	68	.	.	PUNCT
chd-155	289	1	expression	expression	NOUN
chd-155	289	2	of	of	ADP
chd-155	289	3	gdf15	gdf15	NOUN
chd-155	289	4	and	and	CCONJ
chd-155	289	5	nfκb	nfκb	NOUN
chd-155	289	6	according	accord	VERB
chd-155	289	7	to	to	ADP
chd-155	289	8	gleason	gleason	PROPN
chd-155	289	9	grade	grade	PROPN
chd-155	289	10	group	group	NOUN
chd-155	289	11	.	.	PUNCT
chd-155	290	1	grade	grade	NOUN
chd-155	290	2	group	group	NOUN
chd-155	290	3	gdf15	gdf15	NOUN
chd-155	290	4	.	.	PUNCT
chd-155	291	1	tumor	tumor	NOUN
chd-155	291	2	,	,	PUNCT
chd-155	291	3	median	median	NOUN
chd-155	291	4	(	(	PUNCT
chd-155	291	5	range	range	NOUN
chd-155	291	6	)	)	PUNCT
chd-155	291	7	p	p	NOUN
chd-155	291	8	n=	n=	ADJ
chd-155	291	9	gdf15	gdf15	NOUN
chd-155	291	10	.	.	PUNCT
chd-155	292	1	benign	benign	ADJ
chd-155	292	2	,	,	PUNCT
chd-155	292	3	median	median	ADJ
chd-155	292	4	(	(	PUNCT
chd-155	292	5	range	range	NOUN
chd-155	292	6	)	)	PUNCT
chd-155	293	1	p	p	NOUN
chd-155	293	2	n=	n=	ADJ
chd-155	293	3	1	1	NUM
chd-155	293	4	2.06	2.06	NUM
chd-155	293	5	(	(	PUNCT
chd-155	293	6	0	0	NUM
chd-155	293	7	,	,	PUNCT
chd-155	293	8	3	3	NUM
chd-155	293	9	)	)	PUNCT
chd-155	293	10	0.010	0.010	NUM
chd-155	293	11	221	221	NUM
chd-155	293	12	0.83	0.83	NUM
chd-155	293	13	(	(	PUNCT
chd-155	293	14	0	0	NUM
chd-155	293	15	,	,	PUNCT
chd-155	293	16	3	3	X
chd-155	293	17	)	)	PUNCT
chd-155	293	18	0.9475	0.9475	NUM
chd-155	293	19	250	250	NUM
chd-155	293	20	2	2	NUM
chd-155	293	21	2.06	2.06	NUM
chd-155	293	22	(	(	PUNCT
chd-155	293	23	0	0	NUM
chd-155	293	24	,	,	PUNCT
chd-155	293	25	3	3	X
chd-155	293	26	)	)	PUNCT
chd-155	293	27	198	198	NUM
chd-155	293	28	0.83	0.83	NUM
chd-155	293	29	(	(	PUNCT
chd-155	293	30	0	0	NUM
chd-155	293	31	,	,	PUNCT
chd-155	293	32	3	3	NUM
chd-155	293	33	)	)	PUNCT
chd-155	293	34	210	210	NUM
chd-155	293	35	3	3	NUM
chd-155	293	36	2.06	2.06	NUM
chd-155	293	37	(	(	PUNCT
chd-155	293	38	0	0	NUM
chd-155	293	39	,	,	PUNCT
chd-155	293	40	3	3	NUM
chd-155	293	41	)	)	PUNCT
chd-155	293	42	87	87	NUM
chd-155	293	43	0.93	0.93	NUM
chd-155	293	44	(	(	PUNCT
chd-155	293	45	0	0	NUM
chd-155	293	46	,	,	PUNCT
chd-155	293	47	3	3	NUM
chd-155	293	48	)	)	PUNCT
chd-155	293	49	94	94	NUM
chd-155	293	50	4	4	NUM
chd-155	293	51	2.42	2.42	NUM
chd-155	293	52	(	(	PUNCT
chd-155	293	53	0.4	0.4	NUM
chd-155	293	54	,	,	PUNCT
chd-155	293	55	3	3	NUM
chd-155	293	56	)	)	PUNCT
chd-155	293	57	52	52	NUM
chd-155	293	58	0.95	0.95	NUM
chd-155	293	59	(	(	PUNCT
chd-155	293	60	0	0	NUM
chd-155	293	61	,	,	PUNCT
chd-155	293	62	3	3	NUM
chd-155	293	63	)	)	PUNCT
chd-155	293	64	59	59	NUM
chd-155	293	65	5	5	NUM
chd-155	293	66	1.70	1.70	NUM
chd-155	293	67	(	(	PUNCT
chd-155	293	68	0	0	NUM
chd-155	293	69	,	,	PUNCT
chd-155	293	70	3	3	NUM
chd-155	293	71	)	)	PUNCT
chd-155	293	72	70	70	NUM
chd-155	293	73	0.83	0.83	NUM
chd-155	293	74	(	(	PUNCT
chd-155	293	75	0	0	NUM
chd-155	293	76	,	,	PUNCT
chd-155	293	77	3	3	X
chd-155	293	78	)	)	SYM
chd-155	293	79	72	72	NUM
chd-155	293	80	grade	grade	NOUN
chd-155	293	81	group	group	NOUN
chd-155	293	82	nfκb	nfκb	NOUN
chd-155	293	83	.	.	PUNCT
chd-155	294	1	tumor	tumor	NOUN
chd-155	294	2	,	,	PUNCT
chd-155	294	3	median	median	NOUN
chd-155	294	4	(	(	PUNCT
chd-155	294	5	range	range	NOUN
chd-155	294	6	)	)	PUNCT
chd-155	294	7	p	p	PROPN
chd-155	294	8	n=	n=	ADJ
chd-155	294	9	nfκb	nfκb	NOUN
chd-155	294	10	.	.	PUNCT
chd-155	295	1	benign	benign	ADJ
chd-155	295	2	,	,	PUNCT
chd-155	295	3	median	median	ADJ
chd-155	295	4	(	(	PUNCT
chd-155	295	5	range	range	NOUN
chd-155	295	6	)	)	PUNCT
chd-155	296	1	p	p	NOUN
chd-155	296	2	n=	n=	ADJ
chd-155	296	3	1	1	NUM
chd-155	296	4	1.00	1.00	NUM
chd-155	296	5	(	(	PUNCT
chd-155	296	6	0	0	NUM
chd-155	296	7	,	,	PUNCT
chd-155	296	8	3	3	X
chd-155	296	9	)	)	PUNCT
chd-155	296	10	0.009	0.009	NUM
chd-155	296	11	221	221	NUM
chd-155	296	12	0.88(0	0.88(0	NUM
chd-155	296	13	,	,	PUNCT
chd-155	296	14	2.7	2.7	NUM
chd-155	296	15	)	)	PUNCT
chd-155	296	16	0.003	0.003	NUM
chd-155	296	17	248	248	NUM
chd-155	296	18	2	2	NUM
chd-155	296	19	0.97	0.97	NUM
chd-155	296	20	(	(	PUNCT
chd-155	296	21	0	0	NUM
chd-155	296	22	,	,	PUNCT
chd-155	296	23	3	3	X
chd-155	296	24	)	)	PUNCT
chd-155	296	25	195	195	NUM
chd-155	296	26	0.85	0.85	NUM
chd-155	296	27	(	(	PUNCT
chd-155	296	28	0	0	NUM
chd-155	296	29	,	,	PUNCT
chd-155	296	30	2.5	2.5	NUM
chd-155	296	31	)	)	PUNCT
chd-155	296	32	210	210	NUM
chd-155	296	33	3	3	NUM
chd-155	296	34	1.17	1.17	NUM
chd-155	296	35	(	(	PUNCT
chd-155	296	36	0	0	NUM
chd-155	296	37	,	,	PUNCT
chd-155	296	38	3	3	NUM
chd-155	296	39	)	)	PUNCT
chd-155	296	40	87	87	NUM
chd-155	296	41	1.08	1.08	NUM
chd-155	296	42	(	(	PUNCT
chd-155	296	43	0	0	NUM
chd-155	296	44	,	,	PUNCT
chd-155	296	45	2.3	2.3	NUM
chd-155	296	46	)	)	PUNCT
chd-155	296	47	94	94	NUM
chd-155	296	48	4	4	NUM
chd-155	296	49	1.50	1.50	NUM
chd-155	296	50	(	(	PUNCT
chd-155	296	51	0	0	NUM
chd-155	296	52	,	,	PUNCT
chd-155	296	53	2.9	2.9	NUM
chd-155	296	54	)	)	PUNCT
chd-155	296	55	57	57	NUM
chd-155	296	56	1.06	1.06	NUM
chd-155	296	57	(	(	PUNCT
chd-155	296	58	0	0	NUM
chd-155	296	59	,	,	PUNCT
chd-155	296	60	3	3	NUM
chd-155	296	61	)	)	PUNCT
chd-155	296	62	59	59	NUM
chd-155	296	63	5	5	NUM
chd-155	296	64	1.06	1.06	NUM
chd-155	296	65	(	(	PUNCT
chd-155	296	66	0	0	NUM
chd-155	296	67	,	,	PUNCT
chd-155	296	68	3	3	NUM
chd-155	296	69	)	)	PUNCT
chd-155	296	70	72	72	NUM
chd-155	296	71	0.96	0.96	NUM
chd-155	296	72	(	(	PUNCT
chd-155	296	73	0	0	NUM
chd-155	296	74	,	,	PUNCT
chd-155	296	75	2.8	2.8	NUM
chd-155	296	76	)	)	PUNCT
chd-155	296	77	71	71	NUM
chd-155	296	78	n=	n=	ADJ
chd-155	296	79	number	number	NOUN
chd-155	296	80	of	of	ADP
chd-155	296	81	informative	informative	ADJ
chd-155	296	82	cases	case	NOUN
chd-155	296	83	table	table	VERB
chd-155	296	84	3	3	NUM
chd-155	296	85	.	.	PUNCT
chd-155	297	1	expression	expression	NOUN
chd-155	297	2	of	of	ADP
chd-155	297	3	gdf15	gdf15	NOUN
chd-155	297	4	and	and	CCONJ
chd-155	297	5	nfκb	nfκb	NOUN
chd-155	297	6	according	accord	VERB
chd-155	297	7	to	to	ADP
chd-155	297	8	pathologic	pathologic	ADJ
chd-155	297	9	stage	stage	NOUN
chd-155	297	10	.	.	PUNCT
chd-155	298	1	pathologic	pathologic	ADJ
chd-155	298	2	stage	stage	NOUN
chd-155	298	3	gdf15	gdf15	NOUN
chd-155	298	4	.	.	PUNCT
chd-155	299	1	tumor	tumor	NOUN
chd-155	299	2	,	,	PUNCT
chd-155	299	3	median	median	NOUN
chd-155	299	4	(	(	PUNCT
chd-155	299	5	range	range	NOUN
chd-155	299	6	)	)	PUNCT
chd-155	299	7	p	p	NOUN
chd-155	299	8	n=	n=	ADJ
chd-155	299	9	gdf15	gdf15	NOUN
chd-155	299	10	.	.	PUNCT
chd-155	300	1	benign	benign	ADJ
chd-155	300	2	,	,	PUNCT
chd-155	300	3	median	median	ADJ
chd-155	300	4	(	(	PUNCT
chd-155	300	5	range	range	NOUN
chd-155	300	6	)	)	PUNCT
chd-155	301	1	p	p	NOUN
chd-155	301	2	n=	n=	ADJ
chd-155	301	3	2	2	NUM
chd-155	301	4	2.20	2.20	NUM
chd-155	301	5	(	(	PUNCT
chd-155	301	6	0	0	NUM
chd-155	301	7	,	,	PUNCT
chd-155	301	8	3	3	NUM
chd-155	301	9	)	)	PUNCT
chd-155	301	10	0.001	0.001	NUM
chd-155	301	11	462	462	NUM
chd-155	301	12	1.43	1.43	NUM
chd-155	301	13	(	(	PUNCT
chd-155	301	14	0.188	0.188	NUM
chd-155	301	15	,	,	PUNCT
chd-155	301	16	2.56	2.56	NUM
chd-155	301	17	)	)	PUNCT
chd-155	301	18	<	<	X
chd-155	301	19	0.001	0.001	NUM
chd-155	301	20	514	514	NUM
chd-155	301	21	3a	3a	NUM
chd-155	301	22	1.91	1.91	NUM
chd-155	301	23	(	(	PUNCT
chd-155	301	24	0	0	NUM
chd-155	301	25	,	,	PUNCT
chd-155	301	26	3	3	NUM
chd-155	301	27	)	)	PUNCT
chd-155	301	28	106	106	NUM
chd-155	301	29	1.82	1.82	NUM
chd-155	301	30	(	(	PUNCT
chd-155	301	31	0.5	0.5	NUM
chd-155	301	32	,	,	PUNCT
chd-155	301	33	2.81	2.81	NUM
chd-155	301	34	)	)	PUNCT
chd-155	301	35	109	109	NUM
chd-155	301	36	3b	3b	NUM
chd-155	301	37	1.65	1.65	NUM
chd-155	301	38	(	(	PUNCT
chd-155	301	39	0	0	NUM
chd-155	301	40	,	,	PUNCT
chd-155	301	41	3	3	NUM
chd-155	301	42	)	)	PUNCT
chd-155	301	43	56	56	NUM
chd-155	301	44	1.16	1.16	NUM
chd-155	301	45	(	(	PUNCT
chd-155	301	46	0.25	0.25	NUM
chd-155	301	47	,	,	PUNCT
chd-155	301	48	2.56	2.56	NUM
chd-155	301	49	)	)	PUNCT
chd-155	301	50	58	58	NUM
chd-155	301	51	4	4	NUM
chd-155	301	52	1.33	1.33	NUM
chd-155	301	53	(	(	PUNCT
chd-155	301	54	0.6	0.6	NUM
chd-155	301	55	,	,	PUNCT
chd-155	301	56	2.8	2.8	NUM
chd-155	301	57	)	)	PUNCT
chd-155	301	58	4	4	NUM
chd-155	301	59	1.16	1.16	NUM
chd-155	301	60	(	(	PUNCT
chd-155	301	61	0.625	0.625	NUM
chd-155	301	62	,	,	PUNCT
chd-155	301	63	1.69	1.69	NUM
chd-155	301	64	)	)	PUNCT
chd-155	301	65	4	4	NUM
chd-155	301	66	pathologic	pathologic	ADJ
chd-155	301	67	stage	stage	NOUN
chd-155	301	68	nfκb	nfκb	NOUN
chd-155	301	69	.	.	PUNCT
chd-155	302	1	tumor	tumor	NOUN
chd-155	302	2	,	,	PUNCT
chd-155	302	3	median	median	NOUN
chd-155	302	4	(	(	PUNCT
chd-155	302	5	range	range	NOUN
chd-155	302	6	)	)	PUNCT
chd-155	302	7	p	p	PROPN
chd-155	302	8	n=	n=	ADJ
chd-155	302	9	nfκb	nfκb	NOUN
chd-155	302	10	.	.	PUNCT
chd-155	303	1	benign	benign	ADJ
chd-155	303	2	,	,	PUNCT
chd-155	303	3	median	median	ADJ
chd-155	303	4	(	(	PUNCT
chd-155	303	5	range	range	NOUN
chd-155	303	6	)	)	PUNCT
chd-155	304	1	p	p	NOUN
chd-155	304	2	n=	n=	ADJ
chd-155	304	3	2	2	NUM
chd-155	304	4	1.04	1.04	NUM
chd-155	304	5	(	(	PUNCT
chd-155	304	6	0	0	NUM
chd-155	304	7	,	,	PUNCT
chd-155	304	8	3	3	NUM
chd-155	304	9	)	)	PUNCT
chd-155	304	10	0.02	0.02	NUM
chd-155	304	11	466	466	NUM
chd-155	304	12	0.9	0.9	NUM
chd-155	304	13	(	(	PUNCT
chd-155	304	14	0	0	NUM
chd-155	304	15	,	,	PUNCT
chd-155	304	16	3	3	NUM
chd-155	304	17	)	)	PUNCT
chd-155	304	18	0.10	0.10	NUM
chd-155	304	19	511	511	NUM
chd-155	304	20	3a	3a	NUM
chd-155	304	21	0.97	0.97	NUM
chd-155	304	22	(	(	PUNCT
chd-155	304	23	0	0	NUM
chd-155	304	24	,	,	PUNCT
chd-155	304	25	3	3	X
chd-155	304	26	)	)	PUNCT
chd-155	304	27	105	105	NUM
chd-155	304	28	0.9	0.9	NUM
chd-155	304	29	(	(	PUNCT
chd-155	304	30	0	0	NUM
chd-155	304	31	,	,	PUNCT
chd-155	304	32	2.5	2.5	NUM
chd-155	304	33	)	)	PUNCT
chd-155	304	34	109	109	NUM
chd-155	304	35	3b	3b	NOUN
chd-155	304	36	1.20	1.20	NUM
chd-155	304	37	(	(	PUNCT
chd-155	304	38	0	0	NUM
chd-155	304	39	,	,	PUNCT
chd-155	304	40	3	3	NUM
chd-155	304	41	)	)	PUNCT
chd-155	304	42	57	57	NUM
chd-155	304	43	1.08	1.08	NUM
chd-155	304	44	(	(	PUNCT
chd-155	304	45	0	0	NUM
chd-155	304	46	,	,	PUNCT
chd-155	304	47	2.1	2.1	NUM
chd-155	304	48	)	)	PUNCT
chd-155	304	49	58	58	NUM
chd-155	304	50	4	4	NUM
chd-155	304	51	0.54	0.54	NUM
chd-155	304	52	(	(	PUNCT
chd-155	304	53	0	0	NUM
chd-155	304	54	,	,	PUNCT
chd-155	304	55	0.7	0.7	NUM
chd-155	304	56	)	)	PUNCT
chd-155	304	57	4	4	NUM
chd-155	304	58	0.86	0.86	NUM
chd-155	304	59	(	(	PUNCT
chd-155	304	60	0.7	0.7	NUM
chd-155	304	61	,	,	PUNCT
chd-155	304	62	1.2	1.2	NUM
chd-155	304	63	)	)	PUNCT
chd-155	304	64	4	4	NUM
chd-155	304	65	n=	n=	ADJ
chd-155	304	66	number	number	NOUN
chd-155	304	67	of	of	ADP
chd-155	304	68	informative	informative	ADJ
chd-155	304	69	cases	case	NOUN
chd-155	304	70	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-155	304	71	e12	e12	NOUN
chd-155	304	72	cancer	cancer	NOUN
chd-155	304	73	health	health	NOUN
chd-155	304	74	disparities	disparity	NOUN
chd-155	304	75	research	research	NOUN
chd-155	304	76	table	table	NOUN
chd-155	304	77	4	4	NUM
chd-155	304	78	.	.	PUNCT
chd-155	304	79	racial	racial	ADJ
chd-155	304	80	disparity	disparity	NOUN
chd-155	304	81	of	of	ADP
chd-155	304	82	expression	expression	NOUN
chd-155	304	83	of	of	ADP
chd-155	304	84	gdf15	gdf15	NOUN
chd-155	304	85	and	and	CCONJ
chd-155	304	86	nfκb	nfκb	NOUN
chd-155	304	87	according	accord	VERB
chd-155	304	88	to	to	ADP
chd-155	304	89	gleason	gleason	PROPN
chd-155	304	90	grade	grade	PROPN
chd-155	304	91	group	group	NOUN
chd-155	304	92	.	.	PUNCT
chd-155	305	1	african	african	ADJ
chd-155	305	2	-	-	PUNCT
chd-155	305	3	american	american	ADJ
chd-155	305	4	european	european	PROPN
chd-155	305	5	american	american	PROPN
chd-155	305	6	grade	grade	PROPN
chd-155	305	7	group	group	NOUN
chd-155	305	8	gdf15	gdf15	PROPN
chd-155	305	9	.	.	PUNCT
chd-155	306	1	tumor	tumor	NOUN
chd-155	306	2	,	,	PUNCT
chd-155	306	3	median	median	NOUN
chd-155	306	4	(	(	PUNCT
chd-155	306	5	range	range	NOUN
chd-155	306	6	)	)	PUNCT
chd-155	306	7	p	p	NOUN
chd-155	306	8	n=	n=	ADJ
chd-155	306	9	gdf15	gdf15	NOUN
chd-155	306	10	.	.	PUNCT
chd-155	307	1	benign	benign	ADJ
chd-155	307	2	,	,	PUNCT
chd-155	307	3	median	median	ADJ
chd-155	307	4	(	(	PUNCT
chd-155	307	5	range	range	NOUN
chd-155	307	6	)	)	PUNCT
chd-155	307	7	p	p	NOUN
chd-155	307	8	n=	n=	ADJ
chd-155	307	9	gdf15	gdf15	NOUN
chd-155	307	10	.	.	PUNCT
chd-155	308	1	tumor	tumor	NOUN
chd-155	308	2	,	,	PUNCT
chd-155	308	3	median	median	NOUN
chd-155	308	4	(	(	PUNCT
chd-155	308	5	range	range	NOUN
chd-155	308	6	)	)	PUNCT
chd-155	308	7	p	p	NOUN
chd-155	308	8	n=	n=	ADJ
chd-155	308	9	gdf15	gdf15	NOUN
chd-155	308	10	.	.	PUNCT
chd-155	309	1	benign	benign	ADJ
chd-155	309	2	,	,	PUNCT
chd-155	309	3	median	median	ADJ
chd-155	309	4	(	(	PUNCT
chd-155	309	5	range	range	NOUN
chd-155	309	6	)	)	PUNCT
chd-155	310	1	p	p	NOUN
chd-155	310	2	n=	n=	ADJ
chd-155	310	3	1	1	NUM
chd-155	310	4	2.15	2.15	NUM
chd-155	310	5	(	(	PUNCT
chd-155	310	6	0	0	NUM
chd-155	310	7	,	,	PUNCT
chd-155	310	8	3	3	NUM
chd-155	310	9	)	)	PUNCT
chd-155	310	10	0.08	0.08	NUM
chd-155	310	11	107	107	NUM
chd-155	310	12	0.83	0.83	NUM
chd-155	310	13	(	(	PUNCT
chd-155	310	14	0	0	NUM
chd-155	310	15	,	,	PUNCT
chd-155	310	16	3	3	NUM
chd-155	310	17	)	)	PUNCT
chd-155	310	18	0.80	0.80	NUM
chd-155	310	19	118	118	NUM
chd-155	310	20	2.06	2.06	NUM
chd-155	310	21	(	(	PUNCT
chd-155	310	22	0	0	NUM
chd-155	310	23	,	,	PUNCT
chd-155	310	24	3	3	NUM
chd-155	310	25	)	)	PUNCT
chd-155	310	26	0.19	0.19	NUM
chd-155	310	27	114	114	NUM
chd-155	310	28	0.97	0.97	NUM
chd-155	310	29	(	(	PUNCT
chd-155	310	30	0	0	NUM
chd-155	310	31	,	,	PUNCT
chd-155	310	32	2.9	2.9	NUM
chd-155	310	33	)	)	PUNCT
chd-155	310	34	0.01	0.01	NUM
chd-155	310	35	132	132	NUM
chd-155	310	36	2	2	NUM
chd-155	310	37	2.06	2.06	NUM
chd-155	310	38	(	(	PUNCT
chd-155	310	39	0.4	0.4	NUM
chd-155	310	40	,	,	PUNCT
chd-155	310	41	3	3	NUM
chd-155	310	42	)	)	PUNCT
chd-155	310	43	93	93	NUM
chd-155	310	44	0.83	0.83	NUM
chd-155	310	45	(	(	PUNCT
chd-155	310	46	0	0	NUM
chd-155	310	47	,	,	PUNCT
chd-155	310	48	3	3	X
chd-155	310	49	)	)	PUNCT
chd-155	310	50	97	97	NUM
chd-155	310	51	2.00	2.00	NUM
chd-155	310	52	(	(	PUNCT
chd-155	310	53	0	0	NUM
chd-155	310	54	,	,	PUNCT
chd-155	310	55	3	3	X
chd-155	310	56	)	)	PUNCT
chd-155	310	57	105	105	NUM
chd-155	310	58	0.83	0.83	NUM
chd-155	310	59	(	(	PUNCT
chd-155	310	60	0	0	NUM
chd-155	310	61	,	,	PUNCT
chd-155	310	62	3	3	NUM
chd-155	310	63	)	)	PUNCT
chd-155	310	64	113	113	NUM
chd-155	310	65	3	3	NUM
chd-155	310	66	2.17	2.17	NUM
chd-155	310	67	(	(	PUNCT
chd-155	310	68	0.2	0.2	NUM
chd-155	310	69	,	,	PUNCT
chd-155	310	70	3	3	X
chd-155	310	71	)	)	PUNCT
chd-155	310	72	42	42	NUM
chd-155	310	73	0.83	0.83	NUM
chd-155	310	74	(	(	PUNCT
chd-155	310	75	0	0	NUM
chd-155	310	76	,	,	PUNCT
chd-155	310	77	3	3	NUM
chd-155	310	78	)	)	PUNCT
chd-155	310	79	44	44	NUM
chd-155	310	80	2.01	2.01	NUM
chd-155	310	81	(	(	PUNCT
chd-155	310	82	0	0	NUM
chd-155	310	83	,	,	PUNCT
chd-155	310	84	3	3	NUM
chd-155	310	85	)	)	PUNCT
chd-155	310	86	45	45	NUM
chd-155	310	87	1.1	1.1	NUM
chd-155	310	88	(	(	PUNCT
chd-155	310	89	0	0	NUM
chd-155	310	90	,	,	PUNCT
chd-155	310	91	3	3	X
chd-155	310	92	)	)	PUNCT
chd-155	310	93	50	50	NUM
chd-155	310	94	4	4	NUM
chd-155	310	95	2.71	2.71	NUM
chd-155	310	96	(	(	PUNCT
chd-155	310	97	0.4	0.4	NUM
chd-155	310	98	,	,	PUNCT
chd-155	310	99	3	3	NUM
chd-155	310	100	)	)	PUNCT
chd-155	310	101	22	22	NUM
chd-155	310	102	0.88	0.88	NUM
chd-155	310	103	(	(	PUNCT
chd-155	310	104	0	0	NUM
chd-155	310	105	,	,	PUNCT
chd-155	310	106	3	3	NUM
chd-155	310	107	)	)	PUNCT
chd-155	310	108	27	27	NUM
chd-155	310	109	2.34	2.34	NUM
chd-155	310	110	(	(	PUNCT
chd-155	310	111	0.5	0.5	NUM
chd-155	310	112	,	,	PUNCT
chd-155	310	113	3	3	NUM
chd-155	310	114	)	)	PUNCT
chd-155	310	115	30	30	NUM
chd-155	310	116	1.15	1.15	NUM
chd-155	310	117	(	(	PUNCT
chd-155	310	118	0	0	NUM
chd-155	310	119	,	,	PUNCT
chd-155	310	120	3	3	NUM
chd-155	310	121	)	)	PUNCT
chd-155	310	122	32	32	NUM
chd-155	310	123	5	5	NUM
chd-155	310	124	1.63	1.63	NUM
chd-155	310	125	(	(	PUNCT
chd-155	310	126	0	0	NUM
chd-155	310	127	,	,	PUNCT
chd-155	310	128	3	3	NUM
chd-155	310	129	)	)	PUNCT
chd-155	310	130	36	36	NUM
chd-155	310	131	0.96	0.96	NUM
chd-155	310	132	(	(	PUNCT
chd-155	310	133	0	0	NUM
chd-155	310	134	,	,	PUNCT
chd-155	310	135	3	3	X
chd-155	310	136	)	)	PUNCT
chd-155	310	137	37	37	NUM
chd-155	310	138	2.03	2.03	NUM
chd-155	310	139	(	(	PUNCT
chd-155	310	140	0.3	0.3	NUM
chd-155	310	141	,	,	PUNCT
chd-155	310	142	3	3	NUM
chd-155	310	143	)	)	PUNCT
chd-155	310	144	34	34	NUM
chd-155	310	145	0.69	0.69	NUM
chd-155	310	146	(	(	PUNCT
chd-155	310	147	0	0	NUM
chd-155	310	148	,	,	PUNCT
chd-155	310	149	2.5	2.5	NUM
chd-155	310	150	)	)	PUNCT
chd-155	310	151	35	35	NUM
chd-155	310	152	grade	grade	NOUN
chd-155	310	153	group	group	NOUN
chd-155	310	154	nfκb	nfκb	NOUN
chd-155	310	155	.	.	PUNCT
chd-155	311	1	tumor	tumor	NOUN
chd-155	311	2	,	,	PUNCT
chd-155	311	3	median	median	NOUN
chd-155	311	4	(	(	PUNCT
chd-155	311	5	range	range	NOUN
chd-155	311	6	)	)	PUNCT
chd-155	311	7	p	p	PROPN
chd-155	311	8	n=	n=	ADJ
chd-155	311	9	nfκb	nfκb	NOUN
chd-155	311	10	.	.	PUNCT
chd-155	312	1	benign	benign	ADJ
chd-155	312	2	,	,	PUNCT
chd-155	312	3	median	median	ADJ
chd-155	312	4	(	(	PUNCT
chd-155	312	5	range	range	NOUN
chd-155	312	6	)	)	PUNCT
chd-155	312	7	p	p	PROPN
chd-155	312	8	n=	n=	ADJ
chd-155	312	9	nfκb	nfκb	NOUN
chd-155	312	10	.	.	PUNCT
chd-155	313	1	tumor	tumor	NOUN
chd-155	313	2	,	,	PUNCT
chd-155	313	3	median	median	NOUN
chd-155	313	4	(	(	PUNCT
chd-155	313	5	range	range	NOUN
chd-155	313	6	)	)	PUNCT
chd-155	313	7	p	p	PROPN
chd-155	313	8	n=	n=	ADJ
chd-155	313	9	nfκb	nfκb	NOUN
chd-155	313	10	.	.	PUNCT
chd-155	314	1	benign	benign	ADJ
chd-155	314	2	,	,	PUNCT
chd-155	314	3	median	median	ADJ
chd-155	314	4	(	(	PUNCT
chd-155	314	5	range	range	NOUN
chd-155	314	6	)	)	PUNCT
chd-155	315	1	p	p	NOUN
chd-155	315	2	n=	n=	ADJ
chd-155	315	3	1	1	NUM
chd-155	315	4	0.96	0.96	NUM
chd-155	315	5	(	(	PUNCT
chd-155	315	6	0	0	NUM
chd-155	315	7	,	,	PUNCT
chd-155	315	8	3	3	NUM
chd-155	315	9	)	)	PUNCT
chd-155	315	10	0.03	0.03	NUM
chd-155	315	11	107	107	NUM
chd-155	315	12	0.96	0.96	NUM
chd-155	315	13	(	(	PUNCT
chd-155	315	14	0	0	NUM
chd-155	315	15	,	,	PUNCT
chd-155	315	16	2.7	2.7	NUM
chd-155	315	17	)	)	PUNCT
chd-155	315	18	0.37	0.37	NUM
chd-155	315	19	117	117	NUM
chd-155	315	20	1.04(0	1.04(0	NUM
chd-155	315	21	,	,	PUNCT
chd-155	315	22	3	3	NUM
chd-155	315	23	)	)	PUNCT
chd-155	315	24	0.23	0.23	NUM
chd-155	315	25	114	114	NUM
chd-155	315	26	0.82	0.82	NUM
chd-155	315	27	(	(	PUNCT
chd-155	315	28	0	0	NUM
chd-155	315	29	,	,	PUNCT
chd-155	315	30	2.5	2.5	NUM
chd-155	315	31	)	)	PUNCT
chd-155	315	32	0.007	0.007	NUM
chd-155	315	33	131	131	NUM
chd-155	315	34	2	2	NUM
chd-155	315	35	1.04	1.04	NUM
chd-155	315	36	(	(	PUNCT
chd-155	315	37	0	0	NUM
chd-155	315	38	,	,	PUNCT
chd-155	315	39	3	3	NUM
chd-155	315	40	)	)	PUNCT
chd-155	315	41	89	89	NUM
chd-155	315	42	0.91	0.91	NUM
chd-155	315	43	(	(	PUNCT
chd-155	315	44	0	0	NUM
chd-155	315	45	,	,	PUNCT
chd-155	315	46	2.3	2.3	NUM
chd-155	315	47	)	)	PUNCT
chd-155	315	48	97	97	NUM
chd-155	315	49	0.87	0.87	NUM
chd-155	315	50	(	(	PUNCT
chd-155	315	51	0	0	NUM
chd-155	315	52	,	,	PUNCT
chd-155	315	53	3	3	NUM
chd-155	315	54	)	)	PUNCT
chd-155	315	55	106	106	NUM
chd-155	315	56	0.75	0.75	NUM
chd-155	315	57	(	(	PUNCT
chd-155	315	58	0	0	NUM
chd-155	315	59	,	,	PUNCT
chd-155	315	60	2.5	2.5	NUM
chd-155	315	61	)	)	PUNCT
chd-155	315	62	113	113	NUM
chd-155	315	63	3	3	NUM
chd-155	315	64	1.15	1.15	NUM
chd-155	315	65	(	(	PUNCT
chd-155	315	66	0	0	NUM
chd-155	315	67	,	,	PUNCT
chd-155	315	68	3	3	X
chd-155	315	69	)	)	PUNCT
chd-155	315	70	42	42	NUM
chd-155	315	71	1.08	1.08	NUM
chd-155	315	72	(	(	PUNCT
chd-155	315	73	0	0	NUM
chd-155	315	74	,	,	PUNCT
chd-155	315	75	2.3	2.3	NUM
chd-155	315	76	)	)	PUNCT
chd-155	315	77	44	44	NUM
chd-155	315	78	1.25	1.25	NUM
chd-155	315	79	(	(	PUNCT
chd-155	315	80	0	0	NUM
chd-155	315	81	,	,	PUNCT
chd-155	315	82	3	3	NUM
chd-155	315	83	)	)	PUNCT
chd-155	315	84	45	45	NUM
chd-155	315	85	1.04	1.04	NUM
chd-155	315	86	(	(	PUNCT
chd-155	315	87	0	0	NUM
chd-155	315	88	,	,	PUNCT
chd-155	315	89	2.1	2.1	NUM
chd-155	315	90	)	)	PUNCT
chd-155	315	91	50	50	NUM
chd-155	315	92	4	4	NUM
chd-155	315	93	1.50	1.50	NUM
chd-155	315	94	(	(	PUNCT
chd-155	315	95	0	0	NUM
chd-155	315	96	,	,	PUNCT
chd-155	315	97	2.9	2.9	NUM
chd-155	315	98	)	)	PUNCT
chd-155	315	99	25	25	NUM
chd-155	315	100	1.00	1.00	NUM
chd-155	315	101	(	(	PUNCT
chd-155	315	102	0	0	NUM
chd-155	315	103	,	,	PUNCT
chd-155	315	104	3	3	NUM
chd-155	315	105	)	)	PUNCT
chd-155	315	106	27	27	NUM
chd-155	315	107	1.46	1.46	NUM
chd-155	315	108	(	(	PUNCT
chd-155	315	109	0	0	NUM
chd-155	315	110	,	,	PUNCT
chd-155	315	111	2.9	2.9	NUM
chd-155	315	112	)	)	PUNCT
chd-155	315	113	32	32	NUM
chd-155	315	114	1.07	1.07	NUM
chd-155	315	115	(	(	PUNCT
chd-155	315	116	0	0	NUM
chd-155	315	117	,	,	PUNCT
chd-155	315	118	2.1	2.1	NUM
chd-155	315	119	)	)	PUNCT
chd-155	315	120	32	32	NUM
chd-155	315	121	5	5	NUM
chd-155	315	122	1.12	1.12	NUM
chd-155	315	123	(	(	PUNCT
chd-155	315	124	0	0	NUM
chd-155	315	125	,	,	PUNCT
chd-155	315	126	3	3	NUM
chd-155	315	127	)	)	PUNCT
chd-155	315	128	37	37	NUM
chd-155	315	129	0.96	0.96	NUM
chd-155	315	130	(	(	PUNCT
chd-155	315	131	0	0	NUM
chd-155	315	132	,	,	PUNCT
chd-155	315	133	1	1	NUM
chd-155	315	134	.	.	NUM
chd-155	315	135	8)	8)	NUM
chd-155	315	136	36	36	NUM
chd-155	315	137	1.04	1.04	NUM
chd-155	315	138	(	(	PUNCT
chd-155	315	139	0.2	0.2	NUM
chd-155	315	140	,	,	PUNCT
chd-155	315	141	3	3	NUM
chd-155	315	142	)	)	PUNCT
chd-155	315	143	35	35	NUM
chd-155	315	144	0.96	0.96	NUM
chd-155	315	145	(	(	PUNCT
chd-155	315	146	0	0	NUM
chd-155	315	147	,	,	PUNCT
chd-155	315	148	2.8	2.8	NUM
chd-155	315	149	)	)	PUNCT
chd-155	315	150	35	35	NUM
chd-155	315	151	n=	n=	ADJ
chd-155	315	152	number	number	NOUN
chd-155	315	153	of	of	ADP
chd-155	315	154	informative	informative	ADJ
chd-155	315	155	cases	case	NOUN
chd-155	315	156	table	table	VERB
chd-155	315	157	5	5	NUM
chd-155	315	158	.	.	PUNCT
chd-155	316	1	racial	racial	ADJ
chd-155	316	2	disparity	disparity	NOUN
chd-155	316	3	of	of	ADP
chd-155	316	4	expression	expression	NOUN
chd-155	316	5	of	of	ADP
chd-155	316	6	gdf15	gdf15	NOUN
chd-155	316	7	and	and	CCONJ
chd-155	316	8	nfκb	nfκb	NOUN
chd-155	316	9	according	accord	VERB
chd-155	316	10	to	to	ADP
chd-155	316	11	pathologic	pathologic	ADJ
chd-155	316	12	stage	stage	NOUN
chd-155	316	13	.	.	PUNCT
chd-155	317	1	african	african	ADJ
chd-155	317	2	-	-	PUNCT
chd-155	317	3	american	american	ADJ
chd-155	317	4	european	european	PROPN
chd-155	317	5	american	american	PROPN
chd-155	317	6	stage	stage	NOUN
chd-155	317	7	gdf15	gdf15	PROPN
chd-155	317	8	.	.	PUNCT
chd-155	318	1	tumor	tumor	NOUN
chd-155	318	2	,	,	PUNCT
chd-155	318	3	median	median	NOUN
chd-155	318	4	(	(	PUNCT
chd-155	318	5	range	range	NOUN
chd-155	318	6	)	)	PUNCT
chd-155	318	7	p	p	NOUN
chd-155	318	8	n=	n=	ADJ
chd-155	318	9	gdf15	gdf15	NOUN
chd-155	318	10	.	.	PUNCT
chd-155	319	1	benign	benign	ADJ
chd-155	319	2	,	,	PUNCT
chd-155	319	3	median	median	ADJ
chd-155	319	4	(	(	PUNCT
chd-155	319	5	range	range	NOUN
chd-155	319	6	)	)	PUNCT
chd-155	319	7	p	p	NOUN
chd-155	319	8	n=	n=	ADJ
chd-155	319	9	gdf15	gdf15	NOUN
chd-155	319	10	.	.	PUNCT
chd-155	320	1	tumor	tumor	NOUN
chd-155	320	2	,	,	PUNCT
chd-155	320	3	median	median	NOUN
chd-155	320	4	(	(	PUNCT
chd-155	320	5	range	range	NOUN
chd-155	320	6	)	)	PUNCT
chd-155	320	7	p	p	NOUN
chd-155	320	8	n=	n=	ADJ
chd-155	320	9	gdf15	gdf15	NOUN
chd-155	320	10	.	.	PUNCT
chd-155	321	1	benign	benign	ADJ
chd-155	321	2	,	,	PUNCT
chd-155	321	3	median	median	ADJ
chd-155	321	4	(	(	PUNCT
chd-155	321	5	range	range	NOUN
chd-155	321	6	)	)	PUNCT
chd-155	322	1	p	p	NOUN
chd-155	322	2	n=	n=	ADJ
chd-155	322	3	2	2	NUM
chd-155	322	4	2.20	2.20	NUM
chd-155	322	5	(	(	PUNCT
chd-155	322	6	0	0	NUM
chd-155	322	7	,	,	PUNCT
chd-155	322	8	3	3	NUM
chd-155	322	9	)	)	PUNCT
chd-155	322	10	0.007	0.007	NUM
chd-155	322	11	221	221	NUM
chd-155	322	12	0.83	0.83	NUM
chd-155	322	13	(	(	PUNCT
chd-155	322	14	0	0	NUM
chd-155	322	15	,	,	PUNCT
chd-155	322	16	3	3	NUM
chd-155	322	17	)	)	PUNCT
chd-155	322	18	0.003	0.003	NUM
chd-155	322	19	242	242	NUM
chd-155	322	20	2.08	2.08	NUM
chd-155	322	21	(	(	PUNCT
chd-155	322	22	0	0	NUM
chd-155	322	23	,	,	PUNCT
chd-155	322	24	3	3	NUM
chd-155	322	25	)	)	PUNCT
chd-155	322	26	0.07	0.07	NUM
chd-155	322	27	241	241	NUM
chd-155	322	28	1.00	1.00	NUM
chd-155	322	29	(	(	PUNCT
chd-155	322	30	0	0	NUM
chd-155	322	31	,	,	PUNCT
chd-155	322	32	3	3	NUM
chd-155	322	33	)	)	PUNCT
chd-155	322	34	0.01	0.01	NUM
chd-155	322	35	272	272	NUM
chd-155	322	36	3a	3a	NUM
chd-155	322	37	1.61	1.61	NUM
chd-155	322	38	(	(	PUNCT
chd-155	322	39	0.4	0.4	NUM
chd-155	322	40	,	,	PUNCT
chd-155	322	41	3	3	NUM
chd-155	322	42	)	)	PUNCT
chd-155	322	43	49	49	NUM
chd-155	322	44	0.42	0.42	NUM
chd-155	322	45	(	(	PUNCT
chd-155	322	46	0	0	NUM
chd-155	322	47	,	,	PUNCT
chd-155	322	48	2	2	NUM
chd-155	322	49	)	)	PUNCT
chd-155	322	50	50	50	NUM
chd-155	322	51	2.06	2.06	NUM
chd-155	322	52	(	(	PUNCT
chd-155	322	53	0	0	NUM
chd-155	322	54	,	,	PUNCT
chd-155	322	55	3	3	NUM
chd-155	322	56	)	)	PUNCT
chd-155	322	57	57	57	NUM
chd-155	322	58	0.80	0.80	NUM
chd-155	322	59	(	(	PUNCT
chd-155	322	60	0	0	NUM
chd-155	322	61	,	,	PUNCT
chd-155	322	62	3	3	NUM
chd-155	322	63	)	)	PUNCT
chd-155	322	64	59	59	NUM
chd-155	322	65	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-155	322	66	e13	e13	NOUN
chd-155	322	67	cancer	cancer	NOUN
chd-155	322	68	health	health	NOUN
chd-155	322	69	disparities	disparity	NOUN
chd-155	322	70	research	research	VERB
chd-155	322	71	3b	3b	NUM
chd-155	322	72	1.63	1.63	NUM
chd-155	322	73	(	(	PUNCT
chd-155	322	74	0	0	NUM
chd-155	322	75	,	,	PUNCT
chd-155	322	76	3	3	NUM
chd-155	322	77	)	)	PUNCT
chd-155	322	78	28	28	NUM
chd-155	322	79	1.10	1.10	NUM
chd-155	322	80	(	(	PUNCT
chd-155	322	81	0	0	NUM
chd-155	322	82	,	,	PUNCT
chd-155	322	83	2.5	2.5	NUM
chd-155	322	84	)	)	PUNCT
chd-155	322	85	29	29	NUM
chd-155	322	86	1.65	1.65	NUM
chd-155	322	87	(	(	PUNCT
chd-155	322	88	0.3	0.3	NUM
chd-155	322	89	,	,	PUNCT
chd-155	322	90	3	3	NUM
chd-155	322	91	)	)	PUNCT
chd-155	322	92	28	28	NUM
chd-155	322	93	0.75	0.75	NUM
chd-155	322	94	(	(	PUNCT
chd-155	322	95	0	0	NUM
chd-155	322	96	,	,	PUNCT
chd-155	322	97	2.5	2.5	NUM
chd-155	322	98	)	)	PUNCT
chd-155	322	99	29	29	NUM
chd-155	322	100	4	4	NUM
chd-155	322	101	2.01	2.01	NUM
chd-155	322	102	(	(	PUNCT
chd-155	322	103	0	0	NUM
chd-155	322	104	,	,	PUNCT
chd-155	322	105	2.8	2.8	NUM
chd-155	322	106	)	)	PUNCT
chd-155	322	107	2	2	NUM
chd-155	322	108	1.38	1.38	NUM
chd-155	322	109	(	(	PUNCT
chd-155	322	110	0.8	0.8	NUM
chd-155	322	111	,	,	PUNCT
chd-155	322	112	1.9	1.9	NUM
chd-155	322	113	)	)	PUNCT
chd-155	322	114	2	2	NUM
chd-155	322	115	1.02	1.02	NUM
chd-155	322	116	(	(	PUNCT
chd-155	322	117	0.6	0.6	NUM
chd-155	322	118	,	,	PUNCT
chd-155	322	119	1.4	1.4	NUM
chd-155	322	120	)	)	PUNCT
chd-155	322	121	2	2	NUM
chd-155	322	122	0.92	0.92	NUM
chd-155	322	123	(	(	PUNCT
chd-155	322	124	0.2	0.2	NUM
chd-155	322	125	,	,	PUNCT
chd-155	322	126	1.7	1.7	NUM
chd-155	322	127	)	)	SYM
chd-155	322	128	2	2	NUM
chd-155	322	129	stage	stage	NOUN
chd-155	322	130	nfκb	nfκb	NOUN
chd-155	322	131	.	.	PUNCT
chd-155	323	1	tumor	tumor	NOUN
chd-155	323	2	,	,	PUNCT
chd-155	323	3	median	median	NOUN
chd-155	323	4	(	(	PUNCT
chd-155	323	5	range	range	NOUN
chd-155	323	6	)	)	PUNCT
chd-155	323	7	p	p	PROPN
chd-155	323	8	n=	n=	ADJ
chd-155	323	9	nfκb	nfκb	NOUN
chd-155	323	10	.	.	PUNCT
chd-155	324	1	benign	benign	ADJ
chd-155	324	2	,	,	PUNCT
chd-155	324	3	median	median	ADJ
chd-155	324	4	(	(	PUNCT
chd-155	324	5	range	range	NOUN
chd-155	324	6	)	)	PUNCT
chd-155	324	7	p	p	PROPN
chd-155	324	8	n=	n=	ADJ
chd-155	324	9	nfκb	nfκb	NOUN
chd-155	324	10	.	.	PUNCT
chd-155	325	1	tumor	tumor	NOUN
chd-155	325	2	,	,	PUNCT
chd-155	325	3	median	median	NOUN
chd-155	325	4	(	(	PUNCT
chd-155	325	5	range	range	NOUN
chd-155	325	6	)	)	PUNCT
chd-155	325	7	p	p	PROPN
chd-155	325	8	n=	n=	ADJ
chd-155	325	9	nfκb	nfκb	NOUN
chd-155	325	10	.	.	PUNCT
chd-155	326	1	benign	benign	ADJ
chd-155	326	2	,	,	PUNCT
chd-155	326	3	median	median	ADJ
chd-155	326	4	(	(	PUNCT
chd-155	326	5	range	range	NOUN
chd-155	326	6	)	)	PUNCT
chd-155	327	1	p	p	NOUN
chd-155	327	2	n=	n=	ADJ
chd-155	327	3	2	2	NUM
chd-155	327	4	1.04	1.04	NUM
chd-155	327	5	(	(	PUNCT
chd-155	327	6	0	0	NUM
chd-155	327	7	,	,	PUNCT
chd-155	327	8	3	3	NUM
chd-155	327	9	)	)	PUNCT
chd-155	327	10	0.21	0.21	NUM
chd-155	327	11	222	222	NUM
chd-155	327	12	0.96	0.96	NUM
chd-155	327	13	(	(	PUNCT
chd-155	327	14	0	0	NUM
chd-155	327	15	,	,	PUNCT
chd-155	327	16	3	3	NUM
chd-155	327	17	)	)	PUNCT
chd-155	327	18	0.96	0.96	NUM
chd-155	327	19	240	240	NUM
chd-155	327	20	1.08	1.08	NUM
chd-155	327	21	(	(	PUNCT
chd-155	327	22	0	0	NUM
chd-155	327	23	,	,	PUNCT
chd-155	327	24	3	3	NUM
chd-155	327	25	)	)	PUNCT
chd-155	327	26	0.15	0.15	NUM
chd-155	327	27	244	244	NUM
chd-155	327	28	0.86	0.86	NUM
chd-155	327	29	(	(	PUNCT
chd-155	327	30	0	0	NUM
chd-155	327	31	,	,	PUNCT
chd-155	327	32	2.8	2.8	NUM
chd-155	327	33	)	)	PUNCT
chd-155	327	34	0.18	0.18	NUM
chd-155	327	35	271	271	NUM
chd-155	327	36	3a	3a	NUM
chd-155	327	37	1.06	1.06	NUM
chd-155	327	38	(	(	PUNCT
chd-155	327	39	0	0	NUM
chd-155	327	40	,	,	PUNCT
chd-155	327	41	3	3	NUM
chd-155	327	42	)	)	PUNCT
chd-155	327	43	48	48	NUM
chd-155	327	44	0.96	0.96	NUM
chd-155	327	45	(	(	PUNCT
chd-155	327	46	0	0	NUM
chd-155	327	47	,	,	PUNCT
chd-155	327	48	1.9	1.9	NUM
chd-155	327	49	)	)	PUNCT
chd-155	327	50	48	48	NUM
chd-155	327	51	0.89	0.89	NUM
chd-155	327	52	(	(	PUNCT
chd-155	327	53	0	0	NUM
chd-155	327	54	,	,	PUNCT
chd-155	327	55	3	3	NUM
chd-155	327	56	)	)	PUNCT
chd-155	327	57	57	57	NUM
chd-155	327	58	0.88	0.88	NUM
chd-155	327	59	(	(	PUNCT
chd-155	327	60	0	0	NUM
chd-155	327	61	,	,	PUNCT
chd-155	327	62	2.5	2.5	NUM
chd-155	327	63	)	)	PUNCT
chd-155	327	64	59	59	NUM
chd-155	327	65	3b	3b	NOUN
chd-155	327	66	1.23	1.23	NUM
chd-155	327	67	(	(	PUNCT
chd-155	327	68	0	0	NUM
chd-155	327	69	,	,	PUNCT
chd-155	327	70	2.8	2.8	NUM
chd-155	327	71	)	)	PUNCT
chd-155	327	72	28	28	NUM
chd-155	327	73	0.96	0.96	NUM
chd-155	327	74	(	(	PUNCT
chd-155	327	75	0	0	NUM
chd-155	327	76	,	,	PUNCT
chd-155	327	77	1.8	1.8	NUM
chd-155	327	78	)	)	PUNCT
chd-155	327	79	28	28	NUM
chd-155	327	80	1.12	1.12	NUM
chd-155	327	81	(	(	PUNCT
chd-155	327	82	0.2	0.2	NUM
chd-155	327	83	,	,	PUNCT
chd-155	327	84	3	3	NUM
chd-155	327	85	)	)	PUNCT
chd-155	327	86	29	29	NUM
chd-155	327	87	1.12	1.12	NUM
chd-155	327	88	(	(	PUNCT
chd-155	327	89	0.1	0.1	NUM
chd-155	327	90	,	,	PUNCT
chd-155	327	91	2.1	2.1	NUM
chd-155	327	92	)	)	PUNCT
chd-155	327	93	29	29	NUM
chd-155	327	94	4	4	NUM
chd-155	327	95	0.54	0.54	NUM
chd-155	327	96	(	(	PUNCT
chd-155	327	97	0.4	0.4	NUM
chd-155	327	98	,	,	PUNCT
chd-155	327	99	0.7	0.7	NUM
chd-155	327	100	)	)	PUNCT
chd-155	327	101	2	2	NUM
chd-155	327	102	0.93	0.93	NUM
chd-155	327	103	(	(	PUNCT
chd-155	327	104	0.7	0.7	NUM
chd-155	327	105	,	,	PUNCT
chd-155	327	106	1.2	1.2	NUM
chd-155	327	107	)	)	PUNCT
chd-155	327	108	2	2	NUM
chd-155	327	109	0.36	0.36	NUM
chd-155	327	110	(	(	PUNCT
chd-155	327	111	0	0	NUM
chd-155	327	112	,	,	PUNCT
chd-155	327	113	0.7	0.7	NUM
chd-155	327	114	)	)	PUNCT
chd-155	327	115	2	2	NUM
chd-155	327	116	0.86	0.86	NUM
chd-155	327	117	(	(	PUNCT
chd-155	327	118	0.8	0.8	NUM
chd-155	327	119	,	,	PUNCT
chd-155	327	120	1.0	1.0	NUM
chd-155	327	121	)	)	SYM
chd-155	327	122	2	2	NUM
chd-155	327	123	n=	n=	ADJ
chd-155	327	124	number	number	NOUN
chd-155	327	125	of	of	ADP
chd-155	327	126	informative	informative	ADJ
chd-155	327	127	cases	case	NOUN
chd-155	327	128	note	note	VERB
chd-155	327	129	:	:	PUNCT
chd-155	327	130	with	with	ADP
chd-155	327	131	only	only	ADV
chd-155	327	132	2	2	NUM
chd-155	327	133	cases	case	NOUN
chd-155	327	134	for	for	ADP
chd-155	327	135	stage	stage	NOUN
chd-155	327	136	4	4	NUM
chd-155	327	137	,	,	PUNCT
chd-155	327	138	values	value	NOUN
chd-155	327	139	are	be	AUX
chd-155	327	140	probably	probably	ADV
chd-155	327	141	not	not	PART
chd-155	327	142	representative	representative	ADJ
chd-155	327	143	.	.	PUNCT
chd-155	328	1	table	table	NOUN
chd-155	328	2	6	6	NUM
chd-155	328	3	.	.	PUNCT
chd-155	329	1	summary	summary	NOUN
chd-155	329	2	of	of	ADP
chd-155	329	3	inflammatory	inflammatory	ADJ
chd-155	329	4	markers	marker	NOUN
chd-155	329	5	in	in	ADP
chd-155	329	6	prostate	prostate	NOUN
chd-155	329	7	.	.	PUNCT
chd-155	330	1	marker	marker	NOUN
chd-155	330	2	by	by	ADP
chd-155	330	3	increasing	increase	VERB
chd-155	330	4	stagek	stagek	NOUN
chd-155	330	5	by	by	ADP
chd-155	330	6	increasing	increase	VERB
chd-155	330	7	gradek	gradek	NOUN
chd-155	330	8	gdf15	gdf15	NOUN
chd-155	330	9	in	in	ADP
chd-155	330	10	ea	ea	NOUN
chd-155	330	11	men	man	NOUN
chd-155	330	12	decreases	decrease	VERB
chd-155	330	13	in	in	ADP
chd-155	330	14	benign	benign	ADJ
chd-155	330	15	(	(	PUNCT
chd-155	330	16	p=0.01	p=0.01	NUM
chd-155	330	17	)	)	PUNCT
chd-155	330	18	,	,	PUNCT
chd-155	330	19	not	not	PART
chd-155	330	20	in	in	ADP
chd-155	330	21	tumor	tumor	NOUN
chd-155	330	22	decreases	decrease	NOUN
chd-155	330	23	in	in	ADP
chd-155	330	24	benign	benign	NOUN
chd-155	330	25	only	only	ADV
chd-155	330	26	(	(	PUNCT
chd-155	330	27	p=0.01	p=0.01	NOUN
chd-155	330	28	)	)	PUNCT
chd-155	330	29	gdf15	gdf15	NOUN
chd-155	330	30	in	in	ADP
chd-155	330	31	aa	aa	PROPN
chd-155	330	32	men	man	NOUN
chd-155	330	33	decreases	decrease	VERB
chd-155	330	34	in	in	ADP
chd-155	330	35	tumor	tumor	NOUN
chd-155	330	36	(	(	PUNCT
chd-155	330	37	p=0.007	p=0.007	ADP
chd-155	330	38	)	)	PUNCT
chd-155	330	39	as	as	ADV
chd-155	330	40	well	well	ADV
chd-155	330	41	as	as	ADP
chd-155	330	42	benign	benign	ADJ
chd-155	330	43	(	(	PUNCT
chd-155	330	44	p=0.003	p=0.003	NOUN
chd-155	330	45	)	)	PUNCT
chd-155	330	46	no	no	DET
chd-155	330	47	change	change	NOUN
chd-155	330	48	in	in	ADP
chd-155	330	49	benign	benign	ADJ
chd-155	330	50	or	or	CCONJ
chd-155	330	51	tumor	tumor	NOUN
chd-155	330	52	nfκb	nfκb	NOUN
chd-155	330	53	in	in	ADP
chd-155	330	54	ea	ea	PROPN
chd-155	330	55	men	man	NOUN
chd-155	330	56	no	no	DET
chd-155	330	57	change	change	NOUN
chd-155	330	58	in	in	ADP
chd-155	330	59	benign	benign	ADJ
chd-155	330	60	or	or	CCONJ
chd-155	330	61	tumor	tumor	NOUN
chd-155	330	62	increases	increase	NOUN
chd-155	330	63	in	in	ADP
chd-155	330	64	benign	benign	ADJ
chd-155	330	65	(	(	PUNCT
chd-155	330	66	p=0.007	p=0.007	ADP
chd-155	330	67	)	)	PUNCT
chd-155	330	68	but	but	CCONJ
chd-155	330	69	not	not	PART
chd-155	330	70	tumor	tumor	NOUN
chd-155	330	71	(	(	PUNCT
chd-155	330	72	p=0.23	p=0.23	PROPN
chd-155	330	73	)	)	PUNCT
chd-155	330	74	nfκb	nfκb	NOUN
chd-155	330	75	in	in	ADP
chd-155	330	76	aa	aa	PROPN
chd-155	330	77	men	man	NOUN
chd-155	330	78	no	no	DET
chd-155	330	79	change	change	NOUN
chd-155	330	80	in	in	ADP
chd-155	330	81	benign	benign	ADJ
chd-155	330	82	or	or	CCONJ
chd-155	330	83	tumor	tumor	NOUN
chd-155	330	84	increases	increase	NOUN
chd-155	330	85	in	in	ADP
chd-155	330	86	tumor	tumor	NOUN
chd-155	330	87	(	(	PUNCT
chd-155	330	88	p=0.027	p=0.027	X
chd-155	330	89	)	)	PUNCT
chd-155	330	90	but	but	CCONJ
chd-155	330	91	not	not	PART
chd-155	330	92	benign	benign	ADJ
chd-155	330	93	(	(	PUNCT
chd-155	330	94	p=0.37	p=0.37	NOUN
chd-155	330	95	)	)	PUNCT
chd-155	330	96	aa=	aa=	PROPN
chd-155	330	97	african	african	PROPN
chd-155	330	98	-	-	PUNCT
chd-155	330	99	american	american	ADJ
chd-155	330	100	;	;	PUNCT
chd-155	330	101	kkruskal	kkruskal	PROPN
chd-155	330	102	-	-	PUNCT
chd-155	330	103	wallis	wallis	PROPN
chd-155	330	104	;	;	PUNCT
chd-155	330	105	wwilcoxon	wwilcoxon	ADJ
chd-155	330	106	test	test	NOUN
chd-155	330	107	;	;	PUNCT
chd-155	330	108	ea=	ea=	PROPN
chd-155	330	109	european	european	PROPN
chd-155	330	110	american	american	PROPN
chd-155	330	111	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PART
chd-155	330	112	e14	e14	PROPN
chd-155	330	113	cancer	cancer	NOUN
chd-155	330	114	health	health	NOUN
chd-155	330	115	disparities	disparity	NOUN
chd-155	330	116	research	research	VERB
chd-155	330	117	supplementary	supplementary	ADJ
chd-155	330	118	figure	figure	NOUN
chd-155	330	119	1	1	NUM
chd-155	330	120	.	.	PUNCT
chd-155	330	121	normalization	normalization	NOUN
chd-155	330	122	of	of	ADP
chd-155	330	123	gdf15	gdf15	NOUN
chd-155	330	124	and	and	CCONJ
chd-155	330	125	nfκb	nfκb	ADJ
chd-155	330	126	expression	expression	NOUN
chd-155	330	127	in	in	ADP
chd-155	330	128	normal	normal	ADJ
chd-155	330	129	and	and	CCONJ
chd-155	330	130	tumor	tumor	NOUN
chd-155	330	131	regions	region	NOUN
chd-155	330	132	of	of	ADP
chd-155	330	133	prostate	prostate	NOUN
chd-155	330	134	of	of	ADP
chd-155	330	135	men	man	NOUN
chd-155	330	136	with	with	ADP
chd-155	330	137	gleason	gleason	PROPN
chd-155	330	138	grade	grade	PROPN
chd-155	330	139	group	group	NOUN
chd-155	330	140	2	2	NUM
chd-155	330	141	prostate	prostate	NOUN
chd-155	330	142	cancer	cancer	NOUN
chd-155	330	143	from	from	ADP
chd-155	330	144	the	the	DET
chd-155	330	145	three	three	NUM
chd-155	330	146	study	study	NOUN
chd-155	330	147	sites	site	NOUN
chd-155	330	148	.	.	PUNCT
chd-155	331	1	box	box	NOUN
chd-155	331	2	plots	plot	NOUN
chd-155	331	3	showing	show	VERB
chd-155	331	4	digitally	digitally	ADV
chd-155	331	5	assessed	assess	VERB
chd-155	331	6	gdf15	gdf15	NOUN
chd-155	331	7	(	(	PUNCT
chd-155	331	8	a	a	DET
chd-155	331	9	,	,	PUNCT
chd-155	331	10	b	b	NOUN
chd-155	331	11	)	)	PUNCT
chd-155	331	12	and	and	CCONJ
chd-155	331	13	nfκb	nfκb	NOUN
chd-155	331	14	(	(	PUNCT
chd-155	331	15	c	c	NOUN
chd-155	331	16	,	,	PUNCT
chd-155	331	17	d	d	NOUN
chd-155	331	18	)	)	PUNCT
chd-155	331	19	expression	expression	NOUN
chd-155	331	20	in	in	ADP
chd-155	331	21	normal	normal	ADJ
chd-155	331	22	prostate	prostate	NOUN
chd-155	331	23	before	before	ADP
chd-155	331	24	(	(	PUNCT
chd-155	331	25	a	a	DET
chd-155	331	26	,	,	PUNCT
chd-155	331	27	c	c	NOUN
chd-155	331	28	)	)	PUNCT
chd-155	331	29	and	and	CCONJ
chd-155	331	30	after	after	ADP
chd-155	331	31	(	(	PUNCT
chd-155	331	32	b	b	NOUN
chd-155	331	33	,	,	PUNCT
chd-155	331	34	d	d	NOUN
chd-155	331	35	)	)	PUNCT
chd-155	331	36	normalization	normalization	NOUN
chd-155	331	37	.	.	PUNCT
chd-155	332	1	additional	additional	ADJ
chd-155	332	2	box	box	NOUN
chd-155	332	3	plots	plot	NOUN
chd-155	332	4	show	show	VERB
chd-155	332	5	effect	effect	NOUN
chd-155	332	6	of	of	ADP
chd-155	332	7	normalization	normalization	NOUN
chd-155	332	8	on	on	ADP
chd-155	332	9	pathologically	pathologically	ADV
chd-155	332	10	assessed	assess	VERB
chd-155	332	11	gdf15	gdf15	NOUN
chd-155	332	12	(	(	PUNCT
chd-155	332	13	e	e	NOUN
chd-155	332	14	-	-	NOUN
chd-155	332	15	h	h	NOUN
chd-155	332	16	)	)	PUNCT
chd-155	332	17	and	and	CCONJ
chd-155	332	18	nfκb	nfκb	NOUN
chd-155	332	19	(	(	PUNCT
chd-155	332	20	i	i	NOUN
chd-155	332	21	-	-	PUNCT
chd-155	332	22	l	l	NOUN
chd-155	332	23	)	)	PUNCT
chd-155	332	24	expression	expression	NOUN
chd-155	332	25	in	in	ADP
chd-155	332	26	normal	normal	ADJ
chd-155	332	27	(	(	PUNCT
chd-155	332	28	e	e	NOUN
chd-155	332	29	,	,	PUNCT
chd-155	332	30	f	f	PROPN
chd-155	332	31	&	&	CCONJ
chd-155	332	32	i	i	PROPN
chd-155	332	33	,	,	PUNCT
chd-155	332	34	j	j	PROPN
chd-155	332	35	)	)	PUNCT
chd-155	332	36	and	and	CCONJ
chd-155	332	37	malignant	malignant	ADJ
chd-155	332	38	(	(	PUNCT
chd-155	332	39	g	g	NOUN
chd-155	332	40	,	,	PUNCT
chd-155	332	41	h	h	PROPN
chd-155	332	42	&	&	CCONJ
chd-155	332	43	k	k	PROPN
chd-155	332	44	,	,	PUNCT
chd-155	332	45	l	l	NOUN
chd-155	332	46	)	)	PUNCT
chd-155	332	47	prostate	prostate	NOUN
chd-155	332	48	before	before	ADV
chd-155	332	49	(	(	PUNCT
chd-155	332	50	e	e	NOUN
chd-155	332	51	,	,	PUNCT
chd-155	332	52	g	g	PROPN
chd-155	332	53	,	,	PUNCT
chd-155	332	54	i	i	PRON
chd-155	332	55	,	,	PUNCT
chd-155	332	56	k	k	PROPN
chd-155	332	57	)	)	PUNCT
chd-155	332	58	and	and	CCONJ
chd-155	332	59	after	after	ADP
chd-155	332	60	(	(	PUNCT
chd-155	332	61	f	f	X
chd-155	332	62	,	,	PUNCT
chd-155	332	63	h	h	PROPN
chd-155	332	64	,	,	PUNCT
chd-155	332	65	j	j	PROPN
chd-155	332	66	,	,	PUNCT
chd-155	332	67	l	l	NOUN
chd-155	332	68	)	)	PUNCT
chd-155	332	69	normalization	normalization	NOUN
chd-155	332	70	.	.	PUNCT
chd-155	333	1	ford	ford	PROPN
chd-155	333	2	=	=	PROPN
chd-155	333	3	henry	henry	PROPN
chd-155	333	4	ford	ford	PROPN
chd-155	333	5	,	,	PUNCT
chd-155	333	6	hopkins	hopkins	PROPN
chd-155	333	7	=	=	PROPN
chd-155	333	8	johns	johns	PROPN
chd-155	333	9	hopkins	hopkins	PROPN
chd-155	333	10	,	,	PUNCT
chd-155	333	11	mcw	mcw	PROPN
chd-155	333	12	=	=	PROPN
chd-155	333	13	medical	medical	PROPN
chd-155	333	14	college	college	PROPN
chd-155	333	15	of	of	ADP
chd-155	333	16	wisconsin	wisconsin	PROPN
chd-155	333	17	.	.	PUNCT
chd-155	334	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-155	334	2	e15	e15	PROPN
chd-155	334	3	cancer	cancer	NOUN
chd-155	334	4	health	health	NOUN
chd-155	334	5	disparities	disparity	NOUN
chd-155	334	6	research	research	VERB
chd-155	334	7	supplementary	supplementary	ADJ
chd-155	334	8	figure	figure	NOUN
chd-155	334	9	2	2	NUM
chd-155	334	10	.	.	PUNCT
chd-155	334	11	correlation	correlation	NOUN
chd-155	334	12	of	of	ADP
chd-155	334	13	gdf15	gdf15	NOUN
chd-155	334	14	and	and	CCONJ
chd-155	334	15	nfκb	nfκb	ADJ
chd-155	334	16	expression	expression	NOUN
chd-155	334	17	in	in	ADP
chd-155	334	18	normal	normal	ADJ
chd-155	334	19	and	and	CCONJ
chd-155	334	20	tumor	tumor	NOUN
chd-155	334	21	regions	region	NOUN
chd-155	334	22	of	of	ADP
chd-155	334	23	prostate	prostate	NOUN
chd-155	334	24	in	in	ADP
chd-155	334	25	european	european	PROPN
chd-155	334	26	/	/	SYM
chd-155	334	27	white	white	PROPN
chd-155	334	28	american	american	PROPN
chd-155	334	29	(	(	PUNCT
chd-155	334	30	ea	ea	NOUN
chd-155	334	31	)	)	PUNCT
chd-155	334	32	and	and	CCONJ
chd-155	334	33	african	african	ADJ
chd-155	334	34	american	american	PROPN
chd-155	334	35	(	(	PUNCT
chd-155	334	36	aa	aa	NOUN
chd-155	334	37	)	)	PUNCT
chd-155	334	38	men	man	NOUN
chd-155	334	39	with	with	ADP
chd-155	334	40	prostate	prostate	NOUN
chd-155	334	41	cancer	cancer	NOUN
chd-155	334	42	.	.	PUNCT
chd-155	335	1	scatter	scatter	NOUN
chd-155	335	2	plots	plot	NOUN
chd-155	335	3	and	and	CCONJ
chd-155	335	4	associated	associate	VERB
chd-155	335	5	correlation	correlation	NOUN
chd-155	335	6	coefficients	coefficient	NOUN
chd-155	335	7	are	be	AUX
chd-155	335	8	shown	show	VERB
chd-155	335	9	for	for	ADP
chd-155	335	10	all	all	DET
chd-155	335	11	normal	normal	ADJ
chd-155	335	12	samples	sample	NOUN
chd-155	335	13	(	(	PUNCT
chd-155	335	14	a	a	X
chd-155	335	15	)	)	PUNCT
chd-155	335	16	,	,	PUNCT
chd-155	335	17	normal	normal	ADJ
chd-155	335	18	prostate	prostate	NOUN
chd-155	335	19	regions	region	NOUN
chd-155	335	20	in	in	ADP
chd-155	335	21	ea	ea	PROPN
chd-155	335	22	(	(	PUNCT
chd-155	335	23	b	b	NOUN
chd-155	335	24	)	)	PUNCT
chd-155	335	25	,	,	PUNCT
chd-155	335	26	normal	normal	ADJ
chd-155	335	27	prostate	prostate	NOUN
chd-155	335	28	regions	region	NOUN
chd-155	335	29	in	in	ADP
chd-155	335	30	aa	aa	PROPN
chd-155	335	31	(	(	PUNCT
chd-155	335	32	c	c	NOUN
chd-155	335	33	)	)	PUNCT
chd-155	335	34	,	,	PUNCT
chd-155	335	35	all	all	DET
chd-155	335	36	tumor	tumor	NOUN
chd-155	335	37	samples	sample	NOUN
chd-155	335	38	(	(	PUNCT
chd-155	335	39	d	d	NOUN
chd-155	335	40	)	)	PUNCT
chd-155	335	41	,	,	PUNCT
chd-155	335	42	tumor	tumor	NOUN
chd-155	335	43	regions	region	NOUN
chd-155	335	44	in	in	ADP
chd-155	335	45	ea	ea	PROPN
chd-155	335	46	(	(	PUNCT
chd-155	335	47	e	e	NOUN
chd-155	335	48	)	)	PUNCT
chd-155	335	49	,	,	PUNCT
chd-155	335	50	tumor	tumor	NOUN
chd-155	335	51	regions	region	NOUN
chd-155	335	52	in	in	ADP
chd-155	335	53	aa	aa	PROPN
chd-155	335	54	(	(	PUNCT
chd-155	335	55	f	f	NOUN
chd-155	335	56	)	)	PUNCT
chd-155	335	57	.	.	PUNCT
chd-155	336	1	supplemental	supplemental	ADJ
chd-155	336	2	table	table	NOUN
chd-155	336	3	1	1	NUM
chd-155	336	4	.	.	PUNCT
chd-155	336	5	expression	expression	NOUN
chd-155	336	6	of	of	ADP
chd-155	336	7	gdf15	gdf15	NOUN
chd-155	336	8	(	(	PUNCT
chd-155	336	9	top	top	ADJ
chd-155	336	10	)	)	PUNCT
chd-155	336	11	and	and	CCONJ
chd-155	336	12	nfκb	nfκb	NOUN
chd-155	336	13	(	(	PUNCT
chd-155	336	14	bottom	bottom	NOUN
chd-155	336	15	)	)	PUNCT
chd-155	336	16	according	accord	VERB
chd-155	336	17	to	to	ADP
chd-155	336	18	race	race	NOUN
chd-155	336	19	in	in	ADP
chd-155	336	20	benign	benign	ADJ
chd-155	336	21	and	and	CCONJ
chd-155	336	22	tumor	tumor	NOUN
chd-155	336	23	,	,	PUNCT
chd-155	336	24	tissue	tissue	NOUN
chd-155	336	25	microarray	microarray	NOUN
chd-155	336	26	stratified	stratify	VERB
chd-155	336	27	by	by	ADP
chd-155	336	28	study	study	NOUN
chd-155	336	29	site	site	NOUN
chd-155	336	30	.	.	PUNCT
chd-155	337	1	henry	henry	PROPN
chd-155	337	2	ford	ford	PROPN
chd-155	337	3	african	african	PROPN
chd-155	337	4	-	-	PUNCT
chd-155	337	5	american	american	ADJ
chd-155	337	6	,	,	PUNCT
chd-155	337	7	median	median	ADJ
chd-155	337	8	(	(	PUNCT
chd-155	337	9	range	range	NOUN
chd-155	337	10	)	)	PUNCT
chd-155	337	11	white	white	PROPN
chd-155	337	12	american	american	PROPN
chd-155	337	13	,	,	PUNCT
chd-155	337	14	median	median	ADJ
chd-155	337	15	(	(	PUNCT
chd-155	337	16	range	range	NOUN
chd-155	337	17	)	)	PUNCT
chd-155	337	18	overall	overall	ADJ
chd-155	337	19	population	population	NOUN
chd-155	337	20	,	,	PUNCT
chd-155	337	21	median	median	NOUN
chd-155	337	22	(	(	PUNCT
chd-155	337	23	range	range	NOUN
chd-155	337	24	)	)	PUNCT
chd-155	337	25	tumor	tumor	NOUN
chd-155	337	26	benign	benign	ADJ
chd-155	337	27	p	p	X
chd-155	337	28	tumor	tumor	NOUN
chd-155	337	29	benign	benign	NOUN
chd-155	337	30	p	p	X
chd-155	337	31	tumor	tumor	NOUN
chd-155	337	32	benign	benign	NOUN
chd-155	337	33	p	p	PROPN
chd-155	337	34	gdf15	gdf15	NOUN
chd-155	337	35	2.83	2.83	NUM
chd-155	337	36	(	(	PUNCT
chd-155	337	37	0	0	NUM
chd-155	337	38	,	,	PUNCT
chd-155	337	39	3	3	NUM
chd-155	337	40	)	)	PUNCT
chd-155	337	41	1.14	1.14	NUM
chd-155	337	42	(	(	PUNCT
chd-155	337	43	0	0	NUM
chd-155	337	44	,	,	PUNCT
chd-155	337	45	3	3	NUM
chd-155	337	46	)	)	PUNCT
chd-155	337	47	<	<	X
chd-155	337	48	0.0001	0.0001	NUM
chd-155	337	49	2.75	2.75	NUM
chd-155	337	50	(	(	PUNCT
chd-155	337	51	0	0	NUM
chd-155	337	52	,	,	PUNCT
chd-155	337	53	3	3	X
chd-155	337	54	)	)	PUNCT
chd-155	337	55	1.18	1.18	NUM
chd-155	337	56	(	(	PUNCT
chd-155	337	57	0	0	NUM
chd-155	337	58	,	,	PUNCT
chd-155	337	59	3	3	NUM
chd-155	337	60	)	)	PUNCT
chd-155	337	61	<	<	X
chd-155	337	62	0.0001	0.0001	NUM
chd-155	337	63	2.75	2.75	NUM
chd-155	337	64	(	(	PUNCT
chd-155	337	65	0	0	NUM
chd-155	337	66	,	,	PUNCT
chd-155	337	67	3	3	NUM
chd-155	337	68	)	)	PUNCT
chd-155	337	69	1.17	1.17	NUM
chd-155	337	70	(	(	PUNCT
chd-155	337	71	0	0	NUM
chd-155	337	72	,	,	PUNCT
chd-155	337	73	3	3	NUM
chd-155	337	74	)	)	PUNCT
chd-155	337	75	<	<	X
chd-155	337	76	0.0001	0.0001	NUM
chd-155	337	77	p	p	NOUN
chd-155	337	78	(	(	PUNCT
chd-155	337	79	aa	aa	NOUN
chd-155	337	80	-	-	PUNCT
chd-155	337	81	w	w	NOUN
chd-155	337	82	)	)	PUNCT
chd-155	337	83	0.251	0.251	NUM
chd-155	337	84	0.931	0.931	NUM
chd-155	337	85	nfκb	nfκb	NOUN
chd-155	337	86	1.50	1.50	NUM
chd-155	337	87	(	(	PUNCT
chd-155	337	88	0	0	NUM
chd-155	337	89	,	,	PUNCT
chd-155	337	90	3	3	NUM
chd-155	337	91	)	)	PUNCT
chd-155	337	92	1.15	1.15	NUM
chd-155	337	93	(	(	PUNCT
chd-155	337	94	0	0	NUM
chd-155	337	95	,	,	PUNCT
chd-155	337	96	3	3	NUM
chd-155	337	97	)	)	PUNCT
chd-155	337	98	<	<	X
chd-155	337	99	0.0001	0.0001	NUM
chd-155	337	100	1.42	1.42	NUM
chd-155	337	101	(	(	PUNCT
chd-155	337	102	0	0	NUM
chd-155	337	103	,	,	PUNCT
chd-155	337	104	3	3	X
chd-155	337	105	)	)	PUNCT
chd-155	337	106	0.90	0.90	NUM
chd-155	337	107	(	(	PUNCT
chd-155	337	108	0	0	NUM
chd-155	337	109	,	,	PUNCT
chd-155	337	110	2.83	2.83	NUM
chd-155	337	111	)	)	PUNCT
chd-155	337	112	<	<	X
chd-155	337	113	0.0001	0.0001	NUM
chd-155	337	114	1.45	1.45	NUM
chd-155	337	115	(	(	PUNCT
chd-155	337	116	0	0	NUM
chd-155	337	117	,	,	PUNCT
chd-155	337	118	3	3	NUM
chd-155	337	119	)	)	PUNCT
chd-155	337	120	1.00	1.00	NUM
chd-155	337	121	(	(	PUNCT
chd-155	337	122	0	0	NUM
chd-155	337	123	,	,	PUNCT
chd-155	337	124	3	3	NUM
chd-155	337	125	)	)	PUNCT
chd-155	337	126	<	<	X
chd-155	337	127	0.0001	0.0001	NUM
chd-155	337	128	p	p	NOUN
chd-155	337	129	(	(	PUNCT
chd-155	337	130	aa	aa	NOUN
chd-155	337	131	-	-	PUNCT
chd-155	337	132	w	w	NOUN
chd-155	337	133	)	)	PUNCT
chd-155	337	134	0.992	0.992	NUM
chd-155	337	135	0.039	0.039	NUM
chd-155	337	136	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PART
chd-155	337	137	e16	e16	NOUN
chd-155	337	138	cancer	cancer	NOUN
chd-155	337	139	health	health	NOUN
chd-155	337	140	disparities	disparity	NOUN
chd-155	337	141	research	research	PROPN
chd-155	337	142	johns	johns	PROPN
chd-155	337	143	hopkins	hopkins	PROPN
chd-155	337	144	african	african	PROPN
chd-155	337	145	-	-	PUNCT
chd-155	337	146	american	american	ADJ
chd-155	337	147	,	,	PUNCT
chd-155	337	148	median	median	ADJ
chd-155	337	149	(	(	PUNCT
chd-155	337	150	range	range	NOUN
chd-155	337	151	)	)	PUNCT
chd-155	337	152	white	white	PROPN
chd-155	337	153	american	american	PROPN
chd-155	337	154	,	,	PUNCT
chd-155	337	155	median	median	ADJ
chd-155	337	156	(	(	PUNCT
chd-155	337	157	range	range	NOUN
chd-155	337	158	)	)	PUNCT
chd-155	337	159	overall	overall	ADJ
chd-155	337	160	population	population	NOUN
chd-155	337	161	,	,	PUNCT
chd-155	337	162	median	median	ADJ
chd-155	337	163	tumor	tumor	NOUN
chd-155	337	164	benign	benign	ADJ
chd-155	337	165	p	p	X
chd-155	337	166	tumor	tumor	NOUN
chd-155	337	167	benign	benign	NOUN
chd-155	337	168	p	p	X
chd-155	337	169	tumor	tumor	NOUN
chd-155	337	170	benign	benign	ADJ
chd-155	337	171	p	p	NOUN
chd-155	337	172	gdf15	gdf15	PROPN
chd-155	337	173	2.50	2.50	NUM
chd-155	337	174	(	(	PUNCT
chd-155	337	175	0.5	0.5	NUM
chd-155	337	176	,	,	PUNCT
chd-155	337	177	3	3	NUM
chd-155	337	178	)	)	PUNCT
chd-155	337	179	0.83	0.83	NUM
chd-155	337	180	(	(	PUNCT
chd-155	337	181	0	0	NUM
chd-155	337	182	,	,	PUNCT
chd-155	337	183	3	3	NUM
chd-155	337	184	)	)	PUNCT
chd-155	337	185	<	<	X
chd-155	337	186	0.0001	0.0001	NUM
chd-155	337	187	2.00	2.00	NUM
chd-155	337	188	(	(	PUNCT
chd-155	337	189	0	0	NUM
chd-155	337	190	,	,	PUNCT
chd-155	337	191	3	3	NUM
chd-155	337	192	)	)	PUNCT
chd-155	337	193	1.00	1.00	NUM
chd-155	337	194	(	(	PUNCT
chd-155	337	195	0	0	NUM
chd-155	337	196	,	,	PUNCT
chd-155	337	197	3	3	NUM
chd-155	337	198	)	)	PUNCT
chd-155	337	199	<	<	X
chd-155	337	200	0.0001	0.0001	NUM
chd-155	337	201	2.00	2.00	NUM
chd-155	337	202	(	(	PUNCT
chd-155	337	203	0	0	NUM
chd-155	337	204	,	,	PUNCT
chd-155	337	205	3	3	NUM
chd-155	337	206	)	)	PUNCT
chd-155	337	207	1.00	1.00	NUM
chd-155	337	208	(	(	PUNCT
chd-155	337	209	0	0	NUM
chd-155	337	210	,	,	PUNCT
chd-155	337	211	2.6	2.6	NUM
chd-155	337	212	)	)	PUNCT
chd-155	337	213	<	<	X
chd-155	337	214	0.0001	0.0001	NUM
chd-155	337	215	p	p	NOUN
chd-155	337	216	(	(	PUNCT
chd-155	337	217	aa	aa	NOUN
chd-155	337	218	-	-	PUNCT
chd-155	337	219	w	w	NOUN
chd-155	337	220	)	)	PUNCT
chd-155	337	221	<	<	X
chd-155	337	222	0.0001	0.0001	NUM
chd-155	337	223	0.148	0.148	NUM
chd-155	337	224	nfκb	nfκb	NOUN
chd-155	337	225	1.25	1.25	NUM
chd-155	337	226	(	(	PUNCT
chd-155	337	227	0.2	0.2	NUM
chd-155	337	228	,	,	PUNCT
chd-155	337	229	2.94	2.94	NUM
chd-155	337	230	)	)	PUNCT
chd-155	337	231	0.60	0.60	NUM
chd-155	337	232	(	(	PUNCT
chd-155	337	233	0	0	NUM
chd-155	337	234	,	,	PUNCT
chd-155	337	235	2.52	2.52	NUM
chd-155	337	236	)	)	PUNCT
chd-155	337	237	<	<	X
chd-155	337	238	0.0001	0.0001	NUM
chd-155	337	239	1.56	1.56	NUM
chd-155	337	240	(	(	PUNCT
chd-155	337	241	0.38	0.38	NUM
chd-155	337	242	,	,	PUNCT
chd-155	337	243	3	3	NUM
chd-155	337	244	)	)	PUNCT
chd-155	337	245	0.67	0.67	NUM
chd-155	337	246	(	(	PUNCT
chd-155	337	247	0	0	NUM
chd-155	337	248	,	,	PUNCT
chd-155	337	249	2.5	2.5	NUM
chd-155	337	250	)	)	PUNCT
chd-155	338	1	<	<	X
chd-155	338	2	0.0001	0.0001	NUM
chd-155	338	3	1.47	1.47	NUM
chd-155	338	4	(	(	PUNCT
chd-155	338	5	0	0	NUM
chd-155	338	6	,	,	PUNCT
chd-155	338	7	3	3	NUM
chd-155	338	8	)	)	PUNCT
chd-155	338	9	0.67	0.67	NUM
chd-155	338	10	(	(	PUNCT
chd-155	338	11	0	0	NUM
chd-155	338	12	,	,	PUNCT
chd-155	338	13	2.5	2.5	NUM
chd-155	338	14	)	)	PUNCT
chd-155	338	15	<	<	X
chd-155	338	16	0.0001	0.0001	NUM
chd-155	338	17	p	p	NOUN
chd-155	338	18	(	(	PUNCT
chd-155	338	19	aa	aa	NOUN
chd-155	338	20	-	-	PUNCT
chd-155	338	21	w	w	NOUN
chd-155	338	22	)	)	PUNCT
chd-155	338	23	<	<	X
chd-155	338	24	0.0001	0.0001	NUM
chd-155	338	25	0.73	0.73	NUM
chd-155	338	26	medical	medical	ADJ
chd-155	338	27	college	college	PROPN
chd-155	338	28	of	of	ADP
chd-155	338	29	wisconsin	wisconsin	PROPN
chd-155	338	30	(	(	PUNCT
chd-155	338	31	mcw	mcw	PROPN
chd-155	338	32	)	)	PUNCT
chd-155	338	33	african	african	PROPN
chd-155	338	34	-	-	PUNCT
chd-155	338	35	american	american	ADJ
chd-155	338	36	,	,	PUNCT
chd-155	338	37	median	median	ADJ
chd-155	338	38	(	(	PUNCT
chd-155	338	39	range	range	NOUN
chd-155	338	40	)	)	PUNCT
chd-155	338	41	white	white	PROPN
chd-155	338	42	american	american	PROPN
chd-155	338	43	,	,	PUNCT
chd-155	338	44	median	median	ADJ
chd-155	338	45	(	(	PUNCT
chd-155	338	46	range	range	NOUN
chd-155	338	47	)	)	PUNCT
chd-155	338	48	overall	overall	ADJ
chd-155	338	49	population	population	NOUN
chd-155	338	50	,	,	PUNCT
chd-155	338	51	median	median	ADJ
chd-155	338	52	tumor	tumor	NOUN
chd-155	338	53	benign	benign	ADJ
chd-155	338	54	p	p	X
chd-155	338	55	tumor	tumor	NOUN
chd-155	338	56	benign	benign	NOUN
chd-155	338	57	p	p	X
chd-155	338	58	tumor	tumor	NOUN
chd-155	338	59	benign	benign	ADJ
chd-155	338	60	p	p	PROPN
chd-155	338	61	gdf15	gdf15	PROPN
chd-155	338	62	2.00	2.00	NUM
chd-155	338	63	(	(	PUNCT
chd-155	338	64	0.67	0.67	NUM
chd-155	338	65	,	,	PUNCT
chd-155	338	66	3	3	NUM
chd-155	338	67	)	)	PUNCT
chd-155	338	68	0.88	0.88	NUM
chd-155	338	69	(	(	PUNCT
chd-155	338	70	0	0	NUM
chd-155	338	71	,	,	PUNCT
chd-155	338	72	2.33	2.33	NUM
chd-155	338	73	)	)	PUNCT
chd-155	338	74	<	<	X
chd-155	338	75	0.0001	0.0001	NUM
chd-155	338	76	1.00	1.00	NUM
chd-155	338	77	(	(	PUNCT
chd-155	338	78	0	0	NUM
chd-155	338	79	,	,	PUNCT
chd-155	338	80	3	3	NUM
chd-155	338	81	)	)	PUNCT
chd-155	338	82	0.67	0.67	NUM
chd-155	338	83	(	(	PUNCT
chd-155	338	84	0	0	NUM
chd-155	338	85	,	,	PUNCT
chd-155	338	86	2.5	2.5	NUM
chd-155	338	87	)	)	PUNCT
chd-155	338	88	0.082	0.082	NUM
chd-155	338	89	1.58	1.58	NUM
chd-155	338	90	(	(	PUNCT
chd-155	338	91	0	0	NUM
chd-155	338	92	,	,	PUNCT
chd-155	338	93	3	3	NUM
chd-155	338	94	)	)	PUNCT
chd-155	338	95	0.77	0.77	NUM
chd-155	338	96	(	(	PUNCT
chd-155	338	97	0	0	NUM
chd-155	338	98	,	,	PUNCT
chd-155	338	99	2.5	2.5	NUM
chd-155	338	100	)	)	PUNCT
chd-155	339	1	<	<	X
chd-155	339	2	0.0001	0.0001	NUM
chd-155	339	3	p	p	NOUN
chd-155	339	4	(	(	PUNCT
chd-155	339	5	aa	aa	NOUN
chd-155	339	6	-	-	PUNCT
chd-155	339	7	w	w	NOUN
chd-155	339	8	)	)	PUNCT
chd-155	339	9	0.007	0.007	NUM
chd-155	339	10	0.454	0.454	NUM
chd-155	339	11	nfκb	nfκb	NOUN
chd-155	339	12	2.00	2.00	NUM
chd-155	339	13	(	(	PUNCT
chd-155	339	14	0.75	0.75	NUM
chd-155	339	15	,	,	PUNCT
chd-155	339	16	3	3	NUM
chd-155	339	17	)	)	PUNCT
chd-155	339	18	1.83	1.83	NUM
chd-155	339	19	(	(	PUNCT
chd-155	339	20	0.17	0.17	NUM
chd-155	339	21	,	,	PUNCT
chd-155	339	22	3	3	NUM
chd-155	339	23	)	)	PUNCT
chd-155	339	24	0.161	0.161	NUM
chd-155	339	25	2.00	2.00	NUM
chd-155	339	26	(	(	PUNCT
chd-155	339	27	0	0	NUM
chd-155	339	28	,	,	PUNCT
chd-155	339	29	3	3	NUM
chd-155	339	30	)	)	PUNCT
chd-155	339	31	1.67	1.67	NUM
chd-155	339	32	(	(	PUNCT
chd-155	339	33	0.5	0.5	NUM
chd-155	339	34	,	,	PUNCT
chd-155	339	35	3	3	NUM
chd-155	339	36	)	)	PUNCT
chd-155	339	37	0.943	0.943	NUM
chd-155	339	38	2.00	2.00	NUM
chd-155	339	39	(	(	PUNCT
chd-155	339	40	0	0	NUM
chd-155	339	41	,	,	PUNCT
chd-155	339	42	3	3	NUM
chd-155	339	43	)	)	PUNCT
chd-155	339	44	1.75	1.75	NUM
chd-155	339	45	(	(	PUNCT
chd-155	339	46	0.17	0.17	NUM
chd-155	339	47	,	,	PUNCT
chd-155	339	48	3	3	NUM
chd-155	339	49	)	)	PUNCT
chd-155	339	50	0.297	0.297	NUM
chd-155	339	51	p	p	NOUN
chd-155	339	52	(	(	PUNCT
chd-155	339	53	aa	aa	NOUN
chd-155	339	54	-	-	PUNCT
chd-155	339	55	w	w	NOUN
chd-155	339	56	)	)	PUNCT
chd-155	339	57	0.283	0.283	NUM
chd-155	339	58	0.384	0.384	NUM
chd-155	339	59	aa=	aa=	ADJ
chd-155	339	60	african	african	PROPN
chd-155	339	61	-	-	PUNCT
chd-155	339	62	american	american	ADJ
chd-155	339	63	;	;	PUNCT
chd-155	339	64	w=	w=	X
chd-155	339	65	white	white	ADJ
chd-155	339	66	supplemental	supplemental	ADJ
chd-155	339	67	table	table	NOUN
chd-155	339	68	2	2	NUM
chd-155	339	69	.	.	PUNCT
chd-155	339	70	expression	expression	NOUN
chd-155	339	71	of	of	ADP
chd-155	339	72	gdf15	gdf15	NOUN
chd-155	339	73	and	and	CCONJ
chd-155	339	74	nfκb	nfκb	NOUN
chd-155	339	75	according	accord	VERB
chd-155	339	76	to	to	ADP
chd-155	339	77	gleason	gleason	PROPN
chd-155	339	78	grade	grade	PROPN
chd-155	339	79	group	group	NOUN
chd-155	339	80	stratified	stratify	VERB
chd-155	339	81	by	by	ADP
chd-155	339	82	study	study	NOUN
chd-155	339	83	site	site	NOUN
chd-155	339	84	.	.	PUNCT
chd-155	340	1	henry	henry	PROPN
chd-155	340	2	ford	ford	PROPN
chd-155	340	3	grade	grade	PROPN
chd-155	340	4	group	group	NOUN
chd-155	340	5	gdf15	gdf15	PROPN
chd-155	340	6	.	.	PUNCT
chd-155	341	1	tumor	tumor	NOUN
chd-155	341	2	,	,	PUNCT
chd-155	341	3	median	median	NOUN
chd-155	341	4	(	(	PUNCT
chd-155	341	5	range	range	NOUN
chd-155	341	6	)	)	PUNCT
chd-155	341	7	p	p	NOUN
chd-155	341	8	n=	n=	ADJ
chd-155	341	9	gdf15	gdf15	NOUN
chd-155	341	10	.	.	PUNCT
chd-155	342	1	benign	benign	ADJ
chd-155	342	2	,	,	PUNCT
chd-155	342	3	median	median	ADJ
chd-155	342	4	(	(	PUNCT
chd-155	342	5	range	range	NOUN
chd-155	342	6	)	)	PUNCT
chd-155	343	1	p	p	NOUN
chd-155	343	2	n=	n=	ADJ
chd-155	343	3	1	1	NUM
chd-155	343	4	2.81	2.81	NUM
chd-155	343	5	(	(	PUNCT
chd-155	343	6	0	0	NUM
chd-155	343	7	,	,	PUNCT
chd-155	343	8	3	3	NUM
chd-155	343	9	)	)	PUNCT
chd-155	343	10	0.668	0.668	NUM
chd-155	343	11	103	103	NUM
chd-155	343	12	1.17	1.17	NUM
chd-155	343	13	(	(	PUNCT
chd-155	343	14	0	0	NUM
chd-155	343	15	,	,	PUNCT
chd-155	343	16	3	3	NUM
chd-155	343	17	)	)	PUNCT
chd-155	343	18	0.268	0.268	NUM
chd-155	343	19	132	132	NUM
chd-155	343	20	2	2	NUM
chd-155	343	21	2.75	2.75	NUM
chd-155	343	22	(	(	PUNCT
chd-155	343	23	0	0	NUM
chd-155	343	24	,	,	PUNCT
chd-155	343	25	3	3	NUM
chd-155	343	26	)	)	PUNCT
chd-155	343	27	101	101	NUM
chd-155	343	28	1.17	1.17	NUM
chd-155	343	29	(	(	PUNCT
chd-155	343	30	0	0	NUM
chd-155	343	31	,	,	PUNCT
chd-155	343	32	3	3	NUM
chd-155	343	33	)	)	SYM
chd-155	343	34	113	113	NUM
chd-155	343	35	3	3	NUM
chd-155	343	36	2.83	2.83	NUM
chd-155	343	37	(	(	PUNCT
chd-155	343	38	0.167	0.167	NUM
chd-155	343	39	,	,	PUNCT
chd-155	343	40	3	3	NUM
chd-155	343	41	)	)	PUNCT
chd-155	343	42	32	32	NUM
chd-155	343	43	1.30	1.30	NUM
chd-155	343	44	(	(	PUNCT
chd-155	343	45	0.056	0.056	NUM
chd-155	343	46	,	,	PUNCT
chd-155	343	47	3	3	NUM
chd-155	343	48	)	)	PUNCT
chd-155	343	49	39	39	NUM
chd-155	343	50	4	4	NUM
chd-155	343	51	2.75	2.75	NUM
chd-155	343	52	(	(	PUNCT
chd-155	343	53	0.5	0.5	NUM
chd-155	343	54	,	,	PUNCT
chd-155	343	55	3	3	NUM
chd-155	343	56	)	)	PUNCT
chd-155	343	57	43	43	NUM
chd-155	343	58	1.11	1.11	NUM
chd-155	343	59	(	(	PUNCT
chd-155	343	60	0	0	NUM
chd-155	343	61	,	,	PUNCT
chd-155	343	62	3	3	X
chd-155	343	63	)	)	PUNCT
chd-155	343	64	50	50	NUM
chd-155	343	65	5	5	NUM
chd-155	343	66	2.50	2.50	NUM
chd-155	343	67	(	(	PUNCT
chd-155	343	68	0.75	0.75	NUM
chd-155	343	69	,	,	PUNCT
chd-155	343	70	3	3	NUM
chd-155	343	71	)	)	PUNCT
chd-155	343	72	20	20	NUM
chd-155	343	73	0.92	0.92	NUM
chd-155	343	74	(	(	PUNCT
chd-155	343	75	0	0	NUM
chd-155	343	76	,	,	PUNCT
chd-155	343	77	3	3	NUM
chd-155	343	78	)	)	SYM
chd-155	343	79	33	33	NUM
chd-155	343	80	grade	grade	NOUN
chd-155	343	81	group	group	NOUN
chd-155	343	82	nfκb	nfκb	NOUN
chd-155	343	83	.	.	PUNCT
chd-155	344	1	tumor	tumor	NOUN
chd-155	344	2	,	,	PUNCT
chd-155	344	3	median	median	NOUN
chd-155	344	4	(	(	PUNCT
chd-155	344	5	range	range	NOUN
chd-155	344	6	)	)	PUNCT
chd-155	344	7	p	p	PROPN
chd-155	344	8	n=	n=	ADJ
chd-155	344	9	nfκb	nfκb	NOUN
chd-155	344	10	.	.	PUNCT
chd-155	345	1	benign	benign	ADJ
chd-155	345	2	,	,	PUNCT
chd-155	345	3	median	median	ADJ
chd-155	345	4	(	(	PUNCT
chd-155	345	5	range	range	NOUN
chd-155	345	6	)	)	PUNCT
chd-155	346	1	p	p	NOUN
chd-155	346	2	n=	n=	ADJ
chd-155	346	3	1	1	NUM
chd-155	346	4	1.25	1.25	NUM
chd-155	346	5	(	(	PUNCT
chd-155	346	6	0	0	NUM
chd-155	346	7	,	,	PUNCT
chd-155	346	8	3	3	NUM
chd-155	346	9	)	)	PUNCT
chd-155	346	10	0.128	0.128	NUM
chd-155	346	11	106	106	NUM
chd-155	346	12	0.95	0.95	NUM
chd-155	346	13	(	(	PUNCT
chd-155	346	14	0	0	NUM
chd-155	346	15	,	,	PUNCT
chd-155	346	16	2.67	2.67	NUM
chd-155	346	17	)	)	PUNCT
chd-155	346	18	0.544	0.544	NUM
chd-155	346	19	130	130	NUM
chd-155	346	20	2	2	NUM
chd-155	346	21	1.25	1.25	NUM
chd-155	346	22	(	(	PUNCT
chd-155	346	23	0	0	NUM
chd-155	346	24	,	,	PUNCT
chd-155	346	25	3	3	NUM
chd-155	346	26	)	)	PUNCT
chd-155	346	27	101	101	NUM
chd-155	346	28	0.90	0.90	NUM
chd-155	346	29	(	(	PUNCT
chd-155	346	30	0	0	NUM
chd-155	346	31	,	,	PUNCT
chd-155	346	32	2.5	2.5	NUM
chd-155	346	33	)	)	PUNCT
chd-155	346	34	113	113	NUM
chd-155	346	35	3	3	NUM
chd-155	346	36	1.47	1.47	NUM
chd-155	346	37	(	(	PUNCT
chd-155	346	38	0	0	NUM
chd-155	346	39	,	,	PUNCT
chd-155	346	40	3	3	NUM
chd-155	346	41	)	)	PUNCT
chd-155	346	42	32	32	NUM
chd-155	346	43	1.19	1.19	NUM
chd-155	346	44	(	(	PUNCT
chd-155	346	45	0	0	NUM
chd-155	346	46	,	,	PUNCT
chd-155	346	47	2.33	2.33	NUM
chd-155	346	48	)	)	PUNCT
chd-155	346	49	39	39	NUM
chd-155	346	50	4	4	NUM
chd-155	346	51	1.71	1.71	NUM
chd-155	346	52	(	(	PUNCT
chd-155	346	53	0	0	NUM
chd-155	346	54	,	,	PUNCT
chd-155	346	55	2.92	2.92	NUM
chd-155	346	56	)	)	PUNCT
chd-155	346	57	48	48	NUM
chd-155	346	58	1.25	1.25	NUM
chd-155	346	59	(	(	PUNCT
chd-155	346	60	0	0	NUM
chd-155	346	61	,	,	PUNCT
chd-155	346	62	3	3	X
chd-155	346	63	)	)	PUNCT
chd-155	346	64	50	50	NUM
chd-155	346	65	5	5	NUM
chd-155	346	66	1.83	1.83	NUM
chd-155	346	67	(	(	PUNCT
chd-155	346	68	0.167	0.167	NUM
chd-155	346	69	,	,	PUNCT
chd-155	346	70	3	3	NUM
chd-155	346	71	)	)	PUNCT
chd-155	346	72	22	22	NUM
chd-155	346	73	1.23	1.23	NUM
chd-155	346	74	(	(	PUNCT
chd-155	346	75	0	0	NUM
chd-155	346	76	,	,	PUNCT
chd-155	346	77	2.82	2.82	NUM
chd-155	346	78	)	)	PUNCT
chd-155	346	79	21	21	NUM
chd-155	346	80	johns	johns	PROPN
chd-155	346	81	hopkins	hopkins	PROPN
chd-155	346	82	grade	grade	PROPN
chd-155	346	83	group	group	NOUN
chd-155	346	84	gdf15	gdf15	NOUN
chd-155	346	85	.	.	PUNCT
chd-155	347	1	tumor	tumor	NOUN
chd-155	347	2	,	,	PUNCT
chd-155	347	3	median	median	NOUN
chd-155	347	4	(	(	PUNCT
chd-155	347	5	range	range	NOUN
chd-155	347	6	)	)	PUNCT
chd-155	347	7	p	p	NOUN
chd-155	347	8	n=	n=	ADJ
chd-155	347	9	gdf15	gdf15	NOUN
chd-155	347	10	.	.	PUNCT
chd-155	348	1	benign	benign	ADJ
chd-155	348	2	,	,	PUNCT
chd-155	348	3	median	median	ADJ
chd-155	348	4	(	(	PUNCT
chd-155	348	5	range	range	NOUN
chd-155	348	6	)	)	PUNCT
chd-155	349	1	p	p	NOUN
chd-155	349	2	n=	n=	ADJ
chd-155	349	3	1	1	NUM
chd-155	349	4	2	2	NUM
chd-155	349	5	(	(	PUNCT
chd-155	349	6	0,3	0,3	NUM
chd-155	349	7	)	)	PUNCT
chd-155	349	8	0.458	0.458	NUM
chd-155	349	9	112	112	NUM
chd-155	349	10	1	1	NUM
chd-155	349	11	(	(	PUNCT
chd-155	349	12	0,2.56	0,2.56	NOUN
chd-155	349	13	)	)	PUNCT
chd-155	349	14	0.040	0.040	NUM
chd-155	349	15	112	112	NUM
chd-155	349	16	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-155	349	17	e17	e17	NOUN
chd-155	349	18	cancer	cancer	NOUN
chd-155	349	19	health	health	NOUN
chd-155	349	20	disparities	disparity	NOUN
chd-155	349	21	research	research	VERB
chd-155	349	22	2	2	NUM
chd-155	349	23	2.12	2.12	NUM
chd-155	349	24	(	(	PUNCT
chd-155	349	25	0,3	0,3	NUM
chd-155	349	26	)	)	PUNCT
chd-155	349	27	80	80	NUM
chd-155	349	28	0.91	0.91	NUM
chd-155	349	29	(	(	PUNCT
chd-155	349	30	0,2.56	0,2.56	NUM
chd-155	349	31	)	)	PUNCT
chd-155	349	32	81	81	NUM
chd-155	349	33	3	3	NUM
chd-155	349	34	2.41	2.41	NUM
chd-155	349	35	(	(	PUNCT
chd-155	349	36	0.5,3	0.5,3	NOUN
chd-155	349	37	)	)	PUNCT
chd-155	349	38	26	26	NUM
chd-155	349	39	1.47	1.47	NUM
chd-155	349	40	(	(	PUNCT
chd-155	349	41	0,2.56	0,2.56	NUM
chd-155	349	42	)	)	PUNCT
chd-155	349	43	26	26	NUM
chd-155	349	44	4	4	NUM
chd-155	349	45	2.44	2.44	NUM
chd-155	349	46	(	(	PUNCT
chd-155	349	47	2.06,2.83	2.06,2.83	NUM
chd-155	349	48	)	)	PUNCT
chd-155	349	49	9	9	NUM
chd-155	349	50	1.4	1.4	NUM
chd-155	349	51	(	(	PUNCT
chd-155	349	52	0.67,2.56	0.67,2.56	NUM
chd-155	349	53	)	)	PUNCT
chd-155	349	54	9	9	NUM
chd-155	349	55	5	5	NUM
chd-155	349	56	2.12	2.12	NUM
chd-155	349	57	(	(	PUNCT
chd-155	349	58	0.5,3	0.5,3	NOUN
chd-155	349	59	)	)	PUNCT
chd-155	349	60	45	45	NUM
chd-155	349	61	1.44	1.44	NUM
chd-155	349	62	(	(	PUNCT
chd-155	349	63	0.25,2.6	0.25,2.6	NOUN
chd-155	349	64	)	)	PUNCT
chd-155	349	65	45	45	NUM
chd-155	349	66	grade	grade	NOUN
chd-155	349	67	group	group	NOUN
chd-155	349	68	nfκb	nfκb	NOUN
chd-155	349	69	.	.	PUNCT
chd-155	350	1	tumor	tumor	NOUN
chd-155	350	2	,	,	PUNCT
chd-155	350	3	median	median	NOUN
chd-155	350	4	(	(	PUNCT
chd-155	350	5	range	range	NOUN
chd-155	350	6	)	)	PUNCT
chd-155	350	7	p	p	PROPN
chd-155	350	8	n=	n=	ADJ
chd-155	350	9	nfκb	nfκb	NOUN
chd-155	350	10	.	.	PUNCT
chd-155	351	1	benign	benign	ADJ
chd-155	351	2	,	,	PUNCT
chd-155	351	3	median	median	ADJ
chd-155	351	4	(	(	PUNCT
chd-155	351	5	range	range	NOUN
chd-155	351	6	)	)	PUNCT
chd-155	352	1	p	p	NOUN
chd-155	352	2	n=	n=	ADJ
chd-155	352	3	1	1	NUM
chd-155	352	4	1.35	1.35	NUM
chd-155	352	5	(	(	PUNCT
chd-155	352	6	0,3	0,3	NUM
chd-155	352	7	)	)	PUNCT
chd-155	352	8	0.001	0.001	NUM
chd-155	352	9	110	110	NUM
chd-155	352	10	0.40	0.40	NUM
chd-155	352	11	(	(	PUNCT
chd-155	352	12	0,2.38	0,2.38	NOUN
chd-155	352	13	)	)	PUNCT
chd-155	352	14	<	<	X
chd-155	352	15	0.00	0.00	NUM
chd-155	352	16	01	01	NUM
chd-155	352	17	112	112	NUM
chd-155	352	18	2	2	NUM
chd-155	352	19	1.44	1.44	NUM
chd-155	352	20	(	(	PUNCT
chd-155	352	21	0,2.88	0,2.88	NUM
chd-155	352	22	)	)	PUNCT
chd-155	352	23	80	80	NUM
chd-155	352	24	0.42	0.42	NUM
chd-155	352	25	(	(	PUNCT
chd-155	352	26	0,2.12	0,2.12	NOUN
chd-155	352	27	)	)	PUNCT
chd-155	352	28	81	81	NUM
chd-155	352	29	3	3	NUM
chd-155	352	30	1.5	1.5	NUM
chd-155	352	31	(	(	PUNCT
chd-155	352	32	0.25,2.69	0.25,2.69	NOUN
chd-155	352	33	)	)	PUNCT
chd-155	352	34	26	26	NUM
chd-155	352	35	0.86	0.86	NUM
chd-155	352	36	(	(	PUNCT
chd-155	352	37	0.1,2.5	0.1,2.5	PROPN
chd-155	352	38	)	)	PUNCT
chd-155	352	39	26	26	NUM
chd-155	352	40	4	4	NUM
chd-155	352	41	1.62	1.62	NUM
chd-155	352	42	(	(	PUNCT
chd-155	352	43	0.69,2.94	0.69,2.94	NUM
chd-155	352	44	)	)	PUNCT
chd-155	352	45	9	9	NUM
chd-155	352	46	1.06	1.06	NUM
chd-155	352	47	(	(	PUNCT
chd-155	352	48	0.58,1.69	0.58,1.69	NUM
chd-155	352	49	)	)	PUNCT
chd-155	352	50	9	9	NUM
chd-155	352	51	5	5	NUM
chd-155	352	52	2	2	NUM
chd-155	352	53	(	(	PUNCT
chd-155	352	54	0.25,2.81	0.25,2.81	NUM
chd-155	352	55	)	)	PUNCT
chd-155	352	56	45	45	NUM
chd-155	352	57	1.31	1.31	NUM
chd-155	352	58	(	(	PUNCT
chd-155	352	59	0.38,2.52	0.38,2.52	NUM
chd-155	352	60	)	)	PUNCT
chd-155	352	61	45	45	NUM
chd-155	352	62	medical	medical	ADJ
chd-155	352	63	college	college	PROPN
chd-155	352	64	of	of	ADP
chd-155	352	65	wisconsin	wisconsin	PROPN
chd-155	352	66	(	(	PUNCT
chd-155	352	67	mcw	mcw	PROPN
chd-155	352	68	)	)	PUNCT
chd-155	352	69	grade	grade	NOUN
chd-155	352	70	group	group	NOUN
chd-155	352	71	gdf15	gdf15	NOUN
chd-155	352	72	.	.	PUNCT
chd-155	353	1	tumor	tumor	NOUN
chd-155	353	2	,	,	PUNCT
chd-155	353	3	median	median	NOUN
chd-155	353	4	(	(	PUNCT
chd-155	353	5	range	range	NOUN
chd-155	353	6	)	)	PUNCT
chd-155	353	7	p	p	NOUN
chd-155	353	8	n=	n=	ADJ
chd-155	353	9	gdf15	gdf15	NOUN
chd-155	353	10	.	.	PUNCT
chd-155	354	1	benign	benign	ADJ
chd-155	354	2	,	,	PUNCT
chd-155	354	3	median	median	ADJ
chd-155	354	4	(	(	PUNCT
chd-155	354	5	range	range	NOUN
chd-155	354	6	)	)	PUNCT
chd-155	355	1	p	p	NOUN
chd-155	355	2	n=	n=	ADJ
chd-155	355	3	1	1	NUM
chd-155	355	4	1.25	1.25	NUM
chd-155	355	5	(	(	PUNCT
chd-155	355	6	0.5,2	0.5,2	NOUN
chd-155	355	7	)	)	PUNCT
chd-155	355	8	0.085	0.085	NUM
chd-155	355	9	6	6	NUM
chd-155	355	10	0.75	0.75	NUM
chd-155	355	11	(	(	PUNCT
chd-155	355	12	0,1	0,1	NUM
chd-155	355	13	)	)	PUNCT
chd-155	355	14	0.573	0.573	NUM
chd-155	355	15	6	6	NUM
chd-155	355	16	2	2	NUM
chd-155	355	17	1.5	1.5	NUM
chd-155	355	18	(	(	PUNCT
chd-155	355	19	0.5,3	0.5,3	NOUN
chd-155	355	20	)	)	PUNCT
chd-155	355	21	16	16	NUM
chd-155	355	22	0.5	0.5	NUM
chd-155	355	23	(	(	PUNCT
chd-155	355	24	0,2.5	0,2.5	NOUN
chd-155	355	25	)	)	PUNCT
chd-155	355	26	16	16	NUM
chd-155	355	27	3	3	NUM
chd-155	355	28	2.33	2.33	NUM
chd-155	355	29	(	(	PUNCT
chd-155	355	30	0,3	0,3	NUM
chd-155	355	31	)	)	PUNCT
chd-155	355	32	29	29	NUM
chd-155	355	33	1	1	NUM
chd-155	355	34	(	(	PUNCT
chd-155	355	35	0,2.5	0,2.5	PROPN
chd-155	355	36	)	)	PUNCT
chd-155	355	37	29	29	NUM
chd-155	355	38	4	4	NUM
chd-155	355	39	--	--	PUNCT
chd-155	355	40	0	0	NUM
chd-155	355	41	--	--	SYM
chd-155	355	42	0	0	NUM
chd-155	355	43	5	5	NUM
chd-155	355	44	1.67	1.67	NUM
chd-155	355	45	(	(	PUNCT
chd-155	355	46	0.5,2.17	0.5,2.17	NUM
chd-155	355	47	)	)	PUNCT
chd-155	355	48	5	5	NUM
chd-155	355	49	0.5	0.5	NUM
chd-155	355	50	(	(	PUNCT
chd-155	355	51	0,2.33	0,2.33	NOUN
chd-155	355	52	)	)	PUNCT
chd-155	355	53	5	5	NUM
chd-155	355	54	grade	grade	NOUN
chd-155	355	55	group	group	NOUN
chd-155	355	56	nfκb	nfκb	NOUN
chd-155	355	57	.	.	PUNCT
chd-155	356	1	tumor	tumor	NOUN
chd-155	356	2	,	,	PUNCT
chd-155	356	3	median	median	NOUN
chd-155	356	4	(	(	PUNCT
chd-155	356	5	range	range	NOUN
chd-155	356	6	)	)	PUNCT
chd-155	356	7	p	p	PROPN
chd-155	356	8	n=	n=	ADJ
chd-155	356	9	nfκb	nfκb	NOUN
chd-155	356	10	.	.	PUNCT
chd-155	357	1	benign	benign	ADJ
chd-155	357	2	,	,	PUNCT
chd-155	357	3	median	median	ADJ
chd-155	357	4	(	(	PUNCT
chd-155	357	5	range	range	NOUN
chd-155	357	6	)	)	PUNCT
chd-155	358	1	p	p	NOUN
chd-155	358	2	n=	n=	ADJ
chd-155	358	3	1	1	NUM
chd-155	358	4	1.5	1.5	NUM
chd-155	358	5	(	(	PUNCT
chd-155	358	6	0.75,3	0.75,3	PROPN
chd-155	358	7	)	)	PUNCT
chd-155	358	8	0.049	0.049	NUM
chd-155	358	9	5	5	NUM
chd-155	358	10	1.5	1.5	NUM
chd-155	358	11	(	(	PUNCT
chd-155	358	12	0.8,1.8	0.8,1.8	PROPN
chd-155	358	13	)	)	PUNCT
chd-155	358	14	0.000	0.000	NUM
chd-155	358	15	3	3	NUM
chd-155	358	16	6	6	NUM
chd-155	358	17	2	2	NUM
chd-155	358	18	1.5	1.5	NUM
chd-155	358	19	(	(	PUNCT
chd-155	358	20	1,2.83	1,2.83	NUM
chd-155	358	21	)	)	PUNCT
chd-155	358	22	16	16	NUM
chd-155	358	23	1.4	1.4	NUM
chd-155	358	24	(	(	PUNCT
chd-155	358	25	0.17,2	0.17,2	NOUN
chd-155	358	26	)	)	PUNCT
chd-155	358	27	16	16	NUM
chd-155	358	28	3	3	NUM
chd-155	358	29	2.08	2.08	NUM
chd-155	358	30	(	(	PUNCT
chd-155	358	31	0,3	0,3	NUM
chd-155	358	32	)	)	PUNCT
chd-155	358	33	29	29	NUM
chd-155	358	34	2	2	NUM
chd-155	358	35	(	(	PUNCT
chd-155	358	36	0.5,3	0.5,3	NOUN
chd-155	358	37	)	)	PUNCT
chd-155	358	38	29	29	NUM
chd-155	358	39	4	4	NUM
chd-155	358	40	--	--	PUNCT
chd-155	358	41	0	0	NUM
chd-155	358	42	--	--	SYM
chd-155	358	43	0	0	NUM
chd-155	358	44	5	5	NUM
chd-155	358	45	2.5	2.5	NUM
chd-155	358	46	(	(	PUNCT
chd-155	358	47	2.25,2.62	2.25,2.62	NOUN
chd-155	358	48	)	)	PUNCT
chd-155	358	49	5	5	NUM
chd-155	358	50	2	2	NUM
chd-155	358	51	(	(	PUNCT
chd-155	358	52	1.4,2.83	1.4,2.83	NUM
chd-155	358	53	)	)	PUNCT
chd-155	358	54	5	5	NUM
chd-155	358	55	n=	n=	ADJ
chd-155	358	56	number	number	NOUN
chd-155	358	57	of	of	ADP
chd-155	358	58	informative	informative	ADJ
chd-155	358	59	case	case	NOUN
chd-155	358	60	supplemental	supplemental	ADJ
chd-155	358	61	table	table	NOUN
chd-155	358	62	3	3	NUM
chd-155	358	63	.	.	PUNCT
chd-155	358	64	expression	expression	NOUN
chd-155	358	65	of	of	ADP
chd-155	358	66	gdf15	gdf15	NOUN
chd-155	358	67	and	and	CCONJ
chd-155	358	68	nfκb	nfκb	NOUN
chd-155	358	69	according	accord	VERB
chd-155	358	70	to	to	ADP
chd-155	358	71	pathologic	pathologic	ADJ
chd-155	358	72	stage	stage	NOUN
chd-155	358	73	stratified	stratify	VERB
chd-155	358	74	by	by	ADP
chd-155	358	75	study	study	NOUN
chd-155	358	76	site	site	NOUN
chd-155	358	77	.	.	PUNCT
chd-155	359	1	henry	henry	PROPN
chd-155	359	2	ford	ford	PROPN
chd-155	359	3	pathologic	pathologic	ADJ
chd-155	359	4	stage	stage	NOUN
chd-155	359	5	gdf15	gdf15	NOUN
chd-155	359	6	.	.	PUNCT
chd-155	360	1	tumor	tumor	NOUN
chd-155	360	2	,	,	PUNCT
chd-155	360	3	median	median	NOUN
chd-155	360	4	(	(	PUNCT
chd-155	360	5	range	range	NOUN
chd-155	360	6	)	)	PUNCT
chd-155	360	7	p	p	NOUN
chd-155	360	8	n=	n=	ADJ
chd-155	360	9	gdf15	gdf15	NOUN
chd-155	360	10	.	.	PUNCT
chd-155	361	1	benign	benign	ADJ
chd-155	361	2	,	,	PUNCT
chd-155	361	3	median	median	ADJ
chd-155	361	4	(	(	PUNCT
chd-155	361	5	range	range	NOUN
chd-155	361	6	)	)	PUNCT
chd-155	362	1	p	p	NOUN
chd-155	362	2	n=	n=	ADJ
chd-155	362	3	2	2	NUM
chd-155	362	4	2.83	2.83	NUM
chd-155	362	5	(	(	PUNCT
chd-155	362	6	0,3	0,3	NUM
chd-155	362	7	)	)	PUNCT
chd-155	362	8	.015	.015	NUM
chd-155	362	9	243	243	NUM
chd-155	362	10	1.25	1.25	NUM
chd-155	362	11	(	(	PUNCT
chd-155	362	12	0,3	0,3	NUM
chd-155	362	13	)	)	PUNCT
chd-155	362	14	0.01	0.01	NUM
chd-155	362	15	295	295	NUM
chd-155	362	16	3a	3a	NUM
chd-155	362	17	2.71	2.71	NUM
chd-155	362	18	(	(	PUNCT
chd-155	362	19	0.167,3	0.167,3	PROPN
chd-155	362	20	)	)	PUNCT
chd-155	362	21	34	34	NUM
chd-155	362	22	0.88	0.88	NUM
chd-155	362	23	(	(	PUNCT
chd-155	362	24	0,3	0,3	NUM
chd-155	362	25	)	)	PUNCT
chd-155	362	26	37	37	NUM
chd-155	362	27	3b	3b	NOUN
chd-155	362	28	2.2	2.2	NUM
chd-155	362	29	(	(	PUNCT
chd-155	362	30	0.75,3	0.75,3	PROPN
chd-155	362	31	)	)	PUNCT
chd-155	362	32	20	20	NUM
chd-155	362	33	1.19	1.19	NUM
chd-155	362	34	(	(	PUNCT
chd-155	362	35	0.25,2.5	0.25,2.5	NOUN
chd-155	362	36	)	)	PUNCT
chd-155	362	37	22	22	NUM
chd-155	362	38	4	4	NUM
chd-155	362	39	2.1	2.1	NUM
chd-155	362	40	(	(	PUNCT
chd-155	362	41	1.42,2.79	1.42,2.79	NUM
chd-155	362	42	)	)	PUNCT
chd-155	362	43	2	2	NUM
chd-155	362	44	1.06	1.06	NUM
chd-155	362	45	(	(	PUNCT
chd-155	362	46	0.19,1.94	0.19,1.94	NUM
chd-155	362	47	)	)	PUNCT
chd-155	362	48	2	2	NUM
chd-155	362	49	pathologic	pathologic	ADJ
chd-155	362	50	stage	stage	NOUN
chd-155	362	51	nfκb	nfκb	NOUN
chd-155	362	52	.	.	PUNCT
chd-155	363	1	tumor	tumor	NOUN
chd-155	363	2	,	,	PUNCT
chd-155	363	3	median	median	NOUN
chd-155	363	4	(	(	PUNCT
chd-155	363	5	range	range	NOUN
chd-155	363	6	)	)	PUNCT
chd-155	363	7	p	p	PROPN
chd-155	363	8	n=	n=	ADJ
chd-155	363	9	nfκb	nfκb	NOUN
chd-155	363	10	.	.	PUNCT
chd-155	364	1	benign	benign	ADJ
chd-155	364	2	,	,	PUNCT
chd-155	364	3	median	median	ADJ
chd-155	364	4	(	(	PUNCT
chd-155	364	5	range	range	NOUN
chd-155	364	6	)	)	PUNCT
chd-155	365	1	p	p	NOUN
chd-155	365	2	n=	n=	ADJ
chd-155	365	3	2	2	NUM
chd-155	365	4	1.42	1.42	NUM
chd-155	365	5	(	(	PUNCT
chd-155	365	6	0,3	0,3	NUM
chd-155	365	7	)	)	PUNCT
chd-155	365	8	0.203	0.203	NUM
chd-155	365	9	253	253	NUM
chd-155	365	10	1.00	1.00	NUM
chd-155	365	11	(	(	PUNCT
chd-155	365	12	0,3	0,3	NUM
chd-155	365	13	)	)	PUNCT
chd-155	365	14	0.589	0.589	NUM
chd-155	365	15	292	292	NUM
chd-155	365	16	3a	3a	NUM
chd-155	365	17	1.42	1.42	NUM
chd-155	365	18	(	(	PUNCT
chd-155	365	19	0,3	0,3	NUM
chd-155	365	20	)	)	PUNCT
chd-155	365	21	33	33	NUM
chd-155	365	22	0.88	0.88	NUM
chd-155	365	23	(	(	PUNCT
chd-155	365	24	0,2.5	0,2.5	PROPN
chd-155	365	25	)	)	PUNCT
chd-155	365	26	37	37	NUM
chd-155	365	27	3b	3b	NUM
chd-155	365	28	1.62	1.62	NUM
chd-155	365	29	(	(	PUNCT
chd-155	365	30	0,3	0,3	NUM
chd-155	365	31	)	)	PUNCT
chd-155	365	32	21	21	NUM
chd-155	365	33	1.25	1.25	NUM
chd-155	365	34	(	(	PUNCT
chd-155	365	35	0,2.08	0,2.08	NOUN
chd-155	365	36	)	)	PUNCT
chd-155	365	37	22	22	NUM
chd-155	365	38	4	4	NUM
chd-155	365	39	0.18	0.18	NUM
chd-155	365	40	(	(	PUNCT
chd-155	365	41	0,0.36	0,0.36	NOUN
chd-155	365	42	)	)	PUNCT
chd-155	365	43	2	2	NUM
chd-155	365	44	0.71	0.71	NUM
chd-155	365	45	(	(	PUNCT
chd-155	365	46	0.67,0.75	0.67,0.75	NUM
chd-155	365	47	)	)	PUNCT
chd-155	365	48	2	2	NUM
chd-155	365	49	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-155	365	50	e18	e18	PROPN
chd-155	365	51	cancer	cancer	NOUN
chd-155	365	52	health	health	NOUN
chd-155	365	53	disparities	disparity	NOUN
chd-155	365	54	research	research	PROPN
chd-155	365	55	johns	johns	PROPN
chd-155	365	56	hopkins	hopkins	PROPN
chd-155	365	57	pathologic	pathologic	ADJ
chd-155	365	58	stage	stage	NOUN
chd-155	365	59	gdf15	gdf15	NOUN
chd-155	365	60	.	.	PUNCT
chd-155	366	1	tumor	tumor	NOUN
chd-155	366	2	,	,	PUNCT
chd-155	366	3	median	median	NOUN
chd-155	366	4	(	(	PUNCT
chd-155	366	5	range	range	NOUN
chd-155	366	6	)	)	PUNCT
chd-155	366	7	p	p	NOUN
chd-155	366	8	n=	n=	ADJ
chd-155	366	9	gdf15	gdf15	NOUN
chd-155	366	10	.	.	PUNCT
chd-155	367	1	benign	benign	ADJ
chd-155	367	2	,	,	PUNCT
chd-155	367	3	median	median	ADJ
chd-155	367	4	(	(	PUNCT
chd-155	367	5	range	range	NOUN
chd-155	367	6	)	)	PUNCT
chd-155	368	1	p	p	NOUN
chd-155	368	2	n=	n=	ADJ
chd-155	368	3	2	2	NUM
chd-155	368	4	2.25	2.25	NUM
chd-155	368	5	(	(	PUNCT
chd-155	368	6	0,3	0,3	NUM
chd-155	368	7	)	)	PUNCT
chd-155	368	8	0.081	0.081	NUM
chd-155	368	9	183	183	NUM
chd-155	368	10	1	1	NUM
chd-155	368	11	(	(	PUNCT
chd-155	368	12	0,2.56	0,2.56	NOUN
chd-155	368	13	)	)	PUNCT
chd-155	368	14	0.900	0.900	NUM
chd-155	368	15	183	183	NUM
chd-155	368	16	3a	3a	NUM
chd-155	368	17	2	2	NUM
chd-155	368	18	(	(	PUNCT
chd-155	368	19	0.5,3	0.5,3	NOUN
chd-155	368	20	)	)	PUNCT
chd-155	368	21	57	57	NUM
chd-155	368	22	1	1	NUM
chd-155	368	23	(	(	PUNCT
chd-155	368	24	0,2.6	0,2.6	NUM
chd-155	368	25	)	)	PUNCT
chd-155	368	26	58	58	NUM
chd-155	368	27	3b	3b	NOUN
chd-155	368	28	2	2	NUM
chd-155	368	29	(	(	PUNCT
chd-155	368	30	0.5,3	0.5,3	NOUN
chd-155	368	31	)	)	PUNCT
chd-155	368	32	30	30	NUM
chd-155	368	33	1.04	1.04	NUM
chd-155	368	34	(	(	PUNCT
chd-155	368	35	0.25,2.5	0.25,2.5	NOUN
chd-155	368	36	)	)	PUNCT
chd-155	368	37	30	30	NUM
chd-155	368	38	4	4	NUM
chd-155	368	39	1.41	1.41	NUM
chd-155	368	40	(	(	PUNCT
chd-155	368	41	1.31,1.5	1.31,1.5	NOUN
chd-155	368	42	)	)	PUNCT
chd-155	368	43	2	2	NUM
chd-155	368	44	1.16	1.16	NUM
chd-155	368	45	(	(	PUNCT
chd-155	368	46	0.63,1.69	0.63,1.69	NOUN
chd-155	368	47	)	)	PUNCT
chd-155	368	48	2	2	NUM
chd-155	368	49	pathologic	pathologic	ADJ
chd-155	368	50	stage	stage	NOUN
chd-155	368	51	nfκb	nfκb	NOUN
chd-155	368	52	.	.	PUNCT
chd-155	369	1	tumor	tumor	NOUN
chd-155	369	2	,	,	PUNCT
chd-155	369	3	median	median	NOUN
chd-155	369	4	(	(	PUNCT
chd-155	369	5	range	range	NOUN
chd-155	369	6	)	)	PUNCT
chd-155	369	7	p	p	PROPN
chd-155	369	8	n=	n=	ADJ
chd-155	369	9	nfκb	nfκb	NOUN
chd-155	369	10	.	.	PUNCT
chd-155	370	1	benign	benign	ADJ
chd-155	370	2	,	,	PUNCT
chd-155	370	3	median	median	ADJ
chd-155	370	4	(	(	PUNCT
chd-155	370	5	range	range	NOUN
chd-155	370	6	)	)	PUNCT
chd-155	371	1	p	p	NOUN
chd-155	371	2	n=	n=	ADJ
chd-155	371	3	2	2	NUM
chd-155	371	4	1.38	1.38	NUM
chd-155	371	5	(	(	PUNCT
chd-155	371	6	0,3	0,3	NUM
chd-155	371	7	)	)	PUNCT
chd-155	371	8	0.005	0.005	NUM
chd-155	371	9	181	181	NUM
chd-155	371	10	0.58	0.58	NUM
chd-155	371	11	(	(	PUNCT
chd-155	371	12	0,2.5	0,2.5	NOUN
chd-155	371	13	)	)	PUNCT
chd-155	371	14	<	<	X
chd-155	371	15	0.00	0.00	NUM
chd-155	371	16	01	01	NUM
chd-155	371	17	183	183	NUM
chd-155	371	18	3a	3a	NUM
chd-155	371	19	1.38	1.38	NUM
chd-155	371	20	(	(	PUNCT
chd-155	371	21	0,2.88	0,2.88	X
chd-155	371	22	)	)	PUNCT
chd-155	371	23	57	57	NUM
chd-155	371	24	0.5	0.5	NUM
chd-155	371	25	(	(	PUNCT
chd-155	371	26	0,1.98	0,1.98	NOUN
chd-155	371	27	)	)	PUNCT
chd-155	372	1	58	58	NUM
chd-155	373	1	3b	3b	NUM
chd-155	373	2	2.25	2.25	NUM
chd-155	373	3	(	(	PUNCT
chd-155	373	4	0.25,2.81	0.25,2.81	NUM
chd-155	373	5	)	)	PUNCT
chd-155	373	6	30	30	NUM
chd-155	373	7	1.11	1.11	NUM
chd-155	373	8	(	(	PUNCT
chd-155	373	9	0.42,2.52	0.42,2.52	NOUN
chd-155	373	10	)	)	PUNCT
chd-155	373	11	30	30	NUM
chd-155	373	12	4	4	NUM
chd-155	373	13	1.68	1.68	NUM
chd-155	373	14	(	(	PUNCT
chd-155	373	15	1.55,1.81	1.55,1.81	NUM
chd-155	373	16	)	)	PUNCT
chd-155	373	17	2	2	NUM
chd-155	373	18	1.38	1.38	NUM
chd-155	373	19	(	(	PUNCT
chd-155	373	20	1.25,1.5	1.25,1.5	NOUN
chd-155	373	21	)	)	PUNCT
chd-155	373	22	2	2	NUM
chd-155	373	23	medical	medical	ADJ
chd-155	373	24	college	college	PROPN
chd-155	373	25	of	of	ADP
chd-155	373	26	wisconsin	wisconsin	PROPN
chd-155	373	27	(	(	PUNCT
chd-155	373	28	mcw	mcw	PROPN
chd-155	373	29	)	)	PUNCT
chd-155	373	30	pathologic	pathologic	ADJ
chd-155	373	31	stage	stage	NOUN
chd-155	373	32	gdf15	gdf15	NOUN
chd-155	373	33	.	.	PUNCT
chd-155	374	1	tumor	tumor	NOUN
chd-155	374	2	,	,	PUNCT
chd-155	374	3	median	median	NOUN
chd-155	374	4	(	(	PUNCT
chd-155	374	5	range	range	NOUN
chd-155	374	6	)	)	PUNCT
chd-155	374	7	p	p	NOUN
chd-155	374	8	n=	n=	ADJ
chd-155	374	9	gdf15	gdf15	NOUN
chd-155	374	10	.	.	PUNCT
chd-155	375	1	benign	benign	ADJ
chd-155	375	2	,	,	PUNCT
chd-155	375	3	median	median	ADJ
chd-155	375	4	(	(	PUNCT
chd-155	375	5	range	range	NOUN
chd-155	375	6	)	)	PUNCT
chd-155	376	1	p	p	NOUN
chd-155	376	2	n=	n=	ADJ
chd-155	376	3	2	2	NUM
chd-155	376	4	1.5	1.5	NUM
chd-155	376	5	(	(	PUNCT
chd-155	376	6	0.33,3	0.33,3	NUM
chd-155	376	7	)	)	PUNCT
chd-155	376	8	0.589	0.589	NUM
chd-155	376	9	36	36	NUM
chd-155	376	10	1	1	NUM
chd-155	376	11	(	(	PUNCT
chd-155	376	12	0,2.5	0,2.5	NOUN
chd-155	376	13	)	)	PUNCT
chd-155	377	1	0.101	0.101	NUM
chd-155	377	2	36	36	NUM
chd-155	377	3	3a	3a	NUM
chd-155	377	4	1.83	1.83	NUM
chd-155	377	5	(	(	PUNCT
chd-155	377	6	0,3	0,3	NUM
chd-155	377	7	)	)	PUNCT
chd-155	377	8	14	14	NUM
chd-155	377	9	0.5	0.5	NUM
chd-155	377	10	(	(	PUNCT
chd-155	377	11	0,2.5	0,2.5	NOUN
chd-155	377	12	)	)	PUNCT
chd-155	377	13	14	14	NUM
chd-155	377	14	3b	3b	NUM
chd-155	377	15	1.75	1.75	NUM
chd-155	377	16	(	(	PUNCT
chd-155	377	17	0.5,2.67	0.5,2.67	NUM
chd-155	377	18	)	)	PUNCT
chd-155	377	19	6	6	NUM
chd-155	377	20	0.88	0.88	NUM
chd-155	377	21	(	(	PUNCT
chd-155	377	22	0,2.33	0,2.33	NOUN
chd-155	377	23	)	)	PUNCT
chd-155	377	24	6	6	NUM
chd-155	377	25	4	4	NUM
chd-155	377	26	--	--	PUNCT
chd-155	377	27	0	0	NUM
chd-155	377	28	--	--	SYM
chd-155	377	29	0	0	NUM
chd-155	377	30	pathologic	pathologic	ADJ
chd-155	377	31	stage	stage	NOUN
chd-155	377	32	nfκb	nfκb	NOUN
chd-155	377	33	.	.	PUNCT
chd-155	378	1	tumor	tumor	NOUN
chd-155	378	2	,	,	PUNCT
chd-155	378	3	median	median	NOUN
chd-155	378	4	(	(	PUNCT
chd-155	378	5	range	range	NOUN
chd-155	378	6	)	)	PUNCT
chd-155	378	7	p	p	PROPN
chd-155	378	8	n=	n=	ADJ
chd-155	378	9	nfκb	nfκb	NOUN
chd-155	378	10	.	.	PUNCT
chd-155	379	1	benign	benign	ADJ
chd-155	379	2	,	,	PUNCT
chd-155	379	3	median	median	ADJ
chd-155	379	4	(	(	PUNCT
chd-155	379	5	range	range	NOUN
chd-155	379	6	)	)	PUNCT
chd-155	380	1	p	p	NOUN
chd-155	380	2	n=	n=	ADJ
chd-155	380	3	2	2	NUM
chd-155	380	4	2	2	NUM
chd-155	380	5	(	(	PUNCT
chd-155	380	6	0.75,3	0.75,3	PROPN
chd-155	380	7	)	)	PUNCT
chd-155	380	8	0.206	0.206	NUM
chd-155	380	9	35	35	NUM
chd-155	380	10	1.73	1.73	NUM
chd-155	380	11	(	(	PUNCT
chd-155	380	12	0.75,3	0.75,3	PROPN
chd-155	380	13	)	)	PUNCT
chd-155	380	14	0.860	0.860	NUM
chd-155	380	15	36	36	NUM
chd-155	380	16	3a	3a	NUM
chd-155	380	17	1.71	1.71	NUM
chd-155	380	18	(	(	PUNCT
chd-155	380	19	0,2.83	0,2.83	NUM
chd-155	380	20	)	)	PUNCT
chd-155	380	21	14	14	NUM
chd-155	380	22	1.77	1.77	NUM
chd-155	380	23	(	(	PUNCT
chd-155	380	24	0.17,2.88	0.17,2.88	NOUN
chd-155	380	25	)	)	PUNCT
chd-155	380	26	14	14	NUM
chd-155	380	27	3b	3b	NOUN
chd-155	380	28	2.42	2.42	NUM
chd-155	380	29	(	(	PUNCT
chd-155	380	30	1,3	1,3	NUM
chd-155	380	31	)	)	PUNCT
chd-155	380	32	6	6	NUM
chd-155	380	33	1.92	1.92	NUM
chd-155	380	34	(	(	PUNCT
chd-155	380	35	1.4,2.83	1.4,2.83	NUM
chd-155	380	36	)	)	PUNCT
chd-155	380	37	6	6	NUM
chd-155	380	38	4	4	NUM
chd-155	380	39	--	--	SYM
chd-155	380	40	0	0	NUM
chd-155	380	41	--	--	SYM
chd-155	380	42	0	0	NUM
chd-155	380	43	n=	n=	ADJ
chd-155	380	44	number	number	NOUN
chd-155	380	45	of	of	ADP
chd-155	380	46	informative	informative	ADJ
chd-155	380	47	cases	case	NOUN
chd-155	380	48	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-155	380	49	e19	e19	ADJ
chd-155	380	50	cancer	cancer	NOUN
chd-155	380	51	health	health	NOUN
chd-155	380	52	disparities	disparity	NOUN
chd-155	380	53	research	research	VERB
chd-155	380	54	supplemental	supplemental	ADJ
chd-155	380	55	table	table	NOUN
chd-155	380	56	4	4	NUM
chd-155	380	57	.	.	PUNCT
chd-155	381	1	racial	racial	ADJ
chd-155	381	2	disparity	disparity	NOUN
chd-155	381	3	of	of	ADP
chd-155	381	4	expression	expression	NOUN
chd-155	381	5	of	of	ADP
chd-155	381	6	gdf15	gdf15	NOUN
chd-155	381	7	and	and	CCONJ
chd-155	381	8	nfκb	nfκb	NOUN
chd-155	381	9	according	accord	VERB
chd-155	381	10	to	to	ADP
chd-155	381	11	gleason	gleason	PROPN
chd-155	381	12	grade	grade	PROPN
chd-155	381	13	group	group	NOUN
chd-155	381	14	stratified	stratify	VERB
chd-155	381	15	by	by	ADP
chd-155	381	16	study	study	NOUN
chd-155	381	17	site	site	NOUN
chd-155	381	18	.	.	PUNCT
chd-155	382	1	henry	henry	PROPN
chd-155	382	2	ford	ford	PROPN
chd-155	382	3	african	african	PROPN
chd-155	382	4	-	-	PUNCT
chd-155	382	5	american	american	ADJ
chd-155	382	6	white	white	PROPN
chd-155	382	7	american	american	PROPN
chd-155	382	8	grade	grade	PROPN
chd-155	382	9	group	group	NOUN
chd-155	382	10	gdf15	gdf15	PROPN
chd-155	382	11	.	.	PUNCT
chd-155	383	1	tumor	tumor	NOUN
chd-155	383	2	,	,	PUNCT
chd-155	383	3	median	median	NOUN
chd-155	383	4	(	(	PUNCT
chd-155	383	5	range	range	NOUN
chd-155	383	6	)	)	PUNCT
chd-155	383	7	p	p	NOUN
chd-155	383	8	n=	n=	ADJ
chd-155	383	9	gdf15	gdf15	NOUN
chd-155	383	10	.	.	PUNCT
chd-155	384	1	benign	benign	ADJ
chd-155	384	2	,	,	PUNCT
chd-155	384	3	median	median	ADJ
chd-155	384	4	(	(	PUNCT
chd-155	384	5	range	range	NOUN
chd-155	384	6	)	)	PUNCT
chd-155	384	7	p	p	NOUN
chd-155	384	8	n=	n=	ADJ
chd-155	384	9	gdf15	gdf15	NOUN
chd-155	384	10	.	.	PUNCT
chd-155	385	1	tumor	tumor	NOUN
chd-155	385	2	,	,	PUNCT
chd-155	385	3	median	median	NOUN
chd-155	385	4	(	(	PUNCT
chd-155	385	5	range	range	NOUN
chd-155	385	6	)	)	PUNCT
chd-155	385	7	p	p	NOUN
chd-155	385	8	n=	n=	ADJ
chd-155	385	9	gdf15	gdf15	NOUN
chd-155	385	10	.	.	PUNCT
chd-155	386	1	benign	benign	ADJ
chd-155	386	2	,	,	PUNCT
chd-155	386	3	median	median	ADJ
chd-155	386	4	(	(	PUNCT
chd-155	386	5	range	range	NOUN
chd-155	386	6	)	)	PUNCT
chd-155	387	1	p	p	NOUN
chd-155	387	2	n=	n=	ADJ
chd-155	387	3	1	1	NUM
chd-155	387	4	2.69	2.69	NUM
chd-155	387	5	(	(	PUNCT
chd-155	387	6	0,3	0,3	NUM
chd-155	387	7	)	)	PUNCT
chd-155	387	8	0.557	0.557	NUM
chd-155	387	9	48	48	NUM
chd-155	387	10	1.17	1.17	NUM
chd-155	387	11	(	(	PUNCT
chd-155	387	12	0,3	0,3	NUM
chd-155	387	13	)	)	PUNCT
chd-155	387	14	0.591	0.591	NUM
chd-155	387	15	59	59	NUM
chd-155	387	16	2.83	2.83	NUM
chd-155	387	17	(	(	PUNCT
chd-155	387	18	0,3	0,3	NUM
chd-155	387	19	)	)	PUNCT
chd-155	387	20	0.585	0.585	NUM
chd-155	387	21	55	55	NUM
chd-155	387	22	1.18	1.18	NUM
chd-155	387	23	(	(	PUNCT
chd-155	387	24	0,2.88	0,2.88	X
chd-155	387	25	)	)	PUNCT
chd-155	387	26	0.104	0.104	NUM
chd-155	387	27	73	73	NUM
chd-155	387	28	2	2	NUM
chd-155	387	29	2.75	2.75	NUM
chd-155	387	30	(	(	PUNCT
chd-155	387	31	0.5,3	0.5,3	NOUN
chd-155	387	32	)	)	PUNCT
chd-155	387	33	44	44	NUM
chd-155	387	34	1.2	1.2	NUM
chd-155	387	35	(	(	PUNCT
chd-155	387	36	0,3	0,3	NUM
chd-155	387	37	)	)	PUNCT
chd-155	387	38	48	48	NUM
chd-155	387	39	2.75	2.75	NUM
chd-155	387	40	(	(	PUNCT
chd-155	387	41	0,3	0,3	NUM
chd-155	387	42	)	)	PUNCT
chd-155	387	43	57	57	NUM
chd-155	387	44	1.17	1.17	NUM
chd-155	387	45	(	(	PUNCT
chd-155	387	46	0,3	0,3	NUM
chd-155	387	47	)	)	PUNCT
chd-155	387	48	65	65	NUM
chd-155	387	49	3	3	NUM
chd-155	387	50	2.83	2.83	NUM
chd-155	387	51	(	(	PUNCT
chd-155	387	52	0.17,3	0.17,3	NUM
chd-155	387	53	)	)	PUNCT
chd-155	387	54	15	15	NUM
chd-155	387	55	1.42	1.42	NUM
chd-155	387	56	(	(	PUNCT
chd-155	387	57	0.06,3	0.06,3	NUM
chd-155	387	58	)	)	PUNCT
chd-155	387	59	17	17	NUM
chd-155	387	60	2.75	2.75	NUM
chd-155	387	61	(	(	PUNCT
chd-155	387	62	1,3	1,3	NUM
chd-155	387	63	)	)	PUNCT
chd-155	387	64	17	17	NUM
chd-155	387	65	1.27	1.27	NUM
chd-155	387	66	(	(	PUNCT
chd-155	387	67	0.13,3	0.13,3	NOUN
chd-155	387	68	)	)	PUNCT
chd-155	387	69	22	22	NUM
chd-155	387	70	4	4	NUM
chd-155	387	71	2.96	2.96	NUM
chd-155	387	72	(	(	PUNCT
chd-155	387	73	1,3	1,3	NUM
chd-155	387	74	)	)	PUNCT
chd-155	387	75	18	18	NUM
chd-155	387	76	0.92	0.92	NUM
chd-155	387	77	(	(	PUNCT
chd-155	387	78	0,3	0,3	NUM
chd-155	387	79	)	)	PUNCT
chd-155	387	80	23	23	NUM
chd-155	387	81	2.75	2.75	NUM
chd-155	387	82	(	(	PUNCT
chd-155	387	83	0.5,3	0.5,3	NOUN
chd-155	387	84	)	)	PUNCT
chd-155	387	85	25	25	NUM
chd-155	387	86	1.33	1.33	NUM
chd-155	387	87	(	(	PUNCT
chd-155	387	88	0,3	0,3	NUM
chd-155	387	89	)	)	PUNCT
chd-155	387	90	27	27	NUM
chd-155	387	91	5	5	NUM
chd-155	387	92	2.79	2.79	NUM
chd-155	387	93	(	(	PUNCT
chd-155	387	94	0.75,3	0.75,3	PROPN
chd-155	387	95	)	)	PUNCT
chd-155	387	96	9	9	NUM
chd-155	387	97	1.17	1.17	NUM
chd-155	387	98	(	(	PUNCT
chd-155	387	99	0.25,3	0.25,3	NUM
chd-155	387	100	)	)	PUNCT
chd-155	387	101	10	10	NUM
chd-155	387	102	2.25	2.25	NUM
chd-155	387	103	(	(	PUNCT
chd-155	387	104	1.15,3	1.15,3	NUM
chd-155	387	105	)	)	PUNCT
chd-155	387	106	11	11	NUM
chd-155	387	107	0.73	0.73	NUM
chd-155	387	108	(	(	PUNCT
chd-155	387	109	0,2.5	0,2.5	PROPN
chd-155	387	110	)	)	PUNCT
chd-155	387	111	12	12	NUM
chd-155	387	112	grade	grade	NOUN
chd-155	387	113	group	group	NOUN
chd-155	387	114	nfκb	nfκb	NOUN
chd-155	387	115	.	.	PUNCT
chd-155	388	1	tumor	tumor	NOUN
chd-155	388	2	,	,	PUNCT
chd-155	388	3	median	median	NOUN
chd-155	388	4	(	(	PUNCT
chd-155	388	5	range	range	NOUN
chd-155	388	6	)	)	PUNCT
chd-155	388	7	p	p	PROPN
chd-155	388	8	n=	n=	ADJ
chd-155	388	9	nfκb	nfκb	NOUN
chd-155	388	10	.	.	PUNCT
chd-155	389	1	benign	benign	ADJ
chd-155	389	2	,	,	PUNCT
chd-155	389	3	median	median	ADJ
chd-155	389	4	(	(	PUNCT
chd-155	389	5	range	range	NOUN
chd-155	389	6	)	)	PUNCT
chd-155	389	7	p	p	PROPN
chd-155	389	8	n=	n=	ADJ
chd-155	389	9	nfκb	nfκb	NOUN
chd-155	389	10	.	.	PUNCT
chd-155	390	1	tumor	tumor	NOUN
chd-155	390	2	,	,	PUNCT
chd-155	390	3	median	median	NOUN
chd-155	390	4	(	(	PUNCT
chd-155	390	5	range	range	NOUN
chd-155	390	6	)	)	PUNCT
chd-155	390	7	p	p	PROPN
chd-155	390	8	n=	n=	ADJ
chd-155	390	9	nfκb	nfκb	NOUN
chd-155	390	10	.	.	PUNCT
chd-155	391	1	benign	benign	ADJ
chd-155	391	2	,	,	PUNCT
chd-155	391	3	median	median	ADJ
chd-155	391	4	(	(	PUNCT
chd-155	391	5	range	range	NOUN
chd-155	391	6	)	)	PUNCT
chd-155	392	1	p	p	NOUN
chd-155	392	2	n=	n=	ADJ
chd-155	392	3	1	1	NUM
chd-155	392	4	1.17	1.17	NUM
chd-155	392	5	(	(	PUNCT
chd-155	392	6	0,3	0,3	NUM
chd-155	392	7	)	)	PUNCT
chd-155	392	8	0.754	0.754	NUM
chd-155	392	9	48	48	NUM
chd-155	392	10	1.17	1.17	NUM
chd-155	392	11	(	(	PUNCT
chd-155	392	12	0,2.67	0,2.67	NOUN
chd-155	392	13	)	)	PUNCT
chd-155	392	14	0.912	0.912	NUM
chd-155	392	15	58	58	NUM
chd-155	392	16	1.33	1.33	NUM
chd-155	392	17	(	(	PUNCT
chd-155	392	18	0,3	0,3	NUM
chd-155	392	19	)	)	PUNCT
chd-155	392	20	0.122	0.122	NUM
chd-155	392	21	58	58	NUM
chd-155	392	22	0.81	0.81	NUM
chd-155	392	23	(	(	PUNCT
chd-155	392	24	0,2.5	0,2.5	PROPN
chd-155	392	25	)	)	PUNCT
chd-155	392	26	0.511	0.511	NUM
chd-155	392	27	72	72	NUM
chd-155	392	28	2	2	NUM
chd-155	392	29	1.33	1.33	NUM
chd-155	392	30	(	(	PUNCT
chd-155	392	31	0,3	0,3	NUM
chd-155	392	32	)	)	PUNCT
chd-155	392	33	41	41	NUM
chd-155	392	34	1	1	NUM
chd-155	392	35	(	(	PUNCT
chd-155	392	36	0,2.25	0,2.25	NUM
chd-155	392	37	)	)	PUNCT
chd-155	392	38	48	48	NUM
chd-155	392	39	1.21	1.21	NUM
chd-155	392	40	(	(	PUNCT
chd-155	392	41	0,3	0,3	NUM
chd-155	392	42	)	)	PUNCT
chd-155	392	43	60	60	NUM
chd-155	392	44	0.75	0.75	NUM
chd-155	392	45	(	(	PUNCT
chd-155	392	46	0,2.5	0,2.5	PROPN
chd-155	392	47	)	)	PUNCT
chd-155	392	48	65	65	NUM
chd-155	392	49	3	3	NUM
chd-155	392	50	1.6	1.6	NUM
chd-155	392	51	(	(	PUNCT
chd-155	392	52	0,3	0,3	NUM
chd-155	392	53	)	)	PUNCT
chd-155	392	54	15	15	NUM
chd-155	392	55	1.42	1.42	NUM
chd-155	392	56	(	(	PUNCT
chd-155	392	57	0,2.33	0,2.33	NUM
chd-155	392	58	)	)	PUNCT
chd-155	392	59	17	17	NUM
chd-155	392	60	1.25	1.25	NUM
chd-155	392	61	(	(	PUNCT
chd-155	392	62	0,3	0,3	NUM
chd-155	392	63	)	)	PUNCT
chd-155	392	64	17	17	NUM
chd-155	392	65	0.98	0.98	NUM
chd-155	392	66	(	(	PUNCT
chd-155	392	67	0,2.12	0,2.12	NOUN
chd-155	392	68	)	)	PUNCT
chd-155	392	69	22	22	NUM
chd-155	392	70	4	4	NUM
chd-155	392	71	1.75	1.75	NUM
chd-155	392	72	(	(	PUNCT
chd-155	392	73	0,2.88	0,2.88	NOUN
chd-155	392	74	)	)	PUNCT
chd-155	392	75	21	21	NUM
chd-155	392	76	1.25	1.25	NUM
chd-155	392	77	(	(	PUNCT
chd-155	392	78	0,3	0,3	NUM
chd-155	392	79	)	)	PUNCT
chd-155	392	80	23	23	NUM
chd-155	392	81	1.5	1.5	NUM
chd-155	392	82	(	(	PUNCT
chd-155	392	83	0,2.92	0,2.92	NUM
chd-155	392	84	)	)	PUNCT
chd-155	392	85	27	27	NUM
chd-155	392	86	1.25	1.25	NUM
chd-155	392	87	(	(	PUNCT
chd-155	392	88	0,2.08	0,2.08	NOUN
chd-155	392	89	)	)	PUNCT
chd-155	392	90	27	27	NUM
chd-155	392	91	5	5	NUM
chd-155	392	92	1.25	1.25	NUM
chd-155	392	93	(	(	PUNCT
chd-155	392	94	0.36,3	0.36,3	NOUN
chd-155	392	95	)	)	PUNCT
chd-155	392	96	10	10	NUM
chd-155	392	97	1.23	1.23	NUM
chd-155	392	98	(	(	PUNCT
chd-155	392	99	0,1.8	0,1.8	NUM
chd-155	392	100	)	)	PUNCT
chd-155	392	101	9	9	NUM
chd-155	392	102	2.31	2.31	NUM
chd-155	392	103	(	(	PUNCT
chd-155	392	104	0.17,3	0.17,3	NUM
chd-155	392	105	)	)	PUNCT
chd-155	392	106	12	12	NUM
chd-155	392	107	1.12	1.12	NUM
chd-155	392	108	(	(	PUNCT
chd-155	392	109	0,2.83	0,2.83	NUM
chd-155	392	110	)	)	PUNCT
chd-155	392	111	12	12	NUM
chd-155	392	112	johns	johns	PROPN
chd-155	392	113	hopkins	hopkins	PROPN
chd-155	392	114	african	african	PROPN
chd-155	392	115	-	-	PUNCT
chd-155	392	116	american	american	ADJ
chd-155	392	117	white	white	PROPN
chd-155	392	118	american	american	PROPN
chd-155	392	119	grade	grade	PROPN
chd-155	392	120	group	group	NOUN
chd-155	392	121	gdf15	gdf15	PROPN
chd-155	392	122	.	.	PUNCT
chd-155	393	1	tumor	tumor	NOUN
chd-155	393	2	,	,	PUNCT
chd-155	393	3	median	median	NOUN
chd-155	393	4	(	(	PUNCT
chd-155	393	5	range	range	NOUN
chd-155	393	6	)	)	PUNCT
chd-155	393	7	p	p	NOUN
chd-155	393	8	n=	n=	ADJ
chd-155	393	9	gdf15	gdf15	NOUN
chd-155	393	10	.	.	PUNCT
chd-155	394	1	benign	benign	ADJ
chd-155	394	2	,	,	PUNCT
chd-155	394	3	median	median	ADJ
chd-155	394	4	(	(	PUNCT
chd-155	394	5	range	range	NOUN
chd-155	394	6	)	)	PUNCT
chd-155	394	7	p	p	NOUN
chd-155	394	8	n=	n=	ADJ
chd-155	394	9	gdf15	gdf15	NOUN
chd-155	394	10	.	.	PUNCT
chd-155	395	1	tumor	tumor	NOUN
chd-155	395	2	,	,	PUNCT
chd-155	395	3	median	median	NOUN
chd-155	395	4	(	(	PUNCT
chd-155	395	5	range	range	NOUN
chd-155	395	6	)	)	PUNCT
chd-155	395	7	p	p	NOUN
chd-155	395	8	n=	n=	ADJ
chd-155	395	9	gdf15	gdf15	NOUN
chd-155	395	10	.	.	PUNCT
chd-155	396	1	benign	benign	ADJ
chd-155	396	2	,	,	PUNCT
chd-155	396	3	median	median	ADJ
chd-155	396	4	(	(	PUNCT
chd-155	396	5	range	range	NOUN
chd-155	396	6	)	)	PUNCT
chd-155	397	1	p	p	NOUN
chd-155	397	2	n=	n=	ADJ
chd-155	397	3	1	1	NUM
chd-155	397	4	2.38	2.38	NUM
chd-155	397	5	(	(	PUNCT
chd-155	397	6	0.5,3	0.5,3	PROPN
chd-155	397	7	)	)	PUNCT
chd-155	397	8	0.867	0.867	NUM
chd-155	397	9	56	56	NUM
chd-155	397	10	1	1	NUM
chd-155	397	11	(	(	PUNCT
chd-155	397	12	0,2.56	0,2.56	NOUN
chd-155	397	13	)	)	PUNCT
chd-155	397	14	0.872	0.872	NUM
chd-155	397	15	56	56	NUM
chd-155	397	16	1.81	1.81	NUM
chd-155	397	17	(	(	PUNCT
chd-155	397	18	0,3	0,3	NUM
chd-155	397	19	)	)	PUNCT
chd-155	397	20	0.174	0.174	NUM
chd-155	397	21	56	56	NUM
chd-155	397	22	1	1	NUM
chd-155	397	23	(	(	PUNCT
chd-155	397	24	0,2.5	0,2.5	PROPN
chd-155	397	25	)	)	PUNCT
chd-155	397	26	0.007	0.007	NUM
chd-155	397	27	56	56	NUM
chd-155	397	28	2	2	NUM
chd-155	397	29	2.5	2.5	NUM
chd-155	397	30	(	(	PUNCT
chd-155	397	31	0.5,3	0.5,3	PROPN
chd-155	397	32	)	)	PUNCT
chd-155	397	33	41	41	NUM
chd-155	397	34	1.21	1.21	NUM
chd-155	397	35	(	(	PUNCT
chd-155	397	36	0,2.56	0,2.56	NOUN
chd-155	397	37	)	)	PUNCT
chd-155	397	38	41	41	NUM
chd-155	397	39	1.5	1.5	NUM
chd-155	397	40	(	(	PUNCT
chd-155	397	41	0,3	0,3	NUM
chd-155	397	42	)	)	PUNCT
chd-155	397	43	39	39	NUM
chd-155	397	44	0.63	0.63	NUM
chd-155	397	45	(	(	PUNCT
chd-155	397	46	0,2.5	0,2.5	PROPN
chd-155	397	47	)	)	PUNCT
chd-155	397	48	40	40	NUM
chd-155	397	49	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-155	397	50	e20	e20	NOUN
chd-155	397	51	cancer	cancer	NOUN
chd-155	397	52	health	health	NOUN
chd-155	397	53	disparities	disparity	NOUN
chd-155	397	54	research	research	VERB
chd-155	397	55	3	3	NUM
chd-155	397	56	2.5	2.5	NUM
chd-155	397	57	(	(	PUNCT
chd-155	397	58	0.5,3	0.5,3	NOUN
chd-155	397	59	)	)	PUNCT
chd-155	397	60	13	13	NUM
chd-155	397	61	1.06	1.06	NUM
chd-155	397	62	(	(	PUNCT
chd-155	397	63	0,2.56	0,2.56	NUM
chd-155	397	64	)	)	PUNCT
chd-155	397	65	13	13	NUM
chd-155	397	66	2.25	2.25	NUM
chd-155	397	67	(	(	PUNCT
chd-155	397	68	0.5,3	0.5,3	NOUN
chd-155	397	69	)	)	PUNCT
chd-155	397	70	13	13	NUM
chd-155	397	71	1.5	1.5	NUM
chd-155	397	72	(	(	PUNCT
chd-155	397	73	0,2.5	0,2.5	NOUN
chd-155	397	74	)	)	PUNCT
chd-155	397	75	13	13	NUM
chd-155	397	76	4	4	NUM
chd-155	397	77	2.53	2.53	NUM
chd-155	397	78	(	(	PUNCT
chd-155	397	79	2.12,2.83	2.12,2.83	NUM
chd-155	397	80	)	)	PUNCT
chd-155	397	81	4	4	NUM
chd-155	397	82	0.74	0.74	NUM
chd-155	397	83	(	(	PUNCT
chd-155	397	84	0.67,2.35	0.67,2.35	NOUN
chd-155	397	85	)	)	PUNCT
chd-155	397	86	4	4	NUM
chd-155	397	87	2.44(2.06,2.81	2.44(2.06,2.81	NUM
chd-155	397	88	)	)	PUNCT
chd-155	397	89	5	5	NUM
chd-155	397	90	1.81	1.81	NUM
chd-155	397	91	(	(	PUNCT
chd-155	397	92	1,2.56	1,2.56	NUM
chd-155	397	93	)	)	PUNCT
chd-155	397	94	5	5	NUM
chd-155	397	95	5	5	NUM
chd-155	397	96	2.38	2.38	NUM
chd-155	397	97	(	(	PUNCT
chd-155	397	98	0.88,2.94	0.88,2.94	NOUN
chd-155	397	99	)	)	PUNCT
chd-155	397	100	23	23	NUM
chd-155	397	101	1.44	1.44	NUM
chd-155	397	102	(	(	PUNCT
chd-155	397	103	0.38,2.38	0.38,2.38	NOUN
chd-155	397	104	)	)	PUNCT
chd-155	397	105	23	23	NUM
chd-155	397	106	1.88	1.88	NUM
chd-155	397	107	(	(	PUNCT
chd-155	397	108	0.5,3	0.5,3	NOUN
chd-155	397	109	)	)	PUNCT
chd-155	397	110	22	22	NUM
chd-155	397	111	1.34	1.34	NUM
chd-155	397	112	(	(	PUNCT
chd-155	397	113	0.25,2.6	0.25,2.6	NOUN
chd-155	397	114	)	)	PUNCT
chd-155	397	115	22	22	NUM
chd-155	397	116	grade	grade	NOUN
chd-155	397	117	group	group	NOUN
chd-155	397	118	nfκb	nfκb	NOUN
chd-155	397	119	.	.	PUNCT
chd-155	398	1	tumor	tumor	NOUN
chd-155	398	2	,	,	PUNCT
chd-155	398	3	median	median	NOUN
chd-155	398	4	(	(	PUNCT
chd-155	398	5	range	range	NOUN
chd-155	398	6	)	)	PUNCT
chd-155	398	7	p	p	PROPN
chd-155	398	8	n=	n=	ADJ
chd-155	398	9	nfκb	nfκb	NOUN
chd-155	398	10	.	.	PUNCT
chd-155	399	1	benign	benign	ADJ
chd-155	399	2	,	,	PUNCT
chd-155	399	3	median	median	ADJ
chd-155	399	4	(	(	PUNCT
chd-155	399	5	range	range	NOUN
chd-155	399	6	)	)	PUNCT
chd-155	399	7	p	p	PROPN
chd-155	399	8	n=	n=	ADJ
chd-155	399	9	nfκb	nfκb	NOUN
chd-155	399	10	.	.	PUNCT
chd-155	400	1	tumor	tumor	NOUN
chd-155	400	2	,	,	PUNCT
chd-155	400	3	median	median	NOUN
chd-155	400	4	(	(	PUNCT
chd-155	400	5	range	range	NOUN
chd-155	400	6	)	)	PUNCT
chd-155	400	7	p	p	PROPN
chd-155	400	8	n=	n=	ADJ
chd-155	400	9	nfκb	nfκb	NOUN
chd-155	400	10	.	.	PUNCT
chd-155	401	1	benign	benign	ADJ
chd-155	401	2	,	,	PUNCT
chd-155	401	3	median	median	ADJ
chd-155	401	4	(	(	PUNCT
chd-155	401	5	range	range	NOUN
chd-155	401	6	)	)	PUNCT
chd-155	402	1	p	p	NOUN
chd-155	402	2	n=	n=	ADJ
chd-155	402	3	1	1	NUM
chd-155	402	4	1	1	NUM
chd-155	402	5	(	(	PUNCT
chd-155	402	6	0,2.42	0,2.42	NUM
chd-155	402	7	)	)	PUNCT
chd-155	402	8	0.019	0.019	NUM
chd-155	402	9	55	55	NUM
chd-155	402	10	0.33	0.33	NUM
chd-155	402	11	(	(	PUNCT
chd-155	402	12	0,2.38	0,2.38	NOUN
chd-155	402	13	)	)	PUNCT
chd-155	402	14	<	<	X
chd-155	402	15	0.00	0.00	NUM
chd-155	402	16	01	01	NUM
chd-155	402	17	56	56	NUM
chd-155	402	18	1.5	1.5	NUM
chd-155	402	19	(	(	PUNCT
chd-155	402	20	0.38,3	0.38,3	NOUN
chd-155	402	21	)	)	PUNCT
chd-155	402	22	0.034	0.034	NUM
chd-155	402	23	55	55	NUM
chd-155	402	24	0.5	0.5	NUM
chd-155	402	25	(	(	PUNCT
chd-155	402	26	0,1.75	0,1.75	X
chd-155	402	27	)	)	PUNCT
chd-155	402	28	<	<	X
chd-155	402	29	0.000	0.000	NUM
chd-155	402	30	1	1	NUM
chd-155	402	31	56	56	NUM
chd-155	402	32	2	2	NUM
chd-155	402	33	1.19	1.19	NUM
chd-155	402	34	(	(	PUNCT
chd-155	402	35	0,2.81	0,2.81	NUM
chd-155	402	36	)	)	PUNCT
chd-155	402	37	41	41	NUM
chd-155	402	38	0.42	0.42	NUM
chd-155	402	39	(	(	PUNCT
chd-155	402	40	0.08,1.81	0.08,1.81	NOUN
chd-155	402	41	)	)	PUNCT
chd-155	402	42	41	41	NUM
chd-155	402	43	1.5	1.5	NUM
chd-155	402	44	(	(	PUNCT
chd-155	402	45	0.44,2.88	0.44,2.88	NOUN
chd-155	402	46	)	)	PUNCT
chd-155	402	47	39	39	NUM
chd-155	402	48	0.44	0.44	NUM
chd-155	402	49	(	(	PUNCT
chd-155	402	50	0,2.12	0,2.12	NOUN
chd-155	402	51	)	)	PUNCT
chd-155	402	52	40	40	NUM
chd-155	402	53	3	3	NUM
chd-155	402	54	1.62	1.62	NUM
chd-155	402	55	(	(	PUNCT
chd-155	402	56	0.25,2.69	0.25,2.69	NOUN
chd-155	402	57	)	)	PUNCT
chd-155	402	58	13	13	NUM
chd-155	402	59	0.75	0.75	NUM
chd-155	402	60	(	(	PUNCT
chd-155	402	61	0.1,2.08	0.1,2.08	NUM
chd-155	402	62	)	)	PUNCT
chd-155	402	63	13	13	NUM
chd-155	402	64	1.38(0.75,2.69	1.38(0.75,2.69	NUM
chd-155	402	65	)	)	PUNCT
chd-155	402	66	13	13	NUM
chd-155	402	67	0.88	0.88	NUM
chd-155	402	68	(	(	PUNCT
chd-155	402	69	0.25,2.5	0.25,2.5	NOUN
chd-155	402	70	)	)	PUNCT
chd-155	402	71	13	13	NUM
chd-155	402	72	4	4	NUM
chd-155	402	73	1.81	1.81	NUM
chd-155	402	74	(	(	PUNCT
chd-155	402	75	0.83,2.94	0.83,2.94	NUM
chd-155	402	76	)	)	PUNCT
chd-155	402	77	4	4	NUM
chd-155	402	78	1.24	1.24	NUM
chd-155	402	79	(	(	PUNCT
chd-155	402	80	0.75,1.62	0.75,1.62	NOUN
chd-155	402	81	)	)	PUNCT
chd-155	402	82	4	4	NUM
chd-155	402	83	1.62	1.62	NUM
chd-155	402	84	(	(	PUNCT
chd-155	402	85	0.69,2	0.69,2	NOUN
chd-155	402	86	)	)	PUNCT
chd-155	402	87	5	5	NUM
chd-155	402	88	1.06	1.06	NUM
chd-155	402	89	(	(	PUNCT
chd-155	402	90	0.58,1.69	0.58,1.69	NUM
chd-155	402	91	)	)	PUNCT
chd-155	402	92	5	5	NUM
chd-155	402	93	5	5	NUM
chd-155	402	94	1.81	1.81	NUM
chd-155	402	95	(	(	PUNCT
chd-155	402	96	0.25,2.69	0.25,2.69	NOUN
chd-155	402	97	)	)	PUNCT
chd-155	402	98	23	23	NUM
chd-155	402	99	1.28	1.28	NUM
chd-155	402	100	(	(	PUNCT
chd-155	402	101	0.38,2.52	0.38,2.52	NUM
chd-155	402	102	)	)	PUNCT
chd-155	402	103	23	23	NUM
chd-155	402	104	2.12(0.81,2.81	2.12(0.81,2.81	NUM
chd-155	402	105	)	)	PUNCT
chd-155	402	106	22	22	NUM
chd-155	402	107	1.31	1.31	NUM
chd-155	402	108	(	(	PUNCT
chd-155	402	109	0.58,2.25	0.58,2.25	NUM
chd-155	402	110	)	)	PUNCT
chd-155	402	111	22	22	NUM
chd-155	402	112	medical	medical	ADJ
chd-155	402	113	college	college	PROPN
chd-155	402	114	of	of	ADP
chd-155	402	115	wisconsin	wisconsin	PROPN
chd-155	402	116	(	(	PUNCT
chd-155	402	117	mcw	mcw	PROPN
chd-155	402	118	)	)	PUNCT
chd-155	402	119	african	african	ADJ
chd-155	402	120	-	-	PUNCT
chd-155	402	121	american	american	ADJ
chd-155	402	122	white	white	PROPN
chd-155	402	123	american	american	PROPN
chd-155	402	124	grade	grade	PROPN
chd-155	402	125	group	group	NOUN
chd-155	402	126	gdf15	gdf15	PROPN
chd-155	402	127	.	.	PUNCT
chd-155	403	1	tumor	tumor	NOUN
chd-155	403	2	,	,	PUNCT
chd-155	403	3	median	median	NOUN
chd-155	403	4	(	(	PUNCT
chd-155	403	5	range	range	NOUN
chd-155	403	6	)	)	PUNCT
chd-155	403	7	p	p	NOUN
chd-155	403	8	n=	n=	ADJ
chd-155	403	9	gdf15	gdf15	NOUN
chd-155	403	10	.	.	PUNCT
chd-155	404	1	benign	benign	ADJ
chd-155	404	2	,	,	PUNCT
chd-155	404	3	median	median	ADJ
chd-155	404	4	(	(	PUNCT
chd-155	404	5	range	range	NOUN
chd-155	404	6	)	)	PUNCT
chd-155	404	7	p	p	NOUN
chd-155	404	8	n=	n=	ADJ
chd-155	404	9	gdf15	gdf15	NOUN
chd-155	404	10	.	.	PUNCT
chd-155	405	1	tumor	tumor	NOUN
chd-155	405	2	,	,	PUNCT
chd-155	405	3	median	median	NOUN
chd-155	405	4	(	(	PUNCT
chd-155	405	5	range	range	NOUN
chd-155	405	6	)	)	PUNCT
chd-155	405	7	p	p	NOUN
chd-155	405	8	n=	n=	ADJ
chd-155	405	9	gdf15	gdf15	NOUN
chd-155	405	10	.	.	PUNCT
chd-155	406	1	benign	benign	ADJ
chd-155	406	2	,	,	PUNCT
chd-155	406	3	median	median	ADJ
chd-155	406	4	(	(	PUNCT
chd-155	406	5	range	range	NOUN
chd-155	406	6	)	)	PUNCT
chd-155	407	1	p	p	NOUN
chd-155	407	2	n=	n=	ADJ
chd-155	407	3	1	1	NUM
chd-155	407	4	1.5	1.5	NUM
chd-155	407	5	(	(	PUNCT
chd-155	407	6	1.5,2	1.5,2	NOUN
chd-155	407	7	)	)	PUNCT
chd-155	407	8	0.512	0.512	NUM
chd-155	407	9	3	3	NUM
chd-155	407	10	0.5	0.5	NUM
chd-155	407	11	(	(	PUNCT
chd-155	407	12	0,1	0,1	NUM
chd-155	407	13	)	)	PUNCT
chd-155	407	14	0.867	0.867	NUM
chd-155	407	15	3	3	NUM
chd-155	407	16	1	1	NUM
chd-155	407	17	(	(	PUNCT
chd-155	407	18	0.5,1	0.5,1	NOUN
chd-155	407	19	)	)	PUNCT
chd-155	407	20	0.127	0.127	NUM
chd-155	407	21	3	3	NUM
chd-155	407	22	1	1	NUM
chd-155	407	23	(	(	PUNCT
chd-155	407	24	0,1	0,1	NUM
chd-155	407	25	)	)	PUNCT
chd-155	407	26	0.757	0.757	NUM
chd-155	407	27	3	3	NUM
chd-155	407	28	2	2	NUM
chd-155	407	29	2	2	NUM
chd-155	407	30	(	(	PUNCT
chd-155	407	31	1,3	1,3	NUM
chd-155	407	32	)	)	PUNCT
chd-155	407	33	8	8	NUM
chd-155	407	34	0.75	0.75	NUM
chd-155	407	35	(	(	PUNCT
chd-155	407	36	0,1.5	0,1.5	NOUN
chd-155	407	37	)	)	PUNCT
chd-155	407	38	8	8	NUM
chd-155	407	39	1	1	NUM
chd-155	407	40	(	(	PUNCT
chd-155	407	41	0.5,1.5	0.5,1.5	PROPN
chd-155	407	42	)	)	PUNCT
chd-155	407	43	8	8	NUM
chd-155	407	44	0.5	0.5	NUM
chd-155	407	45	(	(	PUNCT
chd-155	407	46	0,2.5	0,2.5	NOUN
chd-155	407	47	)	)	PUNCT
chd-155	407	48	8	8	NUM
chd-155	407	49	3	3	NUM
chd-155	407	50	2.42	2.42	NUM
chd-155	407	51	(	(	PUNCT
chd-155	407	52	0.67,3	0.67,3	NOUN
chd-155	407	53	)	)	PUNCT
chd-155	407	54	14	14	NUM
chd-155	407	55	0.94	0.94	NUM
chd-155	407	56	(	(	PUNCT
chd-155	407	57	0,1.5	0,1.5	PROPN
chd-155	407	58	)	)	PUNCT
chd-155	407	59	14	14	NUM
chd-155	407	60	2.17	2.17	NUM
chd-155	407	61	(	(	PUNCT
chd-155	407	62	0,3	0,3	NUM
chd-155	407	63	)	)	PUNCT
chd-155	407	64	15	15	NUM
chd-155	407	65	1	1	NUM
chd-155	407	66	(	(	PUNCT
chd-155	407	67	0,2.5	0,2.5	PROPN
chd-155	407	68	)	)	PUNCT
chd-155	407	69	15	15	NUM
chd-155	407	70	4	4	NUM
chd-155	407	71	--	--	PUNCT
chd-155	407	72	0	0	NUM
chd-155	407	73	--	--	SYM
chd-155	407	74	0	0	NUM
chd-155	407	75	--	--	PUNCT
chd-155	407	76	0	0	NUM
chd-155	407	77	--	--	SYM
chd-155	407	78	0	0	NUM
chd-155	407	79	5	5	NUM
chd-155	407	80	1.83	1.83	NUM
chd-155	407	81	(	(	PUNCT
chd-155	407	82	1.5,2.17	1.5,2.17	NUM
chd-155	407	83	)	)	PUNCT
chd-155	407	84	4	4	NUM
chd-155	407	85	0.56	0.56	NUM
chd-155	407	86	(	(	PUNCT
chd-155	407	87	0,2.33	0,2.33	NOUN
chd-155	407	88	)	)	PUNCT
chd-155	407	89	4	4	NUM
chd-155	407	90	0.5	0.5	NUM
chd-155	407	91	(	(	PUNCT
chd-155	407	92	0.5,0.5	0.5,0.5	PROPN
chd-155	407	93	)	)	PUNCT
chd-155	407	94	1	1	NUM
chd-155	407	95	0.5	0.5	NUM
chd-155	407	96	(	(	PUNCT
chd-155	407	97	0.5,0.5	0.5,0.5	PROPN
chd-155	407	98	)	)	PUNCT
chd-155	407	99	1	1	NUM
chd-155	407	100	grade	grade	NOUN
chd-155	407	101	group	group	NOUN
chd-155	407	102	nfκb	nfκb	NOUN
chd-155	407	103	.	.	PUNCT
chd-155	408	1	tumor	tumor	NOUN
chd-155	408	2	,	,	PUNCT
chd-155	408	3	median	median	NOUN
chd-155	408	4	(	(	PUNCT
chd-155	408	5	range	range	NOUN
chd-155	408	6	)	)	PUNCT
chd-155	408	7	p	p	PROPN
chd-155	408	8	n=	n=	ADJ
chd-155	408	9	nfκb	nfκb	NOUN
chd-155	408	10	.	.	PUNCT
chd-155	409	1	benign	benign	ADJ
chd-155	409	2	,	,	PUNCT
chd-155	409	3	median	median	ADJ
chd-155	409	4	(	(	PUNCT
chd-155	409	5	range	range	NOUN
chd-155	409	6	)	)	PUNCT
chd-155	409	7	p	p	PROPN
chd-155	409	8	n=	n=	ADJ
chd-155	409	9	nfκb	nfκb	NOUN
chd-155	409	10	.	.	PUNCT
chd-155	410	1	tumor	tumor	NOUN
chd-155	410	2	,	,	PUNCT
chd-155	410	3	median	median	NOUN
chd-155	410	4	(	(	PUNCT
chd-155	410	5	range	range	NOUN
chd-155	410	6	)	)	PUNCT
chd-155	410	7	p	p	PROPN
chd-155	410	8	n=	n=	ADJ
chd-155	410	9	nfκb	nfκb	NOUN
chd-155	410	10	.	.	PUNCT
chd-155	411	1	benign	benign	ADJ
chd-155	411	2	,	,	PUNCT
chd-155	411	3	median	median	ADJ
chd-155	411	4	(	(	PUNCT
chd-155	411	5	range	range	NOUN
chd-155	411	6	)	)	PUNCT
chd-155	412	1	p	p	NOUN
chd-155	412	2	n=	n=	ADJ
chd-155	412	3	1	1	NUM
chd-155	412	4	1	1	NUM
chd-155	412	5	(	(	PUNCT
chd-155	412	6	0.75,1.5	0.75,1.5	NOUN
chd-155	412	7	)	)	PUNCT
chd-155	412	8	0.005	0.005	NUM
chd-155	412	9	3	3	NUM
chd-155	412	10	1.25	1.25	NUM
chd-155	412	11	(	(	PUNCT
chd-155	412	12	0.8,1.8	0.8,1.8	PROPN
chd-155	412	13	)	)	PUNCT
chd-155	412	14	0.010	0.010	NUM
chd-155	412	15	3	3	NUM
chd-155	412	16	2.33	2.33	NUM
chd-155	412	17	(	(	PUNCT
chd-155	412	18	1.67,3	1.67,3	NUM
chd-155	412	19	)	)	PUNCT
chd-155	412	20	0.559	0.559	NUM
chd-155	412	21	2	2	NUM
chd-155	412	22	1.5	1.5	NUM
chd-155	412	23	(	(	PUNCT
chd-155	412	24	1.5,1.5	1.5,1.5	PROPN
chd-155	412	25	)	)	PUNCT
chd-155	412	26	0.078	0.078	NUM
chd-155	412	27	3	3	NUM
chd-155	412	28	2	2	NUM
chd-155	412	29	1.5	1.5	NUM
chd-155	412	30	(	(	PUNCT
chd-155	412	31	1,2.83	1,2.83	NUM
chd-155	412	32	)	)	PUNCT
chd-155	412	33	8	8	NUM
chd-155	412	34	1.5	1.5	NUM
chd-155	412	35	(	(	PUNCT
chd-155	412	36	0.17,2	0.17,2	NOUN
chd-155	412	37	)	)	PUNCT
chd-155	412	38	8	8	NUM
chd-155	412	39	1.69	1.69	NUM
chd-155	412	40	(	(	PUNCT
chd-155	412	41	1,2.75	1,2.75	NUM
chd-155	412	42	)	)	PUNCT
chd-155	412	43	8	8	NUM
chd-155	412	44	1.23	1.23	NUM
chd-155	412	45	(	(	PUNCT
chd-155	412	46	0.75,2	0.75,2	NOUN
chd-155	412	47	)	)	PUNCT
chd-155	412	48	8	8	NUM
chd-155	412	49	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-155	412	50	e21	e21	NUM
chd-155	412	51	cancer	cancer	NOUN
chd-155	412	52	health	health	NOUN
chd-155	412	53	disparities	disparity	NOUN
chd-155	412	54	research	research	VERB
chd-155	412	55	3	3	NUM
chd-155	412	56	2.17	2.17	NUM
chd-155	412	57	(	(	PUNCT
chd-155	412	58	1,3	1,3	NUM
chd-155	412	59	)	)	PUNCT
chd-155	412	60	14	14	NUM
chd-155	412	61	2	2	NUM
chd-155	412	62	(	(	PUNCT
chd-155	412	63	1.4,3	1.4,3	NUM
chd-155	412	64	)	)	PUNCT
chd-155	412	65	14	14	NUM
chd-155	412	66	2	2	NUM
chd-155	412	67	(	(	PUNCT
chd-155	412	68	0,2.5	0,2.5	NOUN
chd-155	412	69	)	)	PUNCT
chd-155	412	70	15	15	NUM
chd-155	412	71	2	2	NUM
chd-155	412	72	(	(	PUNCT
chd-155	412	73	0.5,3	0.5,3	NOUN
chd-155	412	74	)	)	PUNCT
chd-155	412	75	15	15	NUM
chd-155	412	76	4	4	NUM
chd-155	412	77	--	--	PUNCT
chd-155	412	78	0	0	NUM
chd-155	412	79	--	--	SYM
chd-155	412	80	0	0	NUM
chd-155	412	81	--	--	PUNCT
chd-155	412	82	0	0	NUM
chd-155	412	83	--	--	SYM
chd-155	412	84	0	0	NUM
chd-155	412	85	5	5	NUM
chd-155	412	86	2.5	2.5	NUM
chd-155	412	87	(	(	PUNCT
chd-155	412	88	2.33,2.62	2.33,2.62	NUM
chd-155	412	89	)	)	PUNCT
chd-155	412	90	4	4	NUM
chd-155	412	91	2.17	2.17	NUM
chd-155	412	92	(	(	PUNCT
chd-155	412	93	1.4,2.83	1.4,2.83	NUM
chd-155	412	94	)	)	PUNCT
chd-155	412	95	4	4	NUM
chd-155	412	96	2.25	2.25	NUM
chd-155	412	97	(	(	PUNCT
chd-155	412	98	2.25,2.25	2.25,2.25	NUM
chd-155	412	99	)	)	PUNCT
chd-155	412	100	1	1	NUM
chd-155	412	101	1.83	1.83	NUM
chd-155	412	102	(	(	PUNCT
chd-155	412	103	1.83,1.83	1.83,1.83	NUM
chd-155	412	104	)	)	PUNCT
chd-155	412	105	1	1	NUM
chd-155	412	106	n=	n=	ADJ
chd-155	412	107	number	number	NOUN
chd-155	412	108	of	of	ADP
chd-155	412	109	informative	informative	ADJ
chd-155	412	110	cases	case	NOUN
chd-155	412	111	supplemental	supplemental	ADJ
chd-155	412	112	table	table	NOUN
chd-155	412	113	5	5	NUM
chd-155	412	114	.	.	PUNCT
chd-155	412	115	racial	racial	ADJ
chd-155	412	116	disparity	disparity	NOUN
chd-155	412	117	of	of	ADP
chd-155	412	118	expression	expression	NOUN
chd-155	412	119	of	of	ADP
chd-155	412	120	gdf15	gdf15	NOUN
chd-155	412	121	and	and	CCONJ
chd-155	412	122	nfκb	nfκb	NOUN
chd-155	412	123	according	accord	VERB
chd-155	412	124	to	to	ADP
chd-155	412	125	pathologic	pathologic	ADJ
chd-155	412	126	stage	stage	NOUN
chd-155	412	127	stratified	stratify	VERB
chd-155	412	128	by	by	ADP
chd-155	412	129	study	study	NOUN
chd-155	412	130	site	site	NOUN
chd-155	412	131	.	.	PUNCT
chd-155	413	1	henry	henry	PROPN
chd-155	413	2	ford	ford	PROPN
chd-155	413	3	african	african	PROPN
chd-155	413	4	-	-	PUNCT
chd-155	413	5	american	american	ADJ
chd-155	413	6	white	white	PROPN
chd-155	413	7	american	american	ADJ
chd-155	413	8	stage	stage	NOUN
chd-155	413	9	gdf15	gdf15	PROPN
chd-155	413	10	.	.	PUNCT
chd-155	414	1	tumor	tumor	NOUN
chd-155	414	2	,	,	PUNCT
chd-155	414	3	median	median	NOUN
chd-155	414	4	(	(	PUNCT
chd-155	414	5	range	range	NOUN
chd-155	414	6	)	)	PUNCT
chd-155	414	7	p	p	NOUN
chd-155	414	8	n=	n=	ADJ
chd-155	414	9	gdf15	gdf15	NOUN
chd-155	414	10	.	.	PUNCT
chd-155	415	1	benign	benign	ADJ
chd-155	415	2	,	,	PUNCT
chd-155	415	3	median	median	ADJ
chd-155	415	4	(	(	PUNCT
chd-155	415	5	range	range	NOUN
chd-155	415	6	)	)	PUNCT
chd-155	415	7	p	p	NOUN
chd-155	415	8	n=	n=	ADJ
chd-155	415	9	gdf15	gdf15	NOUN
chd-155	415	10	.	.	PUNCT
chd-155	416	1	tumor	tumor	NOUN
chd-155	416	2	,	,	PUNCT
chd-155	416	3	median	median	NOUN
chd-155	416	4	(	(	PUNCT
chd-155	416	5	range	range	NOUN
chd-155	416	6	)	)	PUNCT
chd-155	416	7	p	p	NOUN
chd-155	416	8	n=	n=	ADJ
chd-155	416	9	gdf15	gdf15	NOUN
chd-155	416	10	.	.	PUNCT
chd-155	417	1	benign	benign	ADJ
chd-155	417	2	,	,	PUNCT
chd-155	417	3	median	median	ADJ
chd-155	417	4	(	(	PUNCT
chd-155	417	5	range	range	NOUN
chd-155	417	6	)	)	PUNCT
chd-155	418	1	p	p	NOUN
chd-155	418	2	n=	n=	ADJ
chd-155	418	3	2	2	NUM
chd-155	418	4	2.83	2.83	NUM
chd-155	418	5	(	(	PUNCT
chd-155	418	6	0,3	0,3	NUM
chd-155	418	7	)	)	PUNCT
chd-155	418	8	0.528	0.528	NUM
chd-155	418	9	113	113	NUM
chd-155	418	10	1.21	1.21	NUM
chd-155	418	11	(	(	PUNCT
chd-155	418	12	0,3	0,3	NUM
chd-155	418	13	)	)	PUNCT
chd-155	418	14	0.080	0.080	NUM
chd-155	418	15	134	134	NUM
chd-155	418	16	2.82	2.82	NUM
chd-155	418	17	(	(	PUNCT
chd-155	418	18	0,3	0,3	NUM
chd-155	418	19	)	)	PUNCT
chd-155	418	20	0.009	0.009	NUM
chd-155	418	21	130	130	NUM
chd-155	418	22	1.25	1.25	NUM
chd-155	418	23	(	(	PUNCT
chd-155	418	24	0,3	0,3	NUM
chd-155	418	25	)	)	PUNCT
chd-155	418	26	0.042	0.042	NUM
chd-155	418	27	161	161	NUM
chd-155	418	28	3a	3a	NUM
chd-155	418	29	2.49	2.49	NUM
chd-155	418	30	(	(	PUNCT
chd-155	418	31	1.04,3	1.04,3	NUM
chd-155	418	32	)	)	PUNCT
chd-155	418	33	12	12	NUM
chd-155	418	34	0.9	0.9	NUM
chd-155	418	35	(	(	PUNCT
chd-155	418	36	0.06,1.7	0.06,1.7	ADJ
chd-155	418	37	)	)	PUNCT
chd-155	418	38	13	13	NUM
chd-155	418	39	2.79	2.79	NUM
chd-155	418	40	(	(	PUNCT
chd-155	418	41	0.167,3	0.167,3	PROPN
chd-155	418	42	)	)	PUNCT
chd-155	418	43	22	22	NUM
chd-155	418	44	0.787	0.787	NUM
chd-155	418	45	(	(	PUNCT
chd-155	418	46	0,3	0,3	NUM
chd-155	418	47	)	)	PUNCT
chd-155	418	48	24	24	NUM
chd-155	419	1	3b	3b	NOUN
chd-155	419	2	2.88	2.88	NUM
chd-155	419	3	(	(	PUNCT
chd-155	419	4	0.75,3	0.75,3	PROPN
chd-155	419	5	)	)	PUNCT
chd-155	419	6	8	8	NUM
chd-155	419	7	1.25	1.25	NUM
chd-155	419	8	(	(	PUNCT
chd-155	419	9	0.25,2.5	0.25,2.5	NOUN
chd-155	419	10	)	)	PUNCT
chd-155	419	11	9	9	NUM
chd-155	419	12	2.08	2.08	NUM
chd-155	419	13	(	(	PUNCT
chd-155	419	14	1.15,3	1.15,3	NUM
chd-155	419	15	)	)	PUNCT
chd-155	419	16	12	12	NUM
chd-155	419	17	1.12	1.12	NUM
chd-155	419	18	(	(	PUNCT
chd-155	419	19	0.35,2.5	0.35,2.5	NOUN
chd-155	419	20	)	)	PUNCT
chd-155	419	21	13	13	NUM
chd-155	419	22	4	4	NUM
chd-155	419	23	2.79	2.79	NUM
chd-155	419	24	(	(	PUNCT
chd-155	419	25	2.79,2.79	2.79,2.79	NUM
chd-155	419	26	)	)	PUNCT
chd-155	419	27	1	1	NUM
chd-155	419	28	1.94	1.94	NUM
chd-155	419	29	(	(	PUNCT
chd-155	419	30	1.94,1.94	1.94,1.94	NUM
chd-155	419	31	)	)	PUNCT
chd-155	419	32	1	1	NUM
chd-155	419	33	1.42(1.42,1.42	1.42(1.42,1.42	NUM
chd-155	419	34	)	)	PUNCT
chd-155	419	35	1	1	NUM
chd-155	419	36	0.19	0.19	NUM
chd-155	419	37	(	(	PUNCT
chd-155	419	38	0.19,0.19	0.19,0.19	NOUN
chd-155	419	39	)	)	PUNCT
chd-155	419	40	1	1	NUM
chd-155	419	41	stage	stage	NOUN
chd-155	419	42	nfκb	nfκb	NOUN
chd-155	419	43	.	.	PUNCT
chd-155	420	1	tumor	tumor	NOUN
chd-155	420	2	,	,	PUNCT
chd-155	420	3	median	median	NOUN
chd-155	420	4	(	(	PUNCT
chd-155	420	5	range	range	NOUN
chd-155	420	6	)	)	PUNCT
chd-155	420	7	p	p	PROPN
chd-155	420	8	n=	n=	ADJ
chd-155	420	9	nfκb	nfκb	NOUN
chd-155	420	10	.	.	PUNCT
chd-155	421	1	benign	benign	ADJ
chd-155	421	2	,	,	PUNCT
chd-155	421	3	median	median	ADJ
chd-155	421	4	(	(	PUNCT
chd-155	421	5	range	range	NOUN
chd-155	421	6	)	)	PUNCT
chd-155	421	7	p	p	PROPN
chd-155	421	8	n=	n=	ADJ
chd-155	421	9	nfκb	nfκb	NOUN
chd-155	421	10	.	.	PUNCT
chd-155	422	1	tumor	tumor	NOUN
chd-155	422	2	,	,	PUNCT
chd-155	422	3	median	median	NOUN
chd-155	422	4	(	(	PUNCT
chd-155	422	5	range	range	NOUN
chd-155	422	6	)	)	PUNCT
chd-155	422	7	p	p	PROPN
chd-155	422	8	n=	n=	ADJ
chd-155	422	9	nfκb	nfκb	NOUN
chd-155	422	10	.	.	PUNCT
chd-155	423	1	benign	benign	ADJ
chd-155	423	2	,	,	PUNCT
chd-155	423	3	median	median	ADJ
chd-155	423	4	(	(	PUNCT
chd-155	423	5	range	range	NOUN
chd-155	423	6	)	)	PUNCT
chd-155	424	1	p	p	NOUN
chd-155	424	2	n=	n=	ADJ
chd-155	424	3	2	2	NUM
chd-155	424	4	1.45	1.45	NUM
chd-155	424	5	(	(	PUNCT
chd-155	424	6	0,3	0,3	NUM
chd-155	424	7	)	)	PUNCT
chd-155	424	8	0.545	0.545	NUM
chd-155	424	9	115	115	NUM
chd-155	424	10	1.16	1.16	NUM
chd-155	424	11	(	(	PUNCT
chd-155	424	12	0,3	0,3	NUM
chd-155	424	13	)	)	PUNCT
chd-155	424	14	0.773	0.773	NUM
chd-155	424	15	114	114	NUM
chd-155	424	16	1.38	1.38	NUM
chd-155	424	17	(	(	PUNCT
chd-155	424	18	0,3	0,3	NUM
chd-155	424	19	)	)	PUNCT
chd-155	424	20	0.244	0.244	NUM
chd-155	424	21	138	138	NUM
chd-155	424	22	0.9	0.9	NUM
chd-155	424	23	(	(	PUNCT
chd-155	424	24	0,2.83	0,2.83	NUM
chd-155	424	25	)	)	PUNCT
chd-155	424	26	0.432	0.432	NUM
chd-155	424	27	160	160	NUM
chd-155	424	28	3a	3a	NUM
chd-155	424	29	0.92	0.92	NUM
chd-155	424	30	(	(	PUNCT
chd-155	424	31	0,3	0,3	NUM
chd-155	424	32	)	)	PUNCT
chd-155	424	33	11	11	NUM
chd-155	424	34	1.32	1.32	NUM
chd-155	424	35	(	(	PUNCT
chd-155	424	36	0,1.92	0,1.92	NOUN
chd-155	424	37	)	)	PUNCT
chd-155	424	38	11	11	NUM
chd-155	424	39	1.49	1.49	NUM
chd-155	424	40	(	(	PUNCT
chd-155	424	41	0,3	0,3	NUM
chd-155	424	42	)	)	PUNCT
chd-155	424	43	22	22	NUM
chd-155	424	44	0.71	0.71	NUM
chd-155	424	45	(	(	PUNCT
chd-155	424	46	0,2.5	0,2.5	NOUN
chd-155	424	47	)	)	PUNCT
chd-155	424	48	24	24	NUM
chd-155	424	49	3b	3b	NUM
chd-155	424	50	1.75	1.75	NUM
chd-155	424	51	(	(	PUNCT
chd-155	424	52	0,2.83	0,2.83	NUM
chd-155	424	53	)	)	PUNCT
chd-155	424	54	8	8	NUM
chd-155	424	55	0.91	0.91	NUM
chd-155	424	56	(	(	PUNCT
chd-155	424	57	0,1.75	0,1.75	NUM
chd-155	424	58	)	)	PUNCT
chd-155	424	59	8	8	NUM
chd-155	424	60	1.62	1.62	NUM
chd-155	424	61	(	(	PUNCT
chd-155	424	62	0.17,3	0.17,3	NUM
chd-155	424	63	)	)	PUNCT
chd-155	424	64	13	13	NUM
chd-155	424	65	1.25	1.25	NUM
chd-155	424	66	(	(	PUNCT
chd-155	424	67	0.13,2.08	0.13,2.08	NUM
chd-155	424	68	)	)	PUNCT
chd-155	424	69	13	13	NUM
chd-155	424	70	4	4	NUM
chd-155	424	71	0.36	0.36	NUM
chd-155	424	72	(	(	PUNCT
chd-155	424	73	0.36,0.36	0.36,0.36	NUM
chd-155	424	74	)	)	PUNCT
chd-155	424	75	1	1	NUM
chd-155	424	76	0.67	0.67	NUM
chd-155	424	77	(	(	PUNCT
chd-155	424	78	0.67,0.67	0.67,0.67	INTJ
chd-155	424	79	)	)	PUNCT
chd-155	424	80	1	1	NUM
chd-155	424	81	0	0	NUM
chd-155	424	82	(	(	PUNCT
chd-155	424	83	0,0	0,0	NOUN
chd-155	424	84	)	)	PUNCT
chd-155	424	85	1	1	NUM
chd-155	424	86	0.75	0.75	NUM
chd-155	424	87	(	(	PUNCT
chd-155	424	88	0.75,0.75	0.75,0.75	NUM
chd-155	424	89	)	)	PUNCT
chd-155	424	90	1	1	NUM
chd-155	424	91	johns	johns	PROPN
chd-155	424	92	hopkins	hopkins	PROPN
chd-155	424	93	african	african	PROPN
chd-155	424	94	-	-	PUNCT
chd-155	424	95	american	american	ADJ
chd-155	424	96	white	white	PROPN
chd-155	424	97	american	american	ADJ
chd-155	424	98	stage	stage	NOUN
chd-155	424	99	gdf15	gdf15	PROPN
chd-155	424	100	.	.	PUNCT
chd-155	425	1	tumor	tumor	NOUN
chd-155	425	2	,	,	PUNCT
chd-155	425	3	median	median	NOUN
chd-155	425	4	(	(	PUNCT
chd-155	425	5	range	range	NOUN
chd-155	425	6	)	)	PUNCT
chd-155	425	7	p	p	NOUN
chd-155	425	8	n=	n=	ADJ
chd-155	425	9	gdf15	gdf15	NOUN
chd-155	425	10	.	.	PUNCT
chd-155	426	1	benign	benign	ADJ
chd-155	426	2	,	,	PUNCT
chd-155	426	3	median	median	ADJ
chd-155	426	4	(	(	PUNCT
chd-155	426	5	range	range	NOUN
chd-155	426	6	)	)	PUNCT
chd-155	426	7	p	p	NOUN
chd-155	426	8	n=	n=	ADJ
chd-155	426	9	gdf15	gdf15	NOUN
chd-155	426	10	.	.	PUNCT
chd-155	427	1	tumor	tumor	NOUN
chd-155	427	2	,	,	PUNCT
chd-155	427	3	median	median	NOUN
chd-155	427	4	(	(	PUNCT
chd-155	427	5	range	range	NOUN
chd-155	427	6	)	)	PUNCT
chd-155	427	7	p	p	NOUN
chd-155	427	8	n=	n=	ADJ
chd-155	427	9	gdf15	gdf15	NOUN
chd-155	427	10	.	.	PUNCT
chd-155	428	1	benign	benign	ADJ
chd-155	428	2	,	,	PUNCT
chd-155	428	3	median	median	ADJ
chd-155	428	4	(	(	PUNCT
chd-155	428	5	range	range	NOUN
chd-155	428	6	)	)	PUNCT
chd-155	429	1	p	p	NOUN
chd-155	429	2	n=	n=	ADJ
chd-155	429	3	2	2	NUM
chd-155	429	4	2.5	2.5	NUM
chd-155	429	5	(	(	PUNCT
chd-155	429	6	0.5,3	0.5,3	PROPN
chd-155	429	7	)	)	PUNCT
chd-155	429	8	0.496	0.496	NUM
chd-155	429	9	92	92	NUM
chd-155	429	10	1	1	NUM
chd-155	429	11	(	(	PUNCT
chd-155	429	12	0,2.56	0,2.56	NUM
chd-155	429	13	)	)	PUNCT
chd-155	429	14	0.813	0.813	NUM
chd-155	429	15	92	92	NUM
chd-155	429	16	2	2	NUM
chd-155	429	17	(	(	PUNCT
chd-155	429	18	0,3	0,3	NUM
chd-155	429	19	)	)	PUNCT
chd-155	429	20	0.162	0.162	NUM
chd-155	429	21	91	91	NUM
chd-155	429	22	1	1	NUM
chd-155	429	23	(	(	PUNCT
chd-155	429	24	0,2.56	0,2.56	NOUN
chd-155	429	25	)	)	PUNCT
chd-155	429	26	0.974	0.974	NUM
chd-155	429	27	91	91	NUM
chd-155	429	28	3a	3a	NUM
chd-155	429	29	2.5	2.5	NUM
chd-155	429	30	(	(	PUNCT
chd-155	429	31	0.5,3	0.5,3	NOUN
chd-155	429	32	)	)	PUNCT
chd-155	429	33	29	29	NUM
chd-155	429	34	1	1	NUM
chd-155	429	35	(	(	PUNCT
chd-155	429	36	0,2.56	0,2.56	NOUN
chd-155	429	37	)	)	PUNCT
chd-155	429	38	29	29	NUM
chd-155	429	39	1.5	1.5	NUM
chd-155	429	40	(	(	PUNCT
chd-155	429	41	0.5,2.69	0.5,2.69	NUM
chd-155	429	42	)	)	PUNCT
chd-155	429	43	28	28	NUM
chd-155	429	44	1	1	NUM
chd-155	429	45	(	(	PUNCT
chd-155	429	46	0,2.6	0,2.6	NUM
chd-155	429	47	)	)	PUNCT
chd-155	429	48	29	29	NUM
chd-155	429	49	3b	3b	NUM
chd-155	429	50	2.31	2.31	NUM
chd-155	429	51	(	(	PUNCT
chd-155	429	52	0.88,3	0.88,3	NOUN
chd-155	429	53	)	)	PUNCT
chd-155	429	54	15	15	NUM
chd-155	429	55	1.06	1.06	NUM
chd-155	429	56	(	(	PUNCT
chd-155	429	57	0.38,2.5	0.38,2.5	PROPN
chd-155	429	58	)	)	PUNCT
chd-155	429	59	15	15	NUM
chd-155	429	60	1.81	1.81	NUM
chd-155	429	61	(	(	PUNCT
chd-155	429	62	0.5,2.94	0.5,2.94	NUM
chd-155	429	63	)	)	PUNCT
chd-155	429	64	15	15	NUM
chd-155	429	65	1.02	1.02	NUM
chd-155	429	66	(	(	PUNCT
chd-155	429	67	0.25,2.38	0.25,2.38	NOUN
chd-155	429	68	)	)	PUNCT
chd-155	429	69	15	15	NUM
chd-155	429	70	4	4	NUM
chd-155	429	71	1.31	1.31	NUM
chd-155	429	72	(	(	PUNCT
chd-155	429	73	1.31,1.31	1.31,1.31	NUM
chd-155	429	74	)	)	PUNCT
chd-155	429	75	1	1	NUM
chd-155	429	76	1.69	1.69	NUM
chd-155	429	77	(	(	PUNCT
chd-155	429	78	1.69,1.69	1.69,1.69	NOUN
chd-155	429	79	)	)	PUNCT
chd-155	429	80	1	1	NUM
chd-155	429	81	1.5	1.5	NUM
chd-155	429	82	(	(	PUNCT
chd-155	429	83	1.5,1.5	1.5,1.5	PROPN
chd-155	429	84	)	)	PUNCT
chd-155	429	85	1	1	NUM
chd-155	429	86	0.63	0.63	NUM
chd-155	429	87	(	(	PUNCT
chd-155	429	88	0.63,0.63	0.63,0.63	NUM
chd-155	429	89	)	)	PUNCT
chd-155	429	90	1	1	NUM
chd-155	429	91	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-155	429	92	e22	e22	X
chd-155	429	93	cancer	cancer	NOUN
chd-155	429	94	health	health	NOUN
chd-155	429	95	disparities	disparity	NOUN
chd-155	429	96	research	research	NOUN
chd-155	429	97	stage	stage	NOUN
chd-155	429	98	nfκb	nfκb	NOUN
chd-155	429	99	.	.	PUNCT
chd-155	430	1	tumor	tumor	NOUN
chd-155	430	2	,	,	PUNCT
chd-155	430	3	median	median	NOUN
chd-155	430	4	(	(	PUNCT
chd-155	430	5	range	range	NOUN
chd-155	430	6	)	)	PUNCT
chd-155	430	7	p	p	PROPN
chd-155	430	8	n=	n=	ADJ
chd-155	430	9	nfκb	nfκb	NOUN
chd-155	430	10	.	.	PUNCT
chd-155	431	1	benign	benign	ADJ
chd-155	431	2	,	,	PUNCT
chd-155	431	3	median	median	ADJ
chd-155	431	4	(	(	PUNCT
chd-155	431	5	range	range	NOUN
chd-155	431	6	)	)	PUNCT
chd-155	431	7	p	p	PROPN
chd-155	431	8	n=	n=	ADJ
chd-155	431	9	nfκb	nfκb	NOUN
chd-155	431	10	.	.	PUNCT
chd-155	432	1	tumor	tumor	NOUN
chd-155	432	2	,	,	PUNCT
chd-155	432	3	median	median	NOUN
chd-155	432	4	(	(	PUNCT
chd-155	432	5	range	range	NOUN
chd-155	432	6	)	)	PUNCT
chd-155	432	7	p	p	PROPN
chd-155	432	8	n=	n=	ADJ
chd-155	432	9	nfκb	nfκb	NOUN
chd-155	432	10	.	.	PUNCT
chd-155	433	1	benign	benign	ADJ
chd-155	433	2	,	,	PUNCT
chd-155	433	3	median	median	ADJ
chd-155	433	4	(	(	PUNCT
chd-155	433	5	range	range	NOUN
chd-155	433	6	)	)	PUNCT
chd-155	434	1	p	p	NOUN
chd-155	434	2	n=	n=	ADJ
chd-155	434	3	2	2	NUM
chd-155	434	4	1.25	1.25	NUM
chd-155	434	5	(	(	PUNCT
chd-155	434	6	0,2.94	0,2.94	NUM
chd-155	434	7	)	)	PUNCT
chd-155	434	8	0.250	0.250	NUM
chd-155	434	9	91	91	NUM
chd-155	434	10	0.46	0.46	NUM
chd-155	434	11	(	(	PUNCT
chd-155	434	12	0,2.38	0,2.38	NOUN
chd-155	434	13	)	)	PUNCT
chd-155	434	14	0.008	0.008	NUM
chd-155	434	15	92	92	NUM
chd-155	434	16	1.5	1.5	NUM
chd-155	434	17	(	(	PUNCT
chd-155	434	18	0.38,3	0.38,3	NOUN
chd-155	434	19	)	)	PUNCT
chd-155	434	20	0.010	0.010	NUM
chd-155	434	21	90	90	NUM
chd-155	434	22	0.6	0.6	NUM
chd-155	434	23	(	(	PUNCT
chd-155	434	24	0,2.5	0,2.5	PROPN
chd-155	434	25	)	)	PUNCT
chd-155	434	26	0.002	0.002	NUM
chd-155	434	27	91	91	NUM
chd-155	434	28	3a	3a	NUM
chd-155	434	29	1.12	1.12	NUM
chd-155	434	30	(	(	PUNCT
chd-155	434	31	0,2.75	0,2.75	SYM
chd-155	434	32	)	)	PUNCT
chd-155	434	33	29	29	NUM
chd-155	434	34	0.5	0.5	NUM
chd-155	434	35	(	(	PUNCT
chd-155	434	36	0,1.98	0,1.98	NOUN
chd-155	434	37	)	)	PUNCT
chd-155	434	38	29	29	NUM
chd-155	434	39	1.5	1.5	NUM
chd-155	434	40	(	(	PUNCT
chd-155	434	41	0.5,2.88	0.5,2.88	NUM
chd-155	434	42	)	)	PUNCT
chd-155	434	43	28	28	NUM
chd-155	434	44	0.5	0.5	NUM
chd-155	434	45	(	(	PUNCT
chd-155	434	46	0,1.94	0,1.94	NUM
chd-155	434	47	)	)	PUNCT
chd-155	434	48	29	29	NUM
chd-155	434	49	3b	3b	NUM
chd-155	434	50	1.75	1.75	NUM
chd-155	434	51	(	(	PUNCT
chd-155	434	52	0.25,2.69	0.25,2.69	NOUN
chd-155	434	53	)	)	PUNCT
chd-155	434	54	15	15	NUM
chd-155	434	55	0.94	0.94	NUM
chd-155	434	56	(	(	PUNCT
chd-155	434	57	0.42,2.52	0.42,2.52	NOUN
chd-155	434	58	)	)	PUNCT
chd-155	434	59	15	15	NUM
chd-155	434	60	2.31	2.31	NUM
chd-155	434	61	(	(	PUNCT
chd-155	434	62	0.83,2.81	0.83,2.81	NUM
chd-155	434	63	)	)	PUNCT
chd-155	434	64	15	15	NUM
chd-155	434	65	1.25	1.25	NUM
chd-155	434	66	(	(	PUNCT
chd-155	434	67	0.58,2.25	0.58,2.25	NOUN
chd-155	434	68	)	)	PUNCT
chd-155	434	69	15	15	NUM
chd-155	434	70	4	4	NUM
chd-155	434	71	1.81	1.81	NUM
chd-155	434	72	(	(	PUNCT
chd-155	434	73	1.81,1.81	1.81,1.81	NUM
chd-155	434	74	)	)	PUNCT
chd-155	434	75	1	1	NUM
chd-155	434	76	1.5	1.5	NUM
chd-155	434	77	(	(	PUNCT
chd-155	434	78	1.5,1.5	1.5,1.5	PROPN
chd-155	434	79	)	)	PUNCT
chd-155	434	80	1	1	NUM
chd-155	434	81	1.55	1.55	NUM
chd-155	434	82	(	(	PUNCT
chd-155	434	83	1.55,1.55	1.55,1.55	NUM
chd-155	434	84	)	)	PUNCT
chd-155	434	85	1	1	NUM
chd-155	434	86	1.25	1.25	NUM
chd-155	434	87	(	(	PUNCT
chd-155	434	88	1.25,1.25	1.25,1.25	NUM
chd-155	434	89	)	)	PUNCT
chd-155	434	90	1	1	NUM
chd-155	434	91	medical	medical	ADJ
chd-155	434	92	college	college	PROPN
chd-155	434	93	of	of	ADP
chd-155	434	94	wisconsin	wisconsin	PROPN
chd-155	434	95	(	(	PUNCT
chd-155	434	96	mcw	mcw	PROPN
chd-155	434	97	)	)	PUNCT
chd-155	434	98	african	african	ADJ
chd-155	434	99	-	-	PUNCT
chd-155	434	100	american	american	ADJ
chd-155	434	101	white	white	PROPN
chd-155	434	102	american	american	ADJ
chd-155	434	103	stage	stage	NOUN
chd-155	434	104	gdf15	gdf15	PROPN
chd-155	434	105	.	.	PUNCT
chd-155	435	1	tumor	tumor	NOUN
chd-155	435	2	,	,	PUNCT
chd-155	435	3	median	median	NOUN
chd-155	435	4	(	(	PUNCT
chd-155	435	5	range	range	NOUN
chd-155	435	6	)	)	PUNCT
chd-155	435	7	p	p	NOUN
chd-155	435	8	n=	n=	ADJ
chd-155	435	9	gdf15	gdf15	NOUN
chd-155	435	10	.	.	PUNCT
chd-155	436	1	benign	benign	ADJ
chd-155	436	2	,	,	PUNCT
chd-155	436	3	median	median	ADJ
chd-155	436	4	(	(	PUNCT
chd-155	436	5	range	range	NOUN
chd-155	436	6	)	)	PUNCT
chd-155	436	7	p	p	NOUN
chd-155	436	8	n=	n=	ADJ
chd-155	436	9	gdf15	gdf15	NOUN
chd-155	436	10	.	.	PUNCT
chd-155	437	1	tumor	tumor	NOUN
chd-155	437	2	,	,	PUNCT
chd-155	437	3	median	median	NOUN
chd-155	437	4	(	(	PUNCT
chd-155	437	5	range	range	NOUN
chd-155	437	6	)	)	PUNCT
chd-155	437	7	p	p	NOUN
chd-155	437	8	n=	n=	ADJ
chd-155	437	9	gdf15	gdf15	NOUN
chd-155	437	10	.	.	PUNCT
chd-155	438	1	benign	benign	ADJ
chd-155	438	2	,	,	PUNCT
chd-155	438	3	median	median	ADJ
chd-155	438	4	(	(	PUNCT
chd-155	438	5	range	range	NOUN
chd-155	438	6	)	)	PUNCT
chd-155	439	1	p	p	NOUN
chd-155	439	2	n=	n=	ADJ
chd-155	439	3	2	2	NUM
chd-155	439	4	2	2	NUM
chd-155	439	5	(	(	PUNCT
chd-155	439	6	1,3	1,3	NUM
chd-155	439	7	)	)	PUNCT
chd-155	439	8	0.696	0.696	NUM
chd-155	439	9	16	16	NUM
chd-155	439	10	1	1	NUM
chd-155	439	11	(	(	PUNCT
chd-155	439	12	0,1.5	0,1.5	NOUN
chd-155	439	13	)	)	PUNCT
chd-155	439	14	0.104	0.104	NUM
chd-155	439	15	16	16	NUM
chd-155	439	16	1	1	NUM
chd-155	439	17	(	(	PUNCT
chd-155	439	18	0.33,3	0.33,3	PROPN
chd-155	439	19	)	)	PUNCT
chd-155	439	20	0.435	0.435	NUM
chd-155	439	21	20	20	NUM
chd-155	439	22	1	1	NUM
chd-155	439	23	(	(	PUNCT
chd-155	439	24	0,2.5	0,2.5	PROPN
chd-155	439	25	)	)	PUNCT
chd-155	439	26	0.485	0.485	NUM
chd-155	439	27	20	20	NUM
chd-155	439	28	3a	3a	NUM
chd-155	439	29	2.25	2.25	NUM
chd-155	439	30	(	(	PUNCT
chd-155	439	31	1,3	1,3	NUM
chd-155	439	32	)	)	PUNCT
chd-155	439	33	8	8	NUM
chd-155	439	34	0.5	0.5	NUM
chd-155	439	35	(	(	PUNCT
chd-155	439	36	0,1	0,1	NUM
chd-155	439	37	)	)	PUNCT
chd-155	439	38	8	8	NUM
chd-155	439	39	1.58	1.58	NUM
chd-155	439	40	(	(	PUNCT
chd-155	439	41	0,2.67	0,2.67	NOUN
chd-155	439	42	)	)	PUNCT
chd-155	439	43	6	6	NUM
chd-155	439	44	0.42	0.42	NUM
chd-155	439	45	(	(	PUNCT
chd-155	439	46	0,2.5	0,2.5	NOUN
chd-155	439	47	)	)	PUNCT
chd-155	439	48	6	6	NUM
chd-155	439	49	3b	3b	NUM
chd-155	439	50	2	2	NUM
chd-155	439	51	(	(	PUNCT
chd-155	439	52	0.67,2.67	0.67,2.67	NUM
chd-155	439	53	)	)	PUNCT
chd-155	439	54	5	5	NUM
chd-155	439	55	1.12	1.12	NUM
chd-155	439	56	(	(	PUNCT
chd-155	439	57	0,2.33	0,2.33	NUM
chd-155	439	58	)	)	PUNCT
chd-155	439	59	5	5	NUM
chd-155	439	60	0.5	0.5	NUM
chd-155	439	61	(	(	PUNCT
chd-155	439	62	0.5,0.5	0.5,0.5	PROPN
chd-155	439	63	)	)	PUNCT
chd-155	439	64	1	1	NUM
chd-155	439	65	0.5	0.5	NUM
chd-155	439	66	(	(	PUNCT
chd-155	439	67	0.5,0.5	0.5,0.5	PROPN
chd-155	439	68	)	)	PUNCT
chd-155	439	69	1	1	NUM
chd-155	439	70	4	4	NUM
chd-155	439	71	--	--	PUNCT
chd-155	439	72	0	0	NUM
chd-155	439	73	--	--	SYM
chd-155	439	74	0	0	NUM
chd-155	439	75	--	--	SYM
chd-155	439	76	0	0	NUM
chd-155	439	77	--	--	SYM
chd-155	439	78	0	0	NUM
chd-155	439	79	stage	stage	NOUN
chd-155	439	80	nfκb	nfκb	NOUN
chd-155	439	81	.	.	PUNCT
chd-155	440	1	tumor	tumor	NOUN
chd-155	440	2	,	,	PUNCT
chd-155	440	3	median	median	NOUN
chd-155	440	4	(	(	PUNCT
chd-155	440	5	range	range	NOUN
chd-155	440	6	)	)	PUNCT
chd-155	440	7	p	p	PROPN
chd-155	440	8	n=	n=	ADJ
chd-155	440	9	nfκb	nfκb	NOUN
chd-155	440	10	.	.	PUNCT
chd-155	441	1	benign	benign	ADJ
chd-155	441	2	,	,	PUNCT
chd-155	441	3	median	median	ADJ
chd-155	441	4	(	(	PUNCT
chd-155	441	5	range	range	NOUN
chd-155	441	6	)	)	PUNCT
chd-155	441	7	p	p	PROPN
chd-155	441	8	n=	n=	ADJ
chd-155	441	9	nfκb	nfκb	NOUN
chd-155	441	10	.	.	PUNCT
chd-155	442	1	tumor	tumor	NOUN
chd-155	442	2	,	,	PUNCT
chd-155	442	3	median	median	NOUN
chd-155	442	4	(	(	PUNCT
chd-155	442	5	range	range	NOUN
chd-155	442	6	)	)	PUNCT
chd-155	442	7	p	p	PROPN
chd-155	442	8	n=	n=	ADJ
chd-155	442	9	nfκb	nfκb	NOUN
chd-155	442	10	.	.	PUNCT
chd-155	443	1	benign	benign	ADJ
chd-155	443	2	,	,	PUNCT
chd-155	443	3	median	median	ADJ
chd-155	443	4	(	(	PUNCT
chd-155	443	5	range	range	NOUN
chd-155	443	6	)	)	PUNCT
chd-155	444	1	p	p	NOUN
chd-155	444	2	n=	n=	ADJ
chd-155	444	3	2	2	NUM
chd-155	444	4	1.56	1.56	NUM
chd-155	444	5	(	(	PUNCT
chd-155	444	6	0.75,3	0.75,3	PROPN
chd-155	444	7	)	)	PUNCT
chd-155	444	8	0.589	0.589	NUM
chd-155	444	9	16	16	NUM
chd-155	444	10	1.68	1.68	NUM
chd-155	444	11	(	(	PUNCT
chd-155	444	12	0.8,3	0.8,3	NOUN
chd-155	444	13	)	)	PUNCT
chd-155	444	14	0.546	0.546	NUM
chd-155	444	15	16	16	NUM
chd-155	444	16	2	2	NUM
chd-155	444	17	(	(	PUNCT
chd-155	444	18	0.83,3	0.83,3	NUM
chd-155	444	19	)	)	PUNCT
chd-155	445	1	0.101	0.101	NUM
chd-155	445	2	19	19	NUM
chd-155	445	3	1.75	1.75	NUM
chd-155	445	4	(	(	PUNCT
chd-155	445	5	0.75,3	0.75,3	PROPN
chd-155	445	6	)	)	PUNCT
chd-155	445	7	0.281	0.281	NUM
chd-155	445	8	20	20	NUM
chd-155	445	9	3a	3a	NUM
chd-155	445	10	1.96	1.96	NUM
chd-155	445	11	(	(	PUNCT
chd-155	445	12	1.5,2.83	1.5,2.83	NUM
chd-155	445	13	)	)	PUNCT
chd-155	445	14	8	8	NUM
chd-155	445	15	2.12	2.12	NUM
chd-155	445	16	(	(	PUNCT
chd-155	445	17	0.17,2.88	0.17,2.88	NOUN
chd-155	445	18	)	)	PUNCT
chd-155	445	19	8	8	NUM
chd-155	445	20	1.19	1.19	NUM
chd-155	445	21	(	(	PUNCT
chd-155	445	22	0,2.17	0,2.17	NUM
chd-155	445	23	)	)	PUNCT
chd-155	445	24	6	6	NUM
chd-155	445	25	1.45	1.45	NUM
chd-155	445	26	(	(	PUNCT
chd-155	445	27	0.5,2	0.5,2	NOUN
chd-155	445	28	)	)	PUNCT
chd-155	445	29	6	6	NUM
chd-155	445	30	3b	3b	NUM
chd-155	445	31	2.5	2.5	NUM
chd-155	445	32	(	(	PUNCT
chd-155	445	33	1,3	1,3	NUM
chd-155	445	34	)	)	PUNCT
chd-155	445	35	5	5	NUM
chd-155	445	36	2	2	NUM
chd-155	445	37	(	(	PUNCT
chd-155	445	38	1.4,2.83	1.4,2.83	NUM
chd-155	445	39	)	)	PUNCT
chd-155	445	40	5	5	NUM
chd-155	445	41	2.25	2.25	NUM
chd-155	445	42	(	(	PUNCT
chd-155	445	43	2.25,2.25	2.25,2.25	NUM
chd-155	445	44	)	)	PUNCT
chd-155	445	45	1	1	NUM
chd-155	445	46	1.83	1.83	NUM
chd-155	445	47	(	(	PUNCT
chd-155	445	48	1.83,1.83	1.83,1.83	NUM
chd-155	445	49	)	)	PUNCT
chd-155	445	50	1	1	NUM
chd-155	445	51	4	4	NUM
chd-155	445	52	--	--	PUNCT
chd-155	445	53	0	0	NUM
chd-155	445	54	--	--	SYM
chd-155	445	55	0	0	NUM
chd-155	445	56	--	--	SYM
chd-155	445	57	0	0	NUM
chd-155	445	58	--	--	SYM
chd-155	445	59	0	0	NUM
chd-155	445	60	n=	n=	ADJ
chd-155	445	61	number	number	NOUN
chd-155	445	62	of	of	ADP
chd-155	445	63	informative	informative	ADJ
chd-155	445	64	cases	case	NOUN
chd-155	445	65	note	note	VERB
chd-155	445	66	:	:	PUNCT
chd-155	445	67	with	with	ADP
chd-155	445	68	only	only	ADV
chd-155	445	69	1	1	NUM
chd-155	445	70	cases	case	NOUN
chd-155	445	71	for	for	ADP
chd-155	445	72	stage	stage	NOUN
chd-155	445	73	4	4	NUM
chd-155	445	74	,	,	PUNCT
chd-155	445	75	values	value	NOUN
chd-155	445	76	are	be	AUX
chd-155	445	77	probably	probably	ADV
chd-155	445	78	not	not	PART
chd-155	445	79	representative	representative	ADJ
chd-155	445	80	.	.	PUNCT